Inhibitors of Histone Deacetylase

ABSTRACT

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I) 
     
       
         
         
             
             
         
       
     
     and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

This application claims the benefit of U.S. provisional application No.60/922,505 filed Apr. 9, 2007.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to compounds for the inhibition of histonedeacetylase.

2. Description of Related Art

In eukaryotic cells, nuclear DNA associates with histones to form acompact complex called chromatin. The histones constitute a family ofbasic proteins which are generally highly conserved across eukaryoticspecies. The core histones, termed H2A, H2B, H3, and H4, associate toform a protein core. DNA winds around this protein core, with the basicamino acids of the histones interacting with the negatively chargedphosphate groups of the DNA. Approximately 146 base pairs of DNA wraparound a histone core to make up a nucleosome particle, the repeatingstructural motif of chromatin.

Csordas, Biochem. J., 286: 23-38 (1990) teaches that histones aresubject to posttranslational acetylation of the N-terminal lysineresidues, a reaction that is catalyzed by histone acetyl transferase(HAT 1). Acetylation neutralizes the positive charge of the lysine sidechain, and is thought to impact chromatin structure. Indeed, Taunton etal., Science, 272: 408-411 (1996), teaches that access of transcriptionfactors to chromatin templates is enhanced by histone hyperacetylation.Taunton et al. further teaches that an enrichment in underacetylatedhistone H4 has been found in transcriptionally silent regions of thegenome.

Histone acetylation is a reversible modification, with deacetylationbeing catalyzed by a family of enzymes termed histone deacetylases(HDACs). The molecular cloning of gene sequences encoding proteins withHDAC activity has established the existence of a set of discrete HDACenzyme isoforms. Grozinger et al., Proc. Natl. Acad. Sci. USA,96:4868-4873 (1999), teaches that HDACs may be divided into two classes,the first represented by yeast Rpd3-like proteins, and the secondrepresented by yeast Hd1-like proteins. Grozinger et al. also teachesthat the human HDAC-1, HDAC-2, and HDAC-3 proteins are members of thefirst class of HDACs, and discloses new proteins, named HDAC-4, HDAC-5,and HDAC-6, which are members of the second class of HDACs. Kao et al.,Gene & Development 14:55-66 (2000), discloses an additional member ofthis second class, called HDAC-7. More recently, Hu, E. et al. J. Bio.Chem. 275: 15254-13264 (2000) disclosed another member of the firstclass of histone deacetylases, HDAC-8. Zhou et al., Proc. Natl. Acad.Sci. U.S.A., 98: 10572-10577 (2001) teaches the cloning andcharacterization of a new histone deacetylase, HDAC-9. Kao et al., J.Biol. Chem., 277:187-93 (2002) teaches the isolation andcharacterization of mammalian HDAC 10, a novel histone deacetylase. Gaoet al, J. Biol. Chem. (In press) teaches the cloning and functionalcharacterization of HDAC11, a novel member of the human histonedeacetylase family. Shore, Proc. Natl. Acad. Sci. U.S.A. 97: 14030-2(2000) discloses another class of deacetylase activity, the Sir2 proteinfamily. It has been unclear what roles these individual HDAC enzymesplay.

Studies utilizing known HDAC inhibitors have established a link betweenacetylation and gene expression. Numerous studies have examined therelationship between HDAC and gene expression. Taunton et al., Science272:408-411 (1996), discloses a human HDAC that is related to a yeasttranscriptional regulator. Cress et al., J. Cell. Phys. 184: 1-16(2000), discloses that, in the context of human cancer, the role of HDACis as a corepressor of transcription. Ng et al, TIBS 25: March (2000),discloses HDAC as a pervasive feature of transcriptional repressorsystems. Magnaghi-Jaulin et al., Prog. Cell Cycle Res. 4:41-47 (2000),discloses HDAC as a transcriptional co-regulator important for cellcycle progression.

Richon et al., Proc. Natl. Acad. Sci. USA, 95: 3003-3007 (1998),discloses that HDAC activity is inhibited by trichostatin A (TSA), anatural product isolated from Streptomyces hygroscopicus, which has beenshown to inhibit histone deacetylase activity and arrest cell cycleprogression in cells in the G1 and G2 phases (Yoshida et al., J. Biol.Chem. 265: 17174-17179, 1990; Yoshida et al., Exp. Cell Res. 177:122-131, 1988), and by a synthetic compound, suberoylanilide hydroxamicacid (SAHA). Yoshida and Beppu, Exper. Cell Res., 177: 122-131 (1988),teaches that TSA causes arrest of rat fibroblasts at the G₁ and G₂phases of the cell cycle, implicating HDAC in cell cycle regulation.Indeed, Finnin et al., Nature, 401: 188-193 (1999), teaches that TSA andSAHA inhibit cell growth, induce terminal differentiation, and preventthe formation of tumors in mice. Suzuki et al., U.S. Pat. No. 6,174,905,EP 0847992 and JP 258863/96, disclose benzamide derivatives that inducecell differentiation and inhibit HDAC. Delorme et al., WO 01/38322 andWO 2001/070675, disclose additional compounds that serve as HDACinhibitors. Other inhibitors of histone deacetylase activity, includingtrapoxin, depudecin, FR901228 (Fujisawa Pharmaceuticals), and butyrate,have been found to similarly inhibit cell cycle progression in cells(Taunton et al., Science 272: 408-411, 1996; Kijima et al., J. Biol.Chem. 268(30):22429-22435, 1993; Kwon et al., Proc. Natl. Acad. Sci. USA95(7):3356-61, 1998).

These and other findings suggest that inhibition of HDAC activityrepresents a novel approach for intervening in cell cycle regulation andthat HDAC inhibitors have great therapeutic potential in the studyand/or treatment of diseases or conditions ameliorated by modulatingHDAC activity (in particular, cell proliferative diseases (such ascancer), diabetes, inflammation, cardiac disease, stroke, epilepsy,depression, immunological disease or viral or fungal infection). ManyHDAC inhibitors, however, inhibit all HDAC isoforms. There is a need toidentify selective HDAC inhibitors (i.e., inhibitors that inhibited oneor more but not all HDAC isoforms) and to identify the structuralfeatures required for potent HDAC inhibitory activity.

SUMMARY OF THE INVENTION

The present invention provides compounds useful in the inhibition ofhistone deacetylase, and methods for inhibiting histone deacetylase.

In a first aspect, the present invention provides compounds having theFormula (I),

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic and scalemic mixtures,diastereomers and enantiomers thereof, in which groups L, M, X and Y areas defined below.

In a second aspect, the invention provides a composition comprising apharmaceutically acceptable carrier, diluent or excipient and a compoundhaving the formula (VI)

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof or a racemic or scalemic mixture,diastereomer or enantiomer thereof, in which groups L, M, X and Y are asdefined below.

In a third aspect, the invention provides a method of inhibiting ahistone deacetylase selected from the group consisting of HDAC-4,HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11 the methodcomprising contacting the histone deacetylase or a cell containinghistone deacetylase, with a histone deacetylase inhibiting amount of acompound having the formula (XII)

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, in which groups L, M, X and Y are asdefined below.

The present invention provides novel compounds for use in the studyand/or treatment of diseases or conditions effected by modulation ofHDAC activity.

In some preferred embodiments a patient is administered an effectiveamount of a compound having a formula as described herein, preferablyhaving any of Formulae (XII)-(XVII), or a composition thereof, incombination (simultaneously or sequentially) with at least one otheranti-disease agent.

The present invention provides for the use of compounds having a Formulaas described herein, preferably any of Formulae (XII)-(XVII), or acomposition thereof, for inhibiting histone deacetylase-4, -5, -6, -7,-8, -9, -10 and/or -11 activity. The present invention also provides forthe use of compounds having a Formula has described herein, preferablyhaving any of Formulae (XII)-(XVII), or a composition thereof, for thetreatment of diseases or conditions effected by modulation of HDACactivity, such as cell proliferative diseases (such as cancer),diabetes, inflammation, cardiac disease, stroke, epilepsy, depression,immunological disease or viral or fungal infection.

The present invention provides compounds for use in the manufacture of amedicament for the treatment of diseases or conditions effected bymodulation of HDAC activity, such as cell proliferative diseases (suchas cancer), diabetes, inflammation, cardiac disease, stroke, epilepsy,depression, immunological disease or viral or fungal infection.

The present invention also relates to methods of using a compound havinga Formula as described herein, preferably any of Formulae (XII)-(XVII),or a composition thereof, in the treatment of diseases or conditionseffected by modulation of HDAC activity, such as cell proliferativediseases (such as cancer), diabetes, inflammation, cardiac disease,stroke, epilepsy, depression, immunological disease or viral or fungalinfection.

The foregoing merely summarizes various aspects of the invention and isnot intended to be limiting in nature. These aspects and other aspectsand embodiments are described more fully below. The patent andscientific literature referred to herein establishes knowledge that isavailable to those with skill in the art. The issued patents,applications, and references that are cited herein are herebyincorporated by reference to the same extent as if each was specificallyand individually indicated to be incorporated by reference. In the caseof inconsistencies, the present disclosure will prevail.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides compounds that are useful as inhibitorsof histone deacetylase.

In one aspect, the invention provides certain compounds of the Formula(I)

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic and scalemic mixtures,diastereomers and enantiomers thereof, wherein groups L, M, X and Y areas defined herein.

In the second aspect, the invention provides a composition comprising apharmaceutically acceptable carrier, diluent or excipient and a compoundhaving the Formula (VI)

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, in which groups L, M, X and Y are asdefined below.

In the third aspect, the invention provides a method of inhibiting ahistone deacetylase selected from the group consisting of HDAC-4,HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11. In oneembodiment, the method comprises contacting the histone deacetylase witha histone deacetylase inhibiting amount of a compound having the Formula(XII)

or an N-oxide, hydrate, solvate, pharmaceutically-acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diasteromer or enantiomer thereof, or a preferred embodiment thereof.

In a further embodiment of the third aspect, the method comprisescontacting the histone deacetylase with a histone deacetylase inhibitingamount of a composition comprising the above-described compound, or anN-oxide, hydrate, solvate, pharmaceutically-acceptable salt, prodrug orcomplex thereof, or a racemic or scalemic mixture, diasteromer orenantiomer thereof, or a preferred embodiment thereof, and apharmaceutically-acceptable carrier. In yet another embodiment, themethod comprises inhibiting a histone deacetylase selected from thegroup consisting of HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9,HDAC-10 and HDAC-11 in a cell comprising contacting the cell with ahistone deacetylase inhibiting amount of the above-described compound,or an N-oxide, hydrate, solvate, pharmaceutically-acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diasteromer or enantiomer thereof, or a preferred embodiment thereof. Instill another embodiment, the method comprises inhibiting a histonedeacetylase selected from the group consisting of HDAC-4, HDAC-5,HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11 in a cell comprisingcontacting the cell with a histone deacetylase inhibiting amount of acomposition comprising the above-described compound, or an N-oxide,hydrate, solvate, pharmaceutically-acceptable salt, prodrug or complexthereof, or a racemic or scalemic mixture, diasteromer or enantiomerthereof, or a preferred embodiment thereof, and apharmaceutically-acceptable carrier. According to this aspect, thecompounds and compositions according to the invention are useful astools for exploring the role of histone deacetylases in various diseaseconditions.

In a preferred method of the present invention, the cell in whichinhibition of histone deacetylase is desired is a mammalian cell,preferably a primate cell, more preferably a human cell.

In some preferred embodiments, the contacted cell is in an animal. Thus,the invention provides a method for treating diseases or conditionseffected by modulation of HDAC activity, such as cell proliferativediseases (such as cancer), diabetes, inflammation, cardiac disease,stroke, epilepsy, depression, immunological disease or viral or fungalinfection in an animal, comprising administering to an animal in need ofsuch treatment a therapeutically effective amount of a compound having aFormula as described herein, preferably having a Formula according toany of Formulae (XII)-(XVII), or a pharmaceutical composition thereof.Preferably, the animal is a mammal, more preferably a domesticatedmammal or a primate. Most preferably, the animal is a human.

In some preferred embodiments the animal is administered an effectiveamount of a compound having a Formula as described herein, preferably aFormula according to any of Formulae (XII)-(XVII), or a pharmaceuticalcomposition thereof, in combination (simultaneously or sequentially)with at least one other anti-disease agent, or a composition thereof.The term “anti-disease agent” includes any agent that is useful for thetreatment of the particular disease for which treatment is desired.

Reference to “a compound of the formula (I)” and the like, (orequivalently, “a compound according to the first aspect”, or “a compoundof the present invention”, and the like), herein is understood toinclude reference to N-oxides, hydrates, solvates, pharmaceuticallyacceptable salts, prodrugs and complexes thereof, and racemic andscalemic mixtures, diastereomers, enantiomers and tautomers thereof andunless otherwise indicated.

In preferred embodiments, the individual is a mammal, preferably aprimate, more preferably a human.

For purposes of the present invention, the following definitions will beused (unless expressly stated otherwise).

For simplicity, chemical moieties are defined and referred to throughoutprimarily as univalent chemical moieties (e.g., alkyl, aryl, etc.).Nevertheless, such terms are also used to convey correspondingmultivalent moieties under the appropriate structural circumstancesclear to those skilled in the art. For example, while an “alkyl” moietygenerally refers to a monovalent radical (e.g. CH₃—CH₂—), in certaincircumstances a bivalent linking moiety can be “alkyl,” in which casethose skilled in the art will understand the alkyl to be a divalentradical (e.g., —CH₂—CH₂—), which is equivalent to the term “alkylene.”(Similarly, in circumstances in which a divalent moiety is required andis stated as being “aryl,” those skilled in the art will understand thatthe term “aryl” refers to the corresponding divalent moiety, arylene).All atoms are understood to have their normal number of valences forbond formation (i.e., 4 for carbon, 3 for N, 2 for 0, and 2, 4, or 6 forS, depending on the oxidation state of the S). On occasion a moiety maybe defined, for example, as (A)_(a)-B—, wherein a is 0 or 1. In suchinstances, when a is 0 the moiety is B— and when a is 1 the moiety isA-B—. Also, a number of moietes disclosed here may exist in multipletautomeric forms, all of which are intended to be encompassed by anygiven tautomeric structure.

For simplicity, reference to a “C_(n)-C_(m)” heterocyclyl or“C_(n)-C_(m)” heteroaryl means a heterocyclyl or heteroaryl having from“n” to “m” annular atoms, where “n” and “m” are integers. Thus, forexample, a C₅-C₆-heterocyclyl is a 5- or 6-membered ring having at leastone heteroatom, and includes pyrrolidinyl (C₅) and piperidinyl (C₆);C₆-heteroaryl includes, for example, pyridyl and pyrimidyl.

The term “hydrocarbyl” refers to a straight, branched, or cyclic alkyl,alkenyl, or alkynyl, each as defined herein. A “C₀” hydrocarbyl is usedto refer to a covalent bond. Thus, “C₀-C₃-hydrocarbyl” includes acovalent bond, methyl, ethyl, ethenyl, ethynyl, propyl, propenyl,propynyl, and cyclopropyl.

The term “alkyl” is intended to mean a straight or branched chainaliphatic group having from 1 to 12 carbon atoms, preferably 1-8 carbonatoms, and more preferably 1-6 carbon atoms. Other preferred alkylgroups have from 2 to 12 carbon atoms, preferably 2-8 carbon atoms andmore preferably 2-6 carbon atoms. Preferred alkyl groups include,without limitation, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tert-butyl, pentyl, and hexyl. A “C₀” alkyl (as in“C₀-C₃-alkyl”) is a covalent bond.

The term “alkenyl” is intended to mean an unsaturated straight orbranched chain aliphatic group with one or more carbon-carbon doublebonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms,and more preferably 2-6 carbon atoms. Preferred alkenyl groups include,without limitation, ethenyl, propenyl, butenyl, pentenyl, and hexenyl.

The term “alkynyl” is intended to mean an unsaturated straight orbranched chain aliphatic group with one or more carbon-carbon triplebonds, having from 2 to 12 carbon atoms, preferably 2-8 carbon atoms,and more preferably 2-6 carbon atoms. Preferred alkynyl groups include,without limitation, ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

The terms “alkylene,” “alkenylene,” or “alkynylene” as used herein areintended to mean an alkyl, alkenyl, or alkynyl group, respectively, asdefined hereinabove, that is positioned between and serves to connecttwo other chemical groups. Preferred alkylene groups include, withoutlimitation, methylene, ethylene, propylene, and butylene. Preferredalkenylene groups include, without limitation, ethenylene, propenylene,and butenylene. Preferred alkynylene groups include, without limitation,ethynylene, propynylene, and butynylene.

The term “cycloalkyl” is intended to mean a saturated or unsaturatedmono-, bi, tri- or poly-cyclic hydrocarbon group having about 3 to 15carbons, preferably having 3 to 12 carbons, preferably 3 to 8 carbons,and more preferably 3 to 6 carbons. In certain preferred embodiments,the cycloalkyl group is fused to an aryl, heteroaryl or heterocyclicgroup. Preferred cycloalkyl groups include, without limitation,cyclopenten-2-enone, cyclopenten-2-enol, cyclohex-2-enone,cyclohex-2-enol, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

In certain preferred embodiments, the cycloalkyl group is a bridgedcycloalkyl group, preferably a C₅-C₁₀ bridged bicyclic group. In certainpreferred embodiments, the bridged cycloalkyl group is a C₅ bridgedbicyclic group. In certain preferred embodiments, the bridged cycloalkylgroup is a C₆ bridged bicyclic group. In certain preferred embodiments,the bridged cycloalkyl group is a C₇ bridged bicyclic group. In certainpreferred embodiments, the bridged cycloalkyl group is a C₈ bridgedbicyclic group. In certain preferred embodiments, the bridged cycloalkylgroup is a C₉ bridged bicyclic. In certain preferred embodiments, thebridged cycloalkyl group has a bridge of 0, 1, 2 or 3 carbon atoms. Abridge of 0 carbon atoms is a bond, and equates to a cycloalkyl groupfused to another ring structure. In certain preferred embodiments, thebridged cycloalkyl group has a bridge of 0, 1 or 3 carbon atoms. Incertain preferred embodiments, the bridged cycloalkyl group has a bridgeof 1 or 3 carbon atoms. In certain preferred embodiments, the bridgedcycloalkyl group has a bridge of 1 carbon atom. In certain preferredembodiments, the bridged cycloalkyl group has a bridge of 2 carbonatoms. In certain preferred embodiments, the bridged cycloalkyl grouphas a bridge of 3 carbon atoms. If a bridged cycloalkyl group isdescribed as “optionally substituted”, it is intended to be optionallysubstituted on any position, including the bridge. The bridgedcycloalkyl group is not limited to any particular stereochemistry.

The term “heteroalkyl” is intended to mean a saturated or unsaturated,straight or branched chain aliphatic group, wherein one or more carbonatoms in the chain are independently replaced by a heteroatom selectedfrom the group consisting of O, S, and N.

The term “aliphatic” is intended to mean both saturated and unsaturated,straight chain or branched aliphatic hydrocarbons. As will beappreciated by one of ordinary skill in the art, “aliphatic” is intendedherein to include, but is not limited to, alkyl, alkenyl or alkynylmoieties.

The term “aryl” is intended to mean a mono-, bi-, tri- or polycyclicC₆-C₁₄ aromatic moiety, preferably comprising one to three aromaticrings. Preferably, the aryl group is a C₆-C₁₀ aryl group, morepreferably a C₆ aryl group. Preferred aryl groups include, withoutlimitation, phenyl, naphthyl, anthracenyl, and fluorenyl.

The terms “aralkyl” or “arylalkyl” is intended to mean a groupcomprising an aryl group covalently linked to an alkyl group. If anaralkyl group is described as “optionally substituted”, it is intendedthat either or both of the aryl and alkyl moieties may independently beoptionally substituted or unsubstituted. Preferably, the aralkyl groupis (C₁-C₆)alk(C₆-C₁₀)aryl, including, without limitation, benzyl,phenethyl, and naphthylmethyl. For simplicity, when written as“arylalkyl” this term, and terms related thereto, is intended toindicate the order of groups in a compound as “aryl-alkyl”. Similarly,“alkyl-aryl” is intended to indicate the order of the groups in acompound as “alkyl-aryl”.

The terms “heterocyclyl”, “heterocyclic” or “heterocycle” are intendedto mean a group which is a mono-, bi-, or polycyclic structure havingfrom about 3 to about 14 atoms, wherein one or more atoms areindependently selected from the group consisting of N, O, and S. Thering structure may be saturated, unsaturated or partially unsaturated.In certain preferred embodiments, the heterocyclic group isnon-aromatic. In a bicyclic or polycyclic structure, one or more ringsmay be aromatic; for example one ring of a bicyclic heterocycle or oneor two rings of a tricyclic heterocycle may be aromatic, as in indan and9,10-dihydro anthracene. Preferred heterocyclic groups include, withoutlimitation, epoxy, aziridinyl, tetrahydrofuranyl, pyrrolidinyl,piperidinyl, piperazinyl, thiazolidinyl, oxazolidinyl, oxazolidinonyl,and morpholino. In certain preferred embodiments, the heterocyclic groupis fused to an aryl, heteroaryl, or cycloalkyl group. Examples of suchfused heterocycles include, without limitation, tetrahydroquinoline anddihydrobenzofuran. Specifically excluded from the scope of this term arecompounds where an annular O or S atom is adjacent to another O or Satom.

In certain preferred embodiments, the heterocyclic group is a bridgedheterocyclic group, preferably a C₆-C₁₀ bridged bicyclic group, whereinone or more carbon atoms are independently replaced by a heteroatomselected from the group consisting of N, O and S. In certain preferredembodiments, the bridged heterocyclic group is a C₆ bridged bicyclicgroup. In certain preferred embodiments, the bridged heterocyclic groupis a C₇ bridged bicyclic group. In certain preferred embodiments, thebridged heterocyclic group is a C₈ bridged bicyclic group. In certainpreferred embodiments, the bridged heterocyclic group is a C₉ bridgedbicyclic. In certain preferred embodiments, the bridged heterocyclicgroup has a bridge of 0, 1, 2 or 3 carbon atoms. In certain preferredembodiments, the bridged heterocyclic group has a bridge of 0, 1 or 3carbon atoms. A bridge of 0 carbon atoms is a bond, and equates to aheterocyclic group fused to another ring structure. In certain preferredembodiments, the bridged heterocyclic group has a bridge of 1 or 3carbon atoms. In certain preferred embodiments, the bridged heterocyclicgroup has a bridge of 1 carbon atom. In certain preferred embodiments,the bridged heterocyclic group has a bridge of 2 carbon atoms. Incertain preferred embodiments, the bridged heterocyclic group has abridge of 3 carbon atoms. If a bridged heterocyclic group is describedas “optionally substituted”, it is intended to be optionally substitutedon any position, including the bridge. The bridged heterocyclic group isnot limited to any particular stereochemistry.

In certain preferred embodiments, the heterocyclic group is a heteroarylgroup. As used herein, the term “heteroaryl” is intended to mean amono-, bi-, tri- or polycyclic group having 5 to 14 ring atoms,preferably 5, 6, 9, or 10 ring atoms; having 6, 10, or 14 pi electronsshared in a cyclic array; and having, in addition to carbon atoms,between one or more heteroatoms independently selected from the groupconsisting of N, O, and S. For example, a heteroaryl group may bepyrimidinyl, pyridinyl, benzimidazolyl, thienyl, benzothiazolyl,benzofuranyl and indolinyl. Preferred heteroaryl groups include, withoutlimitation, thienyl, benzothienyl, furyl, benzofuryl, dibenzofuryl,pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl,indolyl, quinolyl, isoquinolyl, quinoxalinyl, tetrazolyl, oxazolyl,thiazolyl, and isoxazolyl. The term “heteroaryl” is also intended toencompass the N-oxide derivative (or N-oxide derivatives, if theheteroaryl group contains more than one nitrogen such that more than oneN-oxide derivative may be formed) of a nitrogen-containing heteroarylgroup. Illustrative examples of N-oxide derivatives of heteroaryl groupsinclude, but are not limited to, pyridyl N-oxide, pyrazinyl N-opxide,pyrimidinyl N-oxide, pyridazinyl N-oxide, triazinyl N-oxide, isoquinolylN-oxide and quinolyl N-oxide.

The terms “arylene,” “heteroarylene,” or “heterocyclylene” are intendedto mean an aryl, heteroaryl, or heterocyclyl group, respectively, asdefined hereinabove, that is positioned between and serves to connecttwo other chemical groups.

Preferred heterocyclyls and heteroaryls include, but are not limited to,acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl,benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl,carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl,cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furyl, furazanyl,imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl,indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl,isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl,isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl,naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl,oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl,phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl,pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl,pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole,pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl,pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl,tetrahydroquinolinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, thiadiazolyl(e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl,1,3,4-thiadiazolyl), thianthrenyl, thiazolyl, thienyl, thienothiazolyl,thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, triazolyl(e.g., 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,1,3,4-triazolyl), and xanthenyl.

Aromatic polycycles include, but are not limited to, bicyclic andtricyclic fused ring systems, including for example naphthyl.

Non-aromatic polycycles include, but are not limited to, bicyclic andtricyclic fused ring systems where each ring can be 4-9 membered andeach ring can containing zero, 1 or more double and/or triple bonds.Suitable examples of non-aromatic polycycles include, but are notlimited to, decalin, octahydroindene, perhydrobenzocycloheptene andperhydrobenzo-[f]-azulene.

Polyheteroaryl groups include bicyclic and tricyclic fused rings systemswhere each ring can independently be 5 or 6 membered and contain one ormore heteroatom, for example, 1, 2, 3 or 4 heteroatoms, independentlychosen from O, N and S such that the fused ring system is aromatic.Suitable examples of polyheteroaryl ring systems include quinoline,isoquinoline, pyridopyrazine, pyrrolopyridine, furopyridine, indole,benzofuran, benzothiofuran, benzindole, benzoxazole, pyrroloquinoline,and the like.

Non-aromatic polyheterocyclic groups include but are not limited tobicyclic and tricyclic ring systems where each ring can be 4-9 membered,contain one or more heteratom, for example 1, 2, 3 or 4 heteratoms,independently chosen from O, N and S, and contain zero, or one or moreC—C double or triple bonds. Suitable examples of non-aromaticpolyheterocycles include but are not limited to, hexitol,cis-perhydro-cyclohepta[b]pyridinyl, decahydro-benzo[f][1,4]oxazepinyl,2,8-dioxabicyclo[3.3.0]octane, hexahydro-thieno[3,2-b]thiophene,perhydropyrrolo[3,2-b]pyrrole, perhydronaphthyridine,perhydrop-1H-dicyclopenta[b,e]pyran.

Mixed aryl and non-aryl polyheterocycle groups include but are notlimited to bicyclic and tricyclic fused ring systems where each ring canbe 4-9 membered, contain one or more heteroatom independently chosenfrom O, N and S and at least one of the rings must be aromatic. Suitableexamples of mixed aryl and non-aryl polyheteorcycles include2,3-dihydroindole, 1,2,3,4-tetrahydroquinoline,5,11-dihydro-10H-dibenz[b,e][1,4]diazepine,5H-dibenzo[b,e][1,4]diazepine,1,2-dihydropyrrolo[3,4-b][1,5]benzodiazepine,1,5-dihydropyrido[2,3-b][1,4]diazepin-4-one,1,2,3,4,6,11-hexhydro-benzo[b]pyrido[2,3-e][1,4]diazepine-5-one,methylenedioxyphenyl, bis-methylenedioxyphenyl,1,2,3,4-tetrahydronaphthalene, dibenzosuberane dihydroanthracene and9H-fluorene.

As employed herein, and unless stated otherwise, when a moiety (e.g.,alkyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, etc.) isdescribed as “optionally substituted” it is meant that the groupoptionally has from one to four, preferably from one to three, morepreferably one or two, non-hydrogen substituents. Suitable substituentsinclude, without limitation, halo, hydroxy, oxo (e.g., an annular —CH—substituted with oxo is —C(O)—) nitro, halohydrocarbyl, hydrocarbyl,alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, alkoxy,aryloxy, amino, acylamino, alkylcarbamoyl, arylcarbamoyl, aminoalkyl,acyl, carboxy, hydroxyalkyl, alkanesulfonyl, arenesulfonyl,alkanesulfonamido, arenesulfonamido, aralkylsulfonamido, alkylcarbonyl,acyloxy, cyano, and ureido groups. Preferred substituents, which arethemselves not further substituted (unless expressly stated otherwise)are:

-   -   (a) halo, cyano, oxo, carboxy, formyl, nitro, amino, amidino,        guanidino,    -   (b) C₁-C₅ alkyl or alkenyl or arylalkyl imino, carbamoyl, azido,        carboxamido, mercapto, hydroxy, hydroxyalkyl, alkylaryl,        arylalkyl, C₁-C₈ alkyl, C₁-C₈ alkenyl, C₁-C₈ alkoxy, C₁-C₈        alkoxycarbonyl, aryloxycarbonyl, C₂-C₈ acyl, C₂-C₈ acylamino,        C₁-C₈ alkylthio, arylalkylthio, arylthio, C₁-C₈ alkylsulfinyl,        arylalkylsulfinyl, arylsulfinyl, C₁-C₈ alkylsulfonyl,        arylalkylsulfonyl, arylsulfonyl, C₀-C₆ N-alkyl carbamoyl, C₂-C₁₅        N,N-dialkylcarbamoyl, C₃-C₇ cycloalkyl, aroyl, aryloxy,        arylalkyl ether, aryl, aryl fused to a cycloalkyl or heterocycle        or another aryl ring, C₃-C₇ heterocycle, C₅-C₁₅ heteroaryl or        any of these rings fused or spiro-fused to a cycloalkyl,        heterocyclyl, or aryl, wherein each of the foregoing is further        optionally substituted with one more moieties listed in (a),        above; and    -   (c) —(CR³²R³³)_(s)—NR³⁰R³¹, wherein        -   s is from 0 (in which case the nitrogen is directly bonded            to the moiety that is substituted) to 6,        -   R³² and R³³ are each independently hydrogen, halo, hydroxyl            or C₁-C₄alkyl, and        -   R³⁰ and R³¹ are each independently hydrogen, cyano, oxo,            hydroxyl, C₁-C₈ alkyl, C₁-C₈heteroalkyl, C₁-C₈alkenyl,            carboxamido-, C₁-C₃alkyl-carboxamido-,            carboxamido-C₁-C₃alkyl-, amidino-, C₂-C₈hydroxyalkyl-,            C₁-C₃alkyl-aryl-, aryl-C₁-C₃ alkyl-, C₁-C₃alkyl-heteroaryl-,            heteroaryl-C₁-C₃alkyl-, C₁-C₃alkyl-heterocyclyl-,            heterocyclyl-C₁-C₃alkyl-, C₁-C₃alkyl-cycloalkyl-,            cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,            C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-,            aryloxy-carbonyl-, aryl-C₁-C₃alkoxy-carbonyl-,            heteroaryloxy-carbonyl-, heteroaryl-C₁-C₃alkoxy-carbonyl-,            C₁-C₈acyl, C₀-C₈alkyl-carbonyl-, aryl-C₀-C₈alkyl-carbonyl-,            heteroaryl-C₀-C₈alkyl-carbonyl-,            cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,            aryl-C₀-C₈alkyl-NH-carbonyl-,            heteroaryl-C₀-C₈alkyl-NH-carbonyl-,            cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,            aryl-C₀-C₈alkyl-O-carbonyl-,            heteroaryl-C₀-C₈alkyl-O-carbonyl-,            cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,            aryl-alkyl-sulfonyl-, aryl-sulfonyl-,            heteroaryl-alkyl-sulfonyl-, heteroaryl-sulfonyl-,            C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,            aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,            heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-,            heterocyclyl-, heteroaryl-, aryl-C₁-C₃alkyl-,            cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,            heteroaryl-C₁-C₃alkyl-, or protecting group, wherein each of            the foregoing is further optionally substituted with one            more moieties listed in (a), above; or        -   R³⁰ and R³¹ taken together with the N to which they are            attached form a heterocyclyl or heteroaryl, each of which is            optionally substituted with from 1 to 3 substituents            selected from the group consisting of (a) above, a            protecting group, and (X³⁰—Y³¹—), wherein said heterocyclyl            may also be bridged (forming a bicyclic moiety with a            methylene, ethylene or propylene bridge); wherein        -   X³⁰ is selected from the group consisting of C₁-C₈alkyl,            C₂-C₈alkenyl-, C₂-C₈alkynyl-,            —C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl,            C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl,            C₀-C₃alkyl-O—C₀-C₃alkyl-, HO—C₀-C₃alkyl-,            CO—C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,            N(R³⁰)(R³¹)—C₀-C₃alkenyl-, N(R³⁰)(R³¹)—C₀-C₃alkynyl-,            (N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-,            CF₃—C₀-C₃alkyl-, C₁-C₈heteroalkyl, aryl, cycloalkyl,            heterocyclyl, heteroaryl, aryl-C₁-C₃alkyl-,            cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,            heteroaryl-C₁-C₃alkyl-,            N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, wherein the aryl,            cycloalkyl, heteroaryl and heterocycyl are optionally            substituted with from 1 to 3 substituents from (a); and    -   Y³¹ is selected from the group consisting of a direct bond, —O—,        —N(R³⁰)—, —C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—,        —C(O)—N(R³⁰)—, —N(R³⁰)—C(S)—, —C(S)—N(R³⁰)—,        —N(R³⁰)—C(O)—N(R³¹)—, —N(R³⁰)—C(NR³⁰)—N(R³¹)—, —N(R³⁰)—C(NR³¹)—,        —C(NR³¹)—N(R³⁰), —N(R³⁰)—C(S)—N(R³¹)—, —N(R³⁰)—C(O)—O—,        —O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—, —O—C(S)—N(R³¹)—, —S(O)₀₋₂—,        —SO₂N(R³¹)—, —N(R³¹)—SO₂— and —N(R³⁰)—SO₂N(R³¹)—.

As a non-limiting example, substituted phenyls include 2-fluorophenyl,3,4-dichlorophenyl, 3-chloro-4-fluoro-phenyl, 2-fluoro-3-propylphenyl.As another non-limiting example, substituted n-octyls include2,4-dimethyl-5-ethyl-octyl and 3-cyclopentyl-octyl. Included within thisdefinition are methylenes (—CH₂—) substituted with oxygen to formcarbonyl —CO—.

When there are two optional substituents bonded to adjacent atoms of aring structure, such as for example phenyl, thiophenyl, or pyridinyl,the substituents, together with the atoms to which they are bonded,optionally form a 5- or 6-membered cycloalkyl or heterocycle having 1,2, or 3 annular heteroatoms.

In a preferred embodiment, hydrocarbyl, alkyl, alkenyl, alkynyl,heteroalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic and mixed aryl and non-aryl polyheterocycle groups areunsubstituted.

In other preferred embodiments, hydrocarbyl, alkyl, alkenyl, alkynyl,heteroalkyl, cycloalkyl, heterocyclic, aryl, heteroaryl, aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic and mixed aryl and non-aryl polyheterocycle groups aresubstituted with from 1 to 3 independently selected substituents morepreferably one or two independently selected substituents.

Preferred substituents on alkyl groups include, but are not limited to,hydroxyl, halogen (e.g., a single halogen substituent or multiple halosubstituents; in the latter case, groups such as CF₃ or an alkyl groupbearing Cl₃), cyano, nitro, alkyl, cycloalkyl, alkenyl, cycloalkenyl,alkynyl, heterocycle, aryl, —OR^(u), —SR^(u), —S(═O)R^(y), —S(═O)₂R^(y),—P(═O)₂R^(y), —S(═O)₂OR^(y), —P(═O)₂OR^(y), —NR^(v)R^(w),—NR^(v)S(═O)₂R^(y), —NR^(v)P(═O)₂R^(y), —S(═O)₂NR^(v)R^(w),—P(═O)₂NR^(v)R^(w), —C(═O)OR^(y), —C(═O)R^(k), —C(═O)NR^(v)R^(w),—OC(═O)R^(u), —OC(═O)NR^(v)R^(w), —NR^(v)C(═O)OR^(y),—NR^(x)C(═O)NR^(v)R^(w), —NR^(x)S(═O)₂NR^(v)R^(w),—NR^(x)P(═O)₂NR^(v)R^(w), —NR^(v)C(═O)R^(u) or —NR^(v)P(═O)₂R^(y),wherein R^(u) is hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl,alkynyl, heterocycle or aryl; R^(v), R^(w) and R^(x) are independentlyhydrogen, alkyl, cycloalkyl, heterocycle or aryl, or said R^(v) andR^(w) together with the N to which they are bonded optionally form aheterocycle; and R^(y) is alkyl, cycloalkyl, alkenyl, cycloalkenyl,alkynyl, heterocycle or aryl. In the aforementioned exemplarysubstituents, groups such as alkyl, cycloalkyl, alkenyl, alkynyl,cycloalkenyl, heterocycle and aryl can themselves be optionallysubstituted.

Preferred substituents on alkenyl and alkynyl groups include, but arenot limited to, alkyl or substituted alkyl, as well as those groupsrecited as preferred alkyl substituents.

Preferred substituents on cycloalkyl groups include, but are not limitedto, nitro, cyano, alkyl or substituted alkyl, as well as those groupsrecited about as preferred alkyl substituents. Other preferredsubstituents include, but are not limited to, spiro-attached or fusedcyclic substituents, preferably spiro-attached cycloalkyl,spiro-attached cycloalkenyl, spiro-attached heterocycle (excludingheteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, orfused aryl, where the aforementioned cycloalkyl, cycloalkenyl,heterocycle and aryl substituents can themselves be optionallysubstituted.

In a preferred embodiment, when a cycloalkyl is substituted by two C₁₋₆alkyl groups, the two alkyl groups may combine together to form analkylene chain, preferably a C₁₋₃ alkylene chain. Cycloalkyl groupshaving this crosslinked structure include bicyclo[2.2.2]octanyl andnorbornanyl.

Preferred substituents on cycloalkenyl groups include, but are notlimited to, nitro, cyano, alkyl or substituted alkyl, as well as thosegroups recited as preferred alkyl substituents. Other preferredsubstituents include, but are not limited to, spiro-attached or fusedcyclic substituents, especially spiro-attached cycloalkyl,spiro-attached cycloalkenyl, spiro-attached heterocycle (excludingheteroaryl), fused cycloalkyl, fused cycloalkenyl, fused heterocycle, orfused aryl, where the aforementioned cycloalkyl, cycloalkenyl,heterocycle and aryl substituents can themselves be optionallysubstituted.

Preferred substituents on aryl groups include, but are not limited to,nitro, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substitutedcycloalkenyl, cyano, alkyl or substituted alkyl, as well as those groupsrecited above as preferred alkyl substituents. Other preferredsubstituents include, but are not limited to, fused cyclic groups,especially fused cycloalkyl, fused cycloalkenyl, fused heterocycle, orfused aryl, where the aforementioned cycloalkyl, cylcoalkenyl,heterocycle and aryl substituents can themselves be optionallysubstituted. Still other preferred substituents on aryl groups (phenyl,as a non-limiting example) include, but are not limited to, haloalkyland those groups recited as preferred alkyl substituents.

Preferred substituents on heterocylic groups include, but are notlimited to, cycloalkyl, substituted cycloalkyl, cycloalkenyl,substituted cycloalkenyl, nitro, oxo (i.e., ═O), cyano, alkyl,substituted alkyl, as well as those groups recited as preferred alkylsubstituents. Other preferred substituents on heterocyclic groupsinclude, but are not limited to, spiro-attached or fused cylicsubstituents at any available point or points of attachment, morepreferably spiro-attached cycloalkyl, spiro-attached cycloalkenyl,spiro-attached heterocycle (excluding heteroaryl), fused cycloalkyl,fused cycloakenyl, fused heterocycle and fused aryl, where theaforementioned cycloalkyl, cycloalkenyl, heterocycle and arylsubstituents can themselves be optionally substituted. In a preferredembodiment, when a heterocyclic is substituted by two C₁₋₆ alkyl groups,the two alkyl groups may combine together to form an alkylene chain,preferably a C₁₋₃ alkylene chain.

In a preferred embodiment, a heterocyclic group is substituted oncarbon, nitrogen and/or sulfur at one or more positions. Preferredsubstituents on nitrogen include, but are not limited to alkyl, aryl,aralkyl, alkylcarbonyl, alkylsulfonyl, arylcarbonyl, arylsulfonyl,alkoxycarbonyl, or aralkoxycarbonyl. Preferred substituents on sulfurinclude, but are not limited to, oxo and C₁₋₆alkyl. In certain preferredembodiments, nitrogen and sulfur heteroatoms may independently beoptionally oxidized and nitrogen heteroatoms may independently beoptionally quaternized.

Especially preferred substituents on alkyl groups include halogen andhydroxy.

Especially preferred substituents on ring groups, such as aryl,heteroaryl, cycloalkyl and heterocyclyl, include halogen, alkoxy andalkyl.

Preferred substituents on aromatic polycycles include, but are notlimited to, oxo, C₁-C₆alkyl, cycloalkylalkyl (e.g., cyclopropylmethyl),oxyalkyl, halo, nitro, amino, alkylamino, aminoalkyl, alkyl ketones,nitrile, carboxyalkyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl andOR^(aa), such as alkoxy, wherein R^(aa) is selected from the groupconsisting of H, C₁-C₆alkyl, C₄-C₉cycloalkyl, C₄-C₉heterocycloalkyl,aryl, heteroaryl, arylalkyl, heteroarylalkyl and (CH₂)₀₋₆Z^(a)R^(bb),wherein Z^(a) is selected from the group consisting of O, NR^(cc), S andS(O), and R^(bb) is selected from the group consisting of H, C₁-C₆alkyl,C₄-C₉cycloalkyl, C₄-C₉heterocycloalkyl, C₄-C₉heterocycloalkylalkyl,aryl, mixed aryl and non-aryl polycycle, heteroaryl, arylalkyl, (e.g.benzyl), and heteroarylalkyl (e.g. pyridylmethyl); and R^(cc) isselected from the group consisting of H, C₁-C₆alkyl, C₄-C₉cycloalkyl,C₄-C₉heterocycloalkyl, aryl, heteroaryl, arylalkyl (e.g. benzyl),heteroarylalkyl (e.g. pyridylmethyl) and amino acyl.

Preferred substituents on non-aromatic polycycles include, but are notlimited to, oxo, C₃-C₉cycloalkyl, such as cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl and the like. Unless otherwise noted,non-aromatic polycycle substituents include both unsubstitutedcycloalkyl groups and cycloalkyl groups that are substituted by one ormore suitable substituents, including but not limited to, C₁-C₆alkyl,oxo, halo, hydroxy, aminoalkyl, oxyalkyl, alkylamino and OR^(aa), suchas alkoxy. Preferred substituents for such cycloalkyl groups includehalo, hydroxy, alkoxy, oxyalkyl, alkylamino and aminoalkyl.

Preferred substituents on carbon atoms of polyheteroaryl groups includebut are not limited to, straight and branched optionally substitutedC₁-C₆alkyl, unsaturation (i.e., there are one or more double or tripleC—C bonds), acyl, oxo, cycloalkyl, halo, oxyalkyl, alkylamino,aminoalkyl, acylamino, OR¹ (for example alkoxy), and a substituent ofthe formula —O—(CH₂CH═CH(CH₃)(CH₂))₁₋₃H. Examples of suitable straightand branched C₁-C₆alkyl substituents include but are not limited tomethyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl and thelike. Preferred substituents include halo, hydroxy, alkoxy, oxyalkyl,alkylamino and aminoalkyl. Preferably substitutions on nitrogen atomsinclude, for example by N-oxide or R^(cc). Preferred substituents onnitrogen atoms include H, C₁-C₄alkyl, acyl, aminoacyl and sulfonyl.Preferably sulfur atoms are unsubstituted. Preferred substituents onsulfur atoms include but are not limited to oxo and lower alkyl.

Preferred substituents on carbon atoms of non-aromatic polyheterocyclicgroups include but are not limited to straight and branched optionallysubstituted C₁-C₆alkyl, unsaturation (i.e., there are one or more doubleor triple C—C bonds), acyl, oxo, cycloalkyl, halo, oxyalkyl, alkylamino,aminoalkyl, acylamino and OR^(aa), for example alkoxy. Examples ofsuitable straight and branched C₁-C₆alkyl substituents include but arenot limited to methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl,t-butyl and the like. Preferred substituents include halo, hydroxy,alkoxy, oxyalkyl, alkylamino and aminoalkyl. Preferably substitutions onnitrogen atoms include, for example, N-oxide or R^(cc). Preferred Nsubstituents include H, C₁-C₄ alkyl, acyl, aminoacyl and sulfonyl.Preferably, sulfur atoms are unsubstituted. Preferred S substituentsinclude oxo and lower alkyl.

Preferred substituents on mixed aryl and non-aryl polyheterocycle groupsinclude, but are not limited to, nitro or as described above fornon-aromatic polycycle groups. Preferred substituents on carbon atomsinclude, but are not limited to, —N—OH, ═N—OH, optionally substitutedalkyl, unsaturation (i.e., there are one or more double or triple C—Cbonds), oxo, acyl, cycloalkyl, halo, oxyalkyl, alkylamino, aminoalkyl,acylamino and OR^(aa), for example alkoxy. Preferably substitutions onnitrogen atoms include, for example, N-oxide or R^(cc). Preferred Nsubstituents include H, C₁₋₄alkyl, acyl aminoacyl and sulfonyl.Preferably sulfur atoms are unsubstituted. Preferred S substituentsinclude oxo and lower alkyl.

A “halohydrocarbyl” is a hydrocarbyl moiety in which from one to allhydrogens have been replaced with one or more halo.

The term “halogen” or “halo” is intended to mean chlorine, bromine,fluorine, or iodine. As herein employed, the term “acyl” refers to analkylcarbonyl or arylcarbonyl substituent. The term “acylamino” refersto an amide group attached at the nitrogen atom (i.e., R—CO—NH—). Theterm “carbamoyl” refers to an amide group attached at the carbonylcarbon atom (i.e., NH₂—CO—). The nitrogen atom of an acylamino orcarbamoyl substituent is additionally optionally substituted. The term“sulfonamido” refers to a sulfonamide substituent attached by either thesulfur or the nitrogen atom. The term “amino” is meant to include NH₂,alkylamino, di-alkylamino, arylamino, and cyclic amino groups. The term“ureido” as employed herein refers to a substituted or unsubstitutedurea moiety.

The term “radical” is intended to mean a chemical moiety comprising oneor more unpaired electrons.

Where optional substituents are chosen from “one or more” groups it isto be understood that this definition includes all substituents beingchosen from one of the specified groups or the substituents being chosenfrom two or more of the specified groups.

In addition, substituents on cyclic moieties (i.e., cycloalkyl,heterocyclyl, aryl, heteroaryl) include 5-6 membered mono- and 9-14membered bi-cyclic moieties fused to the parent cyclic moiety to form abi- or tri-cyclic fused ring system. Substituents on cyclic moietiesalso include 5-6 membered mono- and 9-14 membered bi-cyclic moietiesattached to the parent cyclic moiety by a covalent bond to form a bi- ortri-cyclic bi-ring system. For example, an optionally substituted phenylincludes, but is not limited to, the following:

An “unsubstituted” moiety as defined above (e.g., unsubstitutedcycloalkyl, unsubstituted heteroaryl, etc.) means that moiety as definedabove that does not have any of the optional substituents for which thedefinition of the moiety (above) otherwise provides. Thus, for example,while a “substituted aryl” includes phenyl substituted with a halo,“unsubstituted aryl” does not include phenyl substituted with a halo.

The terms “inhibition effective amount” or “histone deacetylaseinhibiting amount” are meant to denote a dosage or amount sufficient tocause inhibition of histone deacetylase activity in vitro or in vivo.The histone deacetylase may be in a cell, which cell can be in amulticellular organism. The multicellular organism can be a plant orfungus, or an animal, preferably a mammal, more preferably a human. Thefungus may be infecting a plant or a mammal, preferably a human, andcould therefore be located in and/or on the plant or mammal. If thehistone deacetylase is in a multicellular organism, the method accordingto this aspect of the invention comprises administering to the organisma compound or composition according to the present invention.Administration may be by any route, including, without limitation,parenteral, oral, sublingual, transdermal, topical, intranasal,intratracheal, or intrarectal. In certain particularly preferredembodiments, compounds of the invention are administered intravenouslyin a hospital setting. In certain other preferred embodiments,administration may preferably be by the oral route.

The term “therapeutically effective amount” as employed herein is anamount of a compound of the invention, that when administered to apatient, elicits the desired therapeutic effect. The desired therapeuticeffect is dependent upon the disease being treated and the resultsdesired. As such, the therapeutic effect can be treatment of adisease-state. Further, the therapeutic effect can be inhibition of HDACactivity. The amount of a compound of the invention which constitutes a“therapeutically effective amount” will vary depending on the compound,the disease, the disease state and its severity, the age, sex, health,size of the patient to be treated, the results desired, and the like.The therapeutically effective amount can be determined routinely by oneof ordinary skill in the art. Optimal amounts can be determined based onmonitoring of the patient's response to treatment.

The term “patient” as employed herein for the purposes of the presentinvention includes humans and other animals, particularly mammals, andother organisms. Thus the compounds, compositions and methods of thepresent invention are applicable to both human therapy and veterinaryapplications. In a preferred embodiment the patient is a mammal, and ina most preferred embodiment the patient is human.

The terms “treating”, “treatment”, or the like, as used herein coversthe treatment of a disease-state in an animal and includes at least oneof: (i) preventing the disease-state from occurring, in particular, whensuch animal is predisposed to the disease-state but has not yet beendiagnosed as having it; (ii) inhibiting the disease-state, i.e.,partially or completely arresting its development; (iii) relieving thedisease-state, i.e., causing regression of symptoms of thedisease-state, or ameliorating a symptom of the disease; and (iv)reversal or regression of the disease-state, preferably eliminating orcuring of the disease. In a preferred embodiment the terms “treating”,treatment”, or the like, covers the treatment of a disease-state in ananimal and includes at least one of (ii), (iii) and (iv) above. In apreferred embodiment of the present invention the animal is a mammal,preferably a primate, more preferably a human. As is known in the art,adjustments for systemic versus localized delivery, age, body weight,general health, sex, diet, time of administration, drug interaction andthe severity of the condition may be necessary, and will beascertainable with routine experimentation by one of ordinary skill inthe art.

As used herein, the terms “histone deacetylase” and “HDAC” are intendedto refer to any one of a family of enzymes that remove acetyl groupsfrom the ε-amino groups of lysine residues at the N-terminus of aprotein (for example, a histone, or tubulin). Unless otherwise indicatedby context, the term “histone” is meant to refer to any histone protein,including H1, H2A, H2B, H3, H4, and H5, from any species. Preferredhistone deacetylases include class II enzymes. Preferably the histonedeacetylase is a human HDAC, including, but not limited to, HDAC-4,HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-1. In someother preferred embodiments, the histone deacetylase is derived from aprotozoal or fungal source.

The terms “histone deacetylase inhibitor” and “inhibitor of histonedeacetylase” are intended to mean a compound having a structure asdefined herein, which is capable of interacting with a histonedeacetylase and inhibiting its enzymatic activity.

The term “inhibiting histone deacetylase enzymatic activity” is intendedto mean reducing the ability of a histone deacetylase to remove anacetyl group from a protein, such as but not limited to a histone ortubulin. The concentration of inhibitor which reduces the activity of ahistone deacetylase to 50% of that of the uninhibited enzyme isdetermined as the IC₅₀ value. In some preferred embodiments, suchreduction of histone deacetylase activity is at least 50%, morepreferably at least about 75%, and still more preferably at least about90%. In other preferred embodiments, histone deacetylase activity isreduced by at least 95% and more preferably by at least 99%.

Preferably, such inhibition is specific, i.e., the histone deacetylaseinhibitor reduces the ability of a histone deacetylase to remove anacetyl group from a protein at a concentration that is lower than theconcentration of the inhibitor that is required to produce another,unrelated biological effect. Preferably, the concentration of theinhibitor required for histone deacetylase inhibitory activity is atleast 2-fold lower, more preferably at least 5-fold lower, even morepreferably at least 10-fold lower, and most preferably at least 20-foldlower than the concentration required to produce an unrelated biologicaleffect.

The compounds of the present invention form salts which are also withinthe scope of this invention. Reference to a compound of the inventionherein is understood to include reference to salts thereof, unlessotherwise indicated.

The term “salt(s)”, as employed herein, denotes acidic and/or basicsalts formed with inorganic and/or organic acids and bases. In addition,when a compound of the invention contains both a basic moiety, such asbut not limited to a pyridine or imidazole, and an acidic moiety such asbut not limited to a carboxylic acid, zwitterions (“inner salts”) may beformed and are included within the term “salt(s)” as used herein.Pharmaceutically acceptable (i.e., non-toxic (exhibiting minimal or noundesired toxicological effects), physiologically acceptable) salts arepreferred, although other salts are also useful, e.g., in isolation orpurification steps which may be employed during preparation. Salts ofthe compounds of the invention may be formed, for example, by reacting acompound of the present invention with an amount of acid or base, suchas an equivalent amount, in a medium such as one in which the saltsprecipitates or in an aqueous medium followed by lyophilization.

The compounds of the present invention which contain a basic moiety,such as but not limited to an amine or a pyridine or imidazole ring, mayform salts with a variety of organic and inorganic acids. Exemplary acidaddition salts include acetates (such as those formed with acetic acidor trihaloacetic acid, for example, trifluoroacetic acid), adipates,alginates, ascorbates, aspartates, benzoates, benzenesulfonates,bisulfates, borates, butyrates, citrates, camphorates,camphorsulfonates, cyclopentanepropionates, digluconates,dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates,glycerophosphates, hemisulfates, heptanoates, hexanoates,hydrochlorides, hydrobromides, hydroiodides, hydroxyethanesulfanotes(e.g., 2-hydroxyethanesulfonates), lactates, maleates,methanesulfonates, naphthalenesulfonates (e.g.,2-naphthalenesulfonates), nicotinates, nitrates, oxalates, pectinates,persulfates, phenylpropionates (e.g., 3-phenylpropionates), phosphates,picrates, pivalates, propionates, salicylates, succinates, sulfates(such as those formed with sulfuric acid), sulfonates, tartrates,thiocyanates, toluenesulfonates such as tosylates, undecanoates, and thelike.

The compounds of the present invention which contain an acidic moiety,such as but not limited to a carboxylic acid, may form salts with avariety of organic and inorganic bases. Exemplary basic salts includeammonium salts, alkali metal salts such as sodium, lithium and potassiumsalts, alkaline earth metal salts such as calcium and magnesium salts,salts with organic bases (for example, organic amines) such asbenzathines, dicyclohexylamines, hydrabamines (formed withN,N-bis(dehydroabietyl)ethylenediamine), N-methyl-D-glucamines,N-methyl-D-glycamides, t-butyl amines, and salts with amino acids suchas arginine, lysine and the like. Basic nitrogen-containing groups maybe quaternized with agents such as lower alkyl halides (e.g. methyl,ethyl, propyl and butyl chlorides, bromides and iodides), dialkylsulfates (e.g. dimethyl, diethyl, dibutyl and diamyl sulfates), longchain halides (e.g. decyl, lauryl, myristyl and stearyl chlorides,bromides and iodides), aralkyl halides (e.g. benzyl and phenethylbromides), and others.

As used herein, the term “pharmaceutically acceptable salts” is intendedto mean salts that retain the desired biological activity of theabove-identified compounds and exhibit minimal or no undesiredtoxicological effects.

The present invention also includes prodrugs of compounds of theinvention. The term “prodrug” is intended to mean a derivative of acompound of the present invention that requires a transformation, forexample, within the body, to release the active compound. Prodrugs arefrequently, although not necessarily, pharmacologically inactive untilconverted to the parent compound. A hydroxyl containing compound may beconverted to, for example, a sulfonate, ester or carbonate prodrug,which may be hydrolyzed in vivo to provide the hydroxyl compound. Anamino containing compound may be converted, for example, to a carbamate,amide, enamine, imine, N-phosphonyl, N-phosphoryl or N-sulfenyl prodrug,which may be hydrolyzed in vivo to provide the amino compound. Acarboxylic acid compound may be converted to an ester (including silylesters and thioesters), amide or hydrazide prodrug, which be hydrolyzedin vivo to provide the carboxylic acid compound. Prodrugs for drugswhich have functional groups different than those listed above are wellknown to the skilled artisan. Additionally, prodrugs can be converted tothe compounds of the present invention by chemical or biochemicalmethods in an ex vivo environment. For example, prodrugs can be slowlyconverted to the compounds of the present invention when placed in atransdermal patch reservoir with a suitable enzyme or chemical reagent.

Typically, in a prodrug, a polar functional group (e.g., a carboxylicacid, an amino group, a hydroxyl group, etc.) is masked by a promoiety,which is labile under physiological conditions. “Promoiety” refers to aform of protecting group that when used to mask a functional groupwithin a compound molecule converts the drug into a prodrug. Typically,the promoiety will be attached to the compound via bond(s) that arecleaved by enzymatic or non-enzymatic means in vivo.

Prodrugs of compounds of the invention include compounds wherein ahydroxy, amino, carboxylic, or a similar group is modified. Examples ofprodrugs include, but are not limited to esters (e.g., acetate, formate,and benzoate derivatives), carbamates (e.g., N,N-dimethylaminocarbonyl)of hydroxy or amino functional groups in compounds of Formula (I)),amides (e.g., trifluoroacetylamino, acetylamino, and the like), and thelike.

The term “protecting group” is typically intended to mean a group usedin synthesis to temporarily mask the characteristic chemistry of afunctional group because it interferes with another reaction. A goodprotecting group should be easy to put on, easy to remove and in highyielding reactions, and inert to the conditions of the reactionrequired. A protecting group or protective group is introduced into amolecule by chemical modification of a functional group in order toobtain chemoselectivity in a subsequent chemical reaction. One skilledin the art will recognize that during any of the processes forpreparation of the compounds in the present invention, it may benecessary and/or desirable to protect sensitive or reactive groups onany of the molecules concerned. This may be achieved by means ofconventional protecting groups, such as but not limited to Bn— (or—CH₂Ph), —CHPh₂, alloc (or CH₂═CH—CH₂—O—C(O)—), BOC-, -Cbz (or Z-),—F-moc, —C(O)—CF₃, N-Phthalimide, 1-Adoc-, TBDMS-, TBDPS-, TMS-, TIPS-,IPDMS-, —SiR₃, SEM-, t-Bu-, Tr-, THP- and Allyl- and those described instandard textbooks, such as Greene, T. W. et al., Protective Groups inOrganic Synthesis, Wiley, N.Y. (1999). These protecting groups may beremoved at a convenient stage using methods known from the art.

When a functional group is termed “protected”, this means that the groupis in modified form to mitigate, especially preclude, undesired sidereactions at the protected site.

The compounds of the invention may be administered as is or as aprodrug, for example in the form of an in vivo hydrolyzable ester or invivo hydrolyzable amide. An in vivo hydrolyzable ester of a compound ofthe invention containing carboxy or hydroxy group is, for example, apharmaceutically acceptable ester which is hydrolyzed in the human oranimal body to produce the parent acid or alcohol. Suitablepharmaceutically acceptable esters for carboxy include C₁₋₆-alkoxymethylesters (e.g., methoxymethyl), C₁₋₆-alkanoyloxymethyl esters (e.g., forexample pivaloyloxymethyl), phthalidyl esters,C₃₋₈-cycloalkoxycarbonyloxyC₁₋₆-alkyl esters (e.g.,1-cyclohexylcarbonyloxyethyl); 1,3-dioxolen-2-onylmethyl esters (e.g.,5-methyl-1,3-dioxolen-2-onylmethyl; and C₁₋₆-alkoxycarbonyloxyethylesters (e.g., 1-methoxycarbonyloxyethyl) and may be formed at anyappropriate carboxy group in the compounds of this invention.

An in vivo hydrolyzable ester of a compound of the invention containinga hydroxy group includes inorganic esters such as phosphate esters andα-acyloxyalkyl ethers and related compounds which as a result of the invivo hydrolysis of the ester breakdown to give the parent hydroxy group.Examples of α-acyloxyalkyl ethers include acetoxymethoxy and2,2-dimethylpropionyloxy-methoxy. A selection of in vivo hydrolyzableester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyland substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkylcarbonate esters), dialkylcarbamoyl andN—(N,N-dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates),N,N-dialkylaminoacetyl and carboxyacetyl. Examples of substituents onbenzoyl include morpholino and piperazino linked from a ring nitrogenatom via a methylene group to the 3- or 4-position of the benzoyl ring.A suitable value for an in vivo hydrolyzable amide of a compound of theinvention containing a carboxy group is, for example, a N—C₁₋₆-alkyl orN,N-di-C₁₋₆-alkyl amide such as N-methyl, N-ethyl, N-propyl,N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.

Upon administration to a subject, the prodrug undergoes chemicalconversion by metabolic or chemical processes to yield a compound of thepresent invention, or a salt and/or solvate thereof. Solvates of thecompounds of the present invention include, for example, hydrates.

Some compounds of the invention may have chiral centers and/or geometricisomeric centers (E- and Z-isomers), and it is to be understood that theinvention encompasses all such optical, enantiomeric, diastereoisomericand geometric isomers. The invention also comprises all tautomeric formsof the compounds disclosed herein. Where compounds of the inventioninclude chiral centers, the invention encompasses the enantiomericallyand/or diasteromerically pure isomers of such compounds, theenantiomerically and/or diastereomerically enriched mixtures of suchcompounds, and the racemic and scalemic mixtures of such compounds. Forexample, a composition may include a mixture of enantiomers ordiastereomers of a compound of the invention in at least about 30%diastereomeric or enantiomeric excess. In certain embodiments of theinvention, the compound is present in at least about 50% enantiomeric ordiastereomeric excess, in at least about 80% enantiomeric ordiastereomeric excess, or even in at least about 90% enantiomeric ordiastereomeric excess. In certain more preferred embodiments of theinvention, the compound is present in at least about 95%, even morepreferably in at least about 98% enantiomeric or diastereomeric excess,and most preferably in at least about 99% enantiomeric or diastereomericexcess.

The chiral centers of the present invention may have the S or Rconfiguration. The racemic forms can be resolved by physical methods,such as, for example, fractional crystallization, separation orcrystallization of diastereomeric derivates or separation by chiralcolumn chromatography. The individual optical isomers can be obtainedeither starting from chiral precursors/intermediates or from theracemates by any suitable method, including without limitation,conventional methods, such as, for example, salt formation with anoptically active acid followed by crystallization.

Another aspect of the invention provides compositions including acompound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt,complex or prodrug of a compound according to the present invention asdescribed herein, or a racemic or scalemic mixture, diastereomer,enantiomer or tautomer thereof. For example, in one embodiment of theinvention, a composition comprises a compound, N-oxide, hydrate,solvate, pharmaceutically acceptable salt, complex or prodrug of acompound according to the present invention as described herein presentin at least about 30% enantiomeric or diastereomeric excess. In certaindesirable embodiments of the invention, the compound, N-oxide, hydrates,solvate, pharmaceutically acceptable salt, complex or prodrug is presentin at least about 50%, at least about 80%, or even at least about 90%enantiomeric or diastereomeric excess. In certain other desirableembodiments of the invention, the compound, N-oxide, hydrate, solvate,pharmaceutically acceptable salt, complex or prodrug is present in atleast about 95%, more preferably at least about 98% and even morepreferably at least about 99% enantiomeric or diastereomeric excess. Inother embodiments of the invention, a compound, N-oxide, hydrate,solvate, pharmaceutically acceptable salt, complex or prodrug is presentas a substantially racemic mixture.

Throughout the specification, preferred embodiments of one or morechemical substituents are identified. Also preferred are combinations ofpreferred embodiments. For example, the invention describes preferredembodiments of L in the compounds and describes preferred embodiments ofgroup X. Thus, as an example, also contemplated as within the scope ofthe invention are compounds in which preferred examples of L are asdescribed and in which preferred examples of group X are as described.

The foregoing merely summarizes some aspects and preferred embodimentsthereof and is not intended to be limiting in nature. These aspects andpreferred embodiments thereof are described more fully below.

Compounds

In a first aspect, the invention provides novel inhibitors of histonedeacetylase. In one embodiment, the novel inhibitors of histonedeacetylase are represented by Formula (I):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic and scalemic mixtures,diastereomers and enantiomers thereof wherein

M is selected from the group consisting of alkyl, —N(R^(e))OR^(s), —CF₃,—C(O)N(R^(e))(R^(f)), -heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—S(acetyl),—CH₂—SR^(e) and -heterocycloalkyl;

X is selected from the group consisting of CH, C(OH), C(C₁-C₄alkyl),C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y;

L and Y are independently selected from the group consisting ofC₁-C₄alkyl, heteroalkyl, alkenyl, alkynyl, —NR^(a)R^(b), —NR^(c)R^(d),—OR^(e), —C₀-C₃alkyl-aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heterocyclyl, —C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl,—C₂-C₄alkenyl-heteroaryl, —C₂-C₄alkenyl-heterocyclyl,—C₂-C₄alkenyl-cycloalkyl, —C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl-cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH—C₀-C₃alkyl-aryl,—C(O)NH—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))—S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—, —N(R^(e))C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e))—, —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl,

provided that if an L or a Y is bound directly to a nitrogen of X, thenthe L or Y is not —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—S(O)₀₋₁—C₀-C₃alkyl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroaryl or—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl,

in which

each R^(a) and R^(b) together with the nitrogen to which they are boundform a 4 to 7 membered heterocyclyl having 1 or 2 annular heteroatoms,or a 5 to 8 membered bridged heterocyclyl having 1 or 2 annularheteroatoms, the heterocyclyl being optionally substituted with 1-3substituents independently selected from the group consisting of H, OH,oxo (i.e., ═O), —N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl,—C₁-C₆alkyl-aryl, —C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl,—C₂-C₃alkyl-OH, —C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,—C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀₋₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl;

each R^(c) and R^(d) is independently selected from the group consistingof H, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or

R^(c) and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms,

each R^(e) and R^(f) is independently selected from the group consistingof —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl, heteroaryl-aryl,heteroaryl-heteroaryl, C(O)-alkyl and —C(O)CF₃; and

each R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup,

wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moietyis optionally substituted, and

wherein a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl moiety inL is optionally connected to a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl in Y by a bond or by a bridging substituent,

provided that

the compound does not have the formula (A)

in which

each R¹⁰ is selected from the group consisting of H, OH, —CH₂OH, NH₂,COOH and C₁-C₄alkyl; and

each R¹¹ is selected from the group consisting of H, halo, C₁-C₆alkyl,C₁-C₄alkoxy, —OC(O)C₁-C₄alkyl, —NH₂, —NH(C₁-C₄alkyl), —N(C₁-C₄alkyl)₂,—SH, —S—C₁-C₄alkyl, —COOH and —C(O)O—C₁-C₄alkyl;

the compound does not have the formula (B)

in which

R¹² is H, alkyl, halo or alkoxy;

R¹³ is hydrogen or C₁-C₅alkyl; and

R¹⁴ is H or OH;

the compound does not have the formula (B) wherein R¹⁴ is H, R¹² is NO₂and R¹³ is H; and

the compound is not10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-hydroxamic acid.

In a preferred embodiment of the first aspect of the invention, M isNHOH.

In a preferred embodiment of the first aspect of the invention, M is

In another preferred embodiment of the first aspect of the invention, Mis —H.

In another preferred embodiment of the first aspect of the invention, Xis CH.

In another preferred embodiment of the first aspect of the invention, Xis C(OH) or C(halo).

In another preferred embodiment of the first aspect of the invention, Xis

In another preferred embodiment of the first aspect of the invention, Xis

In another preferred embodiment of the first aspect of the invention, Land Y are independently selected from aryl, heteroaryl, O-aryl,heterocyclyl, cycloalkyl, —S-aryl, —S-heteroaryl, —C(O)NH-aryl,—S-heteroaryl-aryl, -aryl-heterocyclyl, -heteroaryl-heterocyclyl,—C₁-C₃alkyl-aryl, —S(O)₂-aryl, —S(O)₂-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,heteroaryl-C₀-C₃alkyl-aryl, -aryl-aryl and -heterocyclyl-O-aryl, each ofwhich is optionally substituted.

In another preferred embodiment of the first aspect of the invention Land Y are independently selected from the group consisting of aryl,heteroaryl, alkyl, —O-aryl, —O-cycloalkyl, heterocyclyl, cycloalkyl,—S-aryl, —S-heteroaryl, —C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, —NHS(O)₂-aryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heterocyclyl-C₀-C₃alkyl-heteroaryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl, -aryl-heteroaryl, -heterocyclyl-O-aryl,-heterocyclyl-O—C₀-C₃alkyl-aryl, -heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.

In another preferred embodiment of the first aspect of the inventioneach cycloalkyl and heterocyclyl moiety is optionally gem or spirosubstituted with —OH, —CN or -alkyl.

In another preferred embodiment of the first aspect of the invention, Land Y are independently selected from the group consisting of aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic and mixed aryl and non-aryl polyheterocycle.

Another preferred embodiment of the first aspect of the inventionprovides a compound having the Formula (II):

wherein

R^(c) is as described above with respect to Formula (I);

each n is independently 0-3; and

R^(g) is selected from the group consisting of —C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl-cycloalkyl, —C₀-C₃alkyl-heterocylyl,—NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof and racemic or scalemic mixtures,diastereomers and enantiomers thereof.

As described above, a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L is optionally connected to a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl in Y by a bond or by a bridgingsubstituent. Such a bridging substituent preferably has 1-6 atoms alongthe shortest path between the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L and the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in Y. For example, another preferred embodiment of thefirst aspect of the invention provides a compound having the Formula(III):

wherein

R⁴ and R⁵ are independently selected from the group consisting of H,halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃;

A is H, phenyl or OH; and

B is a bond, —O—, —N(R⁶)—, S(O)₀₋₂, —CH(R⁴)—, —C(R⁵)(R⁴)—,—C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)—, —C(R⁴)—O—, —O—C(R⁴)—,—S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—, —CH(R⁴)—CH(R⁵)—,—C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—, —C(R⁵)(R⁴)—C(R⁵)(R⁴)—,—C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)-, or

in which R⁶ is alkyl, cycloalkyl or heterocyclyl,

and racemic or scalemic mixtures, diastereomers and enantiomers thereofand N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof.

Another preferred embodiment of the first aspect of the inventionprovides a compound having the Formula (IV):

wherein

n is 0-3;

R^(z) is selected from the group consisting of

R^(c) and L are as described above with respect to Formula (I),

wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.

Another preferred embodiment of the first aspect of the inventionprovides a compound having the Formula (V)

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic or scalemic mixtures,diastereomers and enantiomers thereof, wherein

M is H or alkyl; and

L and Y are as defined in Formula (I).

In a preferred embodiment of the first aspect of the invention Y isfurther selected from the group consisting of -Z¹-Z-Z²-D, -D,-Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D, -Z-Z³-Z²-Z-D,-Z¹-Z-Z², -Z-Z³-D and -Z²-Z¹-Z²-D,

wherein

Z¹ is selected from the group consisting of chemical bond, alkyl, aryl,heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, cycloalkyl,heteroaryl, wherein each aryl, heteroaryl, cycloalkyl and heterocyclylmoiety is optionally substituted and each of which is optionally fusedto one or more aryl or heteroaryl rings, or one or more saturated orpartially unsaturated cycloalkyl or heterocyclyl rings, each of whichring is optionally substituted;

Z is selected from the group consisting of chemical bond, —O—,—S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—, —C(O)N(R^(c))—,—N(R^(c))S(O)₂—, —N(R^(c))—, —N(R^(c))(C₂-C₄alkyl-OR^(d))—, —C(O)—,—C(NOR²¹)—, —CH[C(O)N(R²¹)(R²²)]—C(O)N(R²²)—,—CH(N(R²¹)(R²²))—C(O)N(R²²)—, —CH[C(O)N(R^(e))(R^(f))]—C(O)N(R²²)—,—S(O)₂N(R²¹)—, —N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—, —N(R²¹)C(NR²²)—,—C(NR²²)N(R²¹)—, —N(R²¹)C(O)N(R²²), —N(R²¹)C(O), —OC(O)N(R²¹)—,—N(R²¹)C(S)—, —C(S)N(R²¹)—, —N(R²¹)C(S)N(R²²)—, —N(R²¹)C(S)O—,—OC(S)N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R¹)—C₂-C₄alkyl-S(O)₀₋₂—, —N[C₂-C₄alkyl-N(R¹)(R²)]—,—N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(c))—,—N(R^(c))—C₂-C₄alkyl-O—, —N(R^(c))—C₂-C₄alkyl-N(R^(d))—,—O—C₁-C₄alkyl-S(O)₂N(R²¹)—, —O—C₁-C₄alkyl-O—,—O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—, —S(O)₂N(R²¹)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)S(O)₂—, —N(R²¹)S(O)₂—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-N(R²¹)—, —N(C(O)—C₁-C₄alkyl)-,—N(R²¹)—C₁-C₄alkyl-C(O)—, —O—C₁-C₄alkyl-C(O)N(R²¹)—,—C(O)N(R²¹)—C₂-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₂-C₄alkyl-N(R²¹)C(O)—,—N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(O)—C₁-C₄alkyl-S(O)₀₋₂—,—O—C₁-C₄alkyl-C(O)—, —C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O),—C(O)—C₁-C₄alkyl-N(R²¹)—, —O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-C(S), —C(S)—C₁-C₄alkyl-N(R²¹)—,—N(R²¹)—C₁-C₄alkyl-C(S)—, —O—C₁-C₄alkyl-C(S)N(R²¹)—,—C(S)N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)C(S)—,—N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-S(O)₂—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,—S(O)₂N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,—N(R²¹)S(O)₂—C₁-C₄alkyl-O—, —O—C₂-C₄alkyl-OC(O)N(R²¹)—,—O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein each alkyl moiety is optionallysubstituted;

Z² is selected from the group consisting of a chemical bond, alkyl,alkenyl, alkynyl, alkyl-alkenyl, alkynyl-alkyl and alkyl-alkynyl,wherein each alkyl, alkenyl and alkynyl moiety is optionallysubstituted;

Z³ is selected from the group consisting of a chemical bond,—C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-, —C₀-C₅alkyl-heterocyclyl-,—C₀-C₅alkyl-bridged heterocyclyl-, -spiro heterocyclyl-,—C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-, wherein each aryl,heteroaryl, cycloalkyl and heterocyclyl moiety is optionally substitutedand each of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted;

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,alkenyl, alkynyl, heteroalkyl, cycloalyl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, aromatic polycycles, non-aromaticpolycycles, polyheteroaryl groups, non-aromatic polyheterocyclic, mixedaryl and non-aryl polyheterocycle, each of which is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted, wherein

each R²¹ and R²² is independently selected from the group consisting of—H, -alkyl, -aryl and heteroaryl, wherein each said aryl and heteroarylmoiety is optionally substituted; and

L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.

In another preferred embodiment of the first aspect of the inventioneach cycloalkyl, heterocyclyl, aryl, alkyl, alkenyl and heteroarylmoiety in Z, Z₁, Z₂, Z₃ and D is optionally substituted with asubstituent selected from the group consisting of—N(R^(e))C(O)—C₁-C₆alkyl, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, —O—CF₃, —S—CF₃, aryl,heteroaryl, cycloalkyl, heterocyclyl, —C₁-C₃alkyl-aryl,—C₁-C₃alkyl-heteroaryl, —C₁-C₃alkyl-cycloalkyl,—C₁-C₃alkyl-heterocyclyl, halo, alkyl, —O-alkyl, —S(O)₀₋₂-alkyl,—C₀-C₃alkyl-CN, NO₂, —C(O)-alkyl and —OH.

In a preferred embodiment of the first aspect of the present inventionthe compound has Formula XX:

wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃, and —CF₃; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D.

In another preferred embodiment of the first aspect of the presentinvention the compound has Formula XX-A:

wherein

each L¹ is independently selected from the group consisting of H, halo,—O—CH₃, —CH₃ and —OH; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D;

wherein

Z is selected from the group consisting of —O—, —S(O)₀₋₂—,—N(R^(c))C(O)—, —C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—,—S(O)₂N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d))—, and —O—C₁-C₄alkyl-O—;

Z¹ is selected from the group consisting of aryl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, cycloalkyl and heteroaryl, whereineach aryl, heteroaryl, cycloalkyl and heterocyclyl moiety is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalkyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

In another preferred embodiment of the first aspect of the presentinvention, the compound has the Formula XXI:

wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃ and —CF₃; and

Y² is -Z²-Z¹-Z²-D, —CH₂-D or D;

wherein

Z¹ is selected from the group consisting of aryl, heterocyclyl,cycloalkyl and heteroaryl, wherein each aryl, heteroaryl, cycloalkyl andheterocyclyl moiety is optionally substituted and each of which isoptionally fused to one or more aryl or heteroaryl rings, or one or moresaturated or partially unsaturated cycloalkyl or heterocyclyl rings,each of which ring is optionally substituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

Another preferred embodiment of the first aspect of the inventionprovides a compound, an N-oxide, hydrate, solvate, pharmaceuticallyacceptable salt, prodrug or complex thereof, or racemic or scalemicmixture, diastereomer or enantiomer thereof, as described above withrespect to any of Formulae (I)-(V), in which each aryl, heterocyclyl,cycloalkyl and heteroaryl is independently optionally substituted withone, two or three substituents independently selected from the groupconsisting of H, halo, ═O, OH, C₁-C₃-hydrocarbyl, —OCH₃, —CN,—S(O)₀₋₂—C₁-C₄alkyl, —CF₃, —OCF₃, alkyl, —NH₂, —N(alkyl)₂, —NH(alkyl),—N(aryl)(alkyl), —N(-alkyl-aryl)(alkyl), —N(heteroaryl)(alkyl),—N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl), —NH(-alkyl-aryl),—NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-O-alkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—C₂-C₄alkyl-NR^(a)R^(b), C₂-C₄alkyl-NR^(c)R^(d), —S(O)₀₋₁R^(e),—(CR³²R³³)_(s)—NR³⁰R³¹, and (X³⁰—Y³¹—),

in which

R³⁰ and R³¹ are each independently hydrogen, cyano, oxo, hydroxyl,C₁-C₈alkyl, C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-,C₁-C₃alkyl-carboxamido-, carboxamido-C₁-C₃alkyl-, amidino-,C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-, aryl-C₁-C₃alkyl-,C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or

R³⁰ and R³¹ taken together with the N to which they are attached form aheterocyclyl or heteroaryl, each of which is optionally substituted withfrom 1 to 3 substituents selected from the group consisting of halo,cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, aprotecting group, and (X³⁰—Y³¹—), in which

X³⁰ is selected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, C₀-C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,N(R³⁰)(R³¹)—C₀-C₃alkenyl-, N(R³⁰)(R³¹)—C₀-C₃alkynyl-,(N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-,C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and

Y³¹ is selected from the group consisting of a direct bond, —O—,—N(R³⁰)—, —C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—,—N(R³⁰)—C(S)—, —C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—,—N(R³⁰)—C(NR³⁰)—N(R³¹)—, —N(R³⁰)—C(NR³¹)—, —C(N³¹)—N(R³⁰),—N(R³⁰)—C(S)—N(R³¹), —N(R³⁰)—C(O)—O—, —O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—,—O—C(S)—N(R³¹)—, —S(O)₀₋₂—, —SO₂N(R³¹)—, —N(R³¹)—SO₂— and—N(R³⁰)—SO₂N(R³¹)—; and

R³² and R³³ are independently selected from hydrogen, halo and hydroxyl.

Another preferred embodiment of the first aspect of the inventionprovides the compounds

-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic or scalemic mixtures,diastereomers and enantiomers thereof.

Another preferred embodiment of the first aspect of the inventionprovides the compounds

-   N-hydroxy-2-phenylbutanamide;-   N-hydroxy-2-phenoxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;-   2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-cyclohexyl-N-hydroxy-2-phenylacetamide;-   2-benzyl-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(phenylthio)acetamide;-   N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;-   2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;-   N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;-   2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;-   2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;-   N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;-   2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;-   2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;-   2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and-   2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide,

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof and racemic or scalemic mixtures,diastereomers and enantiomers thereof.

Another preferred embodiment of the first aspect of the inventionprovides the compounds

-   2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;-   N-hydroxy-3,3-diphenylpropanamide;-   2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;-   N-hydroxy-2,2-diphenylpropanamide;-   (E)-N-hydroxy-2,3-diphenylacrylamide;-   N-hydroxy-2,2-di(thiophen-2-yl)acetamide and-   N-hydroxy-9H-xanthene-9-carboxamide,

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic or scalemic mixtures,diastereomers and enantiomers thereof.

Some examples of the compounds according to the first aspect of theinvention are given in Table 1 below. These examples merely serve toexemplify some of the compounds of the first aspect of the invention anddo not limit the scope of the invention.

TABLE 1 Name N-hydroxy-2,2-diphenylacetamideN-hydroxy-2-phenoxy-2-phenylacetamideN-hydroxy-2,2-bis(4-nitrophenyl)acetamideN-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide2-(N-benzylphenylsulfonamido)-N-hydroxyacetamideN-hydroxy-3,3-diphenylpropanamide N-hydroxy-9H-xanthene-9-carboxamide2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide2-cyclohexyl-N-hydroxy-2-phenylacetamideN-hydroxy-2,3-diphenylpropanamideN-hydroxy-2-phenyl-2-(phenylthio)acetamideN-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamideN-hydroxy-2,2-diphenylpropanamide2,2-bis(4-chlorophenyl)-N-hydroxyacetamideN-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide2,2-bis(4-fluorophenyl)-N-hydroxyacetamide2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamideN-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide (E)—N-hydroxy-2,3-diphenylacrylamideN-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamideN-hydroxy-2,2-di(thiophen-2-yl)acetamide2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamideN-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamideN-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamideN,2-dihydroxy-2,2-diphenylacetamide2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamideN-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamideN-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamideN-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2- phenylacetamide2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamideN-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamideN-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamideN-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide

Preferred compounds according to the invention include those describedin the examples below. Compounds were named using Chemdraw Ultra version10.0 or version 8.0.3, which are available through Cambridgesoft.com, orwere derived therefrom.

Synthetic Schemes and Experimental Procedures

The compounds of the invention can be prepared according to the reactionschemes for the examples illustrated below utilizing methods known toone of ordinary skill in the art. These schemes serve to exemplify someprocedures that can be used to make the compounds of the invention. Oneskilled in the art will recognize that other general syntheticprocedures may be used. The compounds of the invention can be preparedfrom starting components that are commercially available. Any kind ofsubstitutions can be made to the starting components to obtain thecompounds of the invention according to procedures that are well knownto those skilled in the art.

EXAMPLE 1 2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide (3)

Step 1: Methyl 2,2-bis(2,3-dihydrobenzofuran-5-yl)acetate (2)

To a solution of 1 (992 mg, 3.35 mmol) in methanol (20 mL) was addedconcentrated sulfuric acid (2 mL) and stirred for 15 h at 60° C. Thesolvent was removed under vacuum. The crude was dissolved in ethylacetate and washed with water. The organic layer was separated, driedover Na₂SO₄, filtered and concentrated to afford compound 2 as a whitesolid (2.25 g, 94%). ¹H NMR (DMSO-d₆) δ (ppm): 7.13 (d, J=1.3 Hz, 2H),6.99 (dd, J=8.2, 1.8 Hz, 2H), 6.68 (d, J=8.2 Hz, 2H), 5.00 (s, 1H), 4.48(t, J=8.8 Hz, 4H), 3.63 (s, 3H), 3.12 (t, J=8.8 Hz, 4H).

Step 2: 2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide (3)

To a solution of 2 (380 mg, 1.22 mmol) and hydroxylamine (50% in water,1.25 mL) in a 1:1 THF:methanol (10 mL) was added base (KOH (275 mg, 4.9mmol) or NaOH). The mixture was stirred at room temperature for 2 h,acidified to pH 7 with 1M HCl solution, diluted with ethyl acetate andwashed with water. The organic layer was separated, dried over Na₂SO₄,filtered and concentrated. The residue was triturated with 50% ethylacetate:hexanes, filtered, and rinsed with hexanes to afford compound 3as a white solid (170 mg, 45%). ¹H NMR (DMSO-d6) δ (ppm): 10.81 (br s,1H), 8.88 (br s, 1H), 7.16 (d, J=1.0 Hz, 2H), 6.99 (dd, J=8.4, 1.8 Hz,2H), 6.67 (d, J=8.1 Hz, 2H), 4.53-4.45 (m, 5H), 3.12 (t, J=8.6 Hz, 4H).LRMS (ESI): (calc) 311.1 (found) 310.3 (M)-.

EXAMPLE 2 N-hydroxy-2-phenoxy-2-phenylacetamide (6)

Step 1: Ethyl 2-phenoxy-2-phenylacetate (5)

To a solution of 4 (0.5 g, 2.06 mmol) and phenol (194 mg, 2.06 mmol) inTHF (15 mL) was added base (NaH (60% dispersion, 90 mg, 2.27 mmol) ortriethylamine) and stirred at room temperature for 2 h. The reactionmixture was quenched with water, diluted with ethyl acetate and washedwith water. The organic layer was separated, dried over Na₂SO₄, filteredand concentrated. The crude material was purified by silica gel columnchromatography with gradient of ethyl acetate (0-25%) in hexane toafford 5 as a colourless oil (140 mg, 27%). ¹H NMR (DMSO-d₆) δ (ppm):7.55-7.52 (m, 2H), 7.44-7.34 (m, 3H), 7.30-7.25 (m, 2H), 6.96-6.92 (m,3H), 5.96 (s, 1H), 4.13-4.05 (m, 2H), 1.09 (t, J=7.0 Hz, 3H).

Alternate Reaction Conditions:

Compound 4 (1 eq), ROH (1 eq), K₂CO₃ (1.5 eq), acetone, 50° C., 18 h.

Compound 4 (1 eq), ROH (1 eq), CsCO₃ or DIPEA (1.5 eq), THF or DCE, roomtemperature, 24 h.

Compound 4 (1 eq), RSH (1 eq), K₂CO₃ (1.5 eq), acetone, 50° C., 18 h.

Step 2: N-hydroxy-2-phenoxy-2-phenylacetamide (6)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 5, the title compound 6 wasobtained in 15% yield (20 mg). ¹H NMR (CD₃OD-d₄) δ (ppm): 5.57-7.54 (m,2H), 7.39-7.32 (m, 3H), 7.27-7.22 (m, 2H), 7.00-6.92 (m, 3H), 5.60 (s,1H). LRMS (ESI): (calc) 243.1 (found) 242.0 (M-H)⁻.

EXAMPLE 3 N-hydroxy-2,2-bis(4-nitrophenyl)acetamide (9)

Step 1: Methyl 2,2-bis(4-nitrophenyl)acetate (8)

Compound 7 (6 g, 26.5 mmol) was dissolved in fuming nitric acid (60 mL)and stirred at room temperature for 16 h. The reaction mixture waspoured onto ice, the resulting light yellow sludge was separated outthen dissolved in ether to provide a solid. Filtration afforded titlecompound 8 as a white solid (1.15 g, 14%). ¹H NMR (DMSO-d₆) δ (ppm):8.22 (d, J=9.0 Hz, 4H), 7.65 (d, J=8.6 Hz, 4H), 5.76 (s, 1H), 3.72 (s,3H).

Step 2: N-hydroxy-2,2-bis(4-nitrophenyl)acetamide (9)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 8, the title compound 9 wasobtained in 25% yield (50 mg). ¹H NMR (CD₃OD-d₄) δ (ppm): 8.21 (d, J=8.8Hz, 4H), 7.61 (d, J=8.6 Hz, 4H), 5.07 (s, 1H). LRMS (ESI): calc. 317.1,found 316.3 (M-H)⁻.

EXAMPLE 4 2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide (14)

Step 1: (4-bromophenyl)(phenyl)methanol (11)

To a solution of p-bromobenzaldehyde 10 (4 g, 21.6 mmol) in THF (20 mL)was added phenyl magnesium bromide (22.7 mL, 22.7 mmol) and the reactionmixture was stirred at room temperature for 30 minutes, quenched withwater and partially concentrated under vacuum. The crude material wasdissolved in ethyl acetate and washed with water. The organic layer wasseparated, dried over Na₂SO₄, filtered and concentrated. The residue waspurified via prep-HPLC (ISCO) in silica gel column with a gradient ofethyl acetate (5-45%) in hexanes to afford title compound 11 as acolorless oil (3.7 g, 65%). ¹H NMR (DMSO-d₆) δ (ppm): 7.49-7.45 (m, 2H),7.36-7.17 (m, 7H), 5.98 (d, J=4.1 Hz, 1H), 5.68 (d, J=3.9 Hz, 1H).

Step 2: (4′-fluorobiphenyl-4-yl)(phenyl)methanol (12)

To a solution of 11 (1 g, 3.80 mmol) and 4-fluorophenyl boronic acid(585 mg, 4.18 mmol) in a 2:1 mixture of DME:water (30 mL), was addedPd(PPh₃)₄ (307 mg, 0.27 mmol), tri-o-toly phosphine (81 mg, 0.27 mmol)and potassium carbonate (2.63 g, 19.0 mmol). The solution was heated to80° C. and stirred for 16 hours. Then water (50 mL) was added and theorganic residue was extracted with ethyl acetate (2×40 mL). The organiclayer was dried over Na₂SO₄, filtered and concentrated. The residue waspurified via prep-HPLC (ISCO) in silica gel column with a gradient ofethyl acetate (2-50%) in hexane to afford compound 12 as a white solid(600 mg, 57%). ¹H NMR (DMSO-d₆) δ (ppm): 7.67-7.63 (m, 2H), 7.56 (d,J=8.4 Hz, 2H), 7.45-7.38 (m, 4H), 7.32-7.17 (m, 5H), 5.93 (d, J=3.9 Hz,1H), 5.73 (d, J=3.8 Hz, 1H).

Step 3: 2-(4′-fluorobiphenyl-4-yl)-2-phenylacetic acid (13)

Compound 12 (600 mg, 2.16 mmol) was dissolved in a 25:1 mixture ofconcentrated sulfuric acid:formic acid (19.76 mL) and left withoutstirring for 2 hours. The reaction mixture was quenched with water andextracted with ethyl acetate. The organic layer was washed with water,dried over Na₂SO₄, filtered and concentrated. The residue was purifiedvia prep-HPLC (ISCO) in silica gel column with a gradient of ethylacetate (20-80%) in hexanes to afford compound 13 as an orange oil (40mg, 6%). ¹H NMR (DMSO-d₆) δ (ppm): 7.68-7.64 (m, 2H), 7.58 (d, J=8.4 Hz,2H), 7.40-7.21 (m, 9H), 5.09 (s, 1H).

Step 4: 2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide (14)

To a solution of 13 (40 mg, 0.14 mmol), BOP (58 mg, 0.13 mmol), andhydroxylamine hydrochloride (9 mg, 0.13 mmol) in pyridine (5 mL) wasadded triethylamine (0.055 mL, 0.39 mmol) and the reaction mixture wasstirred at room temperature for 2 h. The solvents were removed undervacuum and the crude was dissolved in ethyl acetate. The organic layerwas washed with water, dried over Na₂SO₄, filtered and concentrated. Theresidue was purified via HPLC (Gilson) reverse-phase column with agradient of methanol (20-75%) in water to afford compound 14 as a whitesolid (20 mg, 48%). ¹H NMR (CD3OD-d₄) δ (ppm): 7.62-7.57 (m, 2H), 7.53(d, J=8.2 Hz, 2H), 7.40-7.22 (m, 7H), 7.14 (t, J=8.8 Hz, 2H), 4.82 (s,1H). LRMS (ESI): (calc.) 321.1 (found) 320.4 (MH)⁻.

EXAMPLE 5 2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide (17)

Step 1: methyl 2-(4-(dimethylamino)phenyl)-2-phenylacetate (16)

To a solution of methyl phenyl acetate (0.43 mL, 3 mmol) and 15 (1.36mL, 10.71 mmol) in dichloromethane (28 mL) at 0° C. was added TiCl₄(14.28 mL, 14.28 mmol). The reaction mixture was warmed to roomtemperature with stirring for 4 h. The reaction mixture was quenchedwith a saturated solution of NaHCO₃ (aq) and extracted with ethylacetate. The organic layer was washed with water, saturated solutionNaOH (aq), then with 1M HCl, dried over Na₂SO₄, filtered andconcentrated. The residue was purified via prep-HPLC (ISCO) in silicagel column with a gradient of ethyl acetate (2-40%) in hexane to affordcompound 16 as a yellow solid (270 mg, 33%). ¹H NMR (DMSO-d₆) δ (ppm):7.32-7.19 (m, 5H), 7.09 (d, J=8.6 Hz, 2H), 6.65 (d, J=8.8 Hz, 2H), 5.02(s, 1H), 3.63 (s, 3H), 2.84 (s, 6H).

Step 2: 2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide (17)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 16, the title compound 17 wasobtained in 28% yield. ¹H NMR (CD₃OD-d₄) δ (ppm): 7.28-7.19 (m, 5H),7.15 (d, J=8.4 Hz, 2H), 6.72 (d, J=8.8 Hz, 2H), 4.67 (s, 1H), 2.88 (s,6H). LRMS (ESI): (calc) 270.3 (found) 271.4 (MH)+.

EXAMPLE 6 2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide (20)

Step 1: 2-(biphenyl-4-yl)-2-phenylacetic acid (19)

To a solution of 18 (2 g, 8.19 mmol) in THF (20 mL) at 0° C. was addedbutyl lithium in hexanes (4.26 mL, 10.64 mmol). The reaction mixture waswarmed to room temperature, stirred for 1 h and then CO₂ was bubbledthrough the stirring solution for 30 minutes. The solution was quenchedwith H₂O and 1M HCl until pH 6 and extracted with ethyl acetate. Theorganic layer was washed with water, dried over Na₂SO₄, filtered andconcentrated. The residue was purified via prep-HPLC (ISCO) in silicagel column with a gradient of ethyl acetate (2-50%) in hexane to affordcompound 19 as a white solid (670 mg, 28%). ¹H NMR (DMSO-d₆) δ (ppm):12.80 (br s, 1H), 7.62 (t, J=8.2 Hz, 4H), 7.39-7.22 (m, 10H), 5.11 (s,1H).

Step 2: 2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide (20)

Following the same procedure as described in Example 4, step 4, butsubstituting compound 13 for compound 19, the title compound 20 wasobtained in 51% yield (360 mg). ¹H NMR (CD₃OD-d₄) δ(ppm): 7.61-7.55 (m,4H), 7.43-7.23 (m, 10H), 4.83 (s, 1H). LRMS (ESI): calc. 303.4, found302.4 (M)-.

EXAMPLE 7 N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide (23)

Step 1: ethyl 2-phenyl-2-(piperidin-1-yl)acetate (22)

To a solution of ethyl 2-bromo-2-phenylacetate 21 (1.50 g, 6.17 mmol) inTHF (10 mL) at room temperature was added piperidine (0.641 mL, 6.48mmol) and TEA (1.72 mL, 12.34 mmol) and the reaction mixture was stirredfor 3 h then diluted with brine and extracted with ethyl acetate. Theorganic layer was dried over Na₂SO₄, filtered, and concentrated. Thecrude material was purified by silica gel column chromatography withgradient of ethyl acetate (0-50%) in hexane to afford 22 as a colorlessviscous oil (520 mg, 34%). LRMS (ESI): (calc) 247.3 (found) 248.3 (MH)+.

Step 2: N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide (23)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 22, the title compound 23 wasobtained as a white solid in 16% yield (78 mg). ¹H NMR (MeOD-d₄) δ(ppm): 7.53-7.49 (m, 2H), 7.38-7.31 (m, 3H), 3.64 (s, 1H), 2.46-2.30 (m,4H), 1.67-1.58 (m, 4H), 1.53-1.44 (m, 2H). LRMS (ESI): (calc) 234.3(found) 235.2 (MH)+.

EXAMPLE 8 N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide(25)

Step 1: ethyl 2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetate (24)

To a solution of ethyl 2-bromo-2-phenylacetate 21 (1.60 g, 6.58 mmol) insodium azide/DMSO solution (0.5 M, 13.16 mL, 6.58 mmol) which had beenstirred at room temperature for 1 h was added water (10 mL), sodiumascorbate (0.130 g, 0.658 mmol), phenylacetylene (0.723 mL, 6.58 mmol)and aq. copper(II) sulfate solution (1.0 M, 1.30 mL, 1.30 mmol) (in thatorder). The reaction mixture was stirred for 16 h. Brine was added andextraction with ethyl acetate. The organic layer was dried over Na₂SO₄,filtered, and concentrated. The crude material was purified by silicagel column chromatography with gradient of ethyl acetate (0-50%) inhexane to afford compound (24) as a light yellow solid (1.31 g, 65%).LRMS: calc. 307.4, found 308.4 (MH)+.

Step 2: N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide(25)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 24, the title compound 25 wasobtained as a white solid in 16% yield (135 mg). ¹H NMR (MeOD-d₄) δ(ppm): 7.56 (s, 1H), 7.02 (dd, J=8.4, 1.4 Hz, 2H), 6.78-6.53 (m, 8H),5.69 (s, 1H). LRMS: calc. 294.3, found 295.4 (MH)+.

EXAMPLE 9 N-hydroxy-2-(N-methylphenylsulfonamido)acetamide (29)

Step 1: Methyl 2-(benzylamino)acetate hydrochloride (27)

To a N-benzyl glycine 26 (500 mg, 3.0 mmol) in MeOH (6 mL) was added 4Msolution of HCl in dioxane (4 mL) and stirred overnight. The reactionmixture was concentrated to afford compound 27 (649 mg, 99%) as a whitesolid. The crude compound was carried forward without furtherpurification. LRMS (ESI): (calc) 179.2 (found) 180.1 (MH)+.

Step 2: Methyl 2-(N-benzylphenylsulfonamido)acetate (28)

To a solution of compound 27 in CH₂Cl₂ (3 mL) was added pyridine (3 mL)and the stirred overnight. The reaction was partitioned between EtOAc (6mL) and water (6 mL). The organic layer was separated, dried overNa₂SO₄, filtered and concentrated under vacuum. The crude material waspurified by silica gel column chromatography with gradient of ethylacetate (0-70%) in hexane to afford compound 28 (165 mg, 28%) as a thickoil. LRMS (ESI): (calc) 319.4 (found) 320.2 (MH)+.

Step 3: 2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide (29)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 28, the title compound 29 (139 mg,84%) as a white solid. ¹H NMR (CD₃OD-d₄) δ (ppm): 7.91 (d, J=7.2 Hz,2H), 7.57 (m, 3H), 7.28 (m, 5H), 4.47 (s, 2H), 3.72 (s, 2H). LRMS (ESI):(calc.) 320.1 (found) 321.3 (MH)+.

EXAMPLE 10N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide(34)

Step 1: 4-(thiophen-2-yl)benzene-1,2-diamine (30)

To a solution of 4-thienyl-2-nitroaniline (1 equiv, 400 mg, 1.82 mmol)was added 10% Pd/C (0.05 equiv, 97 mg, 0.09 mmol). The resultingsuspension was stirred for overnight over 1 atm of hydrogen. The solidswere filtered through celite pad and the filtrate was concentrated undervacuum. The crude material was purified by silica gel columnchromatography with gradient of MeOH (0-10%) in CH₂Cl₂ to affordcompound 30 (310 mg, 90%) and a white solid. LRMS (ESI): (calc) 190.2(found) 191.0 (MH)+.

Step 2: Benzyl3-(2-amino-4-(thiophen-2-yl)phenylamino)-3-oxo-2-phenylpropanoate (32)

To a solution of compound 30 (275 mg, 1.45 mmol), compound 31 (391 mg,1.45 mmol) and HATU (714 mg, 1.88 mmol) in DMF (3 mL) was added Et₃N(0.81 mL, 5.78 mmol)_and stirred overnight. The reaction was partitionedbetween EtOAc (5 mL) and H₂O (10 mL). The organic layer was separated,dried over Na₂SO₄, filtered and concentrated under vacuum. The crudematerial was purified by silica gel column chromatography with gradientof ethyl acetate (10-90%) in hexane to afford compound 32 (463 mg, 72%)as a clear thick oil. LRMS (ESI): (calc) 442.58 (found) 443.4 (MH)+.

Step 3: Benzyl2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetate (33)

AcOH (3 mL) was added to compound 32 (463 mg, 1.04 mmol) and thereaction heated at 100° C. for 30 min. The solvent was evaporated underreduced pressure.

The crude material was purified by silica gel column chromatography withgradient of ethyl acetate (10-50%) in hexane to afford compound 33 (378mg, 85%) as a clear oil. LRMS (ESI): (calc) 424.5 (found) 425.4 (MH)+.

Step 4:N-Hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide.Formic salt (34)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 33, the title compound 34 (4 mg,7%) as a white solid. ¹H NMR (CD₃OD-d₄) δ (ppm): 8.24 (s, 1H), 7.78 (s,1H), 7.54 (m, 2H), 7.47 (m, 2H), 7.38-7.30 (m, 5H), 7.08-7.06 (m, 1H),5.11 (s, 1H). LRMS (ESI): (calc.) 349.0 (found) 350.4 (MH)+.

EXAMPLE 11N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide(38)

Step 1: Benzyl3-(2-(2-methoxybenzoyl)hydrazinyl)-3-oxo-2-phenylpropanoate (36)

Following the same procedure as described in Example 10, step 2, butsubstituting compound 30 for compound 35, the title compound 36 (427 mg,55%) as a white solid. LRMS (ESI): (calc) 418.4, (found) 419.5 (MH)+.

Step 2: Benzyl2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetate (37)

To a solution of compound 36 (539 mg, 1.02 mmol) in THF (4 mL) was added2,4-bis(4-phenoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide (539mg, 1.02 mmol) and the reaction stirred overnight. The crude materialwas concentrated and purified by silica gel column chromatography withgradient of ethyl acetate (5-40%) in hexane to afford compound 37 (325mg, 76%) as a white solid. LRMS (ESI): (calc) 416.4, (found) 417.4(MH)+.

Step 3:N-Hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide(38)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 37, the title compound 38 (93 mg,35%) as a white solid. ¹H NMR (CD₃OD-d₄) δ (ppm): 8.29 (d, J=6.0 Hz,1H), 7.54-7.48 (m, 3H), 7.39-7.32 (m, 3H), 7.21 (d, J=8.0 Hz, 1H), 7.11(t, J=7.6 Hz, 1H), 5.38 (s, 1H), 4.02 (s, 3H). LRMS (ESI): (calc.)341.1, (found) 342.3 (MH)+.

EXAMPLE 12 N-benzhydryl-N-hydroxyformamide

Step 1: (E)-N-(4-methoxybenzylidene)-1,1-diphenylmethanamine (39)

To a solution of diphenylmethanamine (3.00 g, 16.4 mmol) in methanol (80mL) was added 4-methoxybenzaldehyde (2.45 g, 18.0 mmol) and sodiumcarbonate (2.60 g, 24.6 mmol). The reaction mixture was stirred at roomtemperature for 16 h prior to removal of all solvents under vacuum. Theresidue was then diluted with ethyl acetate, washed with brine, driedover anhydrous Na₂SO₄, filtered, and concentrated to afford compound 39as a white solid (3.62 g, 73%). LRMS (ESI): (calc.) 301.4 (found) 302.4(MH)+.

Step 2: 2-benzhydryl-3-(4-methoxyphenyl)-1,2-oxaziridine (40)

(E)-N-(4-methoxybenzylidene)-1,1-diphenylmethanamine 39 (3.62 g, 12.0mmol) was dissolved in dichloromethane (130 mL) at 0° C., followed bythe portionwise addition of mCPBA (2.96 g, 13.2 mmol). The resultingsolution was warmed to room temperature, and stirred for 16 h prior tobeing transferred to a separatory funnel, and being washed 3 times with50 mL of saturated sodium bicarbonate solution. The organic layer wasthen dried with anhydrous sodium sulfate, filtered, and concentrated toafford 40 as a light yellow oil (3.52 g, 92%). LRMS (ESI): (calc.) 317.4(found) 318.2 (MH)+.

Step 3: N-benzhydrylhydroxylamine (41)

To a solution of 2-benzhydryl-3-(4-methoxyphenyl)-1,2-oxaziridine 40(3.52 g, 11.1 mmol) in methanol (100 mL) was added hydroxylamine-HCl(2.31 g, 33.3 mmol) and stirred at room temperature. for 16 h. Thereaction mixture was concentrated under vacuum and diluted with aqueousNaOH solution (to pH=13), followed by extraction with ethyl acetate. Thecombined organic layers were dried over anhydrous Na₂SO₄, filtered, andconcentrated. The crude material was concentrated and purified by silicagel column chromatography with gradient of ethyl acetate (10-50%) inhexane to afford compound 41 as a light yellow solid (450 mg, 20%). LRMS(ESI): (calc.) 199.3 (found) 167.2 (M-NHOH)+.

Step 4: N-benzhydryl-N-hydroxyformamide (42)

Formic acid (0.53 mL, 14.1 mmol) was added dropwise to acetic anhydride(1.07 mL, 11.3 mmol) at 0° C., stirred for 5 mins. and then warmed to55° C. for 5 mins prior to cooling back down to room temperature.N-benzhydrylhydroxylamine 41 (225 mg, 1.13 mmol) was added, and stirredat room temperature for 3 days. The reaction mixture was diluted withaqueous NaOH solution (to pH=7), the solution was stirred for 5 mins,and then acidified with aqueous HCl solution (to pH=4). Followingextraction with ethyl acetate, the combined organic layers were driedwith anhydrous sodium sulfate, filtered, and concentrated. The crudematerial was concentrated and purified by silica gel columnchromatography with gradient of ethyl acetate (0-75%) in hexane toafford compound 42 as a tan solid (169 mg, 66%). ¹H NMR: (DMSO-d₆) 8.41(br s, 1H), 7.44-7.28 (m, 11H). LRMS (ESI): (calc.) 227.3 (found) 228.2(MH)+.

The compounds in table I were made according to processes described inthe previous examples.

TABLE I Procedure Strucutre Cpd Name MS ¹H NMR of Scheme

1-1 N-hydroxy-2,2- diphenylacetamide LRMS (ESI): (calc.) 227.1 (found)228.2 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm): 10.91 (s, 1 H), 8.95 (s, 1 H),7.33-7.19 (m, 10 H), 4.69 (s, 1 H). 1

1-2 (cpd 6, Ex 2) N-hydroxy-2- phenoxy-2- phenylacetamide LRMS (ESI):(calc.) 243.1 (found) 242.0 (M − H)− ¹H NMR (CD₃OD-d₄) δ (ppm):5.57-7.54 (m, 2 H), 7.39-7.32 (m, 3 H), 7.27-7.22 (m, 2 H), 7.00-6.92(m, 3 H), 5.60 (s, 1 H). 2

1-3 (cpd 9, Ex 3) N-hydroxy-2,2- bis(4- nitrophenyl)- acetamide LRMS(ESI): (calc.) 317.1 (found) 316.3 (M − H)− ¹H NMR (CD₃OD-d₄) δ (ppm):8.21 (d, J = 8.8 Hz, 4 H), 7.61 (d, J = 8.6 Hz, 4 H), 5.07 (s, 1 H). 3

1-4 (cpd 23, Ex 7) N-hydroxy-2- phenyl-2- (piperidin-1- yl)acetamideLRMS (ESI): (calc.) 234.3 (found) 235.2 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.53-7.49 (m, 2 H), 7.38-7.31 (m, 3 H), 3.64 (s, 1 H), 2.46-2.30 (m, 4H), 1.67-1.58 (m, 4 H), 1.53-1.44 (m, 2 H) 7

1-5 (cpd 29, Ex 9) 2-(N- benzylphenyl- sulfonamido)-N- hydroxyacetamideLRMS (ESI): (calc.) 320.1 (found) 321.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.91 (d, J = 7.2 Hz, 2 H), 7.57 (m, 3 H), 7.28 (m, 5 H), 4.47 (s, 2 H),3.72 (s, 2 H) 9

1-6 N-hydroxy-3,3- diphenylpropan- amide LRMS (ESI): (calc.) 241.3(found) 242.2 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.30-7.16 (m, 10 H), 4.58(t, J = 8.2 Hz, 1 H), 2.84 (d, J = 8.0 Hz, 2 H) 1

1-7 N-hydroxy-9H- xanthene-9- carboxamide LRMS (ESI): (calc.) 241.2(found) 242.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.35-7.27 (m, 4 H),7.16-7.09 (m, 4 H), 4.80 (s, 1 H) 1 (step 2)

1-8 (cpd 3, Ex 1) 2,2-bis(2,3- dihydrobenzo- furan-5-yl)-N-hydroxyacetamide LRMS (ESI): (calc.) 311.1 (found) 310.3 (M − H)− ¹H NMR(DMSO-d₆) δ (ppm): 10.81 (br s, 1 H), 8.88 (br s, 1 H), 7.16 (d, J = 1.0Hz, 2 H), 6.99 (dd, J = 8.4, 1.8 Hz, 2 H), 6.67 (d, J = 8.1 Hz, 2 H),4.53-4.45 (m, 5 H), 3.12 (t, J = 8.6 Hz, 4 H). 1

1-9 2-(4- benzylpiperidin- 1-yl)-N- hydroxy-2- phenylacetamide LRMS(ESI): (calc.) 324.4 (found) 325.4 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.52-7.47 (m, 2 H), 7.37-7.23 (m, 5 H), 7.19-7.13 (m, 3 H), 3.62 (s, 1H), 3.10-3.03 (m, 1 H), 2.70-2.63 (m, 1 H), 2.55 (d, J = 6.7 Hz, 2 H),2.09-2.00 (m, 1 H), 1.80-1.71 (m, 1 H), 1.69-1.24 (m, 5 H) 7

1-10 2-cyclohexyl-N- hydroxy-2- phenylacetamide LRMS (ESI): (calc.)233.3 (found) 234.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.40-7.35 (m, 2 H),7.33-7.22 (m, 3 H), 2.93 (d, J = 11.0 Hz, 1 H), 2.16-2.04 (m, 1 H),1.94-1.85 (m, 1 H), 1.83-1.74 (m, 1 H), 1.73-1.60 (m, 2 H), 1.42-1.14(m, 4 H), 1.12-1.00 (m, 1 H), 0.84-0.71 (m, 1 H) 1

1-11 N-hydroxy-2,3- diphenylpropan- amide LRMS (ESI): (calc.) 241.1(found) 242.2 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.42-7.38 (m, 2 H),7.30-7.11 (m, 8 H), 3.63 (dd, J = 9.4, 5.9 Hz, 1 H), 3.40 (dd, J = 13.5,9.6 Hz, 1 H), 2.98 (dd, J = 13.5, 5.9 Hz, 1 H). 1

1-12 N-hydroxy-2- phenyl-2- (phenylthio)- acetamide LRMS(ESI): (calc.)259.1 (found) 258.2 (M − H)− ¹H NMR (DMSO-d₆) δ (ppm): 10.95 (br s, 1H), 9.10 (br s, 1 H), 7.49-7.46 (m, 2 H), 7.35-7.21 (m, 8 H), 4.90 (s, 1H). 2

1-13 N-hydroxy-2- phenyl-2-(1H- pyrrol-1- yl)acetamide LRMS (ESI):(calc.) 216.2 (found) 217.1 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.42-7.26(m, 5 H), 6.82 (t, J = 2.0 Hz, 2 H), 6.14 (t, J = 2.2 Hz, 2 H), 5.76 (s,1 H). 1 (step 2)

1-14 N-hydroxy-2,2- diphenylpropan- amide LRMS (ESI): (calc.) 241.3(found) 242.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.37-7.25 (m, 10 H), 1.96(s, 3 H). 1

1-15 2,2-bis(4- chlorophenyl)- N- hydroxyacetamide LRMS ESI): (calc.)295.0 (found) 294.2 (M − H)− ¹H NMR (CD₃OD-d₄) δ (ppm): 7.29 (s, 8 H),4.78 (s, 1 H). 1

1-16 N-hydroxy-2- phenyl-2-(4- phenylpiperazin- 1-yl)acetamide LRMS(ESI): (calc.) 311.4 (found) 312.4 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.55(d, J = 7.4 Hz, 2 H), 7.42-7.32 (m, 3 H), 7.28-7.21 (m, 2 H), 6.98 (d, J= 8.4 Hz, 2 H), 6.88-6.82 (m, 1 H), 3.73 (s, 1 H), 3.25-3.20 (m, 4 H),2.70-2.54 (m, 4 H). 7

1-17 2-(4- benzylpiperazin- 1-yl)-N- hydroxy-2- phenylacetamide LRMS(ESI): (calc.) 325.4 (found) 326.4 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.53-7.47 (m, 2 H), 7.39-7.25 (m, 8 H), 3.66 (s, 1 H), 3.56 (s, 2 H),2.64-2.37 (m, 8 H). 7

1-18 2,2-bis(4- fluorophenyl)- N- hydroxyacetamide LRMS (ESI): (calc.)263.1 (found) 264.1 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.33 (dd, J = 8.2,5.7 Hz, 4 H), 7.04 (t, J = 8.8 Hz, 4 H), 4.76 (s, 1 H). 4

1-19 2-(4- (diethylamino)- phenyl)-N- hydroxy-2- phenylacetamide LRMS(ESI): (calc.) 298.2 (found) 299.2 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.31-7.19 (m, 5 H), 7.12 (d, J = 8.6 Hz, 2 H), 6.68 (d, J = 8.6 Hz, 2H), 4.66 (s, 1 H), 3.34 (q, J = 7.0 Hz, 4 H), 1.11 (t, J = 7.0 Hz, 6 H).5

1-20 (cpd 34, Ex 10) N-hydroxy-2- phenyl-2-(6- (thiophen-2-yl)- 1H-benzo[d]imidazol- 2-yl)acetamide LRMS (ESI): (calc.) 349.0 (found) 350.4(MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 8.24 (s, 1H; formate proton), 7.78 (s,1 H), 7.54 (m, 2 H), 7.47 (m, 2 H), 7.38-7.30 (m, 5 H), 7.08-7.06 (m, 1H), 5.11 (s, 1 H) 10 

1-21 (E)-N-hydroxy- 2,3- diphenylacryl- amide LRMS (ESI): (calc.) 239.3(found) 240.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.48 (s, 1 H), 7.45-7.40(m, 3 H), 7.29-7.13 (m, 5 H), 7.06-7.01 (m, 2 H). 4 (step 4)

1-22 N-hydroxy-2- (isoindolin-2- yl)-2- phenylacetamide LRMS (ESI):(calc.) 268.3 (found) 269.3 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm): 10.96 (s, 1H), 8.94 (s, 1 H), 7.59-7.54 (m, 2 H), 7.44-7.32 (m, 3 H), 7.28-7.20 (m,4 H), 4.12 (s, 1 H), 3.89-3.76 (m, 4 H). 7

1-23 N-hydroxy-2,2- di(thiopen-2- yl)acetamide LRMS (ESI): (calc.) 239.1(found) 240.2 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm): 11.01 (s, 1 H), 9.14 (s, 1H), 7.39 (dd, J = 5.1, 1.4 Hz, 1 H), 6.99-6.97 (m, 2 H), 6.94-6.91 (m, 2H), 5.26 (s, 1 H). 1

1-24 2- (benzo[d]thiazol- 2-ylthio)-N- hydroxy-2- phenylacetamide LRMS(ESI): (calc.) 316.1 (found) 317.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.86-7.80 (m, 2 H), 7.61-7.58 (m, 2 H), 7.43 (td, J = 7.2, 1.2 Hz, 1 H),7.37-7.30 (m, 4 H), 5.68 (s, 1 H). 2

1-25 2-(5-chloro-6- fluoro-1H- benzo[d]imidazol- 2-yl)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 319.0 (found) 320.3 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 7.61 (d, J = 6.4 Hz, 1 H), 7.46 (m, 2 H), 7.44-7.29(m, 4 H), 5.09 (s, 1 H). 10 

1-26 (cpd 25, Ex 8) N-hydroxy-2- phenyl-2-(4- phenyl-1H-1,2,3-triazol-1- yl)acetamide LRMS (ESI): (calc.) 294.3 (found) 295.4(MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 7.56 (s, 1 H), 7.02 (dd, J = 8.4, 1.4Hz, 2 H), 6.78-6.53 (m, 8 H), 5.69 (s, 1 H). 8

1-27 N-hydroxy-2-(4- phenethyl-1H- 1,2,3-triazol-1- yl)-2-phenylacetamide LRMS (ESI): (calc.) 322.4 (found) 323.5 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 7.62 (s, 1 H), 7.46-7.36 (m, 5 H), 7.26-7.10 (m, 5H), 6.39 (s, 1 H), 3.02-2.87 (m, 4 H) 8

1-28 N,2-dihydroxy- 2,2- diphenylacetamide LRMS (ESI): (calc.) 243.3(found) 242.3 (M − H)− ¹H NMR (CD₃OD-d₄) δ (ppm): 7.46-7.43 (m, 4 H),7.34-7.26 (m, 6 H). 1 (step 2)

1-29 (cpd 17, Ex 5) 2-(4- (dimethylamino) phenyl)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 270.3 (found) 271.4 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 7.28-7.19 (m, 5 H), 7.15 (d, J = 8.4 Hz, 2 H), 6.72(d, J = 8.8 Hz, 2 H), 4.67 (s, 1 H), 2.88 (s, 6 H). 5

1-30 2-(4-(4- fluorobenzyl)- piperidin-1-yl)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 342.4 (found) 343.5 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 7.53-7.47 (m, 2 H), 7.38-7.30 (m, 3 H), 7.20-7.13(m, 2 H), 6.99 (t, J = 8.8 Hz, 2 H), 3.63 (s, 1 H), 3.10-3.03 (m, 1 H),2.70-2.64 (m, 1 H), 2.55 (d, J = 6.7 Hz, 2 H), 2.10-2.00 (m, 1 H),1.80-1.70 (m, 1 H), 1.68-1.24 (m, 5 H). 7

1-31 N-hydroxy-2-(4- phenethylpiperidin- 1-yl)-2- phenylacetamide LRMS(ESI): (calc.) 338.4 (found) 339.5 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm):7.47-7.42 (m, 2 H), 7.38-7.26 (m, 5 H), 7.24-7.16 (m, 3 H), 3.61 (s, 1H), 2.98-2.90 (m, 1 H), 2.66-2.56 (m, 3 H), 1.98 (t, J = 9.4 Hz, 1 H),1.79-1.46 (m, 5 H), 1.31-1.10 (m, 3 H). 7

1-32 (cpd 20, Ex 6) 2-(biphenyl-4- yl)-N-hydroxy- 2- phenylacetamideLRMS (ESI): (calc.) 303.4 (found) 302.4 (M − H)− ¹H NMR (CD₃OD-d₄) δ(ppm): 7.61-7.55 (m, 4 H), 7.43-7.23 (m, 10 H), 4.83 (s, 1 H). 6

1-33 N1-hydroxy-2- phenyl-N3-(3- (trifluoromethyl) phenyl)malon- amideLRMS (ESI): (calc.) 338.0 (found) 337.3 (M − H)− ¹H NMR (CD₃OD-d₄) δ(ppm): 8.01 (s, 1 H), 7.73 (d, J = 8.0 Hz, 1 H), 7.49 (m, 3 H),7.39-7.32 (m, 4 H), 4.52 (s, 1 H) 10  (step 1) 1 (step 2)

1-34 2-(4-(1H-indol- 3-yl)piperidin-1- yl)-N-hydroxy- 2- phenylacetamideLRMS (ESI): (calc.) 349.4 (found) 350.5 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.62-7.54 (m, 3 H), 7.40-7.30 (m, 4 H), 7.11-7.05 (m, 1 H), 7.03-6.96(m, 2 H), 3.74 (s, 1 H), 3.27-3.18 (m, 1 H), 2.90-2.76 (m, 2 H),2.36-2.25 (m, 1 H), 2.10-1.80 (m, 5 H). 7

1-35 2-(4-benzyl-1H- 1,2,3-triazol-1- yl)-N-hydroxy- 2- phenylacetamideLRMS (ESI): (calc.) 308.3 (found) 309.4 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm):7.75 (s, 1 H), 7.50-7.40 (m, 5 H), 7.31-7.16 (m, 5 H), 6.41 (s, 1 H),4.04 (s, 2 H). 8

1-36 N-hydroxy-2- phenyl-2-(4- (pyrimidin-2- yl)piperazin-1-yl)acetamide LRMS (ESI): (calc.) 313.4 (found) 314.5 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 8.32 (d, J = 4.7 Hz, 2 H), 7.54 (dd, J = 7.6, 1.4Hz, 2 H), 7.42-7.32 (m, 3 H), 6.61 (t, J = 4.7 Hz, 1 H), 3.87-3.82 (m, 4H), 3.73 (s, 1 H), 2.57-2.42 (m, 4 H). 7

1-37 2-(4-(4- chlorophenyl)- pyrimidin-2- ylthio)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 371.8 (found) 372.4 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 8.59 (d, J = 5.3 Hz, 1 H), 8.17 (d, J = 8.8 Hz, 2H), 7.65 (d, J = 5.5 Hz, 1 H), 7.60-7.52 (m, 4 H), 7.39-7.30 (m, 3 H),5.56 (s, 1 H). 2

1-38 (cpd 38, Ex 11) N-hydroxy-2-(5- (2- methoxyphenyl)- 1,3,4-thiadiazol-2-yl)- 2- phenylacetamide LRMS (ESI): (calc.) 341.08 (found)342.3 (MH)+ ¹H NMR (CD₃OD-d₄) δ (ppm): 8.29 (d, J = 6.0 Hz, 1 H),7.54-7.48 (m, 3 H), 7.39-7.32 (m, 3 H), 7.21 (d, J = 8.0 Hz, 1 H), 7.11(t, J = 7.6 Hz, 1 H), 5.38 (s, 1 H), 4.02 (s, 3 H). 11 

1-39 2-(5-(4- bromophenyl)- 1,3,4-thiadiazol- 2-yl)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 388.9 (found) 390.3 (MH)+ ¹H NMR(CD₃OD-d₄) δ (ppm): 7.88 (d, J = 8.8 Hz, 2 H), 7.68 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 8.0 Hz, 2 H), 7.39-7.32 (m, 3 H), 5.37 (s, 1 H) 11 

1-40 2-(biphenyl-4- yl)-2-(4- (dimethylamino) phenyl)-N-hydroxyacetamide LRMS (ESI): (calc.) 346.4 (found) 347.4 (MH)+ ¹H NMR(MeOD-d₄) δ (ppm): 7.60-4.53 (m, 4 H), 7.43-7.35 (m, 4 H), 7.33-7.28 (m,1 H), 7.19 (d, J = 8.8 Hz, 2 H), 6.74 (d, J = 8.8 Hz, 2 H), 4.72 (s, 1H), 2.90 (s, 6 H). 5

1-41 N-hydroxy-2- phenyl-2-(4- (pyrrolidin-1- yl)phenyl)- acetamide LRMS(ESI): (calc.) 296.4 (found) 297.5 (MH)+ ¹H NMR (MeOD-d₄) δ (ppm):7.18-7.13 (m, 5 H), 6.93-6.91 (m, 2 H), 6.40-6.30 (m, 2 H), 4.63 (s, 1H), 3.14 (s, 4 H), 1.89 (s, 4 H). 5

1-42 2-(4,5-diphenyl- 1H-imidazol-2- ylthio)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 401.5 (found) 402.5 (MH)+ ¹H NMR(DMSO-d₆) δ (ppm): 12.59 (s, 1 H), 11.09 (s, 1 H), 9.12 (s, 1 H),7.53-7.50 (m, 2 H), 7.45 (d, J = 7.2 Hz, 2 H), 7.38-7.20 (m, 11 H), 5.37(s, 1 H). 2

1-43 N-hydroxy-2-(4- phenoxypiperidin- 1-yl)-2- phenylacetamide LRMS(ESI): (calc.) 326.4 (found) 327.4 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm): 10.86(s, 1 H), 8.93 (s, 1 H), 7.50-7.45 (m, 2 H), 7.40-7.26 (m, 5 H),6.99-6.90 (m, 3 H), 4.44-4.36 (m, 1 H), 3.72 (s, 1 H), 2.76-2.56 (m, 2H), 2.33-2.18 (m, 2 H), 2.01-1.90 (m, 2 H), 1.73-1.60 (m, 2 H). 7

1-44 N-hydroxy-2- phenyl-2-(4- phenylpiperidin- 1-yl)acetamide LRMS(ESI): (calc.) 310.4 (found) 311.4 (MH)+ ¹H NMR (MeOD-d₄) δ (ppm):7.57-7.53 (m, 2 H), 7.41-7.24 (m, 7 H), 7.21-15 (m, 1 H), 3.72 (s, 1 H),3.26-3.20 (m, 1 H), 2.84-2.76 (m, 1 H), 2.60-2.50 (m, 1 H), 2.30-2.20(m, 1 H), 2.02-1.90 (m, 2 H), 1.88-1.68 (m, 3 H). 7

1-45 (cpd 14, Ex 4) 2-(4′- fluorobiphenyl- 4-yl)-N- hydroxy-2-phenylacetamide LRMS (ESI): (calc.) 321.3 (found) 320.4 (M − H)− ¹H NMR(MeOD-d₄) δ (ppm): 7.62-7.57 (m, 2 H), 7.53 (d, J = 8.2 Hz, 2 H),7.40-7.22 (m, 7 H), 7.14 (t, J = 8.8 Hz, 2 H), 4.82 (s, 1 H). 4

1-46 2-(biphenyl-4- ylthio)-N- hydroxy-2- phenylacetamide LRMS (ESI)(calc.) 335.4 (found) 336.4 (MH)+ ¹H NMR (DMSO-d₆) δ (ppm): 10.97 (s, 1H), 9.11 (s, 1 H), 7.65-7.59 (m, 4 H), 7.53-7.50 (m, 2 H), 7.44 (t, J =7.2 Hz, 2 H), 7.3 9-7.26 (m, 6 H), 4.96 (s, 1 H). 2

1-47 (cpd 42, ex 12) N-benzhydryl- N- hydroxyform- amide LRMS (ESI)(calc.) 227.3 (found) 228.2 (MH)+ ¹H NMR: (DMSO-d₆) 8.41 (br s, 1 H),7.44-7.28 (m, 11 H). LRMS: calc. 227.3, found 228.2

EXAMPLE 13 N-hydroxy-2-(4′-methoxybiphenyl-4-yl)-2-phenylacetamide (56)

Step 1: 2-(4-bromophenyl)-2-phenyloxirane (51)

To a stirring solution of trimethylsulfonium iodide (5.27 g, 19.15 mmol)in THF (20 mL) was added sodium hydride (0.957 g, 23.94 mmol) and thereaction mixture was stirred at 55° C. for 6 h. A solution of(4-bromophenyl)(phenyl)methanone 50 (5.0 g, 19.15 mmol) in THF (10 mL)was added and the mixture was stirred an additional 16 h at 55° C. Thereaction mixture was quenched with water, diluted with ether and layerseparated. The organic layer was dried over Na₂SO₄, filtered andconcentrated to afford 2-(4-bromophenyl)-2-phenyloxirane 51(quantitative yield) as a brown oil.

Step 2: 2-(4-bromophenyl)-2-phenylacetaldehyde (52)

A solution of 2-(4-bromophenyl)-2-phenyloxirane 51 (5.27 g, 19.15 mmol)and BF₃OEt₂ (3.29 g, 23.20 mmol) in benzene (50 mL) was shakenvigorously in a separatory funnel for 2 minutes then allowed to standfor 3 minutes. The resulting solution was washed twice with aq. sat.NaHCO₃ and the organic layer was separated, dried over Na₂SO₄ andconcentrated to afford 2-(4-bromophenyl)-2-phenylacetaldehyde 52. Thecrude was used in the next step.

Step 3: 2-(4-bromophenyl)-2-phenylacetic acid (53)

To a stirring solution of compound 52 (5.27 g, 19.15 mmol) in acetone(60 mL) cooled to −10° C. was added Jones Reagent (2.93 mL, 2.5 Msolution) drop wise. Isopropyl alcohol was then added until the reactionmixture turned green. The mixture was filtered through Celite, dilutedwith ethyl acetate and washed with NaOH. The organic layer was discardedand the aqueous layer was acidified with 1M HCl to pH 1 and furtherextracted with ethyl acetate. The combined organics were dried overNa₂SO₄, filtered and concentrated to afford2-(4-bromophenyl)-2-phenylacetic acid 53 (2 g, 36%) as a beige solid.

Step 4: methyl 2-(4-bromophenyl)-2-phenylacetate (54)

A solution of acid 53 (1.9 g, 6.53 mmol) in methanol (20 mL) was addedconcentrated sulfuric acid (2 mL) and the reaction mixture was stirredat 60° C. for 4 h. The organic layer was separated, dried over Na₂SO₄,filtered and concentrated to afford methyl2-(4-bromophenyl)-2-phenylacetate 54 (1.7 g, 85% yield) as a brown oil.

Step 5: methyl 2-(4′-methoxybiphenyl-4-yl)-2-phenylacetate (55)

To a degassed solution of bromide 54 (0.33 g, 1.081 mmol),4-methoxyphenylboronic acid (0.181 g, 1.190 mmol), POT (0.023 g, 0.076mmol) and potassium carbonate (0.747 g, 5.41 mmol) in DME (15 mL) andwater (7.5 mL) was added Pd(PPh₃)₄ (0.087 g, 0.076 mmol). The reactionmixture was stirred at 80° C. for 16 h and diluted with ethyl acetate,washed with water, dried over Na₂SO₄, filtered and concentrated toafford compound 55 (0.11 g, 31% yield) as a white solid afterpurification by ISCO (2 to 40% EtOAc/hexane).

Alternate condition for formation of Ar—Ar′:

PdCl₂(dppf), aryl boronic acid (1.25 eq), 2N Na₂CO₃, toluene, 80° C., 18h.

Step 6: N-hydroxy-2-(4′-methoxybiphenyl-4-yl)-2-phenylacetamide (56)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 55, the title compound 56 wasobtained as white solid in a 40% yield (0.04 g). ¹H NMR (DMSO-d₆) δ(ppm): 10.94 (s, 1H), 8.98 (s, 1H), 7.55 (t, J=8.8 Hz, 4H), 7.37-7.29(m, 6H), 7.25-7.23 (m, 1H), 7.00 (d, J=8.8 Hz, 2H), 4.73 (s, 1H), 3.77(s, 3H). LRMS (ESI): (calc.) 333.4 (found) 334.4 (MH)+.

EXAMPLES 14A AND 14BN-hydroxy-2-phenyl-2-(4-(3-thio-dioxide-morpholinoprop-1-ynyl)phenyl)acetamide(59)N-hydroxy-2-phenyl-2-(4-(3-thio-dioxide-morpholinopropyl)phenyl)acetamide(61)

Step 1: methyl2-phenyl-2-(4-(3-thio-dioxide-morpholinoprop-1-ynyl)phenyl)acetate (58)

To a degassed solution of bromo-ester 54 (0.881 g, 2.89 mmol), alkyne 57(1.0 g, 5.77 mmol), copper iodide (0.110 g, 0.577 mmol), tetrabutylammonium iodide (0.320 g, 0.866 mmol) and triethylamine (4.0 mL)in DMF(8.0 mL) was added PdCl₂(PPh₃)₂ (0.203 g, 0.289 mmol). The reactionmixture was heated at 75° C. for 16 h, cooled to room temperature,diluted with brine and extracted with EtOAc. The combined organicextracts were dried over Na₂SO₄, filtered and concentrated to afford 58(0.527 g, 46% yield) as a light yellow solid after purification by flashchromatography (25 to 100% EtOAc in hexanes). LRMS (ESI): (calc) 397.49(found) 398.5 (MH)+.

Alternate reaction conditions for Sonogashira reaction:

PdCl₂(PPh₃)₂, CuI, piperidine, MeCN, 80° C., 18 h.

PdCl₂(PPh₃)₂, CuI, TEA, 90° C., 18 h.

Pd(PPh₃)₄, CuI, TEA, 90° C., 18 h.

PdCl₂(PPh₃)₂, CuI, K₂CO₃, DMF, 110° C., 18 h.

Pd(PPh₃)₄, CuI, K₂CO₃, DMF, 110° C., 18 h.

Pd(OAc)₂, PPh₃, NaOAc, DMF, 110° C., 18 h.

Step 2:N-hydroxy-2-phenyl-2-(4-(3-thio-dioxide-morpholinoprop-1-ynyl)phenyl)acetamide(59)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 58, the title compound 59 wasobtained in 17% yield (51 mg) as dark beige color.

¹H NMR (MeOH-d4) δ (ppm): 7.42-7.39 (m, 2H), 7.36-7.27 (m, 7H), 4.81 (s,1H), 3.72 (s, 2H), 3.22-3.15 (m, 8H). LRMS (ESI): (calc.) 398.5 (found)397.5 (MH)−.

Step 3: methyl2-phenyl-2-(4-(3-thio-dioxide-morpholinopropyl)phenyl)acetate (60)

Following the same procedure as described in Example 10, step 1, butsubstituting 2-nitro-4-(thiophen-2-yl)aniline for compound 58, the titlecompound 60 (0.205 g, 90%) was obtained as a light yellow oil. LRMS(ESI): (calc) 401.52 (found) 402.3 (MH)+.

Step 4:N-hydroxy-2-phenyl-2-(4-(3-thio-dioxide-morpholinopropyl)phenyl)acetamide(61)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 60, the title compound 61 (33 mg,16%) was obtained.

¹H NMR (MeOH-d4) δ (ppm): 7.36-7.17 (m, 9H), 4.77 (s, 1H), 3.12-3.06 (m,4H), 3.01-2.94 (m, 4H), 2.67 (t, J=7.6 Hz, 2H), 2.54 (t, J=7.6 Hz, 2H),1.88-1.78 (m, 2H). LRMS (ESI): (calc.) 402.5 (found) 403.5 (MH)+.

EXAMPLE 15N-hydroxy-2-phenyl-2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)phenyl)acetamide(64)

Step 1: methyl2-phenyl-2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)phenyl)acetate (63)

To a stirring solution of 1-phenylpiperazine 62 (0.159 g, 0.983 mmol)and bis(tri-tert-butylphosphine)palladium in benzene (2 mL) was addedbromoester 54 (0.250 g, 0.819 mmol) and cesium carbonate (0.587 g, 1.802mmol). The reaction mixture was heated to 110° C. overnight, dilutedwith ethyl acetate, washed with water, dried over Na₂SO₄, filtered andconcentrated to afford the methyl ester 63 (0.134 g, 42% yield) afterpurification by flash chromatography (20 to 90% EtOAc in hexane).Alternate procedures for formation of RR′N—Ar:

-   -   1. Pd (II) acetate, cesium carbonate, tri-tert-butylphosphine        tetrafluoroborate, THF, 100° C., 2 days.    -   2. Copper (I) iodide (0.05 eq),        (1R,2R)—N1,N2-dimethylcyclohexane-1,2-diamine (0.2 eq),        potassium phosphate (2.1 eq) or potassium carbonate (2.2 eq),        toluene or DMSO, 110° C., 16 h.    -   3. Pd₂(dba)₃ (0.02 eq), Xantphos (0.06 eq), cesium carbonate        (1.7 eq), dioxane, 100° C., 16 h.    -   4. Pd₂(dba)₃, P(tBu)₂(PhPh), NaOtBu, toluene, 100° C., 18 h.

Step 2:N-hydroxy-2-phenyl-2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)phenyl)acetamide(64)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 63, the title compound 64 (35 mg,26%) was obtained as white solid. ¹H NMR (MeOH-d4) δ (ppm): 8.32 (d,J=4.8 Hz, 2H), 7.29-7.20 (m, 7H), 6.97 (d, J=8.8 Hz, 2H), 6.60 (t, J=4.8Hz, 1H), 4.69 (s, 1H), 3.93 (m, 4H), 3.20 (m, 4H). LRMS (ESI): (calc.)389.4 (found) 390.5 (MH)+.

EXAMPLES 16A, 16B AND 16C2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide (70)N-hydroxy-2-(4-hydroxyphenyl)-2-phenylacetamide (72)N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide (74)

Step 1: 2-(4-(benzyloxy)phenyl)-2-phenyloxirane (66)

Following the same procedure as described in Example 13 (Scheme 13),step 1, but substituting compound 50 for compound 65, the title compound66 (quantitative yield) was obtained as a light yellow oil.

Step 2: 2-(4-(benzyloxy)phenyl)-2-phenylacetaldehyde (67)

Following the same procedure as described in Example 13 (Scheme 13),step 2, but substituting compound 51 for compound 66, the title compound67 (taken on to Step 3 as a crude mixture).

Step 3: 2-(4-(benzyloxy)phenyl)-2-phenylacetic acid (68)

Following the same procedure as described in Example 13 (Scheme 13),step 3, but substituting compound 52 for compound 67, the title compound68 (4.2 g, 30.4%) was obtained as a white solid.

Step 4: methyl 2-(4-(benzyloxy)phenyl)-2-phenylacetate (69)

Following the same procedure as described in Example 13 (Scheme 13),step 4, but substituting compound 53 for compound 68, the title compound69 (3.8 g, 89%) was obtained as a yellow solid.

¹H NMR (DMSO-d₆) δ (ppm): 7.44-7.21 (m, 12H), 6.99-6.95 (m, 2H), 5.14(s, 1H), 5.07 (s, 2H), 3.65 (s, 3H).

Step 5: 2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide (70)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 69, the title compound 70 (0.07 g,25%) was obtained as a white solid. ¹H NMR (DMSO-d6) δ (ppm) 1H, 10.86(s, 1H), 8.92 (s, 1H), 7.42-7.17 (m, 12H), 6.93 (d, J=8.8 Hz, 2H), 5.05(s, 2H), 4.62 (s, 1H). LRMS (ESI): (calc.) 333.4 (found) 334.4 (MH)+.

Step 6: methyl 2-(4-hydroxyphenyl)-2-phenylacetate (71)

Following the same procedure as described in Example 10, step 1, butsubstituting 2-nitro-4-(thiophen-2-yl)aniline for compound 69, the titlecompound 71 (2.65 g, 96%) was obtained as an orange oil.

Step 7: N-hydroxy-2-(4-hydroxyphenyl)-2-phenylacetamide (72)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 71, the title compound 72 (0.09 g,35%) was obtained as a white solid. ¹H NMR (DMSO-d6) δ (ppm) 1H: 10.83(s, 1H), 9.29 (s, 1H), 8.89 (s, 1H), 7.30-7.16 (m, 5H), 7.10 (d, J=8.6Hz, 2H), 6.67 (d, J=8.6 Hz, 2H), 4.55 (s, 1H). LRMS (ESI): (calc.) 243.3(found) 244.3 (MH)+.

Step 8: methyl 2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetate (73)

A stirring solution of compound 71 (1.5 g, 6.19 mmol),4-(2-chloroethyl)morpholine hydrochloride (1.152 g, 6.19 mmol) andpotassium carbonate (1.709 g, 12.38 mmol) in (1:1) DMF: acetone (60 mL)was heated to 60° C. for 16 h then concentrated. The crude residue wasdiluted with ethyl acetate and washed with water, dried over Na₂SO₄,filtered and concentrated to afford compound 73 (0.92 g, 42%) afterpurification by ISCO-HPLC (20 to 100% ethyl acetate in hexanes).

Supplementary Procedure:

A solution of phenol 71 (3.43 mmol), alcohol (3.43 mmol), DEAD (4.11mmol) and triphenylphosphine (4.45 mmol) in THF was stirred at roomtemperature for 16 h then concentrated. The crude product was dilutedwith ethyl acetate and washed with water, dried over Na₂SO₄, filteredand concentrated to afford the product (26 to 63% yields) which can befurther manipulated using chemistry already described.

Alternate Conditions for Step 8:

KBr, K₂CO₃, KI, acetone, 50° C., 18 h, followed by scavenging withPS-Ph₃ (for remaining hydroxy SM) then ambersep (for remaining alkylhalide).

Step 9: N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide(74)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 73, the title compound 74 (0.315 g,34%) was obtained as a white solid. ¹H NMR (DMSO-d6) δ (ppm) 1H, 10.88(s, 1H), 8.94 (s, 1H), 7.30-7.20 (m, 7H), 6.87 (d, J=8.8 Hz, 2H), 4.62(s, 1H), 4.03 (t, J=5.7 Hz, 2H), 3.56 (t, J=4.7 Hz, 4H), 2.65 (t, J=5.7Hz, 2H), 2.46-2.43 (m, 4H).

EXAMPLE 17 N-hydroxy-2-phenyl-2-(pyridin-3-yl)acetamide (80)

Step 1: Phenyl(pyridin-3-yl)methanol (76)

To a stirring solution of nicotinaldehyde 75 (0.876 mL, 9.34 mmol) inTHF (20 mL) at 0° C. was slowly added a 1M phenylmagnesium bromidesolution (9.34 mL, 9.34 mmol) and the reaction mixture was allowed towarm to room temperature over 30 minutes. The crude solution was dilutedwith ethyl acetate and washed with water, dried over Na₂SO₄, filteredand concentrated to afford compound 76 (1.7 g, 98% yield) afterpurification by flash chromatography (50 to 100% EtOAc in hexanes).

Step 2: 2-phenyl-2-(pyridin-3-yl)acetonitrile (77)

To a solution of triphenylphosphine (3.83 g, 14.61 mmol) in THF (40 mL)at 0° C. was added DEAD (2.54 g, 14.61 mmol) drop wise and the reactionmixture was stirred for 20 minutes. Compound 76 (1.78 g, 9.61 mmol) wasadded to the reaction mixture and stirred for an additional 20 minutes.Then acetone cyanohydrin (1.319 mL, 14.42 mmol) was added, stirred for 1h at 0° C. and 18 h at room temperature. The reaction mixture wasconcentrated then purified by flash chromatography to afford 77 (0.972g, 52%).

Step 4: 2-phenyl-2-(pyridin-3-yl)acetic acid (78)

A solution of compound 77 (0.822 g, 4.23 mmol) in 10% aqueous NaOH(15.24 mL, 38.1 mmol) was heated at reflux for 2 h then neutralized topH 7 by the addition of 3M HCl. The crude was concentrated to affordcompound 78 (0.380 g, 42%). LRMS (ESI): (calc) 213.23 (found) 214.1(MH)⁺

Step 5: methyl 2-phenyl-2-(pyridin-3-yl)acetate (79)

Following the same procedure as described in Example 1, step 1, butsubstituting compound 1 for compound 78 and H₂SO₄ for HCl, the titlecompound 79 (0.326 g, 80%) was obtained. LRMS (ESI): (calc) 227.26(found) 228.3 (MH)+

Step 6: N-hydroxy-2-phenyl-2-(pyridin-3-yl)acetamide (80)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 79, the title compound 80 (0.162 g,50%) was obtained.

¹H NMR (MeOH-d4) δ (ppm): 8.47 (d, J=2.4 Hz, 1H), 8.43 (q, J=1.6, 4.8Hz, 1H), 7.48 (m, 1H), 7.41-7.28 (m, 6H), 4.83 (s, 1H). LRMS (ESI):(calc.) 228.0 (found) 229.2 (MH)+

EXAMPLE 18 10-benzyl-N-hydroxy-9,10-dihydroacridine-9-carboxamide (85)

Step 1: methyl acridine-9-carboxylate (82)

A solution of acridine-9-carboxylic acid 81 (2.0 g, 8.96 mmol), methyliodide (3.82 g, 26.9 mmol) and potassium carbonate (4.95 g, 35.8 mmol)in DMF (25 mL) was stirred at room temperature for 3 h then diluted withbrine and extracted with EtOAc. The combined organic layers were driedover Na₂SO₄, filtered and concentrated to afford compound 82 (1.65 g,78%) as a light yellow solid. LRMS (ESI): (calc) 237.25 (found) 238.2(MH)+

Step 2: 10-benzyl-9-(methoxycarbonyl)acridiniumtrifluoromethanesulfonate (83)

To a stirred solution of triflic anhydride (0.483 mL, 2.87 mmol) in DCM(6 mL) at −78° C. was slowly added a solution of benzyl alcohol (0.298mL, 2.87 mmol) and 2,6-di-t-butyl-4-methylpyridine (0.59 g, 2.87 mmol)in DCM (2 mL). After 10 minutes of stirring, the compound 74 (0.620 g,2.61 mmol) in DCM (2 mL) was added, and the reaction allowed to warm toroom temperature. The solution was stirred a further 16 h. The crude wasconcentrated under reduced pressure, and the residue purified by columnchromatography on silica gel using 10% MeOH in DCM as the eluent toafford the title compound 83 (1.05 g, 85%) as a yellow solid. LRMS(ESI): (calc) 328.38 (found) 328.3 (MH)+

Step 3: methyl 10-benzyl-9,10-dihydroacridine-9-carboxylate (84)

To a stirring solution of compound 83 (1.05 g, 3.20 mmol) and ammoniumchloride (2.67 g, 49.8 mmol) in ethanol (35 mL) was added zinc (2.67 g,40.8 mmol) and the reaction mixture was heated at 80° C. for 30 minutesthen filtered through a pad of Celite®. The solution was diluted withbrine, extracted with EtOAc, and the combined organics were dried over,filtered and concentrated to afford compound 84 (0.248 g, 24%) as awhite solid after purification by flash chromatography (10 to 40% EtOAcin hexanes). LRMS (ESI): (calc) 329.39 (found) 330.5 (MH)+

Step 4: 10-benzyl-N-hydroxy-9,10-dihydroacridine-9-carboxamide (85)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 84, the title compound 85 (29 mg,12%) as a light yellow solid. ¹H NMR (MeOH-d4) δ (ppm): 7.36-7.31 (m,2H), 7.29-7.21 (m, 5H), 7.17-7.11 (m, 2H), 6.91 (td, J=7.4, 1.0 Hz, 2H),6.81-6.78 (m, 2H), 5.22 (s, 2H), 4.85 (s, 1H). LRMS (ESI): (calc.) 330.4(found) 331.4 (MH)+

EXAMPLE 19N-hydroxy-2-phenyl-2-(1-(pyrimidin-2-yl)piperidin-4-yl)acetamide (94)

Step 1: benzyl 4-benzoylpiperidine-1-carboxylate (87)

To a stirring suspension of phenyl(piperidin-4-yl)methanonehydrochloride 86 (1.97 g, 8.73 mmol) and potassium carbonate (3.62 g,26.2 mmol) in THF (40 mL) at 0° C. was added benzyl chloroformate (1.433mL, 10.04 mmol) and the reaction mixture was allowed to slowly warm toroom temperature and stirred for 2 h. The mixture was diluted with ethylacetate, washed with brine, water, dried over Na₂SO₄, filtered andconcentrated to afford compound 87 quantitative yield. LRMS (ESI):(calc) 323.39 (found) 324.31 (MH)+

Step 2: benzyl 4-(2-phenyloxiran-2-yl)piperidine-1-carboxylate (88)

A mixture of trimethylsulfoxonium iodide (2.402 g, 10.91 mmol) andsodium hydride (0.436 g, 10.91 mmol) in THF (20 mL) was heated at 55° C.for 3 h then a solution of compound 87 (2.82 g, 8.73 mmol) in THF (10mL) was added. The reaction mixture was stirred for 36 h, quenched withwater, extracted with ether and the combined organics were washed withwater, brine, dried over Na₂SO₄, filtered and concentrated to affordcompound 88 used as a crude in the next step.

Step 3: benzyl 4-(2-oxo-1-phenylethyl)piperidine-1-carboxylate (89)

Following the same procedure as described in Example 13 (Scheme 13),step 2, but substituting compound 51 for compound 88, the title compound89 was obtained.

Step 4: 2-(1-(benzyloxycarbonyl)piperidin-4-yl)-2-phenylacetic acid (90)

Following the same procedure as described in Example 13 (Scheme 13),step 3, but substituting compound 52 for compound 89, the title compound90 (1.281 g, 42%) was obtained as a white foam. LRMS (ESI): (calc)353.41 (found) 354.31 (MH)+. ¹H NMR (DMSO-d₆) δ (ppm): 12.43 (s, 1H),7.38-7.23 (m, 10H), 5.04 (s, 2H), 4.03 (d, J=13.5 Hz, 1H), 3.90 (d,J=13.3 Hz, 1H), 3.24 (d, J=10.6 Hz, 1H), 2.89-2.67 (m, 2H), 2.13-2.06(m, 1H), 1.77 (d, J=12.3 Hz, 1H), 1.21-1.09 (m, 2H), 0.95-0.85 (m, 1H).

Step 5: benzyl 4-(2-methoxy-2-oxo-1-phenylethyl)piperidine-1-carboxylate(91)

To a stirring solution of compound 90 (1.281 g, 3.62 mmol) in THF (40mL) was added an excess of diazomethane at room temperature and thereaction mixture was stirred for 15 minutes. Nitrogen was bubbled intothe reaction mixture for 15 minutes then it was concentrated to affordcompound 91 (1.032 g, 77%) as a colorless oil after purification by ISCO(0 to 50% EtOAc in hexanes). LRMS (ESI): (calc) 367.44 (found) 368.16(MH)+. ¹H NMR (CD₃OD-d4) δ (ppm):7.33-7.23 (m, 10H), 5.09 (s, 2H),4.18-4.14 (m, 1H), 4.05-4.01 (m, 1H), 3.63 (s, 3H), 3.33-3.30 (m, 1H),2.86-2.72 (m, 2H), 2.21 (qt, J=11.3, 3.5 Hz, 1H), 1.78 (d, J=12.7 Hz,1H), 1.28-1.18 (m, 2H), 0.96 (qd, J=12.5, 4.3 Hz, 1H).

Step 6: methyl 2-phenyl-2-(piperidin-4-yl)acetate (92)

Following the same procedure as described in Example 10, step 1, butsubstituting 2-nitro-4-(thiophen-2-yl)aniline for compound 91, and MeOHfor EtOH, the title compound 92 (0.384 g, 99%) was obtained as acolorless oil. LRMS (ESI): (calc) 233.31 (found) 234.14 (MH)+

Step 7: methyl 2-phenyl-2-(1-(pyrimidin-2-yl)piperidin-4-yl)acetate (93)

Following the same procedure as described in Example 15 (Scheme 15),step 1, but substituting compound 54 for 2-chloropyrimidine, compound 62for compound 92, Cs₂CO₃/Pd(PtBu₃)₂ for potassium carbonate and benzenefor DMSO, the title compound 93 (0.232 g, 78%) was obtained as a whitesolid. LRMS (ESI): (calc) 311.38 (found) 312.32 (MH)+

Alternate Procedure for Methyl2-(1-benzoylpiperidin-4-yl)-2-phenylacetate:

To a stirring solution of compound 92 (0.159 g, 0.682 mmol) andtriethylamine (0.2 mL, 1.435 mmol) in MeCN (10 mL) was added benzoylchloride (0.10 mL, 0.862 mmol) and the reaction mixture was stirred for2 h at room temperature. The reaction was diluted with ethyl acetate,washed with sat. aq. Na₂CO₃, water, brine, dried over Na₂SO₄, filteredand concentrated to afford the desired compound (0.196 g, 85%) as acolorless oil. LRMS (ESI): (calc) 337.41 (found) 338.35 (MH)+

Step 8: N-hydroxy-2-phenyl-2-(1-(pyrimidin-2-yl)piperidin-4-yl)acetamide(94)

Following the same procedure as described in Example 1, step 2, butsubstituting compound 2 for compound 93, the title compound 94 (29 mg,12%) was obtained as a white solid. ¹H NMR (DMSO-d6) δ (ppm): 10.63 (s,1H), 8.82 (s, 1H), 8.31 (d, J=4.8 Hz, 2H), 7.35-7.28 (m, 4H), 7.25-7.21(m, 1H), 6.57 (t, J=4.8 Hz, 1H), 4.65 (d, J=13.6 Hz, 1H), 4.51 (d,J=13.6 Hz, 1H), 2.93-2.84 (m, 2H), 2.75 (td, J=12.6, 2.4 Hz, 1H),2.30-2.22 (m, 1H), 1.77 (d, J=12.0 Hz, 1H), 1.22-1.06 (m, 2H), 0.92-0.82(m, 1H). LRMS (ESI): (calc) 312.37 (found) 313.27 (MH)+

General Procedures

General Procedure for Scheme 20: Step 1: General Structure 20b

To a stirring solution of compound 21 (1 eq), and amine 20a (1 eq), insolvent (acetone, THF, DCE or MeCN) was added base (1.5 eq) (K₂CO₃,CsCO₃, KOH, NaH or DIPEA) at room temperature. The reaction mixture wasstirred for 24 then scavenged with PS-NCO and PS-AMPS, filtered andconcentrated. To this residue was added 4N HCl in dioxane at roomtemperature and the reaction mixture was stirred for 2 h thenconcentrated to provide the HCl salt of 20b.

Step 2: General Structure 20c1, 20c2, 20c3, 20c4 Capping (to ProvideAmides, Sulfonamides or Ureas):

A solution of compound 20b with acid chloride, sulfonyl chloride orisocyante was stirred with PS-DIPEA in DCE at room temperature for 18 h.The reaction mixture was filtered and concentrated to provide 20c-1,20c2 and 20c3.

Reductive Amination (to Provide Amines):

To a stirring solution of compound 20b and aldehyde (1.5-2.0 eq) in DCEwas added NaBH(OAc)₃ and AcOH at room temperature. The reaction mixturewas stirred at room temperature for 18 h followed by basic wash orfiltration onto MP-TsOH to provide amine 20c4.

Step 3: General Structure 20d1, 20d2, 20d3, 20d4

To a stirring solution of compound 20c-1, 20c2, 20c3 and 20c4 inMeOH:THF (1:1) was added 50% NH₂OH in H₂O: 4N KOH (1:1) at roomtemperature and the reaction mixture was stirred for 18 h. The reactionmixture was concentrated and the resulting residue was triturated withDCE, dried with MgSO₄ then filtered to provide 20d1, 20d2, 20d3 and20d4. If required, the final compounds were further purified by prepHPLC.

General Procedure for Scheme 21: Steps 1 and 2: methyl2-(4-nitrophenyl)-2-phenylacetate (21c)

Following the same procedure as described in Scheme 13, steps 1 to 3 butsubstituting compound 50 with compound 21a, the title compound 21c wasobtained.

Step 3: methyl 2-(4-aminophenyl)-2-phenylacetate (21d)

Following the same procedure as described in Scheme 10, step 1 butsubstituting 2-nitro-4-(thiophen-2-yl)aniline with compound 21c, thetitle compound 21d was obtained.

Step 4: General Structure (21e1-4) Capping (to Provide Amides orSulfonamides)

-   -   1. amides: A solution of amine intermediate 21d1, acid chloride        and PS-DIPEA was stirred in DCE at room temperature for 18 h.        The reaction mixture was then scavenged using PS-AMPS and        PS-NCO, filtered and concentrated to provide 21e1.    -   2. sulfonamides: A solution of amine intermediate 21d2, sulfonyl        chloride and DMAP was stirred in pyridine at room temperature        for 18 h. The reaction mixture was then scavenged using PS-AMPS        and PS-NCO, filtered and concentrated to provide 212e.

Reductive Amination (to Provide Amines)

A solution of amine intermediate 21d4, aldehyde and STAB was stirred insolvent at room temperature. The reaction mixture was then scavengedusing PS-AMPS and PS-NCO, filtered and concentrated to provide 21e4.

Step 5: general structure (21f1-4)

To a stirring solution of compound 21e1-4 in MeOH:THF (1:1) was added50% NH₂OH in H₂O: 4N KOH (1:1) at room temperature and the reactionmixture was stirred for 18 h. The reaction mixture was concentrated andthe resulting residue was triturated with DCE, dried with MgSO₄ thenfiltered to provide 21f1-4. If required, the final compounds werefurther purified by prep HPLC.

TABLE II Compounds prepared according general Schemes 20 and 21 andother Schemes. Cpd # Chemical name MS Scheme 2-5 2-(3-butoxyphenyl)-LRMS (ESI): (calc) 299.3642 (found) 300.16 (MH)+ 16 N-hydroxy-2- HPLC:92% RT: 4.13 min phenylacetamide 1H NMR (250 MHz, CHLOROFORM-d) d ppm7.04-7.23 (6H, m), 6.64-6.73 (3H, m), 4.70 (1H, s), 3.79 (2H, t, J =6.40 Hz), 1.55-1.69 (2H, m), 1.28-1.44 (2H, m), 0.86 (3H, t, J = 7.31Hz) 2-6 2-(3- LRMS (ESI): (calc) 333.3804 (found) 334.18 (MH)+ 16(benzyloxy)phenyl)- HPLC: 92% RT: 4.08 min N-hydroxy-2- phenylacetamide2-7 N-hydroxy-2-(3- LRMS (ESI): (calc) 347.407 (found) 348.17 (MH)+ 16phenethoxyphenyl)-2- HPLC: 91% RT: 4.24 min phenylacetamide 2-8 2-(3-(4-LRMS (ESI): (calc) 351.3709 (found) 352.15 (MH)+ 16fluorobenzyloxy)phenyl)- HPLC: 92% RT: 4.13 min N-hydroxy-2-phenylacetamide 2-9 N-hydroxy-2-(3-(3- LRMS (ESI): (calc) 363.4064(found) 364.17 (MH)+ 16 methoxybenzyloxy)phenyl)- HPLC: 100% RT: 4.08min 2- 1H NMR (360 MHz, CHCl₃-d) d ppm 7.19-7.33 (7H, phenylacetamidem), 6.96-7.01 (2H, m), 6.87-6.92 (3H, m), 6.82 (1H, d, J = 7.72 Hz),4.99 (2H, s), 4.84 (1H, s), 3.82 (3H, s) 2-10 2-(4-butoxyphenyl)- LRMS(ESI): (calc) 299.3642 (found) 300.16 (MH)+ 16 N-hydroxy-2- HPLC: 97%RT: 4.14 min phenylacetamide 1H NMR (250 MHz, CHCl₃-d) d ppm 7.17-7.24(3H, m), 7.10-7.17 (2H, m), 7.03 (2H, d, J = 8.53 Hz), 6.75 (2H, d, J =8.53 Hz), 4.75 (1H, s), 3.85 (2H, t, J = 6.55 Hz), 1.61-1.74 (2H, m),1.33-1.48 (2H, m), 0.89 (3H, t, J = 7.31 Hz) 2-11 N-hydroxy-2-(4-(2-LRMS (ESI): (calc) 370.399 (found) 371.2 (MH)+ 16 morpholino-2- HPLC:100% RT: 3.06 min oxoethoxy)phenyl)-2- phenylacetamide 2-12N-hydroxy-2-(4- LRMS (ESI): (calc) 347.407 (found) 348.17 (MH)+ 16phenethoxyphenyl)-2- HPLC: 91% RT: 4.25 min phenylacetamide 2-13(2-(4-(4- LRMS (ESI): (calc) 351.3709 (found) 352.14 (MH)+ 16fluorobenzyloxy)phenyl)- HPLC: 93% RT: 4.14 min N-hydroxy-2-phenylacetamide 2-14 N-hydroxy-2-(4-(3- LRMS (ESI): (calc) 363.4064(found) 364.17 (MH)+ 16 methoxybenzyloxy)phenyl)- HPLC: 90% RT: 4.09 min2- phenylacetamide 2-15 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 257.2845(found) 258.05 (MH)+ 2 2-(p- HPLC: 91% RT: 3.64 min tolyloxy)acetamide2-16 2-(2,3-dihydro-1H- LRMS (ESI): (calc) 283.3217 (found) 284.08 (MH)+2 inden-5-yloxy)-N- HPLC: 86% RT: 3.90 min hydroxy-2- phenylacetamide2-17 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 297.3483 (found) 298.14(MH)+ 2 2-(5,6,7,8- HPLC: 100% RT: 4.11 min tetrahydronaphthalen-1-yloxy)acetamide 2-18 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 301.337(found) 302.11 (MH)+ 2 methoxyethyl)phenoxy)- HPLC: 93% RT: 3.50 min2-phenylacetamide 2-19 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 312.363(found) 313.14 (MH)+ 2 2-(2-(pyrrolidin-1- HPLC: 99% RT: 2.63 minyl)phenoxy)acetamide 2-20 N-hydroxy-2-phenyl- LRMS (ESI): (calc)273.3501 (found) 274.06 (MH)+ 2 2-(p- HPLC: 100% RT: 3.77 mintolylthio)acetamide 1H NMR (400 MHz, DMSO-d6) d ppm 10.93 (1H, br. s.),9.13 (1H, br. s.), 7.50-7.54 (2H, m), 7.31-7.41 (3H, m), 7.24-7.28 (2H,m), 7.15-7.19 (2H, m), 4.87 (1H, s), 2.31 (3H, s) 2-21 N-hydroxy-2-(4-LRMS (ESI): (calc) 301.4032 (found) 302.11 (MH)+ 2 isopropylphenylthio)-HPLC: 100% RT: 4.16 min 2-phenylacetamide 2-22 2-(4-butyryl-1,4- LRMS(ESI): (calc) 319.3987 (found) 320.2 (MH)+ 20 diazepan-1-yl)-N- HPLC:91% RT: 2.23 min hydroxy-2- phenylacetamide 2-23 2-(4-butyrylpiperazin-LRMS (ESI): (calc) 305.3721 (found) 306.21 (MH)+ 20 1-yl)-N-hydroxy-2-HPLC: 100% RT: 2.37 min phenylacetamide 2-24 N-hydroxy-2-phenyl- LRMS(ESI): (calc) 333.4252 (found) 334.2 (MH)+ 20 2-(4-pivaloyl-1,4- HPLC:91% RT: 2.44 min diazepan-1- yl)acetamide 2-25 N-hydroxy-2-phenyl- LRMS(ESI): (calc) 319.3987 (found) 320.2 (MH)+ 20 2-(4- HPLC: 90% RT: 2.56min pivaloylpiperazin-1- yl)acetamide 2-26 2-(4-(furan-2- LRMS (ESI):(calc) 343.377 (found) 344.2 (MH)+ 20 carbonyl)-1,4- HPLC: 92% RT: 2.23min diazepan-1-yl)-N- hydroxy-2- phenylacetamide 2-27 2-(4-(furan-2-LRMS (ESI): (calc) 329.3504 (found) 330.15 (MH)+ 20carbonyl)piperazin-1- HPLC: 94% RT: 2.43 min yl)-N-hydroxy-2-phenylacetamide 2-28 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 353.4149(found) 354.22 (MH)+ 20 2-(4-(2- HPLC: 100% RT: 2.79 minphenylacetyl)piperazin- 1-yl)acetamide 2-29 N-hydroxy-2-(4-(3- LRMS(ESI): (calc) 367.4415 (found) 368.2 (MH)+ 20 methylbenzoyl)-1,4- HPLC:88% RT: 1.36 min diazepan-1-yl)-2- phenylacetamide 2-30N-hydroxy-2-(4-(3- LRMS (ESI): (calc) 353.4149 (found) 354.22 (MH)+ 20methylbenzoyl)piperazin- HPLC: 100% RT: 2.92 min 1-yl)-2-phenylacetamide 2-31 4-(2-(hydroxyamino)- LRMS (ESI): (calc) 334.4133(found) 335.24 (MH)+ 20 2-oxo-1-phenylethyl)- HPLC: 95% RT: 2.10 minN-isopropyl-1,4- diazepane-1- carboxamide 2-32 4-(2-(hydroxyamino)- LRMS(ESI): (calc) 320.3867 (found) 321.2 (MH)+ 20 2-oxo-1-phenylethyl)-HPLC: 93% RT: 2.07 min N- isopropylpiperazine- 1-carboxamide 2-334-(2-(hydroxyamino)- LRMS (ESI): (calc) 369.4176 (found) 370.18 (MH)+ 202-oxo-1-phenylethyl)- HPLC: 90% RT: 2.91 min N-(pyridin-3-yl)-1,4-diazepane-1- carboxamide 2-34 4-(2-(hydroxyamino)- LRMS (ESI): (calc)355.391 (found) 356.17 (MH)+ 20 2-oxo-1-phenylethyl)- HPLC: 95% RT: 1.41min N-(pyridin-3- yl)piperazine-1- carboxamide 2-35 4-(2-(hydroxyamino)-LRMS (ESI): (calc) 382.4561 (found) 383.26 (MH)+ 202-oxo-1-phenylethyl)- HPLC: 92% RT: 2.49 min N-o-tolyl-1,4- diazepane-1-carboxamide 2-36 4-(2-(hydroxyamino)- LRMS (ESI): (calc) 368.4295(found) 369.2 (MH)+ 20 2-oxo-1-phenylethyl)- HPLC: 91% RT: 2.63 minN-o-tolylpiperazine-1- carboxamide 2-37 4-(2-(hydroxyamino)- LRMS (ESI):(calc) 398.4555 (found) 399.2 (MH)+ 20 2-oxo-1-phenylethyl)- HPLC: 89%RT: 2.58 min N-(3- methoxyphenyl)-1,4- diazepane-1- carboxamide 2-38N-hydroxy-2-(4-(1- LRMS (ESI): (calc) 379.434 (found) 380.17 (MH)+ 20methyl-1H-imidazol- HPLC: 97% RT: 2.35 min 4- ylsulfonyl)piperazin-1-yl)-2- phenylacetamide 2-39 N-hydroxy-2-(4-(1- LRMS (ESI): (calc)393.4606 (found) 394.2 (MH)+ 20 methyl-1H-imidazol- HPLC: 94% RT: 2.20min 4-ylsulfonyl)-1,4- diazepan-1-yl)-2- phenylacetamide 2-40N-hydroxy-2-phenyl- LRMS (ESI): (calc) 326.3928 (found) 327.19 (MH)+ 202-(4-(pyridin-3- HPLC: 99% RT: 1.09 min ylmethyl)piperazin-1-yl)acetamide 2-41 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 292.3303(found) 293.16 (MH)+ 7 2-(1,4-dioxa-8- HPLC: 100% RT: 2.00 minazaspiro[4.5]decan-8- yl)acetamide 2-42 N-hydroxy-2-(4- LRMS (ESI):(calc) 319.3987 (found) 320.2 (MH)+ 7 morpholinopiperidin- HPLC: 95% RT:2.97 min 1-yl)-2- phenylacetamide 2-43 N-hydroxy-2-phenyl- LRMS (ESI):(calc) 379.4124 (found) 380.17 (MH)+ 2-(4-(3-(pyridin-3-yl)- HPLC: 91%RT: 2.46 min 1,2,4-oxadiazol-5- yl)piperidin-1- yl)acetamide 2-442-(4-(3- LRMS (ESI): (calc) 422.4338 (found) 423.19 (MH)+(benzo[d][1,3]dioxol- HPLC: 91% RT: 2.99 min 5-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)- N-hydroxy-2- phenylacetamide 2-45N-hydroxy-2-phenyl- LRMS (ESI): (calc) 260.3115 (found) 261.01 (MH)+ 22-(pyridin-4- HPLC: 100% RT: 2.10 min ylthio)acetamide 2-46N-hydroxy-2-(2- LRMS (ESI): (calc) 263.3122 (found) 264.04 (MH)+ 2methylfuran-3-ylthio)- HPLC: 100% RT: 3.53 min 2-phenylacetamide 2-47N-hydroxy-2-phenyl- LRMS (ESI): (calc) 328.3095 (found) 329.08 (MH)+2-(5- HPLC: 90% RT: 3.83 min (trifluoromethyl)pyridin-2-ylthio)acetamide 2-48 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 343.4233(found) 344.08 (MH)+ 2 2-(4-(thiophen-2- HPLC: 94% RT: 3.68 minyl)pyrimidin-2- ylthio)acetamide 2-49 N-hydroxy-2-phenyl- LRMS (ESI):(calc) 378.3682 (found) 379.1 (MH)+ 2 2-(7- HPLC: 100% RT: 3.91 min(trifluoromethyl)quinolin- 1H NMR (400 MHz, DMSO-d6) d ppm 11.38 (1H,4-ylthio)acetamide s), 9.45 (1H, s), 9.05 (1H, d, J = 4.65 Hz), 8.57(1H, d, J = 8.80 Hz), 8.53 (1H, s), 8.11 (1H, dd, J = 8.80, 1.96 Hz),7.79-7.84 (2H, m), 7.66 (1H, d, J = 4.89 Hz), 7.51-7.61 (3H, m), 5.56(1H, s) 2-50 2-(3-(4- LRMS (ESI): (calc) 350.3861 (found) 351.4 (MH)+ 21fluorobenzylamino)phenyl)- HPLC: 94% RT: 3.87 min N-hydroxy-2-phenylacetamide 2-51 2-(4-(4- LRMS (ESI): (calc) 350.3861 (found) 351.4(MH)+ 21 fluorobenzylamino)phenyl)- HPLC: 92% RT: 3.87 min N-hydroxy-2-1H NMR (360 MHz, MeOH) d ppm 7.31-7.38 (2H, phenylacetamide m),7.18-7.28 (5H, m), 6.97-7.05 (4H, m), 6.53-6.59 (2H, m), 4.62 (1H, s),4.28 (2H, s) 2-52 2-(3- LRMS (ESI): (calc) 284.3098 (found) 285 (MH)+ 21acetamidophenyl)-N- HPLC: 87% RT: 2.95 min hydroxy-2- phenylacetamide2-53 N-(4-(2- LRMS (ESI): (calc) 326.3895 (found) 327.1 (MH)+ 21(hydroxyamino)-2- HPLC: 95% RT: 3.49 min oxo-1- phenylethyl)phenyl)-3-methylbutanamide 2-54 N-(3-(2- LRMS (ESI): (calc) 326.3895 (found)327.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 100% RT: 3.53 min oxo-1-phenylethyl)phenyl)- 3-methylbutanamide 2-55 N-(4-(2- LRMS (ESI): (calc)346.3792 (found) 347.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 98% RT: 3.57 minoxo-1- phenylethyl)phenyl)benzamide 2-56 N-(3-(2- LRMS (ESI): (calc)346.3792 (found) 347.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 100% RT: 3.59min oxo-1- 1H NMR (400 MHz, MeOD) d ppm 7.90-7.93 (2H,phenylethyl)phenyl)benzamide m), 7.63-7.68 (2H, m), 7.55-7.60 (1H, m),7.48-7.53 (2H, m), 7.31-7.39 (5H, m), 7.24-7.29 (1H, m), 7.12-7.17 (1H,m), 4.82 (1H, s) 2-57 N-(4-(2- LRMS (ESI): (calc) 352.4268 (found) 353.1(MH)+ 21 (hydroxyamino)-2- HPLC: 91% RT: 3.75 min oxo-1-phenylethyl)phenyl)cyclohexanecarboxamide 2-58 N-(3-(2- LRMS (ESI):(calc) 352.4268 (found) 353.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 90% RT:3.79 min oxo-1- phenylethyl)phenyl)cyclohexanecarboxamide 2-59N-hydroxy-2-phenyl- LRMS (ESI): (calc) 360.4058 (found) 361.1 (MH)+ 212-(4-(2- HPLC: 94% RT: 3.60 min phenylacetamido)phenyl)acetamide 2-60N-hydroxy-2-phenyl- LRMS (ESI): (calc) 360.4058 (found) 361.1 (MH)+ 212-(3-(2- HPLC: 92% RT: 3.63 min phenylacetamido)phenyl)acetamide 2-614-fluoro-N-(4-(2- LRMS (ESI): (calc) 364.3696 (found) 365.1 (MH)+ 21(hydroxyamino)-2- HPLC: 99% RT: 3.65 min oxo-1-phenylethyl)phenyl)benzamide 2-62 4-fluoro-N-(3-(2- LRMS (ESI): (calc)364.3696 (found) 365.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 87% RT: 3.68 minoxo-1- phenylethyl)phenyl)benzamide 2-63 N-(4-(2- LRMS (ESI): (calc)364.3945 (found) 365.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 98% RT: 3.74 minoxo-1- phenylethyl)phenyl)- 2,5-dimethylfuran-3- carboxamide 2-64N-(3-(2- LRMS (ESI): (calc) 364.3945 (found) 365.1 (MH)+ 21(hydroxyamino)-2- HPLC: 91% RT: 3.77 min oxo-1- phenylethyl)phenyl)-2,5-dimethylfuran-3- carboxamide 2-65 N-(4-(2- LRMS (ESI): (calc)366.4335 (found) 367.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 95% RT: 3.66 minoxo-1- phenylethyl)phenyl)- 3-methylthiophene-2- carboxamide 2-66N-(3-(2- LRMS (ESI): (calc) 366.4335 (found) 367.1 (MH)+ 21(hydroxyamino)-2- HPLC: 93% RT: 3.68 min oxo-1- phenylethyl)phenyl)-3-methylthiophene-2- carboxamide 2-67 N-hydroxy-2-(4-(2- LRMS (ESI):(calc) 376.4052 (found) 753 (2M + H)+ 21 phenoxyacetamido)phenyl)- HPLC:100% RT: 3.72 min 2- 1H NMR (400 MHz, MeOD) d ppm 7.53-7.59 (2H,phenylacetamide m), 7.23-7.33 (9H, m), 6.98-7.06 (3H, m), 4.77 (1H, s),4.65 (2H, s) 2-68 N-hydroxy-2-(3-(2- LRMS (ESI): (calc) 376.4052 (found)377.1 (MH)+ 21 phenoxyacetamido)phenyl)- HPLC: 100% RT: 3.74 min 2-phenylacetamide 2-69 N-(3-(2- LRMS (ESI): (calc) 376.4052 (found) 377.1(MH)+ 21 (hydroxyamino)-2- HPLC: 95% RT: 3.61 min oxo-1-phenylethyl)phenyl)- 4-methoxybenzamide 2-70 3-cyclohexyl-N-(4-(2- LRMS(ESI): (calc) 380.48 (found) 381.2 (MH)+ 21 (hydroxyamino)-2- HPLC: 98%RT: 4.18 min oxo-1- phenylethyl)phenyl)propanamide 2-713-cyclohexyl-N-(3-(2- LRMS (ESI): (calc) 380.48 (found) 381.2 (MH)+ 21(hydroxyamino)-2- HPLC: 100% RT: 4.20 min oxo-1-phenylethyl)phenyl)propanamide 2-72 3-chloro-N-(4-(2- LRMS (ESI): (calc)380.8242 (found) 381.5 (MH)+ 21 (hydroxyamino)-2- HPLC: 91% RT: 3.87 minoxo-1- phenylethyl)phenyl)benzamide 2-73 3-chloro-N-(3-(2- LRMS (ESI):(calc) 380.8242 (found) 381.5 (MH)+ 21 (hydroxyamino)-2- HPLC: 99% RT:3.89 min oxo-1- phenylethyl)phenyl)benzamide 2-74 2-chloro-N-(4-(2- LRMS(ESI): (calc) 381.8123 (found) 382.5 (MH)+ 21 (hydroxyamino)-2- HPLC:91% RT: 3.52 min oxo-1- phenylethyl)phenyl)isonicotinamide 2-75 N-(4-(2-LRMS (ESI): (calc) 390.3887 (found) 391.1 (MH)+ 21 (hydroxyamino)-2-HPLC: 98% RT: 3.57 min oxo-1- phenylethyl)phenyl)benzo[d][1,3]dioxole-5- carboxamide 2-76 N-(3-(2- LRMS (ESI): (calc) 390.3887(found) 391.1 (MH)+ 21 (hydroxyamino)-2- HPLC: 100% RT: 3.61 min oxo-1-phenylethyl)phenyl)benzo[d][1, 3]dioxole-5- carboxamide 2-77N-hydroxy-2-(4- LRMS (ESI): (calc) 312.406 (found) 313.4 (MH)+ 21(isopentylamino)phenyl)- HPLC: 92% RT: 3.35 min 2-phenylacetamide 2-782-(4- LRMS (ESI): (calc) 332.3957 (found) 333.4 (MH)+ 21(benzylamino)phenyl)- HPLC: 93% RT: 3.79 min N-hydroxy-2-phenylacetamide 2-79 2-(3- LRMS (ESI): (calc) 332.3957 (found) 333.4(MH)+ 21 (benzylamino)phenyl)- HPLC: 92% RT: 3.80 min N-hydroxy-2-phenylacetamide 2-80 N-hydroxy-2-phenyl- LRMS (ESI): (calc) 333.3837(found) 334.4 (MH)+ 21 2-(4-(pyridin-4- HPLC: 90% RT: 2.49 minylmethylamino)phenyl)acetamide 2-81 N-hydroxy-2-phenyl- LRMS (ESI):(calc) 333.3837 (found) 334.4 (MH)+ 21 2-(3-(pyridin-4- HPLC: 90% RT:2.49 min ylmethylamino)phenyl)acetamide 1H NMR (360 MHz, MeOH) d ppm8.40 (2H, d, J = 6.36 Hz), 7.38 (2H, d, J = 6.36 Hz), 7.19-7.30 (5H, m),6.99-7.05 (1H, m), 6.45-6.59 (3H, m), 4.62 (1H, s), 4.36 (2H, s) 2-822-(4- LRMS (ESI): (calc) 338.4433 (found) 339.4 (MH)+ 21(cyclohexylmethylamino)phenyl)- HPLC: 94% RT: 3.99 min N- hydroxy-2-phenylacetamide 2-83 2-(3- LRMS (ESI): (calc) 338.4433 (found) 339.4(MH)+ 21 (cyclohexylmethylamino)phenyl)- HPLC: 87% RT: 4.06 min N-hydroxy-2- phenylacetamide 2-84 N-hydroxy-2-(4-(3- LRMS (ESI): (calc)362.4216 (found) 363.4 (MH)+ 21 methoxybenzylamino)phenyl)- HPLC: 92%RT: 3.80 min 2- phenylacetamide 2-85 N-hydroxy-2-(3-(3- LRMS (ESI):(calc) 362.4216 (found) 302 (M − CONHOH)+ 21 methoxybenzylamino)phenyl)-HPLC: 92% RT: 3.81 min 2- phenylacetamide 2-86 N-hydroxy-2-phenyl- LRMS(ESI): (calc) 348.4167 (found) 349.1 (MH)+ 21 2-(4- HPLC: 96% RT: 3.33min (propylsulfonamido)phenyl)acetamide 1H NMR (400 MHz, MeOD) d ppm7.22-7.33 (7H, m), 7.16-7.19 (2H, m), 4.74 (1H, s), 2.99-3.05 (2H, m),1.73-1.82 (2H, m), 0.98 (3H, t, J = 7.58 Hz) 2-87 N-hydroxy-2-phenyl-LRMS (ESI): (calc) 348.4167 (found) 349.1 (MH)+ 21 2-(3- HPLC: 92% RT:3.57 min (propylsulfonamido)phenyl)acetamide 2-88 N-hydroxy-2-phenyl-LRMS (ESI): (calc) 382.4329 (found) 383.1 (MH)+ 21 2-(4- HPLC: 95% RT:3.53 min (phenylsulfonamido)phenyl)acetamide 2-89 N-hydroxy-2-phenyl-LRMS (ESI): (calc) 382.4329 (found) 383.1 (MH)+ 21 2-(3- HPLC: 95% RT:3.54 min (phenylsulfonamido)phenyl)acetamide 1H NMR (360 MHz, MeOH) dppm 7.64-7.69 (2H, m), 7.51-7.57 (1H, m), 7.39-7.45 (2H, m), 7.24-7.31(3H, m), 7.08-7.22 (4H, m), 6.96-7.03 (2H, m), 4.67 (1H, s) 2-90N-hydroxy-2-phenyl- LRMS (ESI): (calc) 388.4606 (found) 389.1 (MH)+ 212-(4-(thiophene-2- HPLC: 95% RT: 3.47 min sulfonamido)phenyl)acetamide2-91 N-hydroxy-2-(3-(4- LRMS (ESI): (calc) 412.4589 (found) 413.1 (MH)+21 methoxyphenylsulfonamido)phenyl)- HPLC: 94% RT: 3.58 min 2-phenylacetamide 2-92 2-(4-(4- LRMS (ESI): (calc) 416.8779 (found) 417.6(MH)+ 21 chlorophenylsulfonamido)phenyl)- HPLC: 95% RT: 3.78 min N-hydroxy-2- phenylacetamide 2-93 2-(3-(4- LRMS (ESI): (calc) 416.8779(found) 417.6 (MH)+ 21 chlorophenylsulfonamido)phenyl)- HPLC: 93% RT:3.80 min N- hydroxy-2- phenylacetamide 2-94 N-hydroxy-2-phenyl- LRMS(ESI): (calc) 327.3758 (found) 328.4 (MH)+ 14 2-(3- HPLC: 93% RT: 4.34min (phenylethynyl)phenyl)acetamide 2-95 N-hydroxy-2-phenyl- LRMS (ESI):(calc) 328.3639 (found) 329.4 (MH)+ 14 2-(3-(pyridin-3- HPLC: 89% RT:3.58 min ylethynyl)phenyl)acetamide 2-96 2-(3-(3- LRMS (ESI): (calc)333.4235 (found) 334.4 (MH)+ 14 cyclopentylprop-1- HPLC: 86% RT: 4.71min ynyl)phenyl)-N- 1H NMR (400 MHz, DMSO-d6) d ppm 11.00 (1H,hydroxy-2- s), 9.01 (1H, br. s.), 7.20-7.34 (9H, m), 4.73 (1H,phenylacetamide s), 2.40 (2H, d, J = 6.85 Hz), 1.98-2.18 (1H, m),1.72-1.82 (2H, m), 1.47-1.65 (4H, m), 1.20-1.34 (2H, m) 2-97N-hydroxy-2-phenyl- LRMS (ESI): (calc) 327.3758 (found) 328.4 (MH)+ 142-(4- HPLC: 95% RT: 4.36 min (phenylethynyl)phenyl)acetamide 2-982-(4-(3- LRMS (ESI): (calc) 333.4235 (found) 334.4 (MH)+ 14cyclopentylprop-1- HPLC: 93% RT: 4.76 min ynyl)phenyl)-N- hydroxy-2-phenylacetamide 2-99 2-(4-((4- LRMS (ESI): (calc) 399.4816 (found) 400.5(MH)+ 14 butoxyphenyl)ethynyl)phenyl)- HPLC: 87% RT: 5.08 min N-hydroxy-2-phenylacetamide 2-100 N-hydroxy-2-(4′- LRMS (ESI): (calc) 395.4498(found) 396.4 (MH)+ 13 phenoxybiphenyl-3- HPLC: 89% RT: 4.65 minyl)-2-phenylacetamide 2-101 N-hydroxy-2-phenyl- LRMS (ESI): (calc)269.3382 (found) 270.3 (MH)+ 14 2-(3- HPLC: 94% RT: 4.02 minpropylphenyl)acetamide 1H NMR (400 MHz, DMSO-d6) d ppm 10.92 (1H, s),8.96 (1H, br. s.), 7.28-7.33 (4H, m), 7.19-7.26 (2H, m), 7.11-7.17 (2H,m), 7.03-7.09 (1H, m), 4.68 (1H, s), 2.37-2.61 (2H under DMSO), 1.54(2H, qt, J = 7.50, 7.34 Hz), 0.87 (3H, t, J = 7.3) 2-1022-(4′-ethylbiphenyl-3- LRMS (ESI): (calc) 331.4076 (found) 332.4 (MH)+13 yl)-N-hydroxy-2- HPLC: 90% RT: 4.46 min phenylacetamide 2-1032-(4′-chlorobiphenyl- LRMS (ESI): (calc) 337.7995 (found) 338.8 (MH)+ 133-yl)-N-hydroxy-2- HPLC: 91% RT: 4.32 min phenylacetamide 2-1042-(3-(2,3- LRMS (ESI): (calc) 345.3911 (found) 346.4 (MH)+ 13dihydrobenzofuran-5- HPLC: 92% RT: 4.01 min yl)phenyl)-N- hydroxy-2-phenylacetamide 2-105 2-(4′- LRMS (ESI): (calc) 346.4222 (found) 347.4(MH)+ 13 (dimethylamino)biphenyl- HPLC: 86% RT: 3.53 min3-yl)-N-hydroxy- 2-phenylacetamide 2-106 2-(3′,4′- LRMS (ESI): (calc)363.4064 (found) 364.4 (MH)+ 13 dimethoxybiphenyl-3- HPLC: 91% RT: 3.84min yl)-N-hydroxy-2- phenylacetamide 2-107 2-(4′- LRMS (ESI): (calc)363.4726 (found) 364.5 (MH)+ 13 (ethylthio)biphenyl-3- HPLC: 86% RT:4.48 min yl)-N-hydroxy-2- phenylacetamide 2-108 N-hydroxy-2-phenyl- LRMS(ESI): (calc) 371.3524 (found) 372.4 (MH)+ 13 2-(2′- HPLC: 91% RT: 4.25min (trifluoromethyl)biphenyl- 3-yl)acetamide 2-1093′-(2-(hydroxyamino)- LRMS (ESI): (calc) 374.4323 (found) 375.4 (MH)+ 132-oxo-1-phenylethyl)- HPLC: 89% RT: 3.54 min N,N- dimethylbiphenyl-4-carboxamide 2-110 N-hydroxy-2-(4′- LRMS (ESI): (calc) 381.4448 (found)382.4 (MH)+ 13 (methylsulfonyl)biphenyl- HPLC: 93% RT: 3.58 min 3-yl)-2-phenylacetamide 2-111 2-(4′-ethylbiphenyl-4- LRMS (ESI): (calc) 331.4076(found) 332.4 (MH)+ 13 yl)-N-hydroxy-2- HPLC: 93% RT: 4.48 minphenylacetamide 1H NMR (400 MHz, DMSO-d6) d ppm 8.99 (1H, br. s.),7.53-7.60 (4H, m), 7.23-7.40 (9H, m), 4.75 (1H, s), 2.63 (2H, q, J =7.34 Hz), 1.20 (3H, t) 2-112 2-(4′-chlorobiphenyl- LRMS (ESI): (calc)337.7995 (found) 338.8 (MH)+ 13 4-yl)-N-hydroxy-2- HPLC: 94% RT: 4.36min phenylacetamide 2-113 2-(4-(2,3- LRMS (ESI): (calc) 345.3911 (found)346.4 (MH)+ 13 dihydrobenzofuran-5- HPLC: 94% RT: 4.03 min yl)phenyl)-N-hydroxy-2- phenylacetamide 2-114 2-(3′,4′- LRMS (ESI): (calc) 363.4064(found) 364.4 (MH)+ 13 dimethoxybiphenyl-4- HPLC: 95% yl)-N-hydroxy-2-1H NMR (400 MHz, DMSO-d6) d ppm 10.93 (1H, phenylacetamide br. s.), 8.98(1H, s), 7.57 (2H, d, J = 8.31 Hz), 7.29-7.38 (6H, m), 7.20-7.27 (1H,m), 7.13-7.18 (2H, m), 7.01 (1H, d, J = 8.31 Hz), 4.73 (1H, s), 3.81(3H, s), 3.77 (3H, s) 2-115 2-(4′- LRMS (ESI): (calc) 363.4726 (found)364.5 (MH)+ 13 (ethylthio)biphenyl-4- HPLC: 95% yl)-N-hydroxy-2-phenylacetamide 2-116 4′-(2-(hydroxyamino)- LRMS (ESI): (calc) 374.4323(found) 375.4 (MH)+ 13 2-oxo-1-phenylethyl)- HPLC: 95% N,N-dimethylbiphenyl-4- carboxamide 2-117 N-hydroxy-2-(4′- LRMS (ESI):(calc) 395.4498 (found) 396.4 (MH)+ 13 phenoxybiphenyl-4- HPLC: 92%yl)-2-phenylacetamide

TABLE III Compounds prepared according general Schemes 20 and 21 andother Schemes. Cpd # Name Characterization 3-5N-hydroxy-2-(3-(3-methylbut-2- LRMS (ESI): (calc) 311.3749 (found)enyloxy)phenyl)-2- 312 (MH)+ HPLC: 98% RT: 4.08 min phenylacetamide 3-6N-hydroxy-2-(3-(4- LRMS (ESI): (calc) 363.4064 (found)methoxybenzyloxy)phenyl)-2- 364 (MH)+ HPLC: 98% RT: 4.04 minphenylacetamide 3-7 2-(3-(benzo[d][1,3]dioxol-5- LRMS (ESI): (calc)377.3899 (found) ylmethylbenzo[d][1,3]dioxol-5- 378 (MH)+ HPLC: 98% RT:3.99 min ylmethoxy)phenyl)-N-hydroxy-2- phenylacetamide 3-8N-hydroxy-2-phenyl-2-(3-(1- LRMS (ESI): (calc) 347.407 (found)phenylethoxy)phenyl)acetamide 348 (MH)+ HPLC: 100% RT: 4.15 min 3-9(E)-2-(3-(cinnamyloxy)phenyl)- LRMS (ESI): (calc) 359.4177 (found)N-hydroxy-2-phenylacetamide 360 (MH)+ HPLC: 95% RT: 4.32 min 1H NMR (360MHz, MeOH) d ppm 7.37-7.42 (2H, m), 7.19-7.34 (9H, m), 6.98 (1H, s),6.84-6.92 (2H, m), 6.70 (1H, d, J = 15.89 Hz), 6.34-6.44 (1H, m), 4.76(1H, s), 4.65 (2H, d, J = 5.90 Hz) 3-10 2-(3-(3-chlorobenzyloxy)phenyl)-LRMS (ESI): (calc) 367.8255 (found) N-hydroxy-2-phenylacetamide 368(MH)+ HPLC: 100% RT: 4.31 min 3-11 2-(4-(benzo[d][1,3]dioxol-5- LRMS(ESI): (calc) 377.3899 (found) ylmethylbenzo[d][1,3]dioxol-5- 378 (MH)+HPLC: 100% RT: 3.99 min 1H NMR ylmethoxy)phenyl)-N-hydroxy-2- (360 MHz,MeOH) d ppm 7.27-7.31 (4H, m), phenylacetamide 7.19-7.26 (3H, m),6.86-6.93 (4H, m), 6.79 (1H, d, J = 7.72 Hz), 5.93 (2H, s), 4.95 (2H,s), 4.72 (1H, s) 3-12 N-hydroxy-2-phenyl-2-(3-(4- LRMS (ESI): (calc)402.4888 (found) (pyridin-4-ylmethyl)piperazin-1- 202 ((M2H/2))+ HPLC:100% RT: 2.45 min yl)phenyl)acetamide 3-13 2-(4-acetamidophenyl)-N- LRMS(ESI): (calc) 284.3098 (found) hydroxy-2-phenylacetamide 285 (MH)+ HPLC:86% RT: 2.88 min 3-14 2-chloro-N-(3-(2- LRMS (ESI): (calc) 381.8123(found) (hydroxyamino)-2-oxo-1- 382 (MH)+ HPLC: 100% RT: 3.53 min 1H NMRphenylethyl)phenyl)isonicotinamide (250 MHz, MeOD) d ppm 8.52 (1H, d, J= 5.18 Hz), 7.90 (1H, s), 7.78 (1H, dd, J = 5.10, 1.29 Hz), 7.62-7.71(2H, m), 7.23-7.39 (7H, m), 7.16 (1H, d, J = 7.77 Hz), 4.81 (1H, s) 3-152-(3-(3- LRMS (ESI): (calc) 328.4054 (found)(dimethylamino)propoxy)phenyl)- 329 (MH)+ HPLC: 99% RT: 2.57 minN-hydroxy-2-phenylacetamide 3-16 2-(4-(3- LRMS (ESI): (calc) 328.4054(found) (dimethylamino)propoxy)phenyl)- 329 (MH)+ HPLC: 97% RT: 2.54 minN-hydroxy-2-phenylacetamide 3-17 2-(3-(3-(dimethylamino)-2- LRMS (ESI):(calc) 342.432 (found) methylpropoxy)phenyl)-N- 343 (MH)+ HPLC: 100% RT:2.68 min hydroxy-2-phenylacetamide 3-18 2-(4-(3-(dimethylamino)-2- LRMS(ESI): (calc) 342.432 (found) methylpropoxy)phenyl)-N- 343 (MH)+ HPLC:100% RT: 2.64 min hydroxy-2-phenylacetamide 3-19N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI): (calc) 340.4161 (found)(pyrrolidin-1- 341 (MH)+ HPLC: 100% RT: 2.55 minyl)ethoxy)phenyl)acetamide 3-20 N-hydroxy-2-(3-(2-(1- LRMS (ESI): (calc)354.4427 (found) methylpyrrolidin-2- 355 (MH)+ HPLC: 100% RT: 2.65 minyl)ethoxy)phenyl)-2- phenylacetamide 3-21 N-hydroxy-2-(3-methoxyphenyl)-LRMS (ESI): (calc) 257.2845 (found) 2-phenylacetamide 258 (MH)+ HPLC:96% RT: 3.38 min 3-22 2-(3-ethoxyphenyl)-N-hydroxy-2- LRMS (ESI): (calc)271.311 (found) phenylacetamide 543 (2MH)+ HPLC: 100% RT: 3.6 min 1H NMR(360 MHz, MeOH) d ppm 7.17-7.33 (6H, m), 6.84-6.89 (2H, m), 6.76-6.82(1H, m), 4.74 (1H, s), 3.98 (2H, q, J = 7.11 Hz), 1.34 (3H, t, J = 7.04Hz) 3-23 N-hydroxy-2-phenyl-2-(3-(prop- LRMS (ESI): (calc) 281.3059(found) 2-ynyloxy)phenyl)acetamide 282 (MH)+ HPLC: 94% RT: 3.53 min 3-242-(3-(allyloxy)phenyl)-N- LRMS (ESI): (calc) 283.3217 (found)hydroxy-2-phenylacetamide 567 (2MH)+ HPLC: 97% RT: 3.72 min 3-25 2-(3-LRMS (ESI): (calc) 297.3483 (found) (cyclopropylmethoxy)phenyl)-N- 595(2MH)+ HPLC: 100% RT: 3.83 min hydroxy-2-phenylacetamide 3-262-(3-(but-3-enyloxy)phenyl)-N- LRMS (ESI): (calc) 297.3483 (found)hydroxy-2-phenylacetamide 595 (2MH)+ HPLC: 86% RT: 3.91 min 3-27N-hydroxy-2-(3-(2- LRMS (ESI): (calc) 301.337 (found)methoxyethoxy)phenyl)-2- 603 (2MH)+ HPLC: 90% RT: 3.37 minphenylacetamide 3-28 2-(3-((3,5-dimethylisoxazol-4- LRMS (ESI): (calc)352.3838 (found) yl)methoxy)phenyl)-N-hydroxy-2- 353 (MH)+ HPLC: 98% RT:3.62 min phenylacetamide 3-29 2-(3-(cyclopentyloxy)phenyl)-N- LRMS(ESI): (calc) 311.3749 (found) hydroxy-2-phenylacetamide 623 (2MH)+HPLC: 100% RT: 4.09 min 3-30 N-hydroxy-2-(3- LRMS (ESI): (calc) 313.3908(found) (isopentyloxy)phenyl)-2- 627 (2MH)+ HPLC: 98% RT: 4.3 minphenylacetamide 3-31 2-(3-(2-ethylbutoxy)phenyl)-N- LRMS (ESI): (calc)327.4174 (found) hydroxy-2-phenylacetamide 655 (2MH)+ HPLC: 89% RT: 4.52min 3-32 2-(3- LRMS (ESI): (calc) 339.4281 (found)(cyclohexylmethoxy)phenyl)-N- 679 (2MH)+ HPLC: 100% RT: 4.63 minhydroxy-2-phenylacetamide 3-33 N-hydroxy-2-(3-(3- LRMS (ESI): (calc)347.407 (found) methylbenzyloxy)phenyl)-2- 695 (2MH)+ HPLC: 94% RT: 4.26min phenylacetamide 3-34 2-(3-(2-fluorobenzyloxy)phenyl)- LRMS (ESI):(calc) 351.3709 (found) N-hydroxy-2-phenylacetamide 352 (MH)+ HPLC: 93%RT: 4.08 min 3-35 2-(3-(3,5- LRMS (ESI): (calc) 361.4336 (found)dimethylbenzyloxy)phenyl)-N- 723 (2MH)+ HPLC: 93% RT: 4.46 minhydroxy-2-phenylacetamide 3-36 N-hydroxy-2-phenyl-2-(3-(3- LRMS (ESI):(calc) 361.4336 (found) phenylpropoxy)phenyl)acetamide 723 (2MH)+ HPLC:95% RT: 4.42 min 3-37 2-(3-(2-chlorobenzyloxy)phenyl)- LRMS (ESI):(calc) 367.8255 (found) N-hydroxy-2-phenylacetamide 735 (2MH)+ HPLC: 93%RT: 4.28 min 3-38 2-(3-(2,4- LRMS (ESI): (calc) 369.3613 (found)difluorobenzyloxy)phenyl)-N- 739 (2MH)+ HPLC: 95% RT: 4.14 minhydroxy-2-phenylacetamide 3-39 2-(3-(2- LRMS (ESI): (calc) 377.433(found) (benzyloxy)ethoxy)phenyl)-N- 755 (2MH)+ HPLC: 87% RT: 4.08 minhydroxy-2-phenylacetamide 3-40 2-(3-(2-(4- LRMS (ESI): (calc) 381.3969(found) fluorophenoxy)ethoxy)phenyl)-N- 382 (MH)+ HPLC: 95% RT: 4.12 minhydroxy-2-phenylacetamide 3-41 2-(3-(4-tert- LRMS (ESI): (calc) 389.4867(found) butylbenzyloxy)phenyl)-N- 779 (2MH)+ HPLC: 96% RT: 4.78 minhydroxy-2-phenylacetamide 3-42 N-hydroxy-2-phenyl-2-(3-(3- LRMS (ESI):(calc) 401.3784 (found) (trifluoromethyl)benzyloxy)phenyl)acetamide 402(MH)+ HPLC: 96% RT: 4.38 min 3-43 N-hydroxy-2-(4-methoxyphenyl)- LRMS(ESI): (calc) 257.2845 (found) 2-phenylacetamide 258 (MH)+ HPLC: 100%RT: 3.37 min 3-44 2-(4-ethoxyphenyl)-N-hydroxy-2- LRMS (ESI): (calc)271.311 (found) phenylacetamide 272 (MH)+ HPLC: 91% RT: 3.6 min 3-45N-hydroxy-2-phenyl-2-(4-(prop- LRMS (ESI): (calc) 281.3059 (found)2-ynyloxy)phenyl)acetamide 282 (MH)+ HPLC: 99% RT: 3.53 min 3-462-(4-(allyloxy)phenyl)-N- LRMS (ESI): (calc) 283.3217 (found)hydroxy-2-phenylacetamide 284 (MH)+ HPLC: 87% RT: 3.71 min 1H NMR (400MHz, MeOD) d ppm 7.26-7.31 (4H, m), 7.20-7.25 (3H, m), 6.87 (2H, d, J =8.80 Hz), 5.99-6.09 (1H, m), 5.34-5.41 (1H, m, J = 17.30, 1.62, 1.62,1.47 Hz), 5.20-5.25 (1H, m, J = 10.51, 1.59, 1.59, 1.47 Hz), 4.71 (1H,s), 4.51 (2H, d 3-47 N-hydroxy-2-(4- LRMS (ESI): (calc) 285.3376 (found)isopropoxyphenyl)-2- 571 (2MH)+ HPLC: 90% RT: 3.75 min phenylacetamide3-48 2-(4- LRMS (ESI): (calc) 297.3483 (found)(cyclopropylmethoxy)phenyl)-N- 298 (MH)+ HPLC: 98% RT: 3.82 minhydroxy-2-phenylacetamide 3-49 2-(4-(but-3-enyloxy)phenyl)-N- LRMS(ESI): (calc) 297.3483 (found) hydroxy-2-phenylacetamide 298 (MH)+ HPLC:97% RT: 3.92 min 3-50 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 301.337(found) methoxyethoxy)phenyl)-2- 603 (2MH)+ HPLC: 93% RT: 3.34 minphenylacetamide 3-51 2-(4-((3,5-dimethylisoxazol-4- LRMS (ESI): (calc)352.3838 (found) yl)methoxy)phenyl)-N-hydroxy-2- 353 (MH)+ HPLC: 86% RT:3.62 min phenylacetamide 3-52 N-hydroxy-2-(4-(3-methylbut-2- LRMS (ESI):(calc) 311.3749 (found) enyloxy)phenyl)-2- 312 (MH)+ HPLC: 88% RT: 4.08min phenylacetamide 3-53 2-(4-(cyclopentyloxy)phenyl)-N- LRMS (ESI):(calc) 311.3749 (found) hydroxy-2-phenylacetamide 312 (MH)+ HPLC: 100%RT: 4.11 min 3-54 N-hydroxy-2-(4- LRMS (ESI): (calc) 313.3908 (found)(isopentyloxy)phenyl)-2- 627 (MH)+ HPLC: 86% RT: 4.31 min 1H NMRphenylacetamide (400 MHz, MeOD) d ppm 7.25-7.32 (4H, m), 7.17-7.25 (3H,m), 6.84 (2H, d, J = 8.80 Hz), 4.71 (1H, s), 3.97 (2H, t, J = 6.60 Hz),1.76-1.88 (1H, m), 1.58-1.67 (2H, m), 0.96 (6H, d, J = 6.85 Hz) 3-552-(4-(2-ethylbutoxy)phenyl)-N- LRMS (ESI): (calc) 327.4174 (found)hydroxy-2-phenylacetamide 655 (2MH)+ HPLC: 91% RT: 4.56 min 3-56N-hydroxy-2-(4-(4- LRMS (ESI): (calc) 327.4174 (found)methylpentyloxy)phenyl)-2- 328 (MH)+ HPLC: 92% RT: 4.55 min 1H NMRphenylacetamide (400 MHz, MeOD) d ppm 7.26-7.31 (4H, m), 7.17-7.25 (3H,m), 6.84 (2H, d, J = 8.80 Hz), 4.71 (1H, s), 3.93 (2H, t, J = 6.60 Hz),1.71-1.80 (2H, m), 1.53-1.66 (1H, m), 1.28-1.38 (2H, m), 0.93 (6H, d, J= 6.85 Hz) 3-57 2-(4- LRMS (ESI): (calc) 339.4281 (found)(cyclohexylmethoxy)phenyl)-N- 340 (MH)+ HPLC: 93% RT: 4.65 minhydroxy-2-phenylacetamide 3-58 N-hydroxy-2-(4-(3- LRMS (ESI): (calc)347.407 (found) methylbenzyloxy)phenyl)-2- 695 (2MH)+ HPLC: 100% RT:4.26 min phenylacetamide 3-59 N-hydroxy-2-phenyl-2-(4-(1- LRMS (ESI):(calc) 347.407 (found) phenylethoxy)phenyl)acetamide 695 (2MH)+ HPLC:86% RT: 4.17 min 1H NMR (400 MHz, MeOD) d ppm 7.17-7.36 (10H, m),7.05-7.14 (2H, m), 6.79 (2H, d, J = 8.80 Hz), 5.34 (1H, q, J = 6.36 Hz),4.65 (1H, s), 1.56 (3H, d, J = 6.36 Hz) 3-602-(4-(2-fluorobenzyloxy)phenyl)- LRMS (ESI): (calc) 351.3709 (found)N-hydroxy-2-phenylacetamide 703 (2MH)+ HPLC: 100% RT: 4.1 min 3-612-(4-(2-cyanobenzyloxy)phenyl)- LRMS (ESI): (calc) 358.3899 (found)N-hydroxy-2-phenylacetamide 717 (2MH)+ HPLC: 100% RT: 3.89 min 3-622-(4-(3,5- LRMS (ESI): (calc) 361.4336 (found)dimethylbenzyloxy)phenyl)-N- 723 (2MH)+ HPLC: 86% RT: 4.46 min 1H NMRhydroxy-2-phenylacetamide (400 MHz, MeOD) d ppm 7.26-7.31 (4H, m),7.18-7.25 (3H, m), 7.01 (2H, s), 6.85-6.96 (3H, m), 4.96 (2H, s), 4.71(1H, s), 2.28 (6H, s) 3-63 N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI):(calc) 361.4336 (found) phenylpropoxy)phenyl)acetamide 362 (MH)+ HPLC:90% RT: 4.41 min 3-64 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 363.4064(found) phenoxyethoxy)phenyl)-2- 727 (2MH)+ HPLC: 100% RT: 4.08 minphenylacetamide 3-65 2-(4-(2-chlorobenzyloxy)phenyl)- LRMS (ESI): (calc)367.8255 (found) N-hydroxy-2-phenylacetamide 368 (MH)+ HPLC: 100% RT:4.29 min 3-66 2-(4-(3-chlorobenzyloxy)phenyl)- LRMS (ESI): (calc)367.8255 (found) N-hydroxy-2-phenylacetamide 368 (MH)+ HPLC: 88% RT:4.31 min 3-67 2-(4-(2,4- LRMS (ESI): (calc) 369.3613 (found)difluorobenzyloxy)phenyl)-N- 370 (MH)+ HPLC: 86% RT: 4.15 minhydroxy-2-phenylacetamide 3-68 2-(4-(2- LRMS (ESI): (calc) 377.433(found) (benzyloxy)ethoxy)phenyl)-N- 755 (2MH)+ HPLC: 88% RT: 4.08 minhydroxy-2-phenylacetamide 3-69 2-(4-(2-(4- LRMS (ESI): (calc) 381.3969(found) fluorophenoxy)ethoxy)phenyl)-N- 382 (MH)+ HPLC: 100% RT: 4.12min hydroxy-2-phenylacetamide 3-70 2-(4-(4-tert- LRMS (ESI): (calc)389.4867 (found) butylbenzyloxy)phenyl)-N- 390 (MH)+ HPLC: 90% RT: 4.8min hydroxy-2-phenylacetamide 3-71 N-hydroxy-2-phenyl-2-(4-(3- LRMS(ESI): (calc) 401.3784 (found)(trifluoromethyl)benzyloxy)phenyl)acetamide 402 (MH)+ HPLC: 85% RT: 4.38min 3-72 N-hydroxy-2-(3- LRMS (ESI): (calc) 284.3529 (found)(isopropylamino)phenyl)-2- 285 (MH)+ HPLC: 90% RT: 2.53 minphenylacetamide 373 N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc) 318.3691(found) (phenylamino)phenyl)acetamide 319 (MH)+ HPLC: 94% RT: 3.93 min3-74 N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc) 333.3837 (found)(pyridin-2- 334 (MH)+ HPLC: 91% RT: 2.56 minylmethylamino)phenyl)acetamide 3-75 2-(3-(4-acetylpiperazin-1- LRMS(ESI): (calc) 353.4149 (found) yl)phenyl)-N-hydroxy-2- 354 (MH)+ HPLC:90% RT: 3.13 min phenylacetamide 3-76 N-hydroxy-2-phenyl-2-(3-(4- LRMS(ESI): (calc) 379.4952 (found) (pyrrolidin-1-yl)piperidin-1- 380 (MH)+HPLC: 85% RT: 2.61 min yl)phenyl)acetamide 3-772-(3-(4-benzylpiperidin-1- LRMS (ESI): (calc) 400.5127 (found)yl)phenyl)-N-hydroxy-2- 401 (MH)+ HPLC: 87% RT: 3.57 min phenylacetamide3-78 2-(3-(4-(4-fluorophenyl)piperazin- LRMS (ESI): (calc) 405.4646(found) 1-yl)phenyl)-N-hydroxy-2- 406 (MH)+ HPLC: 93% RT: 4.06 minphenylacetamide 3-79 N-hydroxy-2-(4- LRMS (ESI): (calc) 284.3529 (found)(isopropylamino)phenyl)-2- 285 (MH)+ HPLC: 93% RT: 2.48 minphenylacetamide 3-80 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc)318.3691 (found) (phenylamino)phenyl)acetamide 319 (MH)+ HPLC: 98% RT:3.92 min 1H NMR (400 MHz, MeOD) d ppm 7.27-7.34 (4H, m), 7.15-7.25 (5H,m), 6.99-7.09 (4H, m), 6.79-6.85 (1H, m), 4.70 (1H, s) 3-81N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc) 333.3837 (found) (pyridin-2-334 (MH)+ HPLC: 92% RT: 2.54 min ylmethylamino)phenyl)acetamide 3-822-(4-(4-acetylpiperazin-1- LRMS (ESI): (calc) 353.4149 (found)yl)phenyl)-N-hydroxy-2- 354 (MH)+ HPLC: 91% RT: 3.07 min phenylacetamide3-83 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc) 379.4952 (found)(pyrrolidin-1-yl)piperidin-1- 380 (MH)+ HPLC: 91% RT: 2.54 minyl)phenyl)acetamide 3-84 2-(4-(4-(4-fluorophenyl)piperazin- LRMS (ESI):(calc) 405.4646 (found) 1-yl)phenyl)-N-hydroxy-2- 406 (MH)+ HPLC: 92%RT: 4.04 min phenylacetamide 3-85 (E)-2-(4-(cinnamyloxy)phenyl)- LRMS(ESI): (calc) 359.4177 (found) N-hydroxy-2-phenylacetamide 360 (MH)+HPLC: 85% RT: 4.31 min 3-86 N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI):(calc) 417.3778 (found) (trifluoromethoxy)benzyloxy)phenyl)acetamide 418(MH)+ HPLC: 94% RT: 4.47 min 3-87 N-hydroxy-2-phenyl-2-(3-(3- LRMS(ESI): (calc) 417.3778 (found)(trifluoromethoxy)benzyloxy)phenyl)acetamide 418 (MH)+ HPLC: 92% RT:4.47 min 3-88 2-(3-(2- LRMS (ESI): (calc) 314.3788 (found)(dimethylamino)ethoxy)phenyl)- 315 (MH)+ HPLC: 100% RT: 2.44 min 1H NMRN-hydroxy-2-phenylacetamide (400 MHz, MeOD) d ppm 7.24-7.36 (6H, m),6.92-7.03 (3H, m), 4.80 (1H, s), 4.26-4.34 (2H, m), 3.54-3.59 (2H, m),2.96 (6H, s) 3-89 N-hydroxy-2-(3-(2-(2- LRMS (ESI): (calc) 345.3896(found) methoxyethoxy)ethoxy)phenyl)-2- 691 (2MH)+ HPLC: 89% RT: 3.4 minphenylacetamide 3-90 N-hydroxy-2-(4-(2-(2- LRMS (ESI): (calc) 345.3896(found) methoxyethoxy)ethoxy)phenyl)-2- 346 (MH)+ HPLC: 91% RT: 3.36 minphenylacetamide

TABLE IV Compounds prepared according general Schemes 20 and 21 andother Schemes. Cpd # Name Characterization 4-1 2-(3-(3- LRMS (ESI):(calc) 350.386 (found) 351 [M + H]+ fluorobenzylamino)phenyl)- HPLC: 89%RT: 3.91 min N-hydroxy-2- phenylacetamide 4-3 2-(4-(4- LRMS (ESI):(calc) 366.841 (found) 367 [M + H]+ chlorobenzylamino)phenyl)- HPLC: 87%RT: 4.1 min N-hydroxy-2- phenylacetamide 4-4 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 298.336 (found) 299 [M + H]+ oxo-1- HPLC: 100% RT:3.07 min phenylethyl)phenyl)propionamide 4-5 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 310.347 (found) 311 [M + H]+ oxo-1- HPLC: 93% RT: 3.2min phenylethyl)phenyl)cyclopropanecarboxamide 4-6N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 312.363 (found) 313 [M +H]+ oxo-1- HPLC: 100% RT: 3.29 min 1H NMR (250 MHz,phenylethyl)phenyl)butyramide MeOD) d ppm 7.50 (2H, d, J = 8.68 Hz),7.20-7.34 (7H, m), 4.75 (1H, s), 2.33 (2H, t, J = 7.39 Hz), 1.63-1.78(2H, m), 0.99 (3H, t, J = 7.39 Hz) 4-8 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 312.363 (found) 313 [M + H]+ oxo-1- HPLC: 93% RT: 3.26 minphenylethyl)phenyl)isobutyramide 4-9 N-hydroxy-2-(4-(2- LRMS (ESI):(calc) 314.336 (found) 315 [M + H]+ methoxyacetamido)phenyl)- HPLC: 100%RT: 3.02 min 1H NMR (250 MHz, 2-phenylacetamide MeOD) d ppm 7.55 (2H, d,J = 8.68 Hz), 7.30 (2H, d, J = 2.44 Hz), 7.20-7.35 (5H, m), 4.77 (1H,s), 4.01 (2H, s), 3.46 (3H, s) 4-10 N-hydroxy-2-(3-(2- LRMS (ESI):(calc) 314.336 (found) 315 [M + H]+ methoxyacetamido)phenyl)- HPLC: 100%RT: 3.06 min 2-phenylacetamide 4-11 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 324.374 (found) 325 [M + H]+ oxo-1-phenylethyl)phenyl)-3-HPLC: 100% RT: 3.48 min methylbut-2-enamide 4-12N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 324.374 (found) 325 [M +H]+ oxo-1- HPLC: 100% RT: 3.48 minphenylethyl)phenyl)cyclobutanecarboxamide 4-13 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 326.39 (found) 327 [M + H]+oxo-1-phenylethyl)phenyl)-2- HPLC: 90% RT: 3.45 min methylbutanamide4-14 N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 326.39 (found) 327[M + H]+ oxo-1-phenylethyl)phenyl)-2- HPLC: 88% RT: 3.51 minmethylbutanamide 4-15 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc)326.39 (found) 327 [M + H]+ oxo-1- HPLC: 95% RT: 3.6 minphenylethyl)phenyl)pivalamide 4-16 N-(3-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 326.39 (found) 327 [M + H]+ oxo-1- HPLC: 91% RT: 3.52 minphenylethyl)phenyl)pivalamide 4-17 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 336.341 (found) 337 [M + H]+ oxo-1- HPLC: 100% RT: 3.3 minphenylethyl)phenyl)furan-2- carboxamide 4-18 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 336.341 (found) 337 [M + H]+ oxo-1- HPLC: 100% RT:3.42 min phenylethyl)phenyl)furan-3- carboxamide 4-19N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 339.388 (found) 340 [M +H]+ oxo-1- HPLC: 90% RT: 3.28 min phenylethyl)phenyl)pyrrolidine-1-carboxamide 4-20 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 340.416(found) 341 [M + H]+ oxo-1-phenylethyl)phenyl)- HPLC: 95% RT: 3.64 min1H NMR (250 MHz, 3,3-dimethylbutanamide MeOD) d ppm 7.45 (2H, d, J =8.68 Hz), 7.13-7.33 (7H, m), 4.72 (1H, s), 2.18 (2H, s), 1.02 (9H, s)4-21 N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 340.416 (found) 341[M + H]+ oxo-1-phenylethyl)phenyl)- HPLC: 98% RT: 3.67 min3,3-dimethylbutanamide 4-22 2-ethyl-N-(4-(2- LRMS (ESI): (calc) 340.416(found) 341 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 92% RT: 3.61 minphenylethyl)phenyl)butanamide 4-23 2-ethyl-N-(3-(2- LRMS (ESI): (calc)340.416 (found) 341 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 87% RT: 3.75min phenylethyl)phenyl)butanamide 4-24 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 340.416 (found) 341 [M + H]+ oxo-1-phenylethyl)phenyl)-HPLC: 95% RT: 3.66 min 2,2-dimethylbutanamide 4-25N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 340.416 (found) 341 [M +H]+ oxo-1-phenylethyl)phenyl)-2- HPLC: 95% RT: 3.67 minmethylpentanamide 4-26 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc)347.367 (found) 348 [M + H]+ oxo-1- HPLC: 88% RT: 2.9 minphenylethyl)phenyl)isonicotinamide 4-27 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 351.356 (found) 352 [M + H]+ oxo-1-phenylethyl)phenyl)-5-HPLC: 94% RT: 3.55 min methylisoxazole-3- carboxamide 4-28N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 352.407 (found) 353 [M +H]+ oxo-1- HPLC: 99% RT: 3.5 min phenylethyl)phenyl)thiophene-2-carboxamide 4-29 N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 352.407(found) 353 [M + H]+ oxo-1- HPLC: 95% RT: 3.55 min 1H NMR (250 MHz,phenylethyl)phenyl)thiophene- MeOD) d ppm 7.84 (1H, d, J = 3.65 Hz),7.66 (1H, 2-carboxamide d, J = 5.03 Hz), 7.55-7.62 (2H, m), 7.18-7.35(6H, m), 7.04-7.15 (2H, m), 4.77 (1H, s) 4-31 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 354.4 (found) 355 [M + H]+ oxo-1- HPLC: 96% RT: 3.05min phenylethyl)phenyl)tetrahydro- 2H-pyran-4-carboxamide 4-32N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 355.388 (found) 356 [M +H]+ oxo-1- HPLC: 90% RT: 2.97 min phenylethyl)phenyl)morpholine-4-carboxamide 4-33 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 360.406(found) 361 [M + H]+ oxo-1-phenylethyl)phenyl)-4- HPLC: 98% RT: 3.73 minmethylbenzamide 4-34 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc)360.406 (found) 361 [M + H]+ oxo-1-phenylethyl)phenyl)-2- HPLC: 100% RT:3.62 min methylbenzamide 4-35 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 360.406 (found) 361 [M + H]+ oxo-1-phenylethyl)phenyl)-3- HPLC:98% RT: 3.84 min methylbenzamide 4-36 N-(3-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 360.406 (found) 361 [M + H]+ oxo-1-phenylethyl)phenyl)-3-HPLC: 90% RT: 3.78 min methylbenzamide 4-37 5-chloro-N-(4-(2- LRMS(ESI): (calc) 360.835 (found) 361 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC:92% RT: 3.53 min phenylethyl)phenyl)pentanamide 4-38 2-fluoro-N-(4-(2-LRMS (ESI): (calc) 364.37 (found) 365 [M + H]+ (hydroxyamino)-2-oxo-1-HPLC: 97% RT: 3.68 min phenylethyl)phenyl)benzamide 4-392-fluoro-N-(3-(2- LRMS (ESI): (calc) 364.37 (found) 365 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 91% RT: 3.62 minphenylethyl)phenyl)benzamide 4-40 3-fluoro-N-(4-(2- LRMS (ESI): (calc)364.37 (found) 365 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 100% RT: 3.66min phenylethyl)phenyl)benzamide 4-41 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 364.398 (found) 365 [M + H]+ oxo-1-phenylethyl)phenyl)-HPLC: 88% RT: 3.34 min 1,3-dimethyl-1H-pyrazole-5- carboxamide 4-42N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc) 366.434 (found) 367 [M +H]+ (thiophen-2- HPLC: 93% RT: 3.5 min yl)acetamido)phenyl)acetamide4-43 N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI): (calc) 366.434 (found) 367[M + H]+ (thiophen-2- HPLC: 87% RT: 3.57 minyl)acetamido)phenyl)acetamide 4-44 3-cyclopentyl-N-(4-(2- LRMS (ESI):(calc) 366.453 (found) 367 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 93%RT: 3.97 min phenylethyl)phenyl)propanamide 4-45 3-cyclopentyl-N-(3-(2-LRMS (ESI): (calc) 366.453 (found) 367 [M + H]+ (hydroxyamino)-2-oxo-1-HPLC: 99% RT: 3.99 min 1H NMR (250 MHz, phenylethyl)phenyl)propanamideMeOD) d ppm 7.46 (1H, d, J = 1.98 Hz), 7.50 (1H, s), 7.15-7.33 (6H, m),7.02 (1H, d, J = 7.77 Hz), 4.73 (1H, s), 2.25-2.37 (2H, m), 1.45-1.82(9H, m), 1.02-1.19 (2H, m) 4-46 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 372.417 (found) 373 [M + H]+ oxo-1- HPLC: 100% RT: 3.89 minphenylethyl)phenyl)cinnamamide 4-47 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 374.432 (found) 375 [M + H]+ oxo-1-phenylethyl)phenyl)-3-HPLC: 92% RT: 3.71 min phenylpropanamide 4-48 N-(3-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 374.432 (found) 375 [M + H]+oxo-1-phenylethyl)phenyl)-3- HPLC: 98% RT: 3.85 min phenylpropanamide4-49 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 374.432 (found) 375[M + H]+ oxo-1-phenylethyl)phenyl)- HPLC: 95% RT: 3.88 min 1H NMR (250MHz, 3,4-dimethylbenzamide MeOD) d ppm 7.58-7.73 (4H, m), 7.17-7.37 (8H,m), 4.78 (1H, s), 2.33 (3H, s), 2.33 (3H, s) 4-50N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 374.432 (found) 375 [M +H]+ oxo-1-phenylethyl)phenyl)- HPLC: 91% RT: 3.93 min3,4-dimethylbenzamide 4-51 4-ethyl-N-(4-(2- LRMS (ESI): (calc) 374.432(found) 375 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 92% RT: 3.93 minphenylethyl)phenyl)benzamide 4-52 4-ethyl-N-(3-(2- LRMS (ESI): (calc)374.432 (found) 375 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 91% RT: 3.96min phenylethyl)phenyl)benzamide 4-53 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 376.405 (found) 377 [M + H]+ oxo-1-phenylethyl)phenyl)-3-HPLC: 100% RT: 3.63 min methoxybenzamide 4-54 2-(4-(2-(4- LRMS (ESI):(calc) 378.396 (found) 379 [M + H]+ fluorophenyl)acetamido)phenyl)-HPLC: 95% RT: 3.64 min N-hydroxy-2- phenylacetamide 4-55 2-(3-(2-(4-LRMS (ESI): (calc) 378.396 (found) 379 [M + H]+fluorophenyl)acetamido)phenyl)- HPLC: 88% RT: 3.69 min N-hydroxy-2-phenylacetamide 4-56 5-fluoro-N-(4-(2- LRMS (ESI): (calc) 378.396(found) 379 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 98% RT: 3.72 minphenylethyl)phenyl)-2- methylbenzamide 4-58 3-fluoro-N-(4-(2- LRMS(ESI): (calc) 378.396 (found) 379 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC:88% RT: 3.83 min phenylethyl)phenyl)-4- methylbenzamide 4-594-fluoro-N-(4-(2- LRMS (ESI): (calc) 378.396 (found) 379 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 94% RT: 3.83 min phenylethyl)phenyl)-3-methylbenzamide 5-60 2-chloro-N-(3-(2- LRMS (ESI): (calc) 380.824(found) 381 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 91% RT: 3.64 minphenylethyl)phenyl)benzamide 4-61 4-chloro-N-(4-(2- LRMS (ESI): (calc)380.824 (found) 381 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 98% RT: 3.83min phenylethyl)phenyl)benzamide 4-62 6-chloro-N-(4-(2- LRMS (ESI):(calc) 381.812 (found) 382 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 100%RT: 3.48 min 1H NMR (250 MHz, phenylethyl)phenyl)nicotinamide MeOD) dppm 8.90 (1H, d, J = 1.83 Hz), 8.30 (1H, dd, J = 8.38, 2.28 Hz),7.56-7.71 (3H, m), 7.21-7.39 (7H, m), 4.79 (1H, s) 4-633,4-difluoro-N-(4-(2- LRMS (ESI): (calc) 382.36 (found) 383 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 92% RT: 3.75 minphenylethyl)phenyl)benzamide 4-64 3,4-difluoro-N-(3-(2- LRMS (ESI):(calc) 382.36 (found) 383 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 100%RT: 3.9 min phenylethyl)phenyl)benzamide 4-65 3,5-difluoro-N-(4-(2- LRMS(ESI): (calc) 382.36 (found) 383 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC:95% RT: 3.78 min phenylethyl)phenyl)benzamide 4-66 2,5-difluoro-N-(4-(2-LRMS (ESI): (calc) 382.36 (found) 383 [M + H]+ (hydroxyamino)-2-oxo-1-HPLC: 99% RT: 3.67 min phenylethyl)phenyl)benzamide 4-675-chloro-N-(4-(2- LRMS (ESI): (calc) 384.816 (found) 385 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 99% RT: 3.27 min phenylethyl)phenyl)-1-methyl-1H-pyrazole-4- carboxamide 4-68 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 388.459 (found) 389 [M + H]+ oxo-1-phenylethyl)phenyl)-2-HPLC: 94% RT: 3.92 min phenylbutanamide 4-69 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 388.459 (found) 389 [M + H]+oxo-1-phenylethyl)phenyl)-4- HPLC: 97% RT: 4.14 min propylbenzamide 4-70N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 388.459 (found) 389 [M +H]+ oxo-1-phenylethyl)phenyl)-4- HPLC: 92% RT: 4.17 min propylbenzamide4-71 4-(dimethylamino)-N-(4-(2- LRMS (ESI): (calc) 389.447 (found) 390[M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 95% RT: 3.68 minphenylethyl)phenyl)benzamide 4-73 N-hydroxy-2-(4-(2-(4- LRMS (ESI):(calc) 390.432 (found) 391 [M + H]+ methoxyphenyl)acetamido)phenyl)-HPLC: 93% RT: 3.57 min 2-phenylacetamide 4-74 N-hydroxy-2-(4-(2-(3- LRMS(ESI): (calc) 390.432 (found) 391 [M + H]+methoxyphenyl)acetamido)phenyl)- HPLC: 100% RT: 3.59 min2-phenylacetamide 4.75 N-hydroxy-2-(3-(2-(3- LRMS (ESI): (calc) 390.432(found) 391 [M + H]+ methoxyphenyl)acetamido)phenyl)- HPLC: 90% RT: 3.62min 1H NMR (250 MHz, 2-phenylacetamide MeOD) d ppm 7.43-7.52 (2H m),7.13-7.32 (7H, m), 7.02 (1H, d, J = 7.77 Hz), 6.82-6.88 (2H, m),6.67-6.82 (1H, m), 4.72 (1H, s), 3.72 (3H, s), 3.56 (2H, s) 4-76N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 390.432 (found) 391 [M +H]+ oxo-1-phenylethyl)phenyl)-2- HPLC: 90% RT: 3.78 minphenoxypropanamide 4-78 2-(4-(2- LRMS (ESI): (calc) 390.432 (found) 391[M + H]+ (benzyloxy)acetamido)phenyl)- HPLC: 88% RT: 3.74 minN-hydroxy-2- phenylacetamide 4-79 2-(3-(2- LRMS (ESI): (calc) 390.432(found) 391 [M + H]+ (benzyloxy)acetamido)phenyl)- HPLC: 100% RT: 3.77min N-hydroxy-2- phenylacetamide 4-80 4-ethoxy-N-(4-(2- LRMS (ESI):(calc) 390.432 (found) 391 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 94%RT: 3.78 min phenylethyl)phenyl)benzamide 4-81 4-ethoxy-N-(3-(2- LRMS(ESI): (calc) 390.432 (found) 391 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC:91% RT: 3.92 min phenylethyl)phenyl)benzamide 4-82 2-ethoxy-N-(4-(2-LRMS (ESI): (calc) 390.432 (found) 391 [M + H]+ (hydroxyamino)-2-oxo-1-HPLC: 91% RT: 3.93 min phenylethyl)phenyl)benzamide 4-83N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 391.377 (found) 392 [M +H]+ oxo-1-phenylethyl)phenyl)-2- HPLC: 88% RT: 3.45 min nitrobenzamide4-84 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 391.377 (found) 392[M + H]+ oxo-1-phenylethyl)phenyl)-3- HPLC: 87% RT: 3.65 minnitrobenzamide 4-85 N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc)392.471 (found) 393 [M + H]+ (phenylthio)acetamido)phenyl)acetamideHPLC: 100% RT: 3.72 min 4-86 N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI):(calc) 392.471 (found) 393 [M + H]+(phenylthio)acetamido)phenyl)acetamide HPLC: 100% RT: 3.83 min 4-873-fluoro-N-(4-(2- LRMS (ESI): (calc) 394.396 (found) 395 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 88% RT: 3.65 min phenylethyl)phenyl)-4-methoxybenzamide 4-88 2-(4-(2-(4- LRMS (ESI): (calc) 394.1 (found) 395[M + H]+ chlorophenyl)acetamido)phenyl)- HPLC: 89% RT: 3.82 minN-hydroxy-2- phenylacetamide 4-89 2-(3-(2-(4- LRMS (ESI): (calc) 394.1(found) 395 [M + H]+ chlorophenyl)acetamido)phenyl)- HPLC: 100% RT: 3.87min 1H NMR (250 MHz, N-hydroxy-2- MeOD) d ppm 7.40-7.58 (2H, m),7.17-7.32 (10H, phenylacetamide m), 7.03 (1H, d, J = 7.61 Hz), 4.72 (1H,s), 3.59 (2H, s) 4-90 1-acetyl-N-(4-(2- LRMS (ESI): (calc) 395.452(found) 396 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 100% RT: 2.99 minphenylethyl)phenyl)piperidine- 4-carboxamide 4-91N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 396.438 (found) 397 [M +H]+ oxo-1-phenylethyl)phenyl)-1- HPLC: 89% RT: 3.84 min naphthamide 4-92N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 397.426 (found) 398 [M +H]+ oxo-1- HPLC: 100% RT: 4.05 min phenylethyl)phenyl)quinoline-2-carboxamide 4-93 2-chloro-4-fluoro-N-(4-(2- LRMS (ESI): (calc) 398.083(found) 399 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 95% RT: 3.69 minphenylethyl)phenyl)benzamide 4-94 2,4,5-trifluoro-N-(4-(2- LRMS (ESI):(calc) 400.351 (found) 401 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 100%RT: 3.78 min phenylethyl)phenyl)benzamide 4-95 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 400.427 (found) 401 [M + H]+oxo-1-phenylethyl)phenyl)-3- HPLC: 99% RT: 4.23 min methylbenzofuran-2-carboxamide 4-96 N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 400.427(found) 401 [M + H]+ oxo-1-phenylethyl)phenyl)-3- HPLC: 100% RT: 4.14min 1H NMR (250 MHz, methylbenzofuran-2- MeOD) d ppm 7.58-7.69 (3H, m),7.49-7.56 (1H, carboxamide m), 7.36-7.46 (1H, m), 7.19-7.36 (7H, m),7.11 (1H, d, J = 7.61 Hz), 4.78 (1H, s), 2.56 (3H, s) 4-97N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 402.442 (found) 403 [M +H]+ oxo-1- HPLC: 100% RT: 3.93 min phenylethyl)phenyl)chroman-3-carboxamide 4-98 N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 402.466(found) 403 [M + H]+ oxo-1- HPLC: 91% RT: 4.12 minphenylethyl)phenyl)benzo[b]thiophene- 2-carboxamide 4-99N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 402.466 (found) 403 [M +H]+ oxo-1- HPLC: 97% RT: 4.06 min phenylethyl)phenyl)benzo[b]thiophene-3-carboxamide 4-100 4-tert-butyl-N-(4-(2- LRMS (ESI): (calc) 402.486(found) 403 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 95% RT: 4.23 min 1HNMR (250 MHz, phenylethyl)phenyl)benzamide MeOD) d ppm 7.87 (2H, d, J =8.53 Hz), 7.65 (2H, d, J = 8.53 Hz), 7.53 (2H, d, J = 8.38 Hz),7.21-7.37 (7H, m), 4.80 (1H, s), 1.35 (9H, s) 4-1014-tert-butyl-N-(3-(2- LRMS (ESI): (calc) 402.486 (found) 403 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 92% RT: 4.26 minphenylethyl)phenyl)benzamide 4-102 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 404.415 (found) 405 [M + H]+ oxo-1-phenylethyl)phenyl)- HPLC:100% RT: 3.8 min 1H NMR (250 MHz, 2,3- MeOD) d ppm 7.52 (2H, d, J = 8.68Hz), dihydrobenzo[b][1,4]dioxine- 7.17-7.31 (7H, m), 6.99-7.08 (1H, m),6.80-6.90 (3H, 2-carboxamide m), 4.80 (1H, dd, J = 6.85, 2.59 Hz), 4.73(1H, s), 4.45 (1H, dd, J = 11.42, 2.74 Hz), 4.20-4.30 (1H, m) 4-103N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 404.415 (found) 405 [M +H]+ oxo-1-phenylethyl)phenyl)- HPLC: 100% RT: 3.92 min 1H NMR (250 MHz,2,3- MeOD) d ppm 7.45-7.56 (2H, m), 7.16-7.33 (6H,dihydrobenzo[b][1,4]dioxine- m), 7.08 (1H, d, J = 7.61 Hz), 6.95-7.04(1H, 2-carboxamide m), 6.78-6.89 (3H, m), 4.74 (1H, s), 4.78 (1H, d, J =2.44 Hz), 4.35-4.46 (1H, m), 4.16-4.28 (1H, m) 4-104N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 406.431 (found) 407 [M +H]+ oxo-1-phenylethyl)phenyl)- HPLC: 100% RT: 3.44 min2,6-dimethoxybenzamide 4-105 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 406.431 (found) 407 [M + H]+ oxo-1-phenylethyl)phenyl)- HPLC: 93%RT: 3.72 min 3,5-dimethoxybenzamide 4-106 N-hydroxy-2-(3-(2- LRMS (ESI):(calc) 410.464 (found) 411 [M + H]+ (naphthalen-1- HPLC: 100% RT: 4.05min yl)acetamido)phenyl)-2- phenylacetamide 4-107 2-(4-(2-(4- LRMS(ESI): (calc) 410.85 (found) 411 [M + H]+chlorophenoxy)acetamido)phenyl)- HPLC: 100% RT: 3.93 min N-hydroxy-2-phenylacetamide 4-108 2-chloro-N-(4-(2- LRMS (ESI): (calc) 411.838(found) 412 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 93% RT: 3.9 minphenylethyl)phenyl)-6- methoxyisonicotinamide 4-1096-chloro-2-fluoro-N-(4-(2- LRMS (ESI): (calc) 412.841 (found) 413 [M +H]+ (hydroxyamino)-2-oxo-1- HPLC: 94% RT: 3.78 minphenylethyl)phenyl)-3- methylbenzamide 4-110 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 414.377 (found) 415 [M + H]+oxo-1-phenylethyl)phenyl)-4- HPLC: 94% RT: 4.09 min(trifluoromethyl)benzamide 4-111 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 414.377 (found) 415 [M + H]+ oxo-1-phenylethyl)phenyl)-3- HPLC:95% RT: 3.97 min (trifluoromethyl)benzamide 4-112N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 414.377 (found) 415 [M +H]+ oxo-1-phenylethyl)phenyl)-3- HPLC: 85% RT: 4.01 min(trifluoromethyl)benzamide 4-113 3,4-dichloro-N-(4-(2- LRMS (ESI):(calc) 414.05 (found) 415 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 91% RT:4.11 min phenylethyl)phenyl)benzamide 4-114 3,4-dichloro-N-(3-(2- LRMS(ESI): (calc) 414.05 (found) 415 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC:100% RT: 4.23 min phenylethyl)phenyl)benzamide 4-1153,5-dichloro-N-(4-(2- LRMS (ESI): (calc) 414.05 (found) 415 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 88% RT: 4.19 minphenylethyl)phenyl)benzamide 4-116 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 417.457 (found) 418 [M + H]+ oxo-1-phenylethyl)phenyl)-4- HPLC:100% RT: 3.63 min methyl-3,4-dihydro-2H- benzo[b][1,4]oxazine-7-carboxamide 4-117 4-butoxy-N-(4-(2- LRMS (ESI): (calc) 418.485 (found)419 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 94% RT: 4.23 minphenylethyl)phenyl)benzamide 4-118 2-(4-(2-(3,4- LRMS (ESI): (calc)420.458 (found) 421 [M + H]+ dimethoxyphenyl)acetamido)phenyl)- HPLC:93% RT: 3.4 min N-hydroxy-2- phenylacetamide 4-119 2-(3-(2-(3,4- LRMS(ESI): (calc) 420.458 (found) 421 [M + H]+dimethoxyphenyl)acetamido)phenyl)- HPLC: 93% RT: 3.47 min N-hydroxy-2-phenylacetamide 4-120 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc)427.452 (found) 428 [M + H]+ oxo-1-phenylethyl)phenyl)-5- HPLC: 100% RT:3.77 min methyl-3-phenylisoxazole-4- carboxamide 4-121N-(3-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 427.452 (found) 428 [M +H]+ oxo-1-phenylethyl)phenyl)-5- HPLC: 87% RT: 3.81 minmethyl-3-phenylisoxazole-4- carboxamide 4-123 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 430.377 (found) 431 [M + H]+oxo-1-phenylethyl)phenyl)-4- HPLC: 95% RT: 4.03 min(trifluoromethoxy)benzamide 4-124 N-(3-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 430.377 (found) 431 [M + H]+ oxo-1-phenylethyl)phenyl)-4- HPLC:92% RT: 4.07 min 1H NMR (250 MHz, (trifluoromethoxy)benzamide MeOD) dppm 7.96 (2H, d, J = 8.83 Hz), 7.50-7.69 (2H, m), 7.18-7.37 (8H, m),7.10 (1H, d, J = 7.77 Hz), 4.78 (1H, s) 4-125 N-(4-(2-(hydroxyamino)-2-LRMS (ESI): (calc) 430.377 (found) 431 [M + H]+oxo-1-phenylethyl)phenyl)-3- HPLC: 94% RT: 4.04 min(trifluoromethoxy)benzamide 4-126 N-(3-(2-(hydroxyamino)-2- LRMS (ESI):(calc) 430.377 (found) 431 [M + H]+ oxo-1-phenylethyl)phenyl)-3- HPLC:90% RT: 4.87 min (trifluoromethoxy)benzamide 4-127 2-fluoro-N-(4-(2-LRMS (ESI): (calc) 432.368 (found) 433 [M + H]+ (hydroxyamino)-2-oxo-1-HPLC: 99% RT: 4.1 min phenylethyl)phenyl)-4- (trifluoromethyl)benzamide4-128 2-fluoro-N-(3-(2- LRMS (ESI): (calc) 432.368 (found) 433 [M + H]+(hydroxyamino)-2-oxo-1- HPLC: 99% RT: 4.14 min phenylethyl)phenyl)-4-(trifluoromethyl)benzamide 4-129 4-fluoro-N-(4-(2- LRMS (ESI): (calc)432.368 (found) 433 [M + H]+ (hydroxyamino)-2-oxo-1- HPLC: 95% RT: 3.79min phenylethyl)phenyl)-2- (trifluoromethyl)benzamide 4-1302-(4-(2-(4-tert- LRMS (ESI): (calc) 432.512 (found) 433 [M + H]+butylphenoxy)acetamido)phenyl)- HPLC: 100% RT: 4.48 min N-hydroxy-2-phenylacetamide 4-131 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc)444.403 (found) 445 [M + H]+ oxo-1-phenylethyl)phenyl)-4- HPLC: 94% RT:3.97 min methoxy-3- (trifluoromethyl)benzamide 4-132N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc) 446.442 (found) 447 [M +H]+ oxo-1-phenylethyl)phenyl)-4- HPLC: 93% RT: 4.19 min(trifluoromethylthio)benzamide 4-133 N-(4-(2-(hydroxyamino)-2- LRMS(ESI): (calc) 447.463 (found) 448 [M + H]+ oxo-1-phenylethyl)phenyl)-5-HPLC: 100% RT: 4.17 min nitrobenzo[b]thiophene-2- carboxamide 4-1342-(4- LRMS (ESI): (calc) 296.364 (found) 297 [M + H]+(cyclopropylmethylamino)phenyl)- HPLC: 94% RT: 2.77 min N-hydroxy-2-phenylacetamide 4-135 N-hydroxy-2-(4- LRMS (ESI): (calc) 298.379 (found)299 [M + H]+ (isobutylamino)phenyl)-2- HPLC: 95% RT: 3.42 min 1H NMR(250 MHz, phenylacetamide MeOD) d ppm 7.12-7.30 (5H, m), 7.01 (2H, d, J= 8.53 Hz), 6.53 (2H, d, J = 8.68 Hz), 4.60 (1H, s), 2.83 (2H, d, J =6.85 Hz), 1.66-1.94 (1H, m), 0.92 (6H, d, J = 6.55 Hz) 4-136N-hydroxy-2-(4-(3- LRMS (ESI): (calc) 310.39 (found) 311 [M + H]+methylbut-2- HPLC: 91% RT: 3.14 min enylamino)phenyl)-2- phenylacetamide4-137 N-hydroxy-2-(4- LRMS (ESI): (calc) 312.406 (found) 313 [M + H]+(neopentylamino)phenyl)-2- HPLC: 95% RT: 3.98 min 1H NMR (250 MHz,phenylacetamide MeOD) d ppm 7.10-7.30 (5H, m), 6.99 (2H, d, J = 7.01Hz), 6.55 (2H, d, J = 7.01 Hz), 4.59 (1H, s), 2.82 (2H, s), 0.93 (9H, s)4-138 N-hydroxy-2-(3- LRMS (ESI): (calc) 312.406 (found) 313 [M + H]+(neopentylamino)phenyl)-2- HPLC: 99% RT: 4.01 min 1H NMR (250 MHz,phenylacetamide MeOD) d ppm 7.14-7.31 (5H, m), 6.92-7.07 (1H, m), 6.65(1H, s), 6.50-6.60 (2H, m), 4.64 (1H, s), 2.82 (2H, s), 0.92 (9H, s)4-139 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 312.406 (found) 313 [M + H]+methylbutylamino)phenyl)-2- HPLC: 92% RT: 3.73 min phenylacetamide 4-1402-(4- LRMS (ESI): (calc) 324.417 (found) 325 [M + H]+(cyclopentylmethylamino)phenyl)- HPLC: 90% RT: 3.65 min N-hydroxy-2-phenylacetamide 4-141 2-(4-(2- LRMS (ESI): (calc) 326.433 (found) 327[M + H]+ ethylbutylamino)phenyl)-N- HPLC: 87% RT: 4.04 minhydroxy-2-phenylacetamide 4-142 N-hydroxy-2-(4-(2- LRMS (ESI): (calc)326.433 (found) 327 [M + H]+ methylpentylamino)phenyl)- HPLC: 91% RT:4.05 min 2-phenylacetamide 4-143 2-(4-(3,3- LRMS (ESI): (calc) 326.433(found) 327 [M + H]+ dimethylbutylamino)phenyl)- HPLC: 95% RT: 3.52 minN-hydroxy-2- phenylacetamide 4-144 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc) 333.384 (found) 334 [M + H]+ (pyridin-3- HPLC: 91% RT: 2.51 minylmethylamino)phenyl)acetamide 4-145 N-hydroxy-2-(4-((1-methyl- LRMS(ESI): (calc) 336.388 (found) 337 [M + H]+ 1H-imidazol-2- HPLC: 92% RT:2.39 min yl)methylamino)phenyl)-2- phenylacetamide 4-1462-(4-(cyclohex-3- LRMS (ESI): (calc) 336.427 (found) 337 [M + H]+enylmethylamino)phenyl)-N- HPLC: 90% RT: 3.89 minhydroxy-2-phenylacetamide 4-147 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc) 339.411 (found) 340 [M + H]+ (thiazol-2- HPLC: 100% RT: 3.29 minylmethylamino)phenyl)acetamide 4-148 N-hydroxy-2-phenyl-2-(3- LRMS(ESI): (calc) 339.411 (found) 340 [M + H]+ (thiazol-2- HPLC: 97% RT:3.32 min ylmethylamino)phenyl)acetamide 4-149 N-hydroxy-2-(4-(2- LRMS(ESI): (calc) 346.422 (found) 347 [M + H]+ methylbenzylamino)phenyl)-HPLC: 97% RT: 4 min 2-phenylacetamide 4-150 N-hydroxy-2-(4-(3- LRMS(ESI): (calc) 346.422 (found) 347 [M + H]+ methylbenzylamino)phenyl)-HPLC: 89% RT: 3.99 min 2-phenylacetamide 4-151 N-hydroxy-2-(4-((6- LRMS(ESI): (calc) 347.41 (found) 348 [M + H]+ methylpyridin-2- HPLC: 99% RT:2.54 min yl)methylamino)phenyl)-2- phenylacetamide 4-152N-hydroxy-2-(4-(3- LRMS (ESI): (calc) 348.395 (found) 349 [M + H]+hydroxybenzylamino)phenyl)- HPLC: 93% RT: 3.34 min 2-phenylacetamide4-153 2-(4-(2- LRMS (ESI): (calc) 350.386 (found) 351 [M + H]+fluorobenzylamino)phenyl)- HPLC: 86% RT: 3.9 min N-hydroxy-2-phenylacetamide 4-154 (E)-N-hydroxy-2-phenyl-2- LRMS (ESI): (calc)359.421 (found) 360 [M + H]+ (4-(3-(pyridin-3- HPLC: 92% RT: 2.7 minyl)allylamino)phenyl)acetamide 4-155 N-hydroxy-2-phenyl-2-(4-(2- LRMS(ESI): (calc) 360.449 (found) 361 [M + H]+phenylpropylamino)phenyl)acetamide HPLC: 93% RT: 4.22 min 4-1562-(4-(3,5- LRMS (ESI): (calc) 360.449 (found) 361 [M + H]+dimethylbenzylamino)phenyl)- HPLC: 100% RT: 4.15 min N-hydroxy-2-phenylacetamide 4-157 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 362.422(found) 363 [M + H]+ methoxybenzylamino)phenyl)- HPLC: 85% RT: 3.63 min2-phenylacetamide 4-158 2-(4-(2- LRMS (ESI): (calc) 366.841 (found) 367[M + H]+ chlorobenzylamino)phenyl)- HPLC: 89% RT: 4.11 min N-hydroxy-2-phenylacetamide 4-159 2-(3-(2- LRMS (ESI): (calc) 366.841 (found) 367[M + H]+ chlorobenzylamino)phenyl)- HPLC: 98% RT: 4.2 min N-hydroxy-2-phenylacetamide 4-160 2-(4-((1H-indol-5- LRMS (ESI): (calc) 371.432(found) 372 [M + H]+ yl)methylamino)phenyl)-N- HPLC: 87% RT: 3.36 minhydroxy-2-phenylacetamide 4-161 2-(3-((1H-indol-5- LRMS (ESI): (calc)371.432 (found) 372 [M + H]+ yl)methylamino)phenyl)-N- HPLC: 89% RT:3.37 min hydroxy-2-phenylacetamide 4-162 2-(4-(benzo[d][1,3]dioxol-5-LRMS (ESI): (calc) 376.405 (found) 377 [M + H]+ ylmethylamino)phenyl)-N-HPLC: 86% RT: 3.7 min hydroxy-2-phenylacetamide 4-1632-(3-(benzo[d][1,3]dioxol-5- LRMS (ESI): (calc) 376.405 (found) 377 [M +H]+ ylmethylamino)phenyl)-N- HPLC: 88% RT: 3.7 minhydroxy-2-phenylacetamide 4-164 N-hydroxy-2-(4-(4-methoxy- LRMS (ESI):(calc) 376.448 (found) 377 [M + H]+ 3- HPLC: 99% RT: 3.88 minmethylbenzylamino)phenyl)- 2-phenylacetamide 4-165 N-hydroxy-2-(4-(4-LRMS (ESI): (calc) 378.487 (found) 379 [M + H]+(methylthio)benzylamino)phenyl)- HPLC: 100% RT: 4 min 2-phenylacetamide4-166 N-hydroxy-2-(3-(4- LRMS (ESI): (calc) 378.487 (found) 379 [M + H]+(methylthio)benzylamino)phenyl)- HPLC: 95% RT: 3.99 min2-phenylacetamide 4-167 N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc)383.442 (found) 384 [M + H]+ (quinolin-4- HPLC: 90% RT: 2.85 minylmethylamino)phenyl)acetamide 4-168 (E)-N-hydroxy-2-(4-(3-(4- LRMS(ESI): (calc) 388.459 (found) methoxyphenyl)allylamino)phenyl)- 777[2M + H]+ HPLC: 92% RT: 3.83 min 2-phenylacetamide 4-169(E)-N-hydroxy-2-(4-(3-(2- LRMS (ESI): (calc) 388.459 (found) 389 [M +H]+ methoxyphenyl)allylamino)phenyl)- HPLC: 92% RT: 3.92 min2-phenylacetamide 4-170 2-(4-(4-tert- LRMS (ESI): (calc) 388.502 (found)389 [M + H]+ butylbenzylamino)phenyl)- HPLC: 91% RT: 4.5 minN-hydroxy-2- phenylacetamide 4-171 2-(4-((2,3- LRMS (ESI): (calc)390.432 (found) 391 [M + H]+ dihydrobenzo[b][1,4]dioxin- HPLC: 92% RT:3.67 min 6-yl)methylamino)phenyl)- N-hydroxy-2- phenylacetamide 4-173N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI): (calc) 400.394 (found) 401 [M +H]+ (trifluoromethyl)benzylamino)phenyl)acetamide HPLC: 98% RT: 4.18 min1H NMR (250 MHz, MeOD) d ppm 7.36-7.61 (4H, m), 7.09-7.25 (5H, m), 7.00(2H, d, J = 7.77 Hz), 6.52 (2H, d, J = 7.61 Hz), 4.59 (1H, s), 4.31 (2H,s) 4-174 N-hydroxy-2-phenyl-2-(3-(3- LRMS (ESI): (calc) 400.394 (found)401 [M + H]+ (trifluoromethyl)benzylamino)phenyl)acetamide HPLC: 99% RT:4.18 min 4-175 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc) 400.394(found) 401 [M + H]+ (trifluoromethyl)benzylamino)phenyl)acetamide HPLC:86% RT: 4.21 min 4-176 2-(4-(biphenyl-4- LRMS (ESI): (calc) 408.492(found) 409 [M + H]+ ylmethylamino)phenyl)-N- HPLC: 93% RT: 4.41 minhydroxy-2-phenylacetamide 4-177 2-(3-(biphenyl-4- LRMS (ESI): (calc)408.492 (found) 409 [M + H]+ ylmethylamino)phenyl)-N- HPLC: 99% RT: 4.38min hydroxy-2-phenylacetamide 4-178 N-hydroxy-2-(4- LRMS (ESI): (calc)320.364 (found) 321 [M + H]+ (methylsulfonamido)phenyl)- HPLC: 91% RT:2.99 min 2-phenylacetamide 4-179 2-(4- LRMS (ESI): (calc) 334.39 (found)335 [M + H]+ (ethylsulfonamido)phenyl)- HPLC: 95% RT: 3.13 minN-hydroxy-2- phenylacetamide 4-180 2-(3- LRMS (ESI): (calc) 334.39(found) 335 [M + H]+ (ethylsulfonamido)phenyl)- HPLC: 85% RT: 3.17 minN-hydroxy-2- phenylacetamide 4-181 N-hydroxy-2-(4-(1- LRMS (ESI): (calc)348.417 (found) 349 [M + H]+ methylethylsulfonamido)phenyl)- HPLC: 95%RT: 3.28 min 2-phenylacetamide 4-182 2-(4- LRMS (ESI): (calc) 362.443(found) 363 [M + H]+ (butylsulfonamido)phenyl)- HPLC: 92% RT: 3.53 minN-hydroxy-2- phenylacetamide 4-183 2-(3- LRMS (ESI): (calc) 362.443(found) 363 [M + H]+ (butylsulfonamido)phenyl)- HPLC: 89% RT: 3.56 minN-hydroxy-2- phenylacetamide 4-184 2-(4-(3- LRMS (ESI): (calc) 382.862(found) 383 [M + H]+ chloropropylsulfonamido)phenyl)- HPLC: 100% RT:3.53 min 1H NMR (360 MHz, N-hydroxy-2- MeOH) d ppm 7.25-7.31 (6H, m),7.20-7.24 (1H, phenylacetamide m), 7.15-7.20 (2H, m), 4.74 (1H, s), 3.62(2H, t, J = 6.36 Hz), 3.13-3.23 (2H, m), 2.10-2.23 (2H, m) 4-185N-hydroxy-2-(3-(1-methyl- LRMS (ESI): (calc) 386.425 (found) 387 [M +H]+ 1H-imidazole-4- HPLC: 88% RT: 2.98 min sulfonamido)phenyl)-2-phenylacetamide 4-186 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc)388.362 (found) 389 [M + H]+ (2,2,2- HPLC: 100% RT: 3.47 mintrifluoroethylsulfonamido)phenyl)acetamide 4-187N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc) 388.362 (found) 389 [M + H]+(2,2,2- HPLC: 100% RT: 3.59 mintrifluoroethylsulfonamido)phenyl)acetamide 4-188N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc) 396.46 (found) 397 [M + H]+(phenylmethylsulfonamido)phenyl)acetamide HPLC: 91% RT: 3.6 min 4-189N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc) 396.46 (found) 397 [M + H]+(phenylmethylsulfonamido)phenyl)acetamide HPLC: 89% RT: 3.64 min 4-190N-hydroxy-2-(4-(4- LRMS (ESI): (calc) 396.46 (found) 397 [M + H]+methylphenylsulfonamido)phenyl)- HPLC: 94% RT: 3.68 min2-phenylacetamide 4-191 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 396.46(found) 397 [M + H]+ methylphenylsulfonamido)phenyl)- HPLC: 94% RT: 3.75min 2-phenylacetamide 4-192 N-hydroxy-2-(4-(3- LRMS (ESI): (calc) 396.46(found) 397 [M + H]+ methylphenylsulfonamido)phenyl)- HPLC: 91% RT: 3.68min 2-phenylacetamide 4-193 N-hydroxy-2-(3-(3- LRMS (ESI): (calc) 396.46(found) 397 [M + H]+ methylphenylsulfonamido)phenyl)- HPLC: 91% RT: 3.69min 2-phenylacetamide 4-194 2-(4-(4- LRMS (ESI): (calc) 400.423 (found)401 [M + H]+ fluorophenylsulfonamido)phenyl)- HPLC: 91% RT: 3.7 minN-hydroxy-2- phenylacetamide 4-195 2-(3-(4- LRMS (ESI): (calc) 400.423(found) 401 [M + H]+ fluorophenylsulfonamido)phenyl)- HPLC: 90% RT: 3.63min N-hydroxy-2- phenylacetamide 4-196 2-(4-(3- LRMS (ESI): (calc)400.423 (found) 401 [M + H]+ fluorophenylsulfonamido)phenyl)- HPLC: 100%RT: 3.72 min N-hydroxy-2- phenylacetamide 4-197 2-(4-(2- LRMS (ESI):(calc) 400.423 (found) 401 [M + H]+ fluorophenylsulfonamido)phenyl)-HPLC: 91% RT: 3.56 min N-hydroxy-2- phenylacetamide 4-198 2-(3-(2- LRMS(ESI): (calc) 400.423 (found) 401 [M + H]+fluorophenylsulfonamido)phenyl)- HPLC: 87% RT: 3.55 min N-hydroxy-2-phenylacetamide 4-199 2-(4-(1,2-dimethyl-1H- LRMS (ESI): (calc) 400.452(found) 401 [M + H]+ imidazole-4- HPLC: 90% RT: 3.05 minsulfonamido)phenyl)-N- hydroxy-2-phenylacetamide 4-2002-(4-(3,5-dimethylisoxazole- LRMS (ESI): (calc) 401.436 (found) 402 [M +H]+ 4-sulfonamido)phenyl)-N- HPLC: 94% RT: 3.5 minhydroxy-2-phenylacetamide 4-201 2-(4-(3,4- LRMS (ESI): (calc) 410.486(found) 411 [M + H]+ dimethylphenylsulfonamido)phenyl)- HPLC: 93% RT:3.8 min N-hydroxy-2- phenylacetamide 4-202 2-(3-(3,4- LRMS (ESI): (calc)410.486 (found) 411 [M + H]+ dimethylphenylsulfonamido)phenyl)- HPLC:93% RT: 3.8 min 1H NMR (250 MHz, N-hydroxy-2- MeOD) d ppm 7.42 (1H, s),7.30-7.38 (1H, m), phenylacetamide 7.12-7.26 (6H, m), 7.03-7.11 (2H, m),6.90-7.01 (2H, m), 4.63 (1H, s), 2.22 (3H, s), 2.17 (3H, s) 4-2032-(4-(2,5- LRMS (ESI): (calc) 410.486 (found) 411 [M + H]+dimethylphenylsulfonamido)phenyl)- HPLC: 92% RT: 3.82 min N-hydroxy-2-phenylacetamide 4-204 2-(4-(4- LRMS (ESI): (calc) 410.486 (found) 411[M + H]+ ethylphenylsulfonamido)phenyl)- HPLC: 87% RT: 3.84 minN-hydroxy-2- phenylacetamide 4-205 2-(4-(3,5- LRMS (ESI): (calc) 410.486(found) 411 [M + H]+ dimethylphenylsulfonamido)phenyl)- HPLC: 94% RT:3.83 min N-hydroxy-2- phenylacetamide 4-206 N-hydroxy-2-(4-(3- LRMS(ESI): (calc) 412.459 (found) 413 [M + H]+methoxyphenylsulfonamido)phenyl)- HPLC: 93% RT: 3.61 min 1H NMR (250MHz, 2-phenylacetamide MeOD) d ppm 7.10-7.33 (10H, m), 6.87-7.08 (3H,m), 4.67 (1H, s), 3.63 (3H, s) 4-207 N-hydroxy-2-(3-(3- LRMS (ESI):(calc) 412.459 (found) 413 [M + H]+ methoxyphenylsulfonamido)phenyl)-HPLC: 91% RT: 3.62 min 2-phenylacetamide 4-208 2-(4-(4-fluoro-2- LRMS(ESI): (calc) 414.45 (found) 415 [M + H]+methylphenylsulfonamido)phenyl)- HPLC: 93% RT: 3.75 min N-hydroxy-2-phenylacetamide 4-209 2-(3-(4-fluoro-2- LRMS (ESI): (calc) 414.45(found) 415 [M + H]+ methylphenylsulfonamido)phenyl)- HPLC: 89% RT: 3.74min N-hydroxy-2- phenylacetamide 4-210 2-(4-(2- LRMS (ESI): (calc)416.878 (found) 417 [M + H]+ chlorophenylsulfonamido)phenyl)- HPLC: 94%RT: 3.65 min N-hydroxy-2- phenylacetamide 4-211 2-(4-(3- LRMS (ESI):(calc) 416.878 (found) 417 [M + H]+ chlorophenylsulfonamido)phenyl)-HPLC: 95% RT: 3.78 min 1H NMR (250 MHz, N-hydroxy-2- MeOD) d ppm7.56-7.69 (2H, m), 7.45-7.54 (1H, phenylacetamide m), 7.33-7.44 (1H, m),7.12-7.27 (7H, m), 6.95-7.07 (2H, m), 4.67 (1H, s) 4-212 2-(4-(2,6- LRMS(ESI): (calc) 418.414 (found) 419 [M + H]+difluorophenylsulfonamido)phenyl)- HPLC: 91% RT: 3.55 min N-hydroxy-2-phenylacetamide 4-213 2-(4-(2,4- LRMS (ESI): (calc) 418.414 (found) 419[M + H]+ difluorophenylsulfonamido)phenyl)- HPLC: 93% RT: 3.73 minN-hydroxy-2- phenylacetamide 4-214 2-(3-(2,4- LRMS (ESI): (calc) 418.414(found) 419 [M + H]+ difluorophenylsulfonamido)phenyl)- HPLC: 89% RT:3.64 min N-hydroxy-2- phenylacetamide 4-215 2-(4-(5-chlorothiophene-2-LRMS (ESI): (calc) 422.016 (found) 422 [M + H]+ sulfonamido)phenyl)-N-HPLC: 91% RT: 3.79 min hydroxy-2-phenylacetamide 4-2162-(3-(5-chlorothiophene-2- LRMS (ESI): (calc) 422.016 (found) 422 [M +H]+ sulfonamido)phenyl)-N- HPLC: 99% RT: 3.89 min 1H NMR (250 MHz,hydroxy-2-phenylacetamide MeOD) d ppm 6.97-7.29 (10H, m), 6.86 (1H, d, J= 4.11 Hz), 4.67 (1H, s) 4-217 N-hydroxy-2-(4-(2-methoxy- LRMS (ESI):(calc) 426.485 (found) 427 [M + H]+ 4- HPLC: 100% RT: 3.75 minmethylphenylsulfonamido)phenyl)- 2-phenylacetamide 4-218N-hydroxy-2-(3-(2-methoxy- LRMS (ESI): (calc) 426.485 (found) 427 [M +H]+ 4- HPLC: 91% RT: 3.67 min methylphenylsulfonamido)phenyl)-2-phenylacetamide 4-219 N-hydroxy-2-(3-(4- LRMS (ESI): (calc) 427.43(found) 428 [M + H]+ nitrophenylsulfonamido)phenyl)- HPLC: 100% RT: 3.78min 2-phenylacetamide 4-220 N-hydroxy-2-(4-(2- LRMS (ESI): (calc) 427.43(found) 428 [M + H]+ nitrophenylsulfonamido)phenyl)- HPLC: 88% RT: 3.64min 2-phenylacetamide 4-221 2-(4-(3-chloro-4- LRMS (ESI): (calc) 430.905(found) 431 [M + H]+ methylphenylsulfonamido)phenyl)- HPLC: 100% RT:4.01 min N-hydroxy-2- phenylacetamide 4-222 2-(3-(3-chloro-4- LRMS(ESI): (calc) 430.905 (found) 431 [M + H]+methylphenylsulfonamido)phenyl)- HPLC: 91% RT: 3.93 min N-hydroxy-2-phenylacetamide 4-223 N-hydroxy-2-(4- LRMS (ESI): (calc) 432.492 (found)433 [M + H]+ (naphthalene-1- HPLC: 100% RT: 3.93 minsulfonamido)phenyl)-2- phenylacetamide 4-224 N-hydroxy-2-(3- LRMS (ESI):(calc) 432.492 (found) 433 [M + H]+ (naphthalene-1- HPLC: 91% RT: 3.83min sulfonamido)phenyl)-2- phenylacetamide 4-225 N-hydroxy-2-(4- LRMS(ESI): (calc) 432.492 (found) 433 [M + H]+ (naphthalene-2- HPLC: 100%RT: 3.95 min sulfonamido)phenyl)-2- phenylacetamide 4-226 2-(4-(4-tert-LRMS (ESI): (calc) 438.539 (found) 439 [M + H]+butylphenylsulfonamido)phenyl)- HPLC: 94% RT: 4.1 min N-hydroxy-2-phenylacetamide 4-227 2-(3-(4-tert- LRMS (ESI): (calc) 438.539 (found)439 [M + H]+ butylphenylsulfonamido)phenyl)- HPLC: 100% RT: 4.2 minN-hydroxy-2- phenylacetamide 4-228 2-(4-(4- LRMS (ESI): (calc) 439.484(found) 440 [M + H]+ acetamidophenylsulfonamido)phenyl)- HPLC: 100% RT:3.32 min 1H NMR (250 MHz, N-hydroxy-2- MeOD) d ppm 7.62 (4H, s),7.08-7.28 (7H, m), phenylacetamide 6.93-7.07 (2H, m), 4.66 (1H, s), 2.08(3H, s) 4-229 N-hydroxy-2-(4-((2- LRMS (ESI): (calc) 441.457 (found) 442[M + H]+ nitrophenyl)methylsulfonamido)phenyl)- HPLC: 100% RT: 3.7 min2- phenylacetamide 4-230 2-(4-(3,4- LRMS (ESI): (calc) 442.485 (found)443 [M + H]+ dimethoxyphenylsulfonamido)phenyl)- HPLC: 95% RT: 3.55 minN-hydroxy-2- phenylacetamide 4-231 2-(3-(3,4- LRMS (ESI): (calc) 442.485(found) 443 [M + H]+ dimethoxyphenylsulfonamido)phenyl)- HPLC: 92% RT:3.46 min N-hydroxy-2- phenylacetamide 4-232 N-hydroxy-2-phenyl-2-(4-(3-LRMS (ESI): (calc) 450.431 (found) 451 [M + H]+(trifluoromethyl)phenylsulfonamido)phenyl)acetamide HPLC: 91% RT: 3.89min 4-233 N-hydroxy-2-phenyl-2-(3-(3- LRMS (ESI): (calc) 450.431 (found)451 [M + H]+ (trifluoromethyl)phenylsulfonamido)phenyl)acetamide HPLC:91% RT: 3.91 min 1H NMR (250 MHz, MeOD) d ppm 7.91 (1H, s), 7.81 (2H, d,J = 8.07 Hz), 7.46-7.65 (1H, m), 7.07-7.28 (6H, m), 6.92-7.07 (3H, m),4.64 (1H, s) 4-234 2-(4-(2,5-dichlorothiophene- LRMS (ESI): (calc)455.977 (found) 457 [M + H]+ 3-sulfonamido)phenyl)-N- HPLC: 92% RT: 3.93min hydroxy-2-phenylacetamide 4-235 2-(4-(4,5-dichlorothiophene- LRMS(ESI): (calc) 455.977 (found) 457 [M + H]+ 2-sulfonamido)phenyl)-N-HPLC: 94% RT: 4.04 min hydroxy-2-phenylacetamide 4-2362-(3-(4,5-dichlorothiophene- LRMS (ESI): (calc) 455.977 (found) 457 [M +H]+ 2-sulfonamido)phenyl)-N- HPLC: 88% RT: 4.05 minhydroxy-2-phenylacetamide 4-237 (E)-2-(4- LRMS (ESI): (calc) 358.433(found) 359 [M + H]+ (cinnamylamino)phenyl)-N- HPLC: 89% RT: 3.93 minhydroxy-2-phenylacetamide 4-238 2-(4- LRMS (ESI): (calc) 440.495 (found)441 [M + H]+ (benzo[c][1,2,5]thiadiazole- HPLC: 100% RT: 3.7 min5-sulfonamido)phenyl)-N- hydroxy-2-phenylacetamide

TABLE V Other Compounds prepared according general Schemes above 5-1

N-hydroxy-2-(4-hydroxy-4-phenylpiperidin-1-yl)-2-phenylacetamide Mol wt.326.39 LRMS(ESI): (calc.) 326.4 (found) 327.5 (MH)+ 1 H NMR (MeOD-d4)7.60-7.51 (m, 4 H), 7.41-7.31 (m, 5 H), 7.27-7.21 (m, 1 H), 3.75 (s, 1H), 3.00-2.92 (m, 1 H), 2.68-2.60 (m, 1 H), 2.57-2.50 (m, 1 H),2.39-2.26 (m, 2 H), 2.20-2.10 (m, 1 H), 1.80-1.72 (m, 1 H), 1.67-1.60(m, 1 H)_(—) 5-2

N-hydroxy-2-phenyl-2-(3-phenyl-1H-pyrrol-1-yl)acetamide Mol wt. 292.332LRMS(ESI): (calc.) 292.3 (found) 293.4 (MH)+ (MeOD-d4) 7.53-7.47 (m, 2H), 7.44-7.34 (m, 5 H), 7.32-7.26 (m, 2 H), 7.19 (t, J = 2.0 Hz, 1 H),7.15-7.09 (m, 1 H), 6.85 (t, J = 2.5 Hz, 1 H), 6.49 (dd, J = 2.9, 1.8Hz, 1 H), 5.77 (s, 1 H)_(—) 5-3

2-(5-((1H-indol-3-yl)methyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamideMol wt. 364.421 LRMS(ESI): (calc.) 364.1 (found) 365.4 (MH)+ (CD3OD)d(ppm) 1 H: 7.41 (d, J = 8.0 Hz, 1 H), 7.37-7.23 (m, 7 H), 7.10 (t, J =6.8 Hz, 1 H), 6.98 (t, J = 6.8 Hz, 1 H), 5.22 (s, 1 H), 4.51 (s, 2H)_(—) 5-4

N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1,3,4-thiadiazol-2-yl)acetamideMol wt. 317.386 LRMS(ESI): (calc.) 317.0 (found) 318.3 (MH)+ (CD3OD)d(ppm) 1 H: 7.67 (m, 2 H), 7.48 (m, 2 H), 7.39-7.32 (m, 3 H), 7.17 (m, 1H), 5.34 (s, 1 H)_(—) 5-5

2-(4-(dimethylamino)phenyl)-N-hydroxy-2-(4-hydroxyphenyl)acetamide Molwt. 286.326 LRMS(ESI): (calc.) 286.3 (found) 287.4 (MH)+ (MeOD) d(ppm) 1H: 7.11 (dd, J = 11.3, 8.8 Hz, 4 H), 6.71 (t, J = 8.6 Hz, 4 H), 4.58 (s,1 H), 2.89 (s, 6 H)._(—) 5-6

N-hydroxy-2-phenyl-2-(phenylsulfinyl)acetamide Mol. Wt. 275.323LRMS(ESI): (calc.) 275.3 (found) 274.1 (M − H)− (DMSO-d6) d(ppm) 1 H:10.93 (br s, 1 H), 9.32 (br s, 1 H), 7.58-6.95 (m, 10 H), 4.37 (s, 1H)_(—) 5-7

2-(4-(1H-indol-3-yl)-5,6-dihydropyridin-1(2H)-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 347.41 LRMS(ESI): (calc.) 347.4 (found) 348.2 (MH)+ (MeOD-d4)7.82 (d, J = 8.0 Hz, 1 H), 7.63-7.58 (m, 2 H), 7.43-7.35 (m, 4 H), 7.27(s, 1 H), 7.15-7.10 (m, 1 H), 7.08-7.02 (m, 1 H), 6.18-6.12 (m, 1 H),3.87 (s, 1 H), 3.30-3.12 (m, 2 H), 2.81-2.74 (m, 2 H), 2.70-2.61 (m, 2H)_(—) 5-8

N-hydroxy-2-phenyl-2-(4-(phenylsulfonyl)piperazin-1-yl)acetamide Mol.Wt. 375.442 LRMS(ESI): (calc.) 375.4 (found) 376.5 (MH)+ (MeOD-d4)7.83-7.78 (m, 2 H), 7.76-7.70 (m, 1 H), 7.69-7.63 (m, 2 H), 7.45-7.40(m, 2 H), 7.36-7.30 (m, 3 H), 3.71 (s, 1 H), 3.10-3.02 (m, 4 H),2.58-2.44 (m, 4 H)_(—) 5-9 Cpd 56

N-hydroxy-2-(4′-methoxybiphenyl-4-yl)-2-phenylacetamide Mol. Wt. 333.38LRMS(ESI): (calc.) 333.4 (found) 334.4 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.94(s, 1 H), 8.98 (s, 1 H), 7.55 (t, J = 8.8 Hz, 4 H), 7.37-7.29 (m, 6 H),7.25-7.23 (m, 1 H), 7.00 (d, J = 8.8 Hz, 2 H), 4.73 (s, 1 H), 3.77 (s, 3H)._(—) 5-10

N-hydroxy-2-phenyl-2-(4-(pyridin-4-yl)phenyl)acetamide Mol. Wt. 304.342LRMS(ESI): (calc.) 304.3 (found) 305.4 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.97(s, 1 H), 9.01 (s, 1 H), 8.61 (d, J = 6.3 Hz, 2 H), 7.75 (d, J = 8.4 Hz,2 H), 7.68 (d, J = 7.3 Hz, 2 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.37-7.22(m, 5 H), 4.78 (s, 1 H)._(—) 5-11

N-hydroxy-2-phenyl-2-(4-(5-phenylpyrimidin-2-yl)piperazin-1-yl)acetamideMol. Wt. 389.45 LRMS(ESI): (calc.) 389.5 (found) 390.6 (MH)+ (DMSO-d6)10.92 (s, 1 H), 8.98 (s, 1 H), 8.73 (s, 2 H), 7.69-7.65 (m, 2 H),7.54-7.45 (m, 4 H), 7.42-7.31 (m, 4 H), 3.85-3.79 (m, 4 H), 3.72 (s, 1H), 2.51-2.40 (m, 4 H)_(—) 5-12

N-hydroxy-2-phenyl-2-(4-(pyridin-3-yl)phenyl)acetamide Mol. Wt. 304.342LRMS(ESI): (calc.) 304.3 (found) 305.4 (MH)+ (MeOD) d(ppm) 1 H: 8.77 (d,J = 1.8 Hz, 1 H), 8.50-8.48 (m, 1 H), 8.07 (dt, J = 8.0, 2.0 Hz, 1 H),7.61 (d, J = 8.4 Hz, 2 H), 7.51-7.45 (m, 3 H), 7.38-7.23 (m, 5 H), 4.85(s, 1 H). 5-13

N-hydroxy-2-(4-(naphthalen-1-yl)phenyl)-2-phenylacetamide Mol. Wt.353.413 LRMS(ESI): (calc.) 353.4 (found) 354.5 (MH)+ (DMSO-d6) d(ppm) 1H: 10.97 (s, 1 H), 9.01 (s, 1 H), 8.18 (s, 1 H), 8.00-7.92 (m, 3 H),7.84-7.75 (m, 3 H), 7.54-7.25 (m, 9 H), 4.78 (s, 1 H)._(—) 5-14

2-(biphenyl-4-yloxy)-N-hydroxy-2-phenylacetamide Mol. Wt. 319.354LRMS(ESI): (calc.) 319.4 (found) 320.4 (MH)+ (DMSO-d6) d(ppm) 1 H: 11.17(br s, 1 H), 9.04 (br s, 1 H), 7.60-7.54 (m, 6 H), 7.43-7.27 (m, 6 H),7.05 (d, J = 8.8 Hz, 2 H), 5.67 (s, 1 H)._(—) 5-15 and Cpd 80

N-hydroxy-2-phenyl-2-(pyridin-3-yl)acetamide Mol. Wt. 228.247 LRMS(ESI):(calc.) 228.0 (found) 229.2 (MH)+ (CD3OD) d(ppm) 1 H: 8.47 (d, J = 2.4Hz, 1 H), 8.43 (q, J = 1.6, 4.8 Hz, 1 H), 7.48 (m, 1 H), 7.41-7.28 (m, 6H), 4.83 (s, 1 H)_(—) 5-16

2-(8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-2(5H)-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 339.363 LRMS(ESI): (calc.) 339.4 (found) 340.2 (MH)+ (DMSO-d6)10.98 (s, 2 H), 9.00 (s, 1 H), 7.57-7.51 (m, 2 H), 7.43-7.33 (m, 3 H),7.28 (dd, J = 8.6, 4.5 Hz, 1 H), 6.99 (dd, J = 7.6, 2.5 Hz, 1 H),6.89-6.82 (m, 1 H), 4.02 (s, 1 H), 3.64 (d, J = 13.7 Hz, 1 H), 3.54 (d,J = 13.5 Hz, 1 H), 2.86-2.70 (m, 4 H)_(—) 5-17

2-(4-(1-benzyl-1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 439.549 LRMS(ESI): (calc.) 439.6 (found) 440.6 (MH)+ (DMSO-d6)10.89 (s, 1 H), 8.93 (s, 1 H), 7.61 (d, J = 7.6 Hz, 1 H), 7.52-7.48 (m,2 H), 7.44-7.30 (m, 7 H), 7.29-7.20 (m, 3 H), 7.13-7.07 (m, 1 H),7.04-6.99 (m, 1 H), 5.40 (s, 2 H), 3.72 (s, 1 H), 3.11-3.04 (m, 1 H),2.84-2.70 (m, 2 H), 2.3-2.2 (m, 1 H), 2.02-1.65 (m, 5 H)_(—) 5-18

2-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 369.39 LRMS(ESI): (calc.) 369.4 (found) 370.4 (MH)+ (MeOD-d4)7.73 (dd, J = 8.2, 2.1 Hz, 1 H), 7.63 (dd, J = 9.0, 4.9 Hz, 1 H),7.58-7.53 (m, 2 H), 7.45-7.32 (m, 4 H), 3.79 (s, 1 H), 3.27-3.11 (m, 2H), 2.89-2.82 (m, 1 H), 2.40-2.32 (m, 1 H), 2.29-2.17 (m, 1 H),2.13-1.95 (m, 4 H)_(—) 5-19

N-hydroxy-2-phenyl-2-(5-phenyl-1,3,4-thiadiazol-2-yl)acetamide Mol. Wt.311.358 LRMS(ESI): (calc.) 311.0 (found) 312.3 (MH)+ (CD3OD) d(ppm) 1 H:7.95 (m, 2 H), 7.51 (m, 5 H), 7.38-7.32 (m, 3 H), 5.37 (s, 1 H)_(—) 5-20

(E)-2-(4-(2-chlorodibenzo[b,f][1,4]oxazepin-11-yl)piperazin-1-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 462.928 LRMS(ESI): (calc.) 462.9 (found) 463.6 (MH)+ (MeOD-d4)7.58-7.50 (m, 3 H), 7.42-7.34 (m, 4 H), 7.30 (d, J = 8.6 Hz, 1 H),7.16-7.09 (m, 3 H), 7.06-7.01 (m, 1 H), 3.80 (s, 1 H), 3.62-3.50 (m, 4H), 2.68-2.50 (m, 4 H)_(—) 5-21

2-(4′-(dimethylamino)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide Mol. Wt.346.422 LRMS(ESI): (calc.) 346.4 (found) 347.5 (MH)+ (DMSO-d6) d(ppm) 1H: 10.92 (s, 1 H), 8.96 (s, 1 H), 7.52-7.46 (m, 4 H), 7.36-7.21 (m, 7H), 6.77 (d, J = 9.0 Hz, 2 H), 4.70 (s, 1 H), 2.91 (s, 6 H)._(—) 5-22

N-hydroxy-2-(4-morpholinophenyl)-2-phenylacetamide Mol. Wt. 312.363LRMS(ESI): (calc.) 312.4 (found) 313.4 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.85(s, 1 H), 8.91 (s, 1 H), 7.29-7.15 (m, 7 H), 6.87 (d, J = 8.8 Hz, 2 H),4.58 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4 H), 3.04 (t, J = 4.7 Hz, 4 H)._(—)5-23

N-hydroxy-2-phenyl-2-(4-(pyrimidin-5-yl)phenyl)acetamide Mol. Wt.305.331 LRMS(ESI): (calc.) 305.3 (found) 306.3 (MH)+ (DMSO-d6) d(ppm) 1H: 10.98 (s, 1 H), 9.17 (s, 1 H), 9.11 (s, 2 H), 9.01 (s, 1 H), 7.76 (d,J = 8.2 Hz, 2 H), 7.47 (d, J = 8.4 Hz, 2 H), 7.37-7.23 (m, 5 H), 4.78(s, 1 H)._(—) 5-24

N-hydroxy-2-(4-(4-methoxyphenyl)piperidin-1-yl)-2-phenylacetamide Mol.Wt. 340.416 LRMS(ESI): (calc.) 340.4 (found) 341.4 (MH)+ (DMSO-d6) 10.87(s, 1 H), 8.93 (s, 1 H), 7.52-7.46 (m, 2 H), 7.40-7.28 (m, 3 H),7.22-7.16 (m, 2 H), 6.90-6.85 (m, 2 H), 3.75 (s, 3 H), 3.69 (s, 1 H),3.10-3.03 (m, 1 H), 2.76-2.69 (m, 1 H), 2.51-2.40 (m, 1 H), 2.20-2.11(m, 1 H), 1.92-1.83 (m, 1 H), 1.78-1.55 (m, 4 H)_(—) 5-25

N-hydroxy-9H-fluorene-9-carboxamide Mol wt. 225.243 LRMS(ESI): (calc.)225.2 (found) 224.0 (M − H+) (MeOD-d4) 7.85 (d, J = 7.4 Hz, 2 H),7.59-7.55 (m, 2 H), 7.47-7.43 (m, 2 H), 7.39-7.33 (m, 2 H), 4.68 (s, 1H)_(—) 5-26

N-hydroxy-2-phenyl-2-(4-(4-phenylpiperazin-1-yl)phenyl)acetamide Mol wt.387.474 LRMS(ESI): (calc.) 387.4 (found) 388.4 (MH)+ (CD3OD) d(ppm) 1 H:7.30-7.21 (m, 9 H), 7.02-6.96 (m, 4 H), 6.85 (t, J = 14.8 Hz, 1 H), 4.71(s, 1 H), 3.29 (m, 8 H)_(—) 5-27 and cpd 64

N-hydroxy-2-phenyl-2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)phenyl)acetamideMol wt. 389.45 LRMS(ESI): (calc.) 389.4 (found) 390.5 (MH)+ (CD3OD)d(ppm) 1 H: 8.32 (d, J = 4.8 Hz, 2 H),7.29-7.20 (m, 7 H), 6.97 (d, J =8.8 Hz, 2 H), 6.60 (t, J = 4.8 Hz, 1 H), 4.69 (s, 1 H), 3.93 (m, 4 H),3.20 (m, 4 H)_(—) 5-28

N-hydroxy-2-(naphthalen-2-ylthio)-2-phenylacetamide Mol wt. 309.382LRMS(ESI): (calc.) 309.4 (found) 310.3 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.98(s, 1 H), 9.11 (s, 1 H), 7.87-7.77 (m, 4 H), 7.53-7.40 (m, 5 H),7.34-7.25 (m, 3 H), 5.04 (s, 1 H)._(—) 5-29

2-(biphenyl-3-yl)-N-hydroxy-2-phenylacetamide Mol wt. 303.354 LRMS(ESI):(calc.) 303.4 (found) 302.3 (M − H)− (DMSO-d6) d(ppm) 1 H: 10.95 (s, 1H), 8.98 (s, 1 H), 7.60-7.22 (m, 14 H), 4.78 (s, 1 H)._(—) 5-30

N-hydroxy-2-phenyl-2-(3-(pyridin-4-yl)phenyl)acetamide Mol. Wt. 304.342LRMS(ESI): (calc.) 304.3 (found) 305.2 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.96(s, 1 H), 9.00 (s, 1 H), 8.62 (d, J = 6.1 Hz, 2 H), 7.72 (s, 1 H),7.67-7.65 (m, 1 H), 7.61 (d, J = 6.4 Hz, 2 H), 7.48-7.21 (m, 7 H), 4.80(s, 1 H)._(—) 5-31

Mol wt. 253.296 LRMS(ESI): (calc.) 253.3 (found) 254.2 (MH)+ (DMSO-d6)10.47 (s, 1 H), 8.87 (s, 1 H), 7.33-7.29 (m, 2 H), 7.21-7.14 (m, 6 H),4.81 (s, 1 H), 3.67-3.57 (m, 2 H), 2.85-2.75 (m, 2 H)_(—) 5-32

2-(4-(dimethylamino)naphthalen-1-yl)-N-hydroxy-2-phenylacetamide Mol wt.320.385 LRMS(ESI): (calc.) 320.4 (found) 321.4 (MH)+ (DMSO-d6) d(ppm) 1H: 10.95 (s, 1 H), 8.96 (s, 1 H), 8.19-8.16 (m, 1 H), 8.00-7.96 (m, 1H), 7.49-7.41 (m, 3 H), 7.31-7.18 (m, 5 H), 7.07 (d, J = 8.0 Hz, 1 H),5.43 (s, 1 H), 2.77 (s, 6 H)._(—) 5-33 cpd 70

2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide Mol wt. 333.38LRMS(ESI): (calc.) 333.4 (found) 334.4 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.86(s, 1 H), 8.92 (s, 1 H), 7.42-7.17 (m, 12 H), 6.93 (d, J = 8.8 Hz, 2 H),5.05 (s, 2 H), 4.62 (s, 1 H)._(—) 5-34

N-hydroxy-2-(4′-morpholinobiphenyl-4-yl)-2-phenylacetamide Mol wt.388.459 LRMS(ESI): (calc.) 388.5 (found) 389.5 (MH)+ (DMSO-d6) d(ppm) 1H: 10.92 (s, 1 H), 8.96 (s, 1 H), 7.51 (t, J = 8.6 Hz, 4 H), 7.34-7.20(m, 7 H), 6.98 (d, J = 8.8 Hz, 2 H), 4.70 (s, 1 H), 3.72 (t, J = 4.7 Hz,4 H), 3.12 (t, J = 4.7 Hz, 4 H)._(—) 5-35

2-(4-(benzo[d]oxazol-2-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamideMol. Wt. 351.399 LRMS(ESI): (calc.) 351.4 (found) 352.5 (MH)+ (MeOD-d4)7.68-7.64 (m, 1 H), 7.60-7.51 (m, 3 H), 7.41-7.31 (m, 5 H), 3.78 (s, 1H), 3.18-2.98 (m, 2 H), 2.84-2.75 (m, 1 H), 2.37-2.28 (m, 1 H),2.23-1.97 (m, 5 H)_(—) 5-36 cpd 72

N-hydroxy-2-(4-hydroxyphenyl)-2-phenylacetamide Mol wt. 243.258LRMS(ESI): (calc.) 243.3 (found) 244.3 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.83(s, 1 H), 9.29 (s, 1 H), 8.89 (s, 1 H), 7.30-7.16 (m, 5 H), 7.10 (d, J =8.6 Hz, 2 H), 6.67 (d, J = 8.6 Hz, 2 H), 4.55 (s, 1 H)._(—) 5-37

N-hydroxy-2-phenyl-2-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)acetamideMol wt. 379.356 LRMS(ESI): (calc.) 379.0 (found) 380.3 (MH)+ (CD3OD)d(ppm) 1 H: 8.16 (d, J = 8.0 Hz, 2 H), 7.82 (d, J = 8.4 Hz, 2 H), 7.50(d, J = 8.4 Hz, 2 H), 7.38-7.34 (m, 3 H), 5.40 (s, 1 H)_(—) 5-38

2-(5-(benzo[d][1,3]dioxol-5-yl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamideMol wt. 355.368 LRMS(ESI): (calc.) 355.0 (found) 356.3 (MH)+ (CD3OD)d(ppm) 1 H: 7.49-7.43 (m, 4 H), 7.37-7.35 (m, 3 H), 6.93 (m, 1 H), 6.04(s, 2 H), 5.33 (s, 1 H)_(—) 5-39

2-(5-(biphenyl-2-yl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamideMol wt. 387.454 LRMS(ESI): (calc.) 387.1 (found) 388.4 (MH)+ (CD3OD)d(ppm) 1 H: 7.86 (d, J = 7.6 Hz, 1 H), 7.61 (t, J = 6.0 Hz, 1 H), 7.52(t, J = 7.6 Hz, 1 H), 7.46 (d, J = 8.0 Hz, 1 H), 7.35-7.25 (m, 8 H),7.17 (m, 2 H), 5.23 (s, 1 H)_(—) 5-40 cpd 74

N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide Mol wt.356.416 LRMS(ESI): (calc.) 356.4 (found) 357.3 (MH)+ (MeOD) d(ppm) 1 H:8.36 (s, 1 H), 7.30-7.20 (m, 7 H), 6.90 (d, J = 8.2 Hz, 2 H), 4.72 (s, 1H), 4.20-4.16 (m, 2 H), 3.78-3.72 (m, 4 H), 3.00-2.94 (m, 2 H),2.80-2.74 (m, 4 H)._(—) 5-41

2-(4-(1H-indol-5-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt 342.39LRMS(ESI): (calc.) 342.4 (found) 343.5 (MH)+ (DMSO-d6) d(ppm) 1 H: 11.12(s, 1 H), 10.94 (s, 1 H), 8.97 (s, 1 H), 7.76 (d, J = 1.6 Hz, 1 H), 7.59(d, J = 8.4 Hz, 2 H), 7.44-7.21 (m, 10 H), 6.46-6.44 (m, 1 H), 4.72 (s,1 H)._(—) 5-42

2-(4-benzoylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide Mol wt. 339.388LRMS(ESI): (calc.) 339.4 (found) 340.5 (MH)+ (DMSO-d6) 10.85 (s, 1 H),8.91 (s, 1 H), 7.44-7.39 (m, 5 H), 7.36-7.24 (m, 5 H), 3.68 (s, 1 H),3.65-3.50 (m, 2 H), 3.35-3.30 (m, 2 H), 2.43-2.20 (m, 4 H)_(—) 5-43

N-hydroxy-2-phenyl-2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)acetamideMol wt. 379.376 LRMS(ESI): (calc.) 379.4 (found) 380.5 (MH)+ (MeOD-d4)7.58-7.53 (m, 2 H), 7.51-7.46 (m, 2 H), 7.42-7.33 (m, 3 H), 7.07-7.02(m, 2 H), 3.74 (s, 1 H), 3.38-3.33 (m, 4 H), 2.68-2.53 (m, 4 H)_(—) 5-44

2-(4-(benzyl(ethyl)amino)phenyl)-N-hydroxy-2-phenylacetamide Mol wt.360.449 LRMS(ESI): (calc.) 360.5 (found) 361.6 (MH)+ (DMSO-d6) d(ppm) 1H: 10.79 (s, 1 H), 8.85 (s, 1 H), 7.30-7.15 (m, 10 H), 7.05 (d, J = 8.8Hz, 2 H), 6.57 (d, J = 9.0 Hz, 2 H), 4.50 (s, 1 H), 4.46 (s, 2 H), 3.41(q, J = 7.0 Hz, 2 H), 1.08 (t, J = 6.9 Hz, 3 H)._(—) 5-45

2-(4′-fluoro-3′-methylbiphenyl-4-yl)-N-hydroxy-2-phenylacetamide Mol wt.335.372 LRMS(ESI): (calc.) 335.4 (found) 334.3 (M − H)− (DMSO-d6) d(ppm)1 H: 10.90 (br s, 1 H), 8.99 (br s, 1 H), 7.57-7.53 (m, 3 H), 7.49-7.43(m, 1 H), 7.38-7.28 (m, 6 H), 7.25-7.16 (m, 2 H), 4.73 (s, 1 H), 2.27(d, J = 1.7 Hz, 3 H)._(—) 5-46

N-hydroxy-2-phenyl-2-(thiazolo[5,4-b]pyridin-2-ylthio)acetamide Mol wt.317.386 LRMS(ESI): (calc.) 317.4 (found) 318.0 (MH)+ (DMSO-d6) d(ppm) 1H: 11.24 (s, 1 H), 9.24 (s, 1 H), 8.49 (dd, J = 4.5, 1.4 Hz, 1 H), 8.20(dd, J = 8.2, 1.5 Hz, 1 H), 7.60-7.58 (m, 2 H), 7.54-7.50 (m, 1 H),7.39-7.29 (m, 3 H), 5.70 (s, 1 H)._(—) 5-47

N-hydroxy-10-methyl-9,10-dihydroacridine-9-carboxamide Mol wt. 254.284LRMS(ESI): (calc.) 254.3 (found) 255.2 (MH)+ (MeOD-d4) 7.32-7.27 (m, 2H), 7.26-7.22 (m, 2 H), 7.05 (d, J = 7.6 Hz, 2 H), 6.96 (td, J = 7.4,1.2 Hz, 2 H), 4.74 (s, 1 H), 3.42 (s, 3 H)_(—) 5-48

N-hydroxy-2-phenyl-2-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)acetamideMol wt. 380.364 LRMS(ESI): (calc.) 380.4 (found) 381.5 (MH)+ (MeOD-d4)8.34 (dd, J = 1.8, 0.8 Hz, 1 H), 7.72 (dd, J = 9.1, 2.3 Hz, 1 H),7.58-7.52 (m, 2 H), 7.43-7.34 (m, 3 H), 6.88 (d, J = 9.0 Hz, 1 H), 3.74(s, 1 H), 3.73-3.69 (m, 4 H), 2.62-2.47 (m, 4 H)_(—) 5-49

2-(3′,4′-difluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide Mol wt.339.335 LRMS(ESI): (calc.) 339.3 (found) 338.4 (M − H)− (DMSO-d6) d(ppm)1 H: 10.95 (s, 1 H), 8.99 (s, 1 H), 7.76-7.70 (m, 1 H), 7.62 (d, J = 8.2Hz, 2 H), 7.51-7.47 (m, 2 H), 7.39-7.20 (m, 7 H), 4.74 (s, 1 H)._(—)5-50

N-hydroxy-2-(5-methoxybenzo[d]thiazol-2-ylthio)-2-phenylacetamide Molwt. 346.424 LRMS(ESI): (calc.) 346.4 (found) 347.4 (MH)+ (DMSO-d6)d(ppm) 1 H: 11.22 (s, 1 H), 9.23 (s, 1 H), 7.84 (d, J = 8.8 Hz, 1 H),7.58 (d, J = 6.9 Hz, 2 H), 7.38-7.29 (m, 4 H), 6.99 (dd, J = 8.8, 2.5Hz, 1 H), 5.59 (s, 1 H), 3.81 (s, 3 H)._(—) 5-51

2-(4-(4-benzylpiperidin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt.400.513 LRMS(ESI): (calc.) 400.5 (found) 401.6 (MH)+ (MeOD) d(ppm) 1 H:7.30-7.13 (m, 12 H), 6.91 (d, J = 8.8 Hz, 2 H), 4.68 (s, 1 H), 3.60 (d,J = 12.4 Hz, 2 H), 2.62-2.54 (m, 4 H), 1.73-1.60 (m, 3 H), 1.42-1.31 (m,2 H)._(—) 5-52

N-hydroxy-2-(5-(2-phenoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamideMol wt. 403.454 LRMS(ESI): (calc.) 403.1 (found) 404.4 (MH)+ (CD3OD)d(ppm) 1 H: 8.38 (d, J = 8.0 Hz, 1 H), 7.48-7.20 (m, 10 H), 7.06 (d, J =8.0 Hz, 2 H), 6.97 (d, J = 8.0 Hz, 1 H), 5.36 (s, 1 H)_(—) 5-53

N-hydroxy-2-(5-(phenoxymethyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamideMol wt. 341.384 LRMS(ESI): (calc.) 341.0 (found) 342.3 (MH)+ (CD3OD)d(ppm) 1 H: 7.45 (m, 2 H), 7.38-7.27 (m, 5 H), 7.03-6.96 (m, 3 H), 5.48(s, 2 H), 5.34 (s, 1 H)_(—) 5-54

N-hydroxy-2-(5-(naphthalen-2-yl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamideMol wt. 361.417 LRMS(ESI): (calc.) 361.0 (found) 362.3 (MH)+ (CD3OD)d(ppm) 1 H: 8.43 (s, 1 H), 8.09-7.88 (m, 4 H), 7.56-7.50 (m, 4 H),7.38-7.31 (m, 3 H), 5.38 (s, 1 H)_(—) 5-55

2-(5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamideMol wt. 350.394 LRMS(ESI): (calc.) 350.0 (found) 351.2 (MH)+ (CD3OD)d(ppm) 1 H: 8.16 (s, 1 H), 7.71 (d, J = 2.0 Hz, 1 H), 7.52-7.47 (m, 3H), 7.40-7.32 (m, 4 H), 6.56 (d, J = 3.2 Hz, 1 H), 5.34 (s, 1 H)_(—)5-56 cpd 85

10-benzyl-N-hydroxy-9,10-dihydroacridine-9-carboxamide Mol wt. 330.38LRMS(ESI): (calc.) 330.4 (found) 331.4 (MH)+ (MeOD-d4) 7.36-7.31 (m, 2H), 7.29-7.21 (m, 5 H), 7.17-7.11 (m, 2 H), 6.91 (td, J = 7.4, 1.0 Hz, 2H), 6.81-6.78 (m, 2 H), 5.22 (s, 2 H), 4.85 (s, 1 H)_(—) 5-57

2-(4-(4-fluorophenyl)piperazin-1-yl)-N-hydroxy-2-phenylacetamide Mol wt.329.369 LRMS(ESI): (calc.) 329.4 (found) 330.4 (MH)+ (MeOD-d4) 7.59-7.53(m, 2 H), 7.42-7.32 (m, 3 H), 7.02-6.92 (m, 4 H), 3.75 (s, 1 H),3.20-3.10 (m, 4 H), 2.68-2.52 (m, 4 H)_(—) 5-58

2-(4-(6-(dimethylamino)pyridin-3-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 347.41 LRMS(ESI): (calc.) 347.4 (found) 348.5 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.94 (s, 1 H), 8.98 (s, 1 H), 8.40 (d, J = 2.4 Hz, 1 H),7.79 (dd, J = 8.8, 2.5 Hz, 1 H), 7.54 (d, J = 8.2 Hz, 2 H), 7.36-7.23(m, 7 H), 6.70 (d, J = 8.8 Hz, 1 H), 4.72 (s, 1 H), 3.05 (s, 6 H)._(—)5-59

2-(5-chlorobenzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide Mol wt.350.843 LRMS(ESI): (calc.) 350.0 (found) 351.3 (MH)+ (DLRMSOD6) d(ppm) 1H: 11.24 (s, 1 H), 9.25 (s, 1 H), 8.04 (d, J = 8.6 Hz, 1 H), 7.91 (d, J= 2.2 Hz, 1 H), 7.61-7.58 (m, 2 H), 7.44-7.29 (m, 4 H), 5.62 (s, 1H)._(—) 5-60

1-benzyl-N-hydroxy-4-phenylpiperidine-4-carboxamide Mol wt. 310.39LRMS(ESI): (calc.) 310.4 (found) 311.4 (MH)+ (DLRMSOD6) d(ppm) 1 H:10.49 (s, 1 H), 8.69 (s, 1 H), 7.37-7.18 (m, 10 H), 3.39 (s, 2 H),2.68-2.55 (m, 2 H), 2.48-2.43 (m, 2 H), 2.15 (t, J = 11.1 Hz, 2 H),1.85-1.75 (m, 2 H)._(—) 5-61

benzyl 4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)piperazine-1-carboxylateMol wt. 369.414 LRMS(ESI): (calc.) 369.4 (found) 370.6 (MH)+ (MeOD-d4)7.53-7.49 (m, 2 H), 7.40-7.32 (m, 8 H), 5.13 (s, 2 H), 3.72 (s, 1 H),3.60-3.50 (m, 4 H), 2.49-2.34 (m, 4 H)_(—) 5-62

2-(4-(4-fluorophenyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide Mol wt.328.381 LRMS(ESI): (calc.) 328.4 (found) 329.5 (MH)+ (MeOD-d4) 7.58-7.52(m, 2 H), 7.41-7.33 (m, 3 H), 7.30-7.25 (m, 2 H), 7.06-6.99 (m, 2 H),3.72 (s, 1 H), 3.25-3.18 (m, 1 H), 2.84-2.76 (m, 1 H), 2.61-2.51 (m, 1H), 2.29-2.20 (m, 1 H), 1.99-1.67 (m, 5 H)_(—) 5-63

N-hydroxy-2-phenyl-2-(4-(pyridin-3-ylethynyl)phenyl)acetamide Mol wt.328.364 LRMS(ESI): (calc.) 328.4 (found) 329.4 (MH)+ (DMSO-d6) 11.03 (s,1 H), 9.08 (s, 1 H), 8.78 (dd, J = 2.2, 0.8 Hz, 1 H), 8.62 (dd, J = 4.8,1.8 Hz, 1 H), 8.01 (dt, J = 8.0, 2.0 Hz, 1 H), 7.61-7.57 (m, 2 H),7.52-7.48 (m, 1 H), 7.45-7.41 (m, 2 H), 7.40-7.36 (m, 4 H), 7.33-7.27(m, 1 H), 4.80 (s, 1 H)_(—) 5-64

2-(5-(9H-xanthen-9-yl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamideMol wt. 415.464 LRMS(ESI): (calc.) 415.1 (found) 416.2 (MH)+ (CD3OD)d(ppm) 1 H: 7.35-7.26 (m, 9 H), 7.18-7.07 (m, 4 H), 5.95 (s, 1 H), 5.20(s, 1 H)_(—) 5-65

2-(4-(4-benzylpiperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt.401.501 LRMS(ESI): (calc.) 401.2 (found) 402.6 (MH)+ (CD3OD) d(ppm) 1 H:7.35-7.17 (m, 12 H), 6.91 (d, J = 8.8 Hz, 2 H), 4.68 (s, 1 H), 3.57 (s,2 H), 3.16 (m, 4 H), 2.61 (m, 4 H)_(—) 5-66

N-hydroxy-2-phenyl-2-(4-(4-(pyridin-2-yl)piperazin-1-yl)phenyl)acetamideMol wt. 388.462 LRMS(ESI): (calc.) 388.1 (found) 389.5 (MH)+ (CD3OD)d(ppm) 1 H: 8.09 (d, J = 4.8 Hz, 1 H), 7.57 (t, J = 9.2 Hz, 1 H),7.30-7.21 (m, 7 H), 6.97 (d, J = 6.8 Hz, 2 H), 6.87 (d, J = 8.8 Hz, 1H), 6.69 (t, J = 6.4 Hz, 1 H), 4.70 (s, 1 H), 3.63 (m, 4 H), 3.25 (m, 4H)_(—) 5-67

N-hydroxy-2-phenyl-2-(4-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)phenyl)acetamideMol wt. 455.472 LRMS(ESI): (calc.) 455.1 (found) 456.6 (MH)+ (CD3OD)d(ppm) 1 H: 7.43-7.21 (m, 10 H), 7.09 (d, J = 8.0 Hz, 1 H), 6.98 (m, 2H), 4.70 (s, 1 H), 3.36 (m, 4 H), 3.32 (m, 4 H)_(—) 5-68

N-hydroxy-2-phenyl-2-(4-(4-phenylbutyl)phenyl)acetamide Mol wt. 359.461LRMS(ESI): (calc.) 359.2 (found) 360.4 (MH)+ (CD3OD) d(ppm) 1 H:7.30-7.11 (m, 14 H), 4.73 (s, 1 H), 2.60 (m, 4 H), 1.61 (m, 4 H)_(—)5-69

2-(2,3-dihydrobenzofuran-5-yl)-N-hydroxy-2-(4-(pyrrolidin-1-yl)phenyl)acetamideMol wt. 338.4 LRMS(ESI): (calc.) 338.4 (found) 339.4 (MH)+ (DMSO-d6)d(ppm) 1 H: 10.76 (s, 1 H), 8.84 (s, 1 H), 7.12-7.07 (m, 3 H), 6.95 (dd,J = 8.2, 1.6 Hz, 1 H), 6.64 (d, J = 8.2 Hz, 1 H), 6.45 (d, J = 8.2 Hz, 2H), 4.49-4.44 (m, 3 H), 3.18-3.08 (m, 6 H), 1.94-1.90 (m, 4 H)._(—) 5-70

N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide Mol wt. 310.39LRMS(ESI): (calc.) 310.4 (found) 311.5 (MH)+ (DLRMSOD6) d(ppm) 1 H:10.83 (br s, 1 H), 9.51 (br s, 1 H), 7.29-7.17 (m, 5 H), 7.13 (d, J =8.8 Hz, 2 H), 6.85 (d, J = 8.8 Hz, 2 H), 4.57 (s, 1 H), 3.07 (t, J = 5.1Hz, 4 H), 1.59-1.49 (m, 6 H)._(—) 5-71

2-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-N-hydroxy-2-phenylacetamideMol wt. 248.278 LRMS(ESI): (calc.) 248.1 (found) 249.3 (MH)+ (MeOD)d(ppm) 1 H: 7.52 (d, J = 6.8 Hz, 2 H), 7.37-7.27 (m, 3 H), 4.42-4.27 (m,1 H), 4.15 and 4.10 (2 s, 1 H), 4.07 and 4.04 (2 d, J = 8.0 Hz, 1 H),3.60 and 3.47 (2 dd, J = 7.8 and 1.8 Hz, 1 H), 3.48 (s, 1 H), 3.00 and2.67 (2 dd, J = 10.2 and 0.9 Hz, 1 H), 2.55 and 2.44 (2 d, J = 10.3 Hz,1 H), 2.00-1.93 (m, 1 H), 1.74-1.65 (m, 1 H)._(—) 5-72

2-(4-(1H-pyrazol-1-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt. 293.32LRMS(ESI): (calc.) 293.3 (found) 294.3 (MH)+ (DMSO-d6) 11.02 (br s, 1H), 9.06 (br s, 1 H), 8.49 (d, J = 2.1 Hz, 1 H), 7.84-7.80 (m, 2 H),7.76 (d, J = 1.4 Hz, 1 H), 7.49-7.45 (m, 2 H), 7.40-7.34 (m, 4 H),7.32-7.26 (m, 1 H), 6.57 (q, J = 2.5, 1.8 Hz, 1 H), 4.80 (s, 1 H)_(—)5-73

N-hydroxy-2-phenyl-2-(4-(pyridin-2-yl)piperazin-1-yl)acetamide Mol wt312.366 LRMS(ESI): (calc.) 312.4 (found) 313.5 (MH)+ (DMSO-d6) 10.91 (brs, 1 H), 8.97 (br s, 1 H), 8.14-8.12 (m, 1 H), 7.58-7.48 (m, 3 H),7.42-7.30 (m, 3 H), 6.82 (d, J = 8.6 Hz, 1 H), 6.69-6.64 (m, 1 H), 3.69(s, 1 H), 3.53-3.47 (m, 4 H), 2.52-2.36 (m, 4 H)_(—) 5-74

2-(4-(3-fluoropyridin-2-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt.322.333 LRMS(ESI): (calc.) 322.3 (found) 323.2 (MH)+ (MeOD) d(ppm) 1 H:8.39 (d, J = 2.2 Hz, 1 H), 8.13 (td, J = 8.4, 2.5 Hz, 1 H), 7.55 (d, J =8.2 Hz, 2 H), 7.44 (d, J = 8.2 Hz, 2 H), 7.37-7.22 (m, 5 H), 7.11 (dd, J= 8.4, 2.3 Hz, 1 H), 4.85 (s, 1 H)._(—) 5-75

benzyl4-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)piperazine-1-carboxylateMol wt. 445.51 LRMS(ESI): (calc.) 445.2 (found) 446.5 (MH)+ (CD3OD)d(ppm) 1 H: 7.38-7.18 (m, 12 H), 6.92 (d, J = 8.8 Hz, 2 H), 5.13 (s, 2H), 4.68 (s, 1 H), 3.62 (m, 4 H), 3.11 (m, 4 H)_(—) 5-76

2-(4-(4-(benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 445.51 LRMS(ESI): (calc.) 445.2 (found) 446.5 (MH)+ (CD3OD)d(ppm) 1 H: 7.28-7.17 (m, 7 H), 6.92-6.88 (m, 3 H), 6.79-6.75 (m, 2 H),5.92 (s, 2 H), 4.68 (s, 1 H), 3.51 (s, 2 H), 3.17 (t, J = 4.8 Hz, 4 H),2.62 (t, J = 5.2 Hz, 4 H)_(—) 5-77

2-(4-(4-cyclopentylpiperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 379.495 LRMS(ESI): (calc.) 379.2 (found) 380.5 (MH)+ (CD3OD)d(ppm) 1 H: 7.29-7.18 (m, 7 H), 6.92 (d, J = 8.8 Hz, 2 H), 4.68 (s, 1H), 3.18 (t, J = 5.2 Hz, 4 H), 2.69 (t, J = 5.2 Hz, 4 H), 2.57 (m, 1 H),1.93 (m, 2 H), 1.73 (m, 2 H), 1.60 (m, 2 H), 1.44 (m, 2 H)_(—) 5-78

2-(4-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 324.374 LRMS(ESI): (calc.) 324.2 (found) 325.4 (MH)+ (dLRMSo)d(ppm) 1 H: 10.84 (s, 1 H), 8.90 (s, 1 H), 7.42-7.16 (m, 5 H), 7.12 (d,J = 8.2 Hz, 2 H), 6.55 (d, J = 7.5 Hz, 2 H), 4.58 (s, 1 H), 4.56 (s, 1H), 4.49 (s, 1 H), 3.71 (d, J = 7.2 Hz, 1 H), 6.63 (d, J = 7.2 Hz, 1 H),3.46 (d, J = 9.2 Hz, 1 H), 2.91 (d, J = 7.2 z, 1 H), 1.89 (d, J = 9.3Hz, 1 H), 1.81 (d, J = 9.6 Hz, 1 H)._(—) 5-79

N-hydroxy-2-(4-((1-methyl-1H-imidazol-5-yl)ethynyl)phenyl)-2-phenylacetamideMol wt. 331.368 LRMS(ESI): (calc.) 331.4 (found) 332.4 (MH)+ (DMSO-d6)11.02 (br s, 1 H), 9.07 (br s, 1 H), 7.81 (s, 1 H), 7.58-7.53 (m, 2 H),7.44-7.27 (m, 8 H), 4.79 (s, 1 H), 3.73 (s, 3 H)_(—) 5-80

2-(4-(4,6-dimethylpyrimidin-2-yl)piperazin-1-yl)-N-hydroxy-2-phenylacetamideMol wt. 341.408 LRMS(ESI): (calc.) 341.4 (found) 342.3 (MH)+ (MeOD-d4)7.59-7.52 (m, 2 H), 7.43-7.34 (m, 3 H), 6.40 (s, 1 H), 3.87-3.81 (m, 4H), 3.71 (s, 1 H), 2.55-2.40 (m, 4 H), 2.28 (s, 6 H)_(—) 5-81

2-(4-(1H-indol-1-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt. 342.39LRMS(ESI): (calc.) 342.4 (found) 343.4 (MH)+ (MeOD-d4) 7.66-7.62 (m, 1H), 7.57-7.50 (m, 5 H), 7.46-7.41 (m, 3 H), 7.40-7.35 (m, 2 H),7.33-7.28 (m, 1 H), 7.22-7.17 (m, 1 H), 7.15-7.10 (m, 1 H), 6.67 (d, J =3.3 Hz, 1 H), 4.91 (s, 1 H)_(—) 5-82

2-(4-(diethylamino)phenyl)-2-(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamideMol wt. 340.416 LRMS(ESI): (calc.) 340.4 (found) 341.5 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.75 (s, 1 H), 8.83 (s, 1 H), 7.15 (s, 1 H), 7.07 (d, J =8.8 Hz, 2 H), 6.98 (dd, J = 8.4, 1.8 Hz, 1 H), 6.65 (d, J = 8.2 Hz, 1H), 6.56 (d, J = 9.0 Hz, 2 H), 4.49-4.43 (m, 3 H), 3.28 (q, J = 7.0 Hz,4 H), 3.11 (t, J = 8.6 Hz, 2 H), 1.04 (t, J = 7.0 Hz, 6 H._(—) 5-83

N-hydroxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-2-phenylacetamide Mol wt.325.405 LRMS(ESI): (calc.) 325.4 (found) 326.4 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.84 (s, 1 H), 8.91 (s, 1 H), 7.29-7.19 (m, 5 H), 7.15 (d, J = 8.6Hz, 2 H), 6.86 (d, J = 8.8 Hz, 2 H), 4.57 (s, 1 H), 3.07 (t, J = 4.7 Hz,4 H), 2.42 (t, J = 4.9 Hz, 4 H), 2.20 (s, 3 H)._(—) 5-84

N-hydroxy-2-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2-phenylacetamideMol wt. 417.5 LRMS(ESI): (calc.) 417.2 (found) 418.5 (MH)+ (CD3OD)d(ppm) 1 H: 7.30-7.21 (m, 7 H), 6.98 (t, J = 8.8 Hz, 4 H), 6.85 (d, J =9.2 Hz, 2 H), 4.70 (s, 1 H), 3.74 (s, 3 H), 3.28 (m, 4 H), 3.18 (m, 4H)_(—) 5-85

(E)-2-(4-(4-cinnamylpiperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 427.538 LRMS(ESI): (calc.) 427.3 (found) 428.4 (MH)+ (CD3OD)d(ppm) 1 H: 7.41 (d, J = 6.8 Hz, 2 H), 7.32-7.18 (m, 10 H), 6.92 (d, J =9.2 Hz, 2 H), 6.62 (d, J = 16.0 Hz, 1 H), 6.31 (m, 1 H), 4.68 (s, 1 H),3.21 (m, 6 H), 2.69 (m, 4 H)_(—) 5-86

N-hydroxy-2-phenyl-2-(4-(piperazin-1-yl)phenyl)acetamide Mol wt. 311.378LRMS(ESI): (calc.) 311.1 (found) 312.4 (MH)+ (CD3OD) d(ppm) 1 H:7.29-7.18 (m, 7 H), 6.91 (d, J = 9.2 Hz, 2 H), 4.69 (s, 1 H), 3.10 (m, 4H), 2.95 (m, 4 H)_(—) 5-87

2-(4-(benzylsulfonyl)piperazin-1-yl)-N-hydroxy-2-phenylacetamide Mol wt.389.469 LRMS(ESI): (calc.) 389.5 (found) 390.5 (MH)+ (MeOD-d4) 7.52-7.33(m, 10 H), 4.36 (s, 2 H), 3.71 (s, 1 H), 3.26-3.20 (m, 4 H), 2.50-2.36(m, 4 H)_(—) 5-88

2-(4-(1H-imidazol-1-yl)phenyl)-N-hydroxy-2-phenylacetamide Mol wt.293.32 LRMS(ESI): (calc.) 293.3 (found) 294.4 (MH)+ (MeOD-d4) 8.14 (s, 1H), 7.60-7.47 (m, 5 H), 7.42-7.25 (m, 5 H), 7.16 (s, 1 H), 4.88 (s, 1H)_(—) 5-89

2-(biphenyl-3-yl)-2-(4-fluorophenyl)-N-hydroxyacetamide Mol wt. 321.345LRMS(ESI): (calc.) 321.3 (found) 322.4 (MH)+ (DLRMSOD6) d(ppm) 1 H:10.98 (s, 1 H), 9.02 (s, 1 H), 7.60-7.28 (m, 11 H), 7.16 (t, J = 8.8 Hz,2 H), 4.80 (s, 1 H)._(—) 5-90

2-(4-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide Mol wt.330.354 LRMS(ESI): (calc.) 330.4 (found) 331.5 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.87 (s, 1 H), 8.94 (s, 1 H), 7.34-7.29 (m, 2 H), 7.17-7.09 (m, 4H), 6.87 (d, J = 8.8 Hz, 2 H), 4.60 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4 H),3.05 (t, J = 4.9 Hz, 4 H)._(—) 5-91

Mol wt. 398.475 LRMS(ESI): (calc.) 398.5 (found) 397.5 (M − H+)(MeOD-d4) 7.42-7.39 (m, 2 H), 7.36-7.27 (m, 7 H), 4.81 (s, 1 H), 3.72(s, 2 H), 3.22-3.15 (m, 8 H)_(—) 5-92

N-hydroxy-2-(4-(2-methoxypyrimidin-5-yl)phenyl)-2-phenylacetamide Molwt. 335.357 LRMS(ESI): (calc.) 335.4 (found) 336.5 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.96 (s, 1 H), 8.96 (s, 1 H), 8.90 (s, 2 H), 7.67 (d, J =8.4 Hz, 2 H), 7.43 (d, J = 8.4 Hz, 2 H), 7.37-7.22 (m, 5 H), 4.76 (s, 1H), 3.95 (s, 3 H)._(—) 5-93

N-hydroxy-2-(4-(4-isopropylpiperazin-1-yl)phenyl)-2-phenylacetamide Molwt. 353.458 LRMS(ESI): (calc.) 353.2 (found) 354.3 (MH)+ (CD3OD) d(ppm)1 H: 7.29-7.23 (m, 7 H), 6.96 (d, J = 8.8 Hz, 2 H), 4.70 (s, 1 H),3.50-3.33 (m, 9 H), 1.37 (d, J = 8.0 Hz, 6 H)_(—) 5-94

2-(4-(4-(2-(dimethylamino)ethyl)piperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 382.499 LRMS(ESI): (calc.) 382.2 (found) 383.5 (MH)+ (CD3OD)d(ppm) 1 H: 7.29-7.19 (m, 7 H), 6.92 (d, J = 8.8 Hz, 2 H), 4.69 (s, 1H), 3.28 (t, J = 5.2 Hz, 2 H), 3.19 (t, J = 4.8 Hz, 4 H), 3.89 (s, 6 H),2.75 (t, J = 6.0 Hz, 2 H), 2.69 (t, J = 5.2 Hz, 4 H)_(—) 5-95

Mol wt. 402.507 LRMS(ESI): (calc.) 402.5 (found) 403.5 (MH)+ (MeOD-d4)7.36-7.17 (m, 9 H), 4.77 (s, 1 H), 3.12-3.06 (m, 4 H), 3.01-2.94 (m, 4H), 2.67 (t, J = 7.6 Hz, 2 H), 2.54 (t, J = 7.6 Hz, 2 H), 1.88-1.78 (m,2 H)_(—) 5-96

N-hydroxy-2-phenyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)acetamide Molwt. 340.416 LRMS(ESI): (calc.) 340.4 (found) 341.5 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.89 (br s, 1 H), 8.95 (br s, 1 H), 7.30-7.21 (m, 7 H),6.87 (d, J = 8.8 Hz, 2 H), 4.63 (s, 1 H), 4.01 (t, J = 5.9 Hz, 2 H),2.74 (t, J = 5.9 Hz, 2 H), 2.50-2.46 (m, 4 H), 1.68-1.64 (m, 4 H)._(—)5-97

N-hydroxy-2-phenyl-2-(4-(4-(phenylsulfonyl)piperazin-1-yl)phenyl)acetamideMol wt. 451.538 LRMS(ESI): (calc.) 451.16 (found) 452.4 (MH)+ (CD3OD)d(ppm) 1 H: 7.80 (m, 2 H), 7.71-7.61 (m, 3 H), 7.27-7.15 (m, 7 H), 6.87(d, J = 8.8 Hz, 2 H), 4.66 (s, 1 H), 3.18 (m, 4 H), 3.11 (m, 4 H)_(—)5-98

N-((4-(benzyloxy)phenyl)(phenyl)methyl)-N-hydroxyformamide Mol wt.333.38 LRMS(ESI): (calc.) 333.4 (found) 356.2 (MNa)+ (DLRMSOD6) d(ppm) 1H: 7.46-7.24 (m, 11 H), 7.18 (d, J = 8.6 Hz, 2 H), 7.00 (d, J = 8.6 Hz,2 H), 8.34 (br s, 1 H), 5.09 (s, 2 H)._(—) 5-99

N-hydroxy-2-(4-(1-methylpiperidin-4-yloxy)phenyl)-2-phenylacetamide Molwt. 340.416 LRMS(ESI): (calc.) 340.4 (found) 341.3 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.87 (br s, 1 H), 8.94 (br s, 1 H), 7.35-7.18 (m, 7 H),6.87 (d, J = 8.8 Hz, 2 H), 4.62 (s, 1 H), 4.32-4.27 (m, 1 H), 2.58-2.54(m, 2 H), 2.20-2.10 (m, 5 H), 1.90-1.87 (m, 2 H), 1.63-1.54 (m, 2H)._(—) 5-100

N-hydroxy-2-(4-(4-(2-methoxyethyl)piperazin-1-yl)phenyl)-2-phenylacetamideMol wt. 369.457 LRMS(ESI): (calc.) 369.2(found) 370.4 (MH)+ (CD3OD)d(ppm) 1 H: 7.29-7.20 (m, 7 H), 6.91 (d, J = 8.8 Hz, 2 H), 4.69 (s, 1H), 3.57 (t, J = 5.2 Hz, 2 H), 3.34 (s, 3 H), 3.17 (m, 4 H), 2.67 (m, 4H), 2.63 (t, J = 4.0 Hz, 2 H)_(—) 5-101

2-(4-(3-(diethylamino)prop-1-ynyl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 336.428 LRMS(ESI): (calc.) 336.4 (found) 337.4 (MH)+ (DMSO-d6)10.98 (br s, 1 H), 9.04 (br s, 1 H), 7.42-7.38 (m, 2 H), 7.37-7.26 (m, 7H), 4.75 (s, 1 H), 3.61 (s, 2 H), 2.58-2.51 (m, 4 H), 1.04 (t, J = 7.2Hz, 6 H)_(—) 5-102

N-hydroxy-2-phenyl-2-(4-propylphenyl)acetamide Mol wt. 269.338LRMS(ESI): (calc.) 269.3 (found) 270.3 (MH)+ (MeOd-d4) 7.36-7.22 (m, 7H), 7.17-7.13 (m, 2 H), 4.77 (s, 1 H), 2.62-2.57 (m, 2 H), 1.70-1.60 (m,2 H), 0.96 (t, J = 7.4 Hz, 3 H)_(—) 5-103

N-hydroxy-2-(4-(2-hydroxyphenyl)piperazin-1-yl)-2-phenylacetamide Molwt. 327.378 C18H21N3O3 LRMS(ESI): (calc.) 327.4 (found) 328.2 (MH)+(MeOD-d4) 7.58-7.53 (m, 2 H), 7.42-7.32 (m, 3 H), 7.10-7.05 (m, 1 H),6.97-6.91 (m, 1 H), 6.85-6.80 (m, 2 H), 3.76 (s, 1 H), 3.10-3.00 (m, 4H), 2.73-2.56 (m, 4 H)_(—) 5-104

N-hydroxy-2-(4-morpholinophenyl)-2-(thiophen-2-yl)acetamide Mol wt.318.391 LRMS(ESI): (calc.) 318.4 (found) 319.3 (MH)+ (MeOD) d(ppm) 1 H:7.30-7.26 (m, 3 H), 6.97-6.88 (m, 4 H), 4.91 (s, 1 H), 3.81 (t, J = 4.9Hz, 4 H), 3.11 (t, J = 4.9 Hz, 4 H)._(—) 5-105

2-(4-(4-(cyclopropylmethyl)piperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 365.469 LRMS(ESI): (calc.) 365.4 (found) 366.4 (MH)+ (CD3OD)d(ppm) 1 H: 6.92-6.85 (m, 7 H), 6.59 (d, J = 8.4 Hz, 2 H), 4.33 (s, 1H), 3.00 (m, 4 H), 2.87 (m, 4 H), 2.50 (d, J = 6.8 Hz, 2 H), 0.71 (m, 1H), 0.37 (m, 2 H), 0.01 (m, 2 H)_(—) 5-106

N-hydroxy-2-(4-(2-oxopyrrolidin-1-yl)phenyl)-2-phenylacetamide Mol wt.310.347 LRMS(ESI): (calc.) 310.3 (found) 309.2 (M − H+) (DMSO-d6) 10.96(br s, 1 H), 9.01 (br s, 1 H), 7.64-7.60 (m, 2 H), 7.38-7.24 (m, 7 H),4.72 (s, 1 H), 3.84 (t, J = 7.0 Hz, 2 H), 2.51 (t, J = 8.4 Hz, 2 H),2.13-2.03 (m, 2 H)_(—) 5-107

N-hydroxy-2-(4-(isoindolin-2-yl)phenyl)-2-phenylacetamide Mol wt.344.406 LRMS(ESI): (calc.) 344.4 (found) 345.4 (MH)+ (MeOD-d4) 7.42-7.22(m, 11 H), 6.74-6.67 (m, 2 H), 4.73 (s, 1 H), 4.63 (s, 4 H)_(—) 5-108

N-(2-aminophenyl)-4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)benzamide Molwt. 361.394 LRMS(ESI): (calc.) 361.39 (found) 362.2 (MH)+ (DMSO-d6)d(ppm) 1 H: 10.98 (s, 1 H), 9.60 (s, 1 H), 9.02 (s, 1 H), 7.92 (d, J =8.2 Hz, 2 H), 7.44 (d, J = 8.4 Hz, 2 H), 7.34-7.30 (m, 4 H), 7.29-7.23(m, 1 H), 7.15 (d, J = 7.1 Hz, 1 H), 6.96 (td, J = 8.0, 1.6 Hz, 1 H),6.76 (dd, J = 8.0, 1.4 Hz, 1 H), 6.58 (td, J = 7.6, 1.4 z, 1 H), 4.88(s, 2 H), 4.80 (s, 1 H)._(—) 5-109

N-hydroxy-2-(4-(2-methoxybenzyloxy)phenyl)-2-phenylacetamide Mol wt.363.406 LRMS(ESI): (calc.) 363.4 (found) 364.4 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.89 (s, 1 H), 8.94 (s, 1 H), 7.38-7.20 (m, 9 H), 7.03 (d, J = 7.7Hz, 1 H), 6.97-6.90 (m, 3 H), 5.01 (s, 2 H), 4.63 (s, 1 H), 3.80 (s, 3H)._(—) 5-110

N-hydroxy-2-(4-(2-oxopiperidin-1-yl)phenyl)-2-phenylacetamide Mol wt.324.374 LRMS(ESI): (calc.) 324.4 (found) 323.3 (M − H+) (DMSO-d6) 10.98(br s, 1 H), 9.01 (br s, 1 H), 7.41-7.20 (m, 9 H), 4.74 (s, 1 H),3.62-3.57 (m, 2 H), 2.43-2.37 (m, 2 H), 1.92-1.78 (m, 4 H)_(—) 5-111

N-hydroxy-2-(4-phenoxyphenyl)-2-phenylacetamide Mol wt. 319.354LRMS(ESI): (calc.) 319.4 (found) 320.3 (MH)+ (DMSO-d6) 10.97 (s, 1 H),9.03 (s, 1 H), 7.46-7.32 (m, 8 H), 7.31-7.26 (m, 1 H), 7.19-7.14 (m, 1H), 7.04-6.98 (m, 4 H), 4.74 (s, 1 H)_(—) 5-112

N-hydroxy-2-(4-morpholinophenyl)-2-(thiophen-3-yl)acetamide Mol wt.318.391 LRMS(ESI): (calc.) 318.4 (found) 319.3 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.83 (s, 1 H), 8.91 (s, 1 H), 7.45 (dd, J = 5.1, 3.1 Hz, 1 H),7.29-7.27 (m, 1 H), 7.17 (d, J = 8.8 Hz, 2 H), 7.04-7.01 (m, 1 H), 6.87(d, J = 8.8 Hz, 2 H), 4.64 (s, 1 H), 3.72 (t, J = 4.5 Hz, 4 H), 3.05 (t,J = 4.9 Hz, 4 H)._(—) 5-113

N-hydroxy-2-(3-methoxyphenyl)-2-(4-morpholinophenyl)acetamide Mol wt.342.389 LRMS(ESI): (calc.) 342.4 (found) 343.4 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.83 (s, 1 H), 8.91 (s, 1 H), 7.23-7.16 (m, 3 H), 6.84-6.78 (m, 5H), 4.55 (s, 1 H), 3.73-3.70 (m, 7 H), 3.05 (t, J = 4.9 Hz, 4 H)._(—)5-113b

N-hydroxy-2-morpholino-2-phenylacetamide Mol wt. 236.267 LRMS(ESI):(calc.) 236.3 (found) 237.2 (MH)+ (DLRMSOD6) d(ppm) 1 H: 10.84 (s, 1 H),8.90 (s, 1 H), 7.45-7.41 (m, 2 H), 7.35-7.25 (m, 3 H), 3.59-3.54 (m, 5H), 2.30-2.23 (m, 4 H)._(—) 5-114

2-(4-morpholinophenyl)-2-phenyl-N-(propionyloxy)acetamide Mol wt.368.426 LRMS(ESI): (calc.) 368.4 (found) 369.2 (MH)+ (DLRMSOD6) d(ppm) 1H: 12.13 (s, 1 H), 7.33-7.21 (m, 5 H), 7.16 (d, J = 8.8 Hz, 2 H), 6.89(d, J = 8.8 Hz, 2 H), 4.81 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4 H), 3.06 (t,J = 4.9 Hz, 4 H), 2.46 (q, J = 7.4 Hz, 2 H), 1.07 (t, J = 7.4 Hz, 3H)._(—) 5-115

N-hydroxy-2-(4-morpholinophenyl)-2-p-tolylacetamide Mol wt. 326.39LRMS(ESI): (calc.) 326.4 (found) 327.3 (MH)+ (DLRMSOD6) d(ppm) 1 H:10.81 (s, 1 H), 8.88 (s, 1 H), 7.17-7.07 (m, 6 H), 6.85 (d, J = 8.8 Hz,2 H), 4.53 (s, 1 H), 3.70 (t, J = 4.7 Hz, 4 H), 3.03 (t, J = 4.9 Hz, 4H), 2.24 (s, 3 H)._(—) 5-116

N-hydroxy-2-(phenylthio)-2-(4-(pyridin-4-yl)phenyl)acetamide Mol wt.336.408 LRMS(ESI): (calc.) 336.4 (found) 337.3 (MH)+ (DMSO-d6) 11.07 (s,1 H), 9.19 (s, 1 H), 8.61-8.71 (m, 2 H), 7.85-7.80 (m, 2 H), 7.76-7.71(m, 2 H), 7.69-7.64 (m, 2 H), 7.40-7.24 (m, 5 H), 5.06 (s, 1 H) 5-117

N-acetoxy-2-(4-morpholinophenyl)-2-phenylacetamide Mol wt. 354.4LRMS(ESI): (calc.) 354.4 (found) 355.3 (MH)+ (DMSO-d6) d(ppm) 1 H: 12.13(br s, 1 H), 7.34-7.21 (m, 5 H), 7.16 (d, J = 8.8 Hz, 2 H), 6.89 (d, J =8.8 Hz, 2 H), 4.81 (s, 1 H), 3.72 (t, J = 4.7 Hz, 4 H), 3.06 (t, J = 4.7Hz, 4 H), 2.15 (s, 3 H)._(—) 5-118

2-(3-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide Mol wt.330.354 LRMS(ESI): (calc.) 330.4 (found) 331.3 (MH)+ (DMSO-d6) d(ppm) 1H: 10.89 (s, 1 H), 8.97 (s, 1 H), 7.37-7.31 (m, 1 H), 7.19-7.03 (m, 5H), 6.89 (d, J = 8.8 Hz, 2 H), 4.63 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4 H),3.06 (t, J = 4.7 Hz, 4 H)._(—) 5-119

1-(4-fluorophenyl)-N-hydroxycyclohexanecarboxamide Mol wt. 237.27LRMS(ESI): (calc.) 237.1 (found) 238.1 (MH)+ (CD3OD) d(ppm) 1 H: 7.42(m, 2 H), 7.02 t, J = 8.8 Hz, 2 H), 2.37 (m, 2 H), 1.77 (m, 2 H),1.64-1.54 (m, 5 H), 1.35 (m, 1 H)_(—) 5-120

1-(4-fluorophenyl)-N-hydroxycyclopentanecarboxamide Mol wt. 223.244LRMS(ESI): (calc.) 223.1 (found) 224.1 (MH)+ (CD3OD) d(ppm) 1 H: 7.38(m, 2 H), 7.02 (t, J = 8.8 Hz, 2 H), 2.47 (m, 2 H), 1.93 (m, 2 H), 1.71(m, 4 H)_(—) 5-121

N-(isobutyryloxy)-2-(4-morpholinophenyl)-2-phenylacetamide Mol wt.382.453 LRMS(ESI): (calc.) 382.5 (found) 383.5 (MH)+ (DLRMSOD6) d(ppm) 1H: 12.12 (br s, 1 H), 7.35-7.21 (m, 5 H), 7.16 (d, J = 8.8 Hz, 2 H),6.89 (d, J = 8.8 Hz, 2 H), 4.80 (s, 1 H), 3.72 (t, J = 4.7 Hz, 4 H),3.06 (t, J = 4.9 Hz, 4 H), 2.75-2.67 (m, 1 H), 1.14 (d, J = 5.8 Hz, 6H)._(—) 5-122

N-hydroxy-2-(4-morpholinophenyl)-2-(naphthalen-1-yl)acetamide Mol wt.362.422 LRMS(ESI): (calc.) 362.4 (found) 363.4 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.95 (s, 1 H), 8.95 (br s, 1 H), 8.07-8.04 (m, 1 H), 7.94-7.91 (m, 1H), 7.82 (d, J = 8.2 Hz, 1 H), 7.56-7.44 (m, 4 H), 7.16 (d, J = 8.8 Hz,2 H), 6.88 (d, J = 8.8 Hz, 2 H), 5.43 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4H), 3.05 (t, J = 4.9 Hz, 4 H)._(—) 5-123

2-(4-(1-benzylpiperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamide Molwt. 416.512 LRMS(ESI): (calc.) 416.5 (found) 417.4 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.87 (s, 1 H), 8.94 (s, 1 H), 7.32-7.16 (m, 12 H), 6.87 (d,J = 8.8 Hz, 2 H), 4.61 (s, 1 H), 4.35-4.30 (m, 1 H), 3.46 (s, 2 H),2.66-2.62 (m, 2 H), 2.20 (t, J = 8.8 Hz, 2 H), 1.95-1.85 (m, 2 H),1.62-1.55 (m, 2 H)._(—) 5-124

2-(2-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide Mol wt. 333.38 LRMS(ESI): (calc) 333.38 (found) 334.36 (MH)+ (DMSO-d6) d(ppm) 1 H: 10.90(s, 1 H), 8.88 (s, 1 H), 7.45 (dd, J = 7.6, 1.6 Hz, 1 H), 7.36-7.27 (m,7 H), 7.24-7.18 (m, 4 H), 7.03-7.01 (m, 1 H), 6.91 (td, J = 7.6, 0.8 Hz,1 H), 5.12 (s, 1 H), 5.10 (d, rotamers, J = 12.4 Hz, 1 H), 5.04 (d,rotamers, 12.4 Hz, 1 H)_(—) 5-125

N-hydroxy-2-(4-morpholinophenyl)-2-m-tolylacetamide Mol wt. 326.39LRMS(ESI): (calc.) 326.4 (found) 327.3 (MH)+ (DLRMSOD6) d(ppm) 1 H:10.83 (s, 1 H), 8.90 (s, 1 H), 7.23-7.01 (m, 6 H), 6.87 (d, J = 9.0 Hz,2 H), 4.55 (s, 1 H), 3.71 (t, J = 4.7 Hz, 4 H), 3.05 (t, J = 4.9 Hz, 4H), 2.25 (s, 3 H)._(—) 5-126 and cpd-94

N-hydroxy-2-phenyl-2-(1-(pyrimidin-2-yl)piperidin-4-yl)acetamide Mol wt.312.366 LRMS (ESI): (calc) 312.37 (found) 313.27 (MH)+ (DMSO-d6) d(ppm)1 H: 10.63 (s, 1 H), 8.82 (s, 1 H), 8.31 (d, J = 4.8 Hz, 2 H), 7.35-7.28(m, 4 H), 7.25-7.21 (m, 1 H), 6.57 (t, J = 4.8 Hz, 1 H), 4.65 (d, J =13.6 Hz, 1 H), 4.51 (d, J = 13.6 Hz, 1 H), 2.93-2.84 (m, 2 H), 2.75 (td,J = 12.6, 2.4 Hz, 1 H), 2.30-2.22 (m, 1 H), 1.77 (d, J = 12.0 Hz, 1 H),1.22-1.06 (m, 2 H), 0.92-0.82 (m, 1 H)_(—) 5-127

2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-phenylacetamide Mol wt. 338.4LRMS (ESI): (calc) 338.40 (found) 339.2 (MH)+ (MeOH d-4) d(ppm) 1 H:7.46-7.24 (m, 10 H), 4.58 (d, J = 12.0 Hz, 0.5 H, rotamers), 4.52 (d, J= 10.8 Hz, 0.5 H, rotamers), 3.75 (d, J = 12.0 Hz, 0.5 H, rotamers),3.62 (d, J = 13.2 Hz, 0.5 H, rotamers), 3.19-2.73 (m, 3 H), 2.44-2.35(m, 1 H), 1.98 (d, J = 11.2 Hz, 0.5 H, rotamers), 1.79 (d, J = 11.2 Hz,0.5 H, rotamers), 1.41-0.98 (m, 3 H)_(—) 5-128

N-(butyryloxy)-2-(4-morpholinophenyl)-2-phenylacetamide Mol wt. 382.453LRMS(ESI): (calc.) 382.4 (found) 383.1 (MH)+ (DMSO-d6) d(ppm) 1 H: 12.12(br s, 1 H), 7.33-7.21 (m, 5 H), 7.16 (d, J = 8.8 Hz, 2 H), 6.89 (d, J =8.8 Hz, 2 H), 4.80 (s, 1 H), 3.71 (t, J = 4.5 Hz, 4 H), 3.06 (t, J = 5.1Hz, 4 H), 2.41 (t, J = 7.0 Hz, 2 H), 1.58 (hextet, J = 7.2 Hz, 2 H),0.92 (t, J = 7.4 Hz, 3 H)._(—) 5-129

N-hydroxy-2-(2-methoxyphenyl)-2-(4-morpholinophenyl)acetamide Mol wt.342.389 LRMS(ESI): (calc.) 342.4 (found) 343.4 (MH)+ (DLRMSOD6) d(ppm) 1H: 10.73 (s, 1 H), 8.78 (s, 1 H), 7.33-7.30 (m, 1 H), 7.23-7.08 (m, 1H), 7.10 (d, J = 8.8 Hz, 2 H), 6.96-6.93 (m, 1 H), 6.89-6.84 (m, 3 H),4.94 (s, 1 H), 3.74-3.70 (m, 7 H), 3.05 (t, J = 4.7 Hz, 4 H)._(—) 5-130

2-(4-(1-(cyclopropylmethyl)piperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamideMol wt. 380.48 LRMS(ESI): (calc.) 380.5 (found) 381.5 (MH)+ (DLRMSOD6)d(ppm) 1 H: 10.85 (br s, 1 H), 8.91 (br s, 1 H), 7.27-7.13 (m, 7 H),6.84 (d, J = 8.8 Hz, 2 H), 4.59 (s, 1 H), 4.28-4.26 (m, 1 H), 2.72-2.70(m, 2 H), 2.21-2.12 (m, 4 H), 1.89-1.86 (m, 2 H), 1.59-1.51 (m, 2 H),0.80-0.76 (m, 1 H), 0.44-0.38 (m, 2 H), 0.04-0.00 (m, 2 H)._(—) 5-131

N-hydroxy-9,10-dihydroanthracene-9-carboxamide Mol wt. 239.269LRMS(ESI): (calc.) 239.09 (found) 240.2 (MH)+ (MeOD) d(ppm) 1 H: 7.34(d, J = 7.2 Hz, 4 H), 7.28-7.18 (m, 4 H), 4.68 (s, 1 H), 4.46 (d, J =18.5 Hz, 1 H), 3.87 (d, J = 18.4 Hz, 1 H)._(—) 5-132

N-hydroxy-2-(4-(1-((2-methyl-1H-indol-3-yl)methyl)piperidin-4-yloxy)phenyl)-2-phenylacetamide Mol wt. 469.575 LRMS(ESI): (calc.) 469.6 (found) 470.6(MH)+ (DMSOD6) d(ppm) 1 H: 10.86 (s, 1 H), 10.80 (s, 1 H), 8.93 (s, 1H), 7.48 (d, J = 7.4 Hz, 1 H), 7.34-7.17 (m, 8 H), 6.98-6.84 (m, 4 H),4.60 (s, 1 H), 4.32-4.25 (m, 1 H), 3.55 (s, 2 H), 2.72-2.65 (m, 2 H),2.33 (s, 3 H), 2.22-2.18 (m, 2 H), 1.90-1.82 (m, 2 H), 1.58-1.50 (m, 2H)._(—)

TABLE VI Compounds prepared according general Schemes above StructureCmpd # MS ¹H NMR Name

6-1 LRMS (ESI): (calc.) 179.2 (found) 180.2 (MH)+ 1H NMR (CD3OD- d4) d(ppm): 7.41-7.22 (m, 5H), 3.28-3.18 (m, 1H), 2.18-2.03 (m, 1H),1.89-1.73 (m, 1H), 0.94 (t, J = 7.2 Hz, 3H) N-hydroxy-2-phenylbutanamide

6-2 LRMS (ESI): (calc.) 244.05 (found) 243.2 (MH)− 1H NMR (CD3OD- d4) d(ppm): 7.84 (d, J = 7.2 Hz, 2H), 7.63 (m, 3H), 3.67 (s, 2H), 2.80 (s,3H) N-hydroxy-2-(N- methylphenylsulfonamido) acetamide

6-3 LRMS (ESI): (calc.) 465.2 (found) 464.5 (MH)− 1H NMR (CD3OD- d4) d(ppm): 7.93- 7.90 (m, 4H), 7.66 (d, J = 8.6 Hz, 4H), 7.59- 7.54 (m, 2H)7.52- 7.47 (m, 4H), 7.35 (d, J = 8.6 Hz, 4H), 4.80 (s, 1H).N,N′-(4,4′-(2- (hydroxyamino)-2- oxoethane-1,1- diyl)bis(4,1-phenylene)) dibenzamide

6-4 LRMS (ESI): (calc.) 303.1 (found) 304.3 (MH)+ 1H NMR (CD3OD- d4) d(ppm): 1H: 7.32- 7.22 (m, 15H). N-hydroxy-2,2,2- triphenylacetamide

6-5 LRMS (ESI): (calc.) 306.1 (found) 305.3 (MH)− 1H NMR (CD3OD- d4) d(ppm): 7.76 (d, J = 8.2 Hz, 2H), 7.53 (t, J = 7.6 Hz, 1H), 7.43 (t, J =7.6 Hz, 2H), 7.21 (s, 5H), 4.81 (s, 1H). N-hydroxy-2- phenyl-2-(phenylsulfonamido) acetamide

6-6 LRMS (ESI): (calc.) 300.4 (found) 301.4 (MH)+ 1H NMR (CD3OD- d4) d(ppm): 7.19 (d, J = 8.4 Hz, 2H), 7.13 (d, J = 8.4 Hz, 2H), 6.84 (d, J =8.8 Hz, 2H), 6.72 (d, J = 8.6 Hz, 2H), 4.61 (s, 2H), 3.76 (s, 3H), 2.89(s, 6H). 2-(4- (dimethylamino) phenyhl)-N-hydroxy- 2-(4- methoxyphenyl)acetamide

6-7 LRMS (ESI): (calc.) 300.4 (found) 301.4 (MH)+ 1H NMR (CD3OD- d4) d(ppm): 7.31- 7.19 (m, 5H), 6.91 (d, J = 8.6 Hz, 1H), 6.34 (d, J = 2.6Hz, 1H), 6.26 (dd, J = 8.6, 2.5 Hz, 1H), 5.03 (s, 1H), 3.79 (s, 3H),2.90 (s, 6H). 2-(4- (dimethylamino)- 2-methoxyphenyl)- N-hydroxy-2-phenylacetamide

6-8 LRMS (ESI): (calc.) 342.4 (found) 343.4 (MH)+ (DMSOD6) d (ppm) 1H:11.17 (s, 1H), 9.21 (s, 1H), 8.02 (s, 1H), 7.95-7.92 (m, 2H), 7.57 (dd,J = 8.4, 1.4 Hz, 2H), 7.47- 7.42 (m, 2H), 7.38- 7.30 (m, 4H), 5.50 (s,1H). N-hydroxy-2- phenyl-2-(4- phenylthiazol-2- ylthio)acetamide

6-9a LRMS (ESI): (calc) 368.43 (found) 369.41 (MH)+ (MeOH-d4) d (ppm)1H: 7.38-7.22 (m, 10H), 5.09 (s, 2H), 4.16 (d, J = 13.5 Hz, 1H), 4.03(d, J = 13.3 Hz, 1H), 2.94- 2.75 (m, 3H), 2.32- 2.22 (m, 1H), 1.83 (d, J= 12.5 Hz, 1H), 1.28- 1.14 (m, 2H), 0.98- 0.88 (m, 1H) benzyl 4-(2-(hydroxyamino)-2- oxo-1- phenylethyl)piperidine- 1-carboxylate

6-16 LRMS (ESI): (calc.) 452.1/ 454.1 (found) 451.39/ 453.4 (MH)− 1H NMR(CD3OD- d4) d(ppm): 7.43 (m, 2H), 7.12-7.28 (m, 8H), 6.61 (d, J = 8.4Hz, 2H), 4.66 (s, 1H), 3.93 (d, J = 8.8 Hz, 1H), 3.66 (d, J = 8.8 Hz,1H), 3.31 (m, 2H), 2.10 (m, 1H), 1.10 (m, 2H). 2-(4-((1S,5R)-1- (3,4-dichlorophenyl)-3- azabicyclo[3.1.0]h exan-3-yl)phenyl)- N-hydroxy-2-phenylacetamide

6-17 LRMS (ESI): (calc.) 330.4 (found) 331.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.89 (s, 1H), 8.94 (s, 1H), 7.46-7.41 (m, 1H), 7.31-7.25 (m,1H), 7.16-7.09 (m, 4H), 6.89 (d, J = 9.0 Hz, 2H), 4.89 (s, 1H), 3.71 (t,J = 4.5 Hz, 4H), 3.05 (t, J = 4.9 Hz, 4H). 2-(2- fluorophenyl)-N-hydroxy-2-(4- morpholinophenyl) acetamide

6-18 LRMS (ESI): (calc.) 415.51 (found) 416.5 (MH)+ 1H NMR (CD3OD- d4) d(ppm): 6.76 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 7.27 (d, J =7.4 Hz, 1H), 7.25-7.13 (m, 3H), 3.18-2.96 (m, 5.5H), 2.60-2.40 (m,5.5H), 2.46 (s, 3H), 2.18-2.08 (m, 1H). N-hydroxy-1-(4- (p-tolylsulfonyl) piperazin- 1-yl)-2,3- dihydro-1H- indene-1- carboxamide

6-19 LRMS (ESI): (calc.) 326.4 (found) 327.3 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.79 (s, 1H), 8.88 (s, 1H), 7.41- 7.38 (m, 1H), 7.13- 7.03 (m,5H), 6.85 (d, J = 8.8 Hz, 2H), 4.76 (s, 1H), 3.69 (t, J = 4.7 Hz, 4H),3.03 (t, J = 4.7 Hz, 4H), 3.03 (t, J = 4.7 Hz, 4H), 2.19 (s, 3H).N-hydroxy-2-(4- morpholionphenyl)- 2-o- tolylacetamide

6-20 LRMS (ESI): (calc.) 396.4 (found) 397.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.90 (s, 1H), 8.98 (s, 1H), 7.43 (t, J = 8.2 Hz, 1H), 7.29-7.28(m, 2H), 7.24-7.21 (m, 1H), 7.16 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8Hz, 2H), 4.64 (s, 1H), 3.70 (t, J = 4.7 Hz, 4H), 3.04 (t, J = 4.9 Hz,4H). N-hydroxy-2-(4- morpholinophenyl)- 2-(3- (trifluoromethoxy)phenyl)acetamide

6-21 LRMS (ESI): (calc.) 380.4 (found) 381.3 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.92 (s, 1H), 9.00 (s, 1H), 7.65-7.52 (m, 4H), 7.16 (d, J = 8.6Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 4.71 (s, 1H), 3.70 (t, J = 4.5 Hz,4H), 3.14 (t, J = 4.9 Hz, 4H). N-hydroxy-2-(4- morpholinophenyl)- 2-(3-(trifluoromethyl) phenyl)acetamide

6-22 LRMS (ESI): (calc.) 348.3 (found) 349.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.93 (s, 1H), 8.99 (s, 1H), 7.36-7.11 (m, 5H), 6.90 (d, J = 9.0Hz, 2H), 4.93 (s, 1H), 3.72 (t, J = 4.7 Hz, 4H), 3.07 (t, J = 4.7 Hz,4H). 2-(2,3- difluorophenyl)-N- 2-(3- hydroxy-2-(4- morpholinophenyl)acetamide

6-23 LRMS (ESI): (calc.) 328.4 (found) 329.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.79 (d, J = 1.2 Hz, 1H), 9.27 (s, 1H), 8.87 (d, J = 1.4 Hz,1H), 7.15 (d, J = 8.6 Hz, 2H), 7.04 (t, J = 7.8 Hz, 1H), 6.85 (d, J =8.8 Hz, 2H), 6.72 (t, J = 2.0 Hz, 1H), 6.67 (d, J = 7.6 Hz, 1H),6.59-6.55 (m, 1H), 4.47 (s, 1H), 3.70 (t, J = 4.7 Hz, 4H), 3.03 (t, J =4.7 Hz, 4H). N-hydroxy-2-(3- hydroxyphenyl)-2-(4- morpholinophenyl)acetamide

6-24 LRMS (ESI): (calc.) 348.3 (found) 349.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.90 (s, 1H), 8.95 (s, 1H), 7.47-7.40 (m, 1H), 7.21-7.00 (m,4H), 6.88 (d, J = 8.8 Hz, 2H), 4.83 (s, 1H), 3.70 (t, J = 4.5 Hz, 4H),3.04 (t, J = 4.9 Hz, 4H). 2-(2,6- difluorophenyl)-N- hydroxy-2-(4-morpholinophenyl) acetamide

6-25 LRMS (ESI): (calc.) 358.5 (found) 359.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.83 (s, 1H), 8.92 (s, 1H), 7.28-7.08 (m, 5H), 7.05-7.02 (m,1H), 6.86 (d, J = 8.8 Hz, 2H), 4.55 (s, 1H), 3.70 (t, J = 4.7 Hz, 4H),3.03 (t, J = 4.7 Hz, 4H). 2.41 (s, 3H). N-hydroxy-2-(3-(methylthio)phenyl)- 2-(4- morpholinophenyl) acetamide

6-26 LRMS (ESI): (calc.) 328.4 (found) 329.2 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.84 (d, J = 1.6 Hz, 1H), 9.67 (s, 1H), 8.86 (d, J = 1.8 Hz,1H), 7.24 (dd, J = 7.6, 1.4 Hz, 1H), 7.08-6.99 (m, 3H), 6.83 (d, J = 8.8Hz, 2H), 6.76-6.68 (m, 2H), 4.86 (s, 1H), 3.69 (t, J = 4.5 Hz, 4H), 3.02(t, J = 4.7 Hz, 4H). N-hydroxy-2-(2- hydroxyphenyl)-2- (4-morpholinophenyl) acetamide

6-27 LRMS (ESI): (calc.) 263.2 (found) 264.2 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.99 (s, 1H), 9.05 (s, 1H), 7.39-7.33 (m, 2H 7.16-7.06 (m, 6H),4.76 (s, 1H). 2,2-bis(3- fluorophenyl)-N- hydroxyacetamide

6-28 LRMS (ESI): (calc.) 372.4 (found) 373.5 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.79 (s, 1H), 8.89 (s, 1H), 7.15 (d, J = 8.8 Hz, 2H), 6.85 (d, J= 9.0 Hz, 2H), 6.44 (d, J = 2.4 Hz, 2H), 6.35 (t, J = 2.4 Hz, 1H), 4.48(s, 1H), 3.71-3.66 (m, 10H), 3.03 (t, J = 4.7 Hz, 4H). 2-(3,5-dimethoxyphenyl)- N-hydroxy-2-(4- morpholinophenyl) acetamide

6-29 LRMS (ESI): (calc.) 261.3 (found) 262.0 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 11.09 (s, 1H), 9.07 (s, 1H), 8.60 (d, J = 4.9 Hz, 2H), 7.54- 7.51(m, 2H), 7.34- 7.23 (m, 3H), 7.20 (t, J = 4.9 Hz, 1H), 5.48 (s, 1H).N-hydroxy-2- phenyl-2- (pyrimidin-2- ylthio)acetamide

6-30 LRMS (ESI): (calc.) 326.4 (found) 327.2 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.78 (s, 1H), 8.86 (s, 1H), 7.17 (t, J = 8.2 Hz, 1H), 7.09 (d, J= 8.7 Hz, 2H), 6.83-6.74 (m, 3H), 6.44 (d, J = 8.8 Hz, 2H), 4.49 (s,1H), 3.68 (s, 3H), 3.15 (t, J = 6.5 Hz, 4H), 1.92- 1.88 (m, 4H).N-hydroxy-2-(3- methoxyphenyl)-2- (4-(pyrrolidin-1- yl)phenyl) acetamide

6-31 LRMS (ESI): (calc.) 389.8 (found) 390.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 11.17 (s, 1H), 9.14 (s, 1H), 8.67 (d, J = 5.3 Hz, 1H), 8.20 (d, J= 8.6 Hz, 2H), 7.79 (d, J = 5.3 Hz, 1H), 7.62-7.58 (m, 4H), 7.18 (t, J =8.8 Hz, 2H), 5.59 (s, 1H). 2-(4-(4- chlorophenyl)pyrimidin- 2-ylthio)-2-(4-fluorophenyl)- N- hydroxyacetamide

6-32 LRMS (ESI): (calc.) 358.4 (found) 359.5 (MH)+ 1H NMR (CD3OD-d4) d(ppm): 7.32-7.17 (m, 5H), 7.10 (d, J = 8.6 Hz, 2H), 6.65 (d, J = 8.8 Hz,2H), 4.65 (s, 1H), 3.56-3.48 (m, 8H), 3.34-3.00 (s, 6H) 2-(4-(bis(2-methoxyethyl)amino) phenyl)-N- hydroxy-2- phenylacetamide

6-33 LRMS (ESI): (calc.) 314.4 (found) 315.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.84 (s, 1H), 8.91 (s, 1H), 7.34- 7.28 (m, 1H), 7.12- 6.99 (m,5H), 6.45 (d, J = 8.8 Hz, 2H), 4.56 (s, 1H), 3.16 (t, J = 6.5 Hz, 4H),1.93-1.87 (m, 4H). 2-(3- fluorophenyl)-N- hydroxy-2-(4- (pyrrolidin-1-yl)phenyl) acetamide

6-34 LRMS (ESI): (calc.) 405.0/ 407.0 (found) 406.4/ 408.4 (MH)+ 1H NMR(DMSO-d6) δ (ppm): 11.19 (s, 1H), 9.16 (s, 1H), 8.67 (d, J = 5.3 Hz,1H), 8.19 (d, J = 8.8 Hz, 2H), 7.79 (d, J = 5.3 Hz, 1H), 7.63-7.58 (m,4H), 7.41 (d, J = 8.6 Hz, 2H), 5.59 (s, 1H). 2-(4- chlorophenyl)-2-(4-(4- chlorophenyl)pyrimidin- 2-ylthio)-N- hydroxyacetamide

6-35 LRMS (ESI): (calc.) 360.4 (found) 361.4 (MH)+ 1H NMR (CD3OD-d4) d(ppm): 7.37-7.23 (m, 7H), 7.04- 6.98 (m, 2H), 4.73 (s, 1H), 3.90-3.83(m, 4H), 3.16-3.11 (m, 4H) N-hydroxy-2- phenyl-2-(4- thiomorpholinodioxide- phenyl)acetamide

6-36 LRMS (ESI): (calc.) 327.4 (found) 328.5 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.86 (s, 1H), 8.92 (s, 1H), 7.37-7.30 (m, 4H), 7.28-7.22 (m,1H), 7.18-7.13 (m, 2H), 6.68-6.62 (m, 2H), 4.58 (s, 1H), 3.44-3.36 (m,2H), 2.89 (s, 3H), 2.40-2.35 (m, 2H), 2.20 (s, 6H) 2-(4-((2-(dimethylamino)ethyl (methyl)amino) phenyl)-N- hydroxy-2-phenylacetamide

6-37 LRMS (ESI): (calc.) 316.4 (found) 317.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.83 (s, 1H), 8.91 (s, 1H), 7.35-7.28 (m, 1H), 7.11-7.00 (m,5H), 6.57 (d, J = 9.0 Hz, 2H), 4.54 (s, 1H), 3.27 (q, J = 7.0 Hz, 4H),1.03 (t, J = 7.0 Hz, 6H). 2-(4- (dimethylamino) phenyl)-2-(3-fluorophenyl)-N- hydroxyacetamide

6-38 LRMS (ESI): (calc.) 275.3 (found) 276.3 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.92 (br s, 1H), 9.54 (br s, 1H), 9.08 (br s, 1H), 7.48- 7.44(m, 2H), 7.34- 7.23 (m, 3H), 7.06 (t, J = 8.0 Hz, 1H), 6.70- 6.65 (m,2H), 6.60- 6.57 (m, 1H), 4.85 (s, 1H) N-hydroxy-2-(3-hydroxyphenylthio)- 2-phenylacetamide

6-39 LRMS (ESI): (calc.) 282.3 (found) 283.2 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.87 (s, 1H), 8.94 (s, 1H), 7.34-7.30 (m, 4H), 7.28-7.21 (m,1H), 7.18-7.14 (m, 2H), 6.40-6.36 (m, 2H), 4.59 (s, 1H), 3.78 (t, J =7.2 Hz, 4H), 2.35-2.26 (m, 2H), 2-(4-(azetidin-1- yl)phenyl)-N-hydroxy-2- phenylacetamide

6-40 LRMS (ESI): (calc.) 360.5 (found) 361.5 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.81 (s, 1H), 8.87 (s, 1H), 7.31-7.11 (m, 12H), 6.65 (d, J = 9.0Hz, 2H), 4.54 (s, 1H), 3.47 (t, J = 7.6 Hz, 2H), 2.81 (s, 3H), 2.72 (t,J = 8.0 Hz, 2H). N-hydroxy-2-(4- (methyl(phenethyl) amino)phenyl)-2-phenylacetamide

6-41 LRMS (ESI): (calc.) 328.4 (found) 329.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.77 (s, 1H), 8.86 (s, 1H), 7.18 (t, J = 7.8 Hz, 1H), 7.07 (d, J= 8.8 Hz, 2H), 6.84-6.82 (m, 2H), 6.79-6.75 (m, 1H), 6.55 (d, J = 8.8Hz, 2H), 4.47 (s, 1H), 3.68 (s, 3H), 3.26 (q, J = 7.2 Hz, 4H), 1.03 (t,J = 6.8 Hz, 6H). 2-(4- (diethylamino) phenyl)-N-hydroxy-2- (3-methoxyphenyl) acetamide

6-42 LRMS (ESI): (calc.) 367.4 (found) 368.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 11.16 (s, 1H), 9.09 (s, 1H), 8.56 (d, J = 5.5 Hz, 1H), 8.17 (d, J= 9.0 Hz, 2H), 7.69 (d, J = 5.3 Hz, 1H), 7.59- 7.56 (m, 2H), 7.35- 7.23(m, 3H), 7.07 (d, J = 9.0 Hz, 2H), 5.59 (s, 1H), 3.84 (s, 3H).N-hydroxy-2-(4- (4- methoxyphenyl) pyrimidin-2-ylthio)-2-phenylacetamide

6-43 LRMS (ESI): (calc.) 341.5 (found) 342.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.85 (s, 1H), 8.92 (s, 1H), 7.37-7.30 (m, 4H), 7.27-7.22 (m,1H), 7.16-7.11 (m, 2H), 6.64-6.58 (m, 2H), 4.57 (s, 1H), 3.44-3.30 (m,4H), 2.38 (t, J = 7.2 Hz, 2H), 2.22 (s, 6H), 1.08 (t, J = 6.9 Hz, 3H)2-(4-((2- (dimethylamino) ethyl(ethyl)amino) phenyl)-N-hydroxy-2-phenylacetamide

6-44 LRMS (ESI): (calc.) 314.4 (found) 315.3 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.81 (s, 1H), 8.88 (s, 1H),7.30- 7.25 (m, 2H), 7.11- 7.06 (m,4H), 6.44 (d, J = 8.8 Hz, 2H), 4.53 (s, 1H), 3.17-3.13 (m, 4H),1.92-1.88 (m, 4H). 2-(4- fluorophenyl)-N- hydroxy-2-(4- (pyrrolidin-1-yl)phenyl)acetamide

6-45 LRMS (ESI): (calc.) 363.5 (found) 364.5 (MH)+ 1H NMR (CD3OD-d4) d(ppm): 7.62- 7.54 (m, 3H), 7.41- 7.30 (m, 4H), 7.18 7.13 (m, 1H), 7.04-6.99 (m, 1H), 6.96 (s, 1H), 3.76 (s, 3H), 3.74 (s, 1H), 3.30-3.20 (m,1H), 2.90-2.78 (m, 2H), 2.36-2.26 (m, 1H), 2.07-1.80 (m, 5H)N-hydroxy-2-(4- (1-methyl-1H- indol-3- yl)piperidin-1-yl)-2-phenylacetamide

6-46 LRMS (ESI): (calc.) 328.4 (found) 329.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.85 (s, 1H), 8.91 (s, 1H), 7.37-7.30 (m, 4H), 7.28-7.22 (m,1H), 7.16-7.10 (m, 2H), 6.66-6.60 (m, 2H), 4.57 (s, 1H), 3.50-3.42 (m,4H), 3.40-3.34 (m, 2H), 3.29 (s, 3H), 1.07 (t, J = 7.0 Hz, 3H)2-(4-(ethyl(2- methoxyethyl) amino)phenyl)-N- hydroxy-2- phenylacetamide

6-47 LRMS (ESI): (calc.) 328.4 (found) 329.4 (MH)+ 1H NMR (DMSO-d6) δ(ppm): 10.75 (s, 1H), 8.82 (s, 1H), 7.19 (d, J = 8.6 Hz, 2H), 7.04 (d, J= 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.55 (d, J = 9.0 Hz, 2H), 4.44(s, 1H), 3.69 (s, 3H), 3.26 (q, J = 7.1 Hz, 4H), 1.02 (t, J = 7.0 Hz,6H). 2-(4- (dimethylamino) phenyl)-N-hydroxy-2- (4- methoxyphenyl)acetamide

Structure Name Cpd No. HPLC MS

N-hydroxy-2- phenyl-2-(o- tolyloxy)acetamide 7-1 96% RT: 3.62 min LRMS(ESI): (calc) 257.2845 (found) 258.05 (MH)+

N-hydroxy-2- phenyl-2-(m- tolyloxy)acetamide 7-2 96% RT: 3.59 min LRMS(ESI): (calc) 257.2845 (found) 258.05 (MH)+

N-hydroxy-2-(4- methylpyridin-2- yloxy)-2- phenylacetamide 7-3 94% RT:2.9 min LRMS (ESI): (calc) 258.2726 (found) 259.06 (MH)+

N-hydroxy-2-(5- methylpyridin-2- yloxy)-2- phenylacetamide 7-4 95% RT:2.88 min LRMS (ESI): (calc) 258.2726 (found) 259.06 (MH)+

2-(2- fluorophenoxy)- N-hydroxy-2- phenylacetamide 7-5 89% RT: 3.41 minLRMS (ESI): (calc) 261.2484 (found) 262.02 (MH)+

2-(4- fluorophenoxy)- N-hydroxy-2- phenylacetamide 7-6 91% RT: 3.45 minLRMS (ESI): (calc) 261.2484 (found) 262.02 (MH)+

2-(3- fluorophenoxy)- N-hydroxy-2- phenylacetamide 7-8 94% RT: 3.48 minLRMS (ESI): (calc) 261.2484 (found) 262.02 (MH)+

N-hydroxy-2-(3- methoxyphenoxy)- 2- phenylacetamide 7-9 96% RT: 3.43 minLRMS (ESI): (calc) 273.2839 (found) 274.06 (MH)+

N-hydroxy-2-(2- methoxyphenoxy)- 2- phenylacetamide 7-10 90% RT: 3.39min LRMS (ESI): (calc) 273.2839 (found) 274.06 (MH)+

N-hydroxy-2-(4- methoxyphenoxy)- 2- phenylacetamide 7-11 93% RT: 3.36min LRMS (ESI): (calc) 273.2839 (found) 274.06 (MH)+

N-hydroxy-2-(2- isopropylphenoxy)- 2- phenylacetamide 7-12 92% RT: 4 minLRMS (ESI): (calc) 285.3376 (found) 286.1 (MH)+

N-hydroxy-2-(3- isopropylphenoxy)- 2- phenylacetamide 7-13 92% RT: 3.98min LRMS (ESI): (calc) 285.3376 (found) 286.1 (MH)+

N-hydroxy-2-(4- isopropylphenoxy)- 2- phenylacetamide 7-14 90% RT: 4 minLRMS (ESI): (calc) 285.3376 (found) 286.1 (MH)+

N-hydroxy-2- phenyl-2- (pyridin-2- yloxy)acetamide 7-15 96% RT: 2.66 minLRMS (ESI): (calc) 244.246 (found) 245.01 (MH)+ 1H NMR (360 MHz, DMSO-d6) d ppm 11.36 (1H, s), 9.29 (1H, s), 7.44-7.53 (4H, m), 7.41 (1H, dd,J = 7.04, 1.59 Hz), 7.34 (2H, d, J = 6.81 Hz), 6.66 (1H, s), 6.51 (1H,d, J = 9.08 Hz), 6.25 (1H, td, J = 6.81, 1.36 Hz)

2-(3- (dimethylamino) phenoxy)-N- hydroxy-2- phenylacetamide 7-16 89%RT: 2.87 min LRMS (ESI): (calc) 286.3257 (found) 287.11 (MH)+

2- (benzo[d][1,3]dioxol- 5-yloxy)-N- hydroxy-2- phenylacetamide 7-17 96%RT: 3.35 min LRMS (ESI): (calc) 287.2674 (found) 288.06 (MH)+

N-hydroxy-2-(4- (methylthio) phenoxy)-2- phenylacetamide 7-18 100% RT:3.65 min LRMS (ESI): (calc) 289.3495 (found) 290.02 (MH)+

2-(4-fluoro-2- methoxyphenoxy)- N-hydroxy-2- phenylacetamide 7-19 94%RT: 3.49 min LRMS (ESI): (calc) 291.2744 (found) 292.06 (MH)+

2-(2-chloro-4- methylphenoxy)- N-hydroxy-2- phenylacetamide 7-20 90% RT:3.38 min LRMS (ESI): (calc) 291.7296 (found) 292.03 (MH)+

2-(2-chloro-5- methylphenoxy)- N-hydroxy-2- phenylacetamide 7-21 95% RT:3.81 min LRMS (ESI): (calc) 291.7296 (found) 292.03 (MH)+

2-(2-chloro-6- methylphenoxy)- N-hydroxy-2- phenylacetamide 7-30 97% RT:369 min LRMS (ESI): (calc) 291.7296 (found) 292.03 (MH)+

N-hydroxy-2- (naphthalen-1- yloxy)-2- phenylacetamide 7-31 92% RT: 3.85min LRMS (ESI): (calc) 293.3166 (found) 294.05 (MH)+

N-hydroxy-2- phenyl-2- (quinolin-8- yloxy)acetamide 7-32 100% RT: 2.76min LRMS (ESI): (calc) 294.3047 (found) 295.11 (MH)+

2-(2-chloro-4- fluorophenoxy)- N-hydroxy-2- phenylacetamide 7-33 90% RT:3.69 min LRMS (ESI): (calc) 295.6935 (found) 296.01 (MH)+

2-(3-chloro-4- fluorophenoxy)- N-hydroxy-2- phenylacetamide 7-34 96% RT:3.73 min LRMS (ESI): (calc) 295.6935 (found) 296 (MH)+

N-hydroxy-2-(7- methyl-2,3- dihydro-1H- inden-4-yloxy)-2-phenylacetamide 7-35 94% RT: 4.05 min LRMS (ESI): (calc) 297.3484(found) 298.1 (MH)+

N-hydroxy-2- phenyl-2- (5,6,7,8- tetrahydronaphthalen- 2-yloxy)acetamide 7-36 90% RT: min 1H NMR (360 MHz, DMSO- d6) d ppm 11.15(1H, s), 9.08 (1H, s), 7.60 (2H, d, J = 7.27 Hz), 7.38-7.49 (3H, m),7.01 (1H, d, J = 8.17 Hz), 6.73- 6.81 (2H, m), 5.63 (1H, s), 2.70 (4H,d, J = 12.26 Hz), 1.76 (4H, br. s.)

2-(4-tert- butylphenoxy)- N-hydroxy-2- phenylacetamide 7-37 93% RT: 4.16min LRMS (ESI): (calc) 299.3642 (found) 300.09 (MH)+

2-(3-tert- butylphenoxy)- N-hydroxy-2- phenylacetamide 7-38 91% RT: 4.12min LRMS (ESI): (calc) 299.3642 (found) 300.09 (MH)+

2-(4- butylphenoxy)-N-hydroxy-2- phenylacetamide 7-39 94% RT: 4.29 minLRMS (ESI): (calc) 299.3642 (found) 300.13 (MH)+

N-hydroxy-2-(2- isopropoxyphenoxy)- 2- phenylacetamide 7-40 91% RT: 3.78min LRMS (ESI): (calc) 301.3371 (found) 302.11 (MH)+

N-hydroxy-2- phenyl-2-(4- propoxyphenoxy) acetamide 7-41 96% RT: 3.85min LRMS (ESI): (calc) 301.3371 (found) 302.11 (MH)+

2-(3,4- dimethoxyphenoxy)- N-hydroxy-2- phenylacetamide 7-42 95% RT:3.21 min LRMS (ESI): (calc) 303.3099 (found) 304.13 (MH)+

2-(4-chloro-3- ethylphenoxy)-N- hydroxy-2- phenylacetamide 7-43 99% RT:4.07 min LRMS (ESI): (calc) 305.7561 (found) 306.03 (MH)+ 1H NMR (360MHz, DMSO- d6) d ppm 11.13 (1H, s), 9.04 (1H, s), 7.53 (2H, d, J = 6.36Hz), 7.23-7.46 (4H, m), 6.99 (1H, d, J = 3.18 Hz), 6.81 (1H, dd, J =9.08, 3.18 Hz), 5.63 (1H, s), 2.62 (2H, q, J = 7.42 Hz), 1.14 (3H, t, J= 7.49 Hz)

N-hydroxy-2- phenyl-2-(4- (trifluoromethyl) phenoxy) acetamide 7-44 94%RT: 3.83 min LRMS (ESI): (calc) 311.2559 (found) 312.06 (MH)+ 1H NMR(250 MHz, DMSO- d6) d ppm 11.20 (1H, s), 9.08 (1H, s), 7.65 (2H, d, J =8.68 Hz), 7.53 (2H, d, J = 6.24 Hz), 7.30-7.43 (3H, m), 7.14 (2H, d, J =8.53 Hz), 5.77 (1H, s)

N-hydroxy-2- phenyl-2-(2- trifluoromethyl) phenoxy) acetamide 7-45 91%RT: 3.79 min LRMS (ESI): (calc) 311.2559 (found) 312.07 (MH)+

N-hydroxy-2- phenyl-2-(3- trifluoromethyl) phenoxy) acetamide 7-46 92%RT: 3.82 min LRMS (ESI): (calc) 311.2559 (found) 312.07 (MH)+ 1H NMR(360 MHz, DMSO- d6) d ppm 11.22 (1H, br. s.), 9.10 (1H, br. s.),7.51-7.59 (3H, m), 7.38-7.45 (4H, m), 7.28-7.38 (2H, m), 5.82 (1H, s)

2-(biphenyl-2- yloxy)-N- hydroxy-2- phenylacetamilde 7-47 97% RT: 4.05min LRMS (ESI): (calc) 319.3539 (found) 320.09 (MH)+ 1H NMR (360 MHz,DMSO- d6) d ppm 11.08 (1H, br. s.), 9.10 (1H, br. s.), 7.65-7.78 (2H,m), 7.38-7.51 (4H, m), 7.26-7.38 (6H, m), 7.00- 7.12 (2H, m), 5.62 (1H,s)

2-(biphenyl-3- yloxy)-N- hydroxy-2- phenylacetamide 7-48 90% RT: 4.05min LRMS (ESI): (calc) 319.3539 (found) 320.13 (MH)+

2-(3,4- dimethylphenoxy)- N-hydroxy-2- phenylacetamide 7-49 90% RT: 3.76min LRMS (ESI): (calc) 271.3111 (found) 272.05 (MH)+

2-(4- chlorophenoxy)- N-hydroxy-2- phenylacetamide 7-50 95% RT: 3.68 minLRMS (ESI): (calc) 277.703 (found) 278.03 (MH)+

2-(2- chlorophenoxy)- N-hydroxy-2- phenylacetamide 7-51 95% RT: 3.61 minLRMS (ESI): (calc) 277.703 (found) 278.03 (MH)+

2-(3- chlorophenoxy)- N-hydroxy-2- phenylacetamide 7-52 94% RT: 3.68 minLRMS (ESI): (calc) 277.703 (found) 277.99 (MH)+

N-hydroxy-2- (naphthalen-2- yloxy)-2- phenylacetamide 7-53 95% RT: 3.81min LRMS (ESI): (calc) 293.3166 (found) 294.09 (MH)+

2-(2-tert- butylphenoxy)- N-hydroxy-2- phenylacetamide 7-54 92% RT: 4.16min LRMS (ESI): (calc) 299.3642 (found) 300.15 (MH)+ 1H NMR (360 MHz,DMSO- d6) d ppm 11.24 (1H, br. s.), 9.16 (1H, br. s.), 7.65 (2H, d, J =7.27 Hz), 7.35-7.49 (3H, m), 7.28 (1H, d, J = 7.72 Hz), 7.16 (1H, t, J =7.72 Hz), 6.82- 6.94 (2H, m), 5.68 (1H, s), 1.43 (9H, s)

N-hydroxy-2- phenyl-2-(o- tolylthio) acetamide 7-55 92% RT: 3.67 minLRMS (ESI): (calc) 273.3501 (found) 274.03 (MH)+

N-hydroxy-2- phenyl-2-(m- tolylthio) acetamide 7-56 93% RT: 3.7 min LRMS(ESI): (calc) 273.3501 (found) 274.06 (MH)+

N-hydroxy-2-(6- methylpyridin-2- ylthio)-2- phenylacetamide 7-57 100%RT: 3.31 min LRMS (ESI): (calc) 274.3382 (found) 275.01 (MH)+

2-(2- fluorophenylthio)- N-hydroxy-2- phenylacetamide 7-58 97% RT: 3.51min LRMS (ESI): (calc) 277.314 (found) 278.03 (MH)+

2-(3- fluorophenylthio)- N-hydroxy-2- phenylacetamide 7-59 94% RT: 3.59min LRMS (ESI): (calc) 277.314 (found) 278.03 (MH)+

2-(2,6- dimethylphenylthio)- N-hydroxy-2- phenylacetamide 7-60 92% RT:3.88 min LRMS (ESI): (calc) 287.3767 (found) 288.06 (MH)+

2-(3,4- dimethylphenylthio)- N-hydroxy-2- phenylacetamide 7-61 93% RT:3.87 min LRMS (ESI): (calc) 287.3767 (found) 288.06 (MH)+

2-(3,5- dimethylphenylthio)- N-hydroxy-2- phenylacetamide 7-62 92% RT:3.91 min LRMS (ESI): (calc) 287.3767 (found) 288.06 (MH)+

N-hydroxy-2-(2- methoxyphenylthio)- 2- phenylacetamide 7-63 96% RT: 3.47min LRMS (ESI): (calc) 289.3495 (found) 290.01 (MH)+

N-hydroxy-2-(4- methoxyphenylthio)- 2- phenylacetamide 7-64 97% RT: 3.52min LRMS (ESI): (calc) 289.3495 (found) 290.02 (MH)+

N-hydroxy-2-(3- methoxyphenylthio)- 2- phenylacetamide 7-65 93% RT: 3.56min LRMS (ESI): (calc) 289.3495 (found) 290.01 (MH)+

2-(4- chlorophenylthio)- N-hydroxy-2- phenylacetamide 7-66 94% RT: 3.79min LRMS (ESI): (calc) 293.7686 (found) 293.98 (MH)+

2-(2- chlorophenylthio)- N-hydroxy-2- phenylacetamide 7-67 86% RT: 3.68min LRMS (ESI): (calc) 293.7686 (found) 293.98 (MH)+

2-(3- chlorophenylthio)- N-hydroxy-2- phenylacetamide 7-68 89% RT: 3.79min LRMS (ESI): (calc) 293.7686 (found) 293.98 (MH)+

N-hydroxy-2-(2- isopropylphenylthio)- 2- phenylacetamide 7-69 100% RT:4.06 min LRMS (ESI): (calc) 301.4033 (found) 302.05 (MH)+ 1H NMR (360MHz, DMSO- d6) d ppm 10.90 (1H, br. s.), 9.04-9.07 (1H, m), 7.39- 7.45(2H, m), 7.18-7.34 (6H, m), 7.07-7.13 (1H, m), 4.73 (1H, s), 3.35-3.44(1H, m), 1.14 (3H, d, J = 6.81 Hz), 1.01 (3H, d, J = 6.81 Hz)

N-hydroxy-2-(4- methylthio) phenylthio)-2- phenylacetamide 7-70 87% RT:3.76 min LRMS (ESI): (calc) 305.4151 (found) 306.02 (MH)+

N-hydroxy-2- naphthalen-1- ylthio)-2- phenylacetamide 7-71 100% RT: 3.94min LRMS (ESI): (calc) 309.3822 (found) 310.05 (MH)+ 1H NMR (360 MHz,DMSO- d6) d ppm 10.90 (1H, br. s.), 9.08 (1H, br. s.), 8.33 (1H, d, J =8.17 Hz), 7.92-7.99 (1H, m), 7.87 (1H, d, J = 8.17 Hz), 7.54-7.66 (2H,m), 7.37- 7.54 (4H, m), 7.22-7.36 (3H, m), 4.87 (1H, s)

2-(2-chloro-4- fluorophenylthio)- N-hydroxy-2- phenylacetamide 7-72 90%RT: 3.77 min LRMS (ESI): (calc) 311.759 (found) 312 (MH)+

2-(2-tert- butylphenylthio)- N-hydroxy-2- phenylacetamide 7-73 100% RT:4.19 min LRMS (ESI): (calc) 315.4298 (found) 316.1 (MH)+

2-(4-tert butylphenylthio)-N-hydroxy-2-phenylacetamide 7-74 90% RT: 4.27min LRMS (ESI): (calc) 315.4298 (found) 316.1 (MH)+

2-(4- acetamidophenylthio)- N-hydroxy- 2- phenylacetamide 7-75 96% RT:3.08 min LRMS (ESI): (calc) 316.3748 (found) 317.05 (MH)+ 1H NMR (360MHz, DMSO- d6) d ppm 10.87 (1H, br. s.), 10.01 (1H, br. s.), 9.05 (1H,br. s.), 7.47-7.52 (2H, m), 7.40-7.46 (2H, m), 7.20- 7.34 (5H, m),4.72-4.78 (1H, m), 2.02 (3H, s)

2-(3,4- dimethoxyphenylthio)- N-hydroxy- 2- phenylacetamide 7-76 94% RT:3.38 min LRMS (ESI): (calc) 319.3755 (found) 320.07 (MH)+

2-(2,5- dimethoxyphenylthio)- N-hydroxy- 2- phenylacetamide 7-78 92% RT:3.51 min LRMS (ESI): (calc) 319.3755 (found) 320.07 (MH)+

N-hydroxy-2- phenyl-2-(4- (trifluoromethyl) phenylthio) acetamide 7-7995% RT: 3.94 min LRMS (ESI): (calc) 327.3215 (found) 328.07 (MH)+

N-hydroxy-2- phenyl-2-(2- (trifluoromethyl) phenylthio) acetamide 7-8093% RT: 3.82 min LRMS (ESI): (calc) 327.3215 (found) 328.07 (MH)+

N-hydroxy-2- phenyl-2-(3- (trifluoromethyl) phenylthio acetamide 7-8194% RT: 3.93 min LRMS (ESI): (calc) 327.3215 (found) 328.04 (MH)+

1-(2- hydroxyamino)- 2-oxo-1- phenylethyl)-N- methylpiperidine-4-carboxamide 7-82 98.41% RT: 1.07 min LRMS (ESI): (calc) 291.3456(found) 292.15 (MH)+ 1H NMR (250 MHz, DMSO- d6) d ppm 11.09 (1H, br.s.), 9.04 (1H, br. s.) 7.79 (1H, d, J = 4.42 Hz), 7.20-7.62 (5H, m),3.95 (1H, br. s.), 2.87- 3.15 (1H, m), 2.59-2.77 (1H, m), 2.54 (3H, d, J= 4.57 Hz), 1.89-2.40 (3H, m), 1.36- 1.89 (4H, m)

N-hydroxy-2- phenyl-2-(1,5- dioxa-9- azaspiro[5.5] undecan-9-yl)acetamide 7-83 87.56% RT: 1.99 min LRMS (ESI): (calc) 306.3569(found) 307.15 (MH)+ ¹H NMR (250 MHz, DMSO- d₆) d ppm 10.84 (1H, br.s.), 8.92 (1H, br. s.) 7.13-7.58 (5H, m), 3.60-3.95 (5H, m), 2.14-2.45(4H, m), 1.67- 1.97 (4H, m), 1.44-1.65 (2H, m)

2-(4-cyano-4- phenylpiperidin- 1-yl)-N-hydroxy- 2- phenylacetamide 7-22100% RT: 3 min LRMS (ESI): (calc) 335.3996 (found) 336.14 (MH)+

N-hydroxy-2- phenyl-2-(4- (piperidine-1- carbonyl)piperidin-1-yl)acetamide 7-84 88.5% RT: 2.4 min LRMS (ESI): (calc) 345.436 (found)346.22 (MH)+

N-hydroxy-2-(4- (2-oxoindolin-1- yl)piperidin-1- yl)-2- phenylacetamide7-85 92.16% RT: 2.71 min LRMS (ESI): (calc) 365.4256 (found) 366.13(MH)+

N-hydroxy-2- phenyl-2-(4-(5- phenyl-1,3,4- oxadiazol-2- yl)piperidin-1-yl)acetamide 7-86 86.72% RT: 2.74 min LRMS (ESI): (calc) 378.4244(found) 379.17 (MH)+ 1H NMR (250 MHz, DMSO- d6) d ppm 10.86 (1H, br.s.), 8.92 (1H, br. s.), 7.88-8.09 (2H, m), 7.51-7.70 (3H, m), 7.40-7.50(2H, m), 7.21- 7.39 (3H, m), 3.70 (1H, s), 2.98-3.14 (1H, m), 2.83- 2.98(1H, m), 2.59-2.74 (1H, m), 2.15-2.32 (1H, m), 1.67-2.14 (5H, m)

N-hydroxy-2- phenyl-2-(4-(3- (pyridin-4-yl)- 1,2,4-oxadiazol-5-yl)piperidin-1- yl)acetamide 7-87 88.54% RT: 2.36 min LRMS (ESI):(calc) 379.4124 (found) 380.14 (MH)+

N-hydroxy-2- phenyl-2-(4-(3- pyrazin-2-yl)- 1,2,4-oxadiazol-5-yl)piperidin-1- yl)acetamide 7-88 86.96% RT: 2.36 min LRMS (ESI):(calc) 380.4005 (found) 381.12 (MH)+ 1H NMR (250 MHz, DMSO- d6) d ppm10.90 (1H, br. s.), 9.23 (1H, d, J = 1.37 Hz), 8.88- 9.11 (1H, m),8.74-9.11 (2H, m), 7.40-7.59 (3H, m), 7.19-7.42 (2H, m), 3.66- 3.86 (1H,m), 3.07-3.27 (1H, m), 2.84-3.03 (1H, m), 2.60-2.79 (1H, m), 1.67- 2.39(6H, m)

N-(1-(2- hydroxyamino)- 2-oxo-1- phenylethyl) piperidin-4-yl)-N-phenylpropionamide 7-89 97.35% RT: 2.79 min LRMS (ESI): (calc) 381.4681(found) 382.19 (MH)+ 1H NMR (250 MHz, DMSO- d6) d ppm 10.03-11.33 (1H,m), 8.18-9.50 (1H, m), 7.37- 7.55 (3H, m), 7.10-7.37 (7H, m), 4.44 (1H,t, J = 11.95 Hz), 3.56 (1H, s), 2.79-3.03 (1H, m), 2.52-2.61 (1H, m),1.97-2.17 (1H, m), 1.51- 1.88 (5H, m), 1.00-1.40 (2H, m), 0.86 (3H, t, J= 7.39 Hz)

N-hydroxy-2- phenyl-2-(4-(3- (thiophen-2-(4-(3- 1,2,4-oxadiazol-5-yl)piperidin-1- yl)acetamide 7-90 98.42% RT: 2.89 min LRMS (ESI):(calc) 384.4521 (found) 385.09 (MH)+

N-hydroxy-2-(4- (4- methylpiperidine- 1- carbonyl) piperidin-1-yl)-2-phenylacetamide 7-91 97.92% RT: 2.65 min LRMS (ESI): (calc) 359.4626(found) 360.2 (MH)+

N-hydroxy-2-(1- methyl-1H- ilmidazol-2-ylthio)-2- phenylacetamide 7-9285% RT: 1.83 min LRMS (ESI): (calc) 263.3155 (found) 363.99 (MH)+ 1H NMR(360 MHz, DMSO- d6) d ppm 11.00 (1H, s), 9.10 (1H, s), 7.22-7.40 (5H,m), 7.19 (1H, d, J = 1.36 Hz), 6.97 (1H, d, J = 0.91 Hz,), 4.98 (1H, s),3.36 (3H, s)

N-hydroxy-2- phenyl-2- (thiazol-2- ylthio)acetamide 7-93 99% RT: 3.09min LRMS (ESI): (calc) 266.3393 (found) 266.94 (MH)+

2-(4,6- dimethylpyrimidin- 2-ylthio)-N- hydroxy-2- phenylacetamide 7-9496% RT: 3.22 min LRMS (ESI): (calc) 389.3528 (found) 290.07 (MH)+

N-hydroxy-2-(5- nitro-1H- benzo[d]imidazol- 2-ylthio)-2- phenylacetamide7-95 96% RT: 3.4 min LRMS (ESI): (calc) 344.3452 (found) 345.02 (MH)+

2-(5-ethoxy-1H- benzo[d]imidazol- 2-ylthio)-N- hydroxy-2-phenylacetamide 7-96 92% RT: 3.06 min LRMS (ESI): (calc) 343.4002(found) 344.11 (MH)+

TABLE VIII Compounds prepared according general Schemes above Cpd # NameCharacterization 8-1 N-hydroxy-2-(3-(4- LRMS (ESI): (calc.) 327.4174,(found) 328 [M + H], HPLC methylpentyloxy)phenyl)-2- (215 nM): 100%, RT4.54 min. phenylacetamide 8-2 N-hydroxy-2-phenyl-2-(3- LRMS (ESI):(calc.) 296.3636, (found) 297 [M + H], HPLC (pyrrolidin-1- (215 nM):92%, RT 3.59 min. yl)phenyl)acetamide 8-3 2-(3-(butylamino)phenyl)-N-LRMS (ESI): (calc.) 298.37948, (found) 299 [M + H], HPLChydroxy-2-phenylacetamide (215 nM): 90% , RT 3.14 min. 8-4 2-(3-(tert-LRMS (ESI): (calc.) 298.37948, (found) 299 [M + H], HPLCbutylamino)phenyl)-N- (215 nM): 89% RT 2.53 min.hydroxy-2-phenylacetamide 8-5 N-hydroxy-2-(3-(2- LRMS (ESI): (calc.)300.3523, (found) 301 [M + H], HPLC methoxyethylamino)phenyl)- (215 nM):96%, RT 2.93 min. 2-phenylacetamide 8-6 N-hydroxy-2-phenyl-2-(3- LRMS(ESI): (calc.) 310.39018, (found) 311 [M + H], HPLC (piperidin-1- (215nM): 96%, RT 2.52 min. yl)phenyl)acetamide 8-7 2-(3- LRMS (ESI): (calc.)310.39018, (found) 311 [M + H], HPLC (cyclopentylamino)phenyl)- (215nM): 94%, RT 3 min. 1H NMR (250 MHz, MeOD) d N-hydroxy-2- ppm 7.16-7.46(5H, m), 6.95-7.14 (1H, m), 6.43-6.72 (3H, phenylacetamide m), 4.69 (1H,s), 3.56-3.82 (1H, m), 1.83-2.05 (2H, m), 1.53-1.79 (4H, m), 1.37-1.52(2H, m) 8-8 2-(3- LRMS (ESI): (calc.) 312.40606, (found) 313 [M + H],HPLC (ethyl(propyl)amino)phenyl)- (215 nM): 92%, RT 2.68 min. 1H NMR(250 MHz, MeOD) N-hydroxy-2- d ppm 7.20-7.42 (5H, m), 6.98-7.20 (1H, m),phenylacetamide 6.50-6.77 (3H, m), 4.71 (1H, s), 3.33-3.43 (2H, m),3.15-3.26 (2H, m), 1.46-1.66 (2H, m), 1.08 (3H, t), 0.89 (3H, t) 8-9N-hydroxy-2-(3-(3- LRMS (ESI): (calc.) 314.37888, (found) 315 [M + H],HPLC methoxypropylamino)phenyl)- (215 nM): 91%, RT 2.84 min.2-phenylacetamide 8-10 N-hydroxy-2-(3-(2- LRMS (ESI): (calc.) 316.4179,(found) 317 [M + H], HPLC (methylthio)ethylamino)phenyl)- (215 nM):100%, RT 3.41 min. 2-phenylacetamide 8-11 2-(3-(furan-2- LRMS (ESI):(calc.) 322.35782, (found) 323 [M + H], HPLC ylmethylamino)phenyl)-N-(215 nM): 89%, RT 3.53 min. hydroxy-2-phenylacetamide 8-12 2-(3- LRMS(ESI): (calc.) 324.41676, (found) 325 [M + H], HPLC(cyclohexylamino)phenyl)-N- (215 nM): 92%, RT 3.04 min.hydroxy-2-phenylacetamide 8-13 N-hydroxy-2-(3-(4- LRMS (ESI): (calc.)325.40482, (found) 326 [M + H], HPLC methylpiperazin-1- (215 nM): 92%,RT 2.43 min. yl)phenyl)-2-phenylacetamide 8-14 N-hydroxy-2-phenyl-2-(3-LRMS (ESI): (calc.) 326.38958, (found) 327 [M + H], HPLC(tetrahydro-2H-pyran-4- (215 nM): 90%, RT 2.77 min.ylamino)phenyl)acetamide 8-15 N-hydroxy-2-phenyl-2-(3- LRMS (ESI):(calc.) 326.38958, (found) 327 [M + H], HPLC ((tetrahydrofuran-2- (215nM): 100%, RT 3.23 min. yl)methylamino)phenyl)acetamide 8-16N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc.) 328.4286, (found) 329 [M +H], HPLC thiomorpholinophenyl)acetamide (215 nM): 96%, RT 3.46 min. 8-172-(3-(2-(1H-pyrrol-1- LRMS (ESI): (calc.) 335.39964, (found) 336 [M +H], HPLC yl)ethylamino)phenyl)-N- (215 nM): 89%, RT 3.68 min.hydroxy-2-phenylacetamide 8-18 N-hydroxy-2-phenyl-2-(3- LRMS (ESI):(calc.) 338.42342, (found) 339 [M + H], HPLC (thiophen-2- (215 nM): 93%,RT 3.71 min. ylmethylamino)phenyl)acetamide 8-19 2-(3- LRMS (ESI):(calc.) 338.44334, (found) 339 [M + H], HPLC(cyclohexyl(methyl)amino)phenyl)- (215 nM): 93%, RT 2.86 min.N-hydroxy-2- phenylacetamide 8-20 N-hydroxy-2-phenyl-2-(3-(2- LRMS(ESI): (calc.) 339.4314, (found) 340 [M + H], HPLC (pyrrolidin-1- (215nM): 99%, RT 2.53 min. yl)ethylamino)phenyl)acetamide 8-212-(3-(4-ethylpiperazin-1- LRMS (ESI): (calc.) 339.4314, (found) 340 [M +H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 88%, RT 2.51 min.phenylacetamide 8-22 2-(3-(3- LRMS (ESI): (calc.) 339.4314, (found) 340[M + H], HPLC (dimethylamino)pyrrolidin-1- (215 nM): 85%, RT 2.59 min.yl)phenyl)-N-hydroxy-2- phenylacetamide 8-23 N-hydroxy-2-(3-(4- LRMS(ESI): (calc.) 340.41616, (found) 341 [M + H], HPLC(hydroxymethyl)piperidin-1- (215 nM): 95%, RT 2.36 min. 1H NMR (250 MHz,MeOD) yl)phenyl)-2-phenylacetamide d ppm 7.12-7.38 (6H, m), 6.95-7.04(1H, m), 6.85-6.94 (1H, m), 6.79 (1H, d, J = 7.31 Hz), 4.73 (1H, s),3.52-3.73 (2H, m), 3.43 (2H, d, J = 6.40 Hz), 2.58-2.73 (2H, m),1.74-1.88 (2H, m), 1.48-1.69 (1H, m), 1.23-1.39 (2H, m) 8-24 2-(3-(2,6-LRMS (ESI): (calc.) 340.41616, (found) 341 [M + H], HPLCdimethylmorpholino)phenyl)- (215 nM): 92%, RT 3.55 min. N-hydroxy-2-phenylacetamide 8-25 N-hydroxy-2-(3-(isoindolin- LRMS (ESI): (calc.)344.4064, (found) 345 [M + H], HPLC 2-yl)phenyl)-2- (215 nM): 93%, RT4.23 min. phenylacetamide 8-26 2-(3- LRMS (ESI): (calc.) 346.42228,(found) 347 [M + H], HPLC (benzyl(methyl)amino)phenyl)- (215 nM): 91%,RT 3.88 min. N-hydroxy-2- phenylacetamide 8-27N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI): (calc.) 347.41034, (found) 348[M + H], HPLC (pyridin-2- (215 nM): 94%, RT 2.56 min. 1H NMR (250 MHz,MeOD) yl)ethylamino)phenyl)acetamide d ppm 8.43 (1H, d, J = 5.18 Hz),7.66-7.76 (1H, m), 7.19-7.35 (7H, m), 7.00-7.09 (1H, m), 6.49-6.65 (3H,m), 4.69 (1H, s), 3.40 (2H, t, J = 7.16 Hz), 3.00 (2H, t, J = 7.16 Hz)8-28 N-hydroxy-2-(3- LRMS (ESI): (calc.) 347.41034, (found) 348 [M + H],HPLC (methyl(pyridin-3- (215 nM): 94%, RT 2.71 min.ylmethyl)amino)phenyl)-2- phenylacetamide 8-29N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI): (calc.) 347.41034, (found) 348[M + H], HPLC (pyridin-3- (215 nM): 87%, RT 2.58 min.yl)ethylamino)phenyl)acetamide 8-30 N-hydroxy-2-phenyl-2-(3-(2- LRMS(ESI): (calc.) 347.41034, (found) 348 [M + H], HPLC (pyridin-4- (215nM): 99%, RT 2.55 min. yl)ethylamino)phenyl)acetamide 8-31N-hydroxy-2-(3-(4- LRMS (ESI): (calc.) 348.3951, (found) 349 [M + H],HPLC methoxyphenylamino)phenyl)- (215 nM): 93%, RT 3.82 min.2-phenylacetamide 8-32 2-(3-(3-(1H-imidazol-1- LRMS (ESI): (calc.)350.41428, (found) 351 [M + H], HPLC yl)propylamino)phenyl)-N- (215 nM):98%, RT 2.47 min. hydroxy-2-phenylacetamide 8-33N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI): (calc.) 352.45, (found) 353 [M +H], HPLC (thiophen-2- (215 nM): 92%, RT 3.85 min.yl)ethylamino)phenyl)acetamide 8-34 2-(3-(3-acetamidopyrrolidin- LRMS(ESI): (calc.) 353.41492, (found) 354 [M + H], HPLC1-yl)phenyl)-N-hydroxy-2- (215 nM): 97%, RT 3.19 min. 1H NMR (250 MHz,MeOD) phenylacetamide d ppm 7.17-7.37 (5H, m), 7.04-7.16 (1H, m),6.52-6.66 (2H, m), 6.40-6.51 (1H, m), 4.72 (1H, s), 4.29-4.52 (1H, m),3.36-3.55 (2H, m), 3.18-3.28 (1H, m), 3.03-3.14 (1H, m), 2.14-2.31 (1H,m), 1.83-2.04 (4H, m) 8-35 N-hydroxy-2-phenyl-2-(3-(2- LRMS (ESI):(calc.) 353.45798, (found) 354 [M + H], HPLC (piperidin-1- (215 nM):98%, RT 2.6 min. yl)ethylamino)phenyl)acetamide 8-362-(3-(3,4-dihydroisoquinolin- LRMS (ESI): (calc.) 358.43298, (found) 359[M + H], HPLC 2(1H)-yl)phenyl)-N-hydroxy- (215 nM): 95%, RT 3.98 min.2-phenylacetamide 8-37 N-hydroxy-2-(3-(methyl(2- LRMS (ESI): (calc.)361.43692, (found) 362 [M + H], HPLC (pyridin-2- (215 nM): 92%, RT 2.72min. yl)ethyl)amino)phenyl)-2- phenylacetamide 8-38 N-hydroxy-2-(3-(2-LRMS (ESI): (calc.) 362.42168, (found) 363 [M + H], HPLCphenoxyethylamino)phenyl)- (215 nM): 89%, RT 3.9 min. 2-phenylacetamide8-39 2-(3-(4- LRMS (ESI): (calc.) 366.84076, (found) 367 [M + H], HPLCchlorobenzylamino)phenyl)- (215 nM): 87%, RT 4.05 min. N-hydroxy-2-phenylacetamide 8-40 2-(3-(4-acetyl-1,4-diazepan- LRMS (ESI): (calc.)367.4415, (found) 368 [M + H], HPLC 1-yl)phenyl)-N-hydroxy-2- (215 nM):95%, RT 3.21 min. phenylacetamide 8-41 N-hydroxy-2-(3-(3-(2- LRMS (ESI):(calc.) 367.4415, (found) 368 [M + H], HPLC oxopyrrolidin-1- (215 nM):94%, RT 2.82 min. yl)propylamino)phenyl)-2- phenylacetamide 8-422-(3-(4-butylpiperazin-1- LRMS (ESI): (calc.) 367.48456, (found) 368[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 94%, RT 2.75 min.phenylacetamide 8-43 N-hydroxy-2-(3-(4-(2- LRMS (ESI): (calc.)369.45738, (found) 370 [M + H], HPLC methoxyethyl)piperazin-1- (215 nM):93%, RT 2.56 min. yl)phenyl)-2-phenylacetamide 8-44 N-hydroxy-2-(3-(3-LRMS (ESI): (calc.) 369.45738, (found) 370 [M + H], HPLCmorpholinopropylamino)phenyl)- (215 nM): 93%, RT 2.44 min.2-phenylacetamide 8-45 N-hydroxy-2-phenyl-2-(3-(4- LRMS (ESI): (calc.)378.3881496, (found) 379 [M + H], (trifluoromethyl)piperidin-1- HPLC(215 nM): 93%, RT 3.84 min. yl)phenyl)acetamide 8-46N-hydroxy-2-phenyl-2-(3-(4- LRMS (ESI): (calc.) 388.46226, (found) 389[M + H], HPLC (pyridin-4-yl)piperazin-1- (215 nM): 97%, RT 2.76 min.yl)phenyl)acetamide 8-47 N-hydroxy-2-phenyl-2-(3-(4- LRMS (ESI): (calc.)388.46226, (found) 389 [M + H], HPLC (pyridin-2-yl)piperazin-1- (215nM): 92%, RT 2.78 min. yl)phenyl)acetamide 8-48N-hydroxy-2-phenyl-2-(3-(4- LRMS (ESI): (calc.) 389.45032, (found) 390[M + H], HPLC (pyrazin-2-yl)piperazin-1- (215 nM): 88%, RT 3.48 min.yl)phenyl)acetamide 8-49 2-(3-(1,4′-bipiperidin-1′- LRMS (ESI): (calc.)393.52184, (found) 394 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):87%, RT 2.65 min. phenylacetamide 8-50 2-(3-(4-benzylpiperazin-1- LRMS(ESI): (calc.) 401.50078, (found) 402 [M + H], HPLCyl)phenyl)-N-hydroxy-2- (215 nM): 86%, RT 2.87 min. phenylacetamide 8-51N-hydroxy-2-(3-(4-(4- LRMS (ESI): (calc.) 417.50018, (found) 418 [M +H], HPLC methoxyphenyl)piperazin-1- (215 nM): 100%, RT 3.45 min.yl)phenyl)-2-phenylacetamide 8-52 N-hydroxy-2-(3-(4-(2- LRMS (ESI):(calc.) 424.53588, (found) 425 [M + H], morpholinoethyl)piperazin- HPLC(215 nM): 95%, RT 2.33 min. 1-yl)phenyl)-2- phenylacetamide 8-532-(4-(allylamino)phenyl)- LRMS (ESI): (calc.) 282.3, (found) 283 [M +H], HPLC N-hydroxy-2- (215 nM): 96%, RT 3.02 min phenylacetamide 8-542-(4-(2,5-dihydro-1H- LRMS (ESI): (calc.) 294.34772, (found) 295 [M +H], pyrrol-1-yl)phenyl)-N- HPLC (215 nM): 94%, RT 3.78 min. hydroxy-2-phenylacetamide 8-55 2-(4-(butylamino)phenyl)-N- LRMS (ESI): (calc.)298.37948, (found) 299 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):93%, RT 3.04 min. 8-56 2-(4-(tert- LRMS (ESI): (calc.) 298.37948,(found) 299 [M + H], HPLC butylamino)phenyl)-N- (215 nM): 97%, RT 2.47min. 1H NMR (250 MHz, MeOD) hydroxy-2-phenylacetamide d ppm 7.22-7.37(5H, m), 7.18 (2H, d, J = 8.22 Hz), 6.91 (2H, d, J = 8.53 Hz), 4.71 (1H,s), 1.28 (9H, s) 8-57 N-hydroxy-2-(4-(2- LRMS (ESI): (calc.) 300.3523,(found) 301 [M + H], HPLC methoxyethylamino)phenyl)- (215 nM): 97%, RT2.84 min. 2-phenylacetamide 8-58 2-(4- LRMS (ESI): (calc.) 310.39018,(found) 311 [M + H], HPLC (cyclopentylamino)phenyl)- (215 nM): 96%, RT2.9 min. N-hydroxy-2- phenylacetamide 8-59 N-hydroxy-2-(4-(pentan-3-LRMS (ESI): (calc.) 312.40606, (found) 313 [M + H], HPLCylamino)phenyl)-2- (215 nM): 96%, RT 3.35 min. phenylacetamide 8-602-(4- LRMS (ESI): (calc.) 312.40606, (found) 313 [M + H], HPLC(ethyl(propyl)amino)phenyl)- (215 nM): 97%, RT 2.63 min. N-hydroxy-2-phenylacetamide 8-61 N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 314.37888,(found) 315 [M + H], HPLC methoxypropylamino)phenyl)- (215 nM): 94%, RT2.75 min. 2-phenylacetamide 8-62 N-hydroxy-2-(4-(2- LRMS (ESI): (calc.)316.4179, (found) 317 [M + H], HPLC (methylthio)ethylamino)phenyl)- (215nM): 100%, RT 3.34 min. 2-phenylacetamide 8-63 N-hydroxy-2-(4- LRMS(ESI): (calc.) 256.29974, (found) 257 [M + H], HPLC(methylamino)phenyl)-2- (215 nM): 98%, RT 2.27 min. phenylacetamide 8-642-(4-(furan-2- LRMS (ESI): (calc.) 322.35782, (found) 323 [M + H], HPLCylmethylamino)phenyl)-N- (215 nM): 94%, RT 3.51 min.hydroxy-2-phenylacetamide 8-65 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.)324.41676, (found) 325 [M + H], HPLC methylpiperidin-1-yl)phenyl)- (215nM): 88%, RT 2.75 min. 2-phenylacetamide 8-662-(4-(azepan-1-yl)phenyl)-N- LRMS (ESI): (calc.) 324.41676, (found) 325[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 96%, RT 3.78 min. 8-672-(4- LRMS (ESI): (calc.) 324.41676, (found) 325 [M + H], HPLC(cyclohexylamino)phenyl)-N- (215 nM): 95%, RT 2.98 min.hydroxy-2-phenylacetamide 8-68 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.)325.40482, (found) 326 [M + H], HPLC methylpiperazin-1- (215 nM): 96%,RT 2.36 min. yl)phenyl)-2-phenylacetamide 8-69 N-hydroxy-2-phenyl-2-(4-LRMS (ESI): (calc.) 326.38958, (found) 327 [M + H], HPLC(tetrahydro-2H-pyran-4- (215 nM): 96%, RT 2.66 min.ylamino)phenyl)acetamide 8-70 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 326.38958, (found) 327 [M + H], HPLC ((tetrahydrofuran-2- (215nM): 96%, RT 3.15 min. yl)methylamino)phenyl)acetamide 8-71N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 326.38958, (found) 327 [M + H],HPLC hydroxypiperidin-1- (215 nM): 100%, RT 2.27 min.yl)phenyl)-2-phenylacetamide 8-72 2-(4-(2-(1H-pyrrol-1- LRMS (ESI):(calc.) 335.39964, (found) 336 [M + H], HPLC yl)ethylamino)phenyl)-N-(215 nM): 94%, RT 3.65 min. hydroxy-2-phenylacetamide 8-73N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 338.42342, (found) 339 [M +H], HPLC (thiophen-2- (215 nM): 94%, RT 3.7 min. 1H NMR (250 MHz, MeOD)d ylmethylamino)phenyl)acetamide ppm 7.15-7.33 (6H, m), 7.05 (2H, m),6.95-7.01 (1H, m), 6.87-6.94 (1H, m), 6.62 (2H, m), 4.65 (1H, s), 4.45(2H, s) 8-74 2-(4- LRMS (ESI): (calc.) 338.44334, (found) 339 [M + H],HPLC (cyclohexyl(methyl)amino)phenyl)- (215 nM): 96%, RT 2.86 min.N-hydroxy-2- phenylacetamide 8-75 2-(4- LRMS (ESI): (calc.) 338.44334,(found) 339 [M + H], HPLC ((cyclopropylmethyl)(propyl)amino)phenyl)-(215 nM): 97%, RT 2.87 min. N-hydroxy-2- phenylacetamide 8-76N-hydroxy-2-(4-(4-methyl- LRMS (ESI): (calc.) 339.4314, (found) 340 [M +H], HPLC 1,4-diazepan-1-yl)phenyl)-2- (215 nM): 87%, RT 2.53 min.phenylacetamide 8-77 2-(4-(4-ethylpiperazin-1- LRMS (ESI): (calc.)339.4314, (found) 340 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):97%, RT 2.42 min. phenylacetamide 8-78 2-(4-(3- LRMS (ESI): (calc.)339.4314, (found) 340 [M + H], HPLC (dimethylamino)pyrrolidin-1- (215nM): 89%, RT 2.52 min. yl)phenyl)-N-hydroxy-2- phenylacetamide 8-792-(4-(2,6- LRMS (ESI): (calc.) 340.41616, (found) 341 [M + H], HPLCdimethylmorpholino)phenyl)- (215 nM): 92%, RT 3.52 min. N-hydroxy-2-phenylacetamide 8-80 2-(4- LRMS (ESI): (calc.) 346.42228, (found) 347[M + H], HPLC (benzyl(methyl)amino)phenyl)- (215 nM): 95%, RT 3.95 min.N-hydroxy-2- phenylacetamide 8-81 2-(4-(4- LRMS (ESI): (calc.)346.42228, (found) 347 [M + H], HPLC ethylphenylamino)phenyl)-N- (215nM): 94%, RT 4.26 min. hydroxy-2-phenylacetamide 8-82N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.) 347.41034, (found) 348[M + H], HPLC (pyridin-2- (215 nM): 94%, RT 2.51 min.yl)ethylamino)phenyl)acetamide 8-83 N-hydroxy-2-(4- LRMS (ESI): (calc.)347.41034, (found) 348 [M + H], HPLC (methyl(pyridin-3- (215 nM): 98%,RT 2.71 min. ylmethyl)amino)phenyl)-2- phenylacetamide 8-84N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.) 347.41034, (found) 348[M + H], HPLC (pyridin-3- (215 nM): 95%, RT 2.5 min.yl)ethylamino)phenyl)acetamide 8-85 N-hydroxy-2-phenyl-2-(4-(2- LRMS(ESI): (calc.) 347.41034, (found) 348 [M + H], HPLC (pyridin-4- (215nM): 96%, RT 2.49 min. 1H NMR (250 MHz, MeOD)yl)ethylamino)phenyl)acetamide d ppm 8.30-8.46 (2H, m), 7.18-7.37 (7H,m), 7.09 (2H, m, J = 8.53 Hz), 6.59 (2H, m, J = 8.53 Hz), 4.65 (1H, s),3.36-3.42 (2H, m), 2.91 (2H, t, J = 7.01 Hz) 8-86 N-hydroxy-2-(4-(4-LRMS (ESI): (calc.) 348.3951, (found) 349 [M + H], HPLCmethoxyphenylamino)phenyl)- (215 nM): 91%, RT 3.8 min. 2-phenylacetamide8-87 2-(4-(3- LRMS (ESI): (calc.) 350.3861632, (found) 351 [M + H],fluorobenzylamino)phenyl)- HPLC (215 nM): 93%, RT 3.88 min. N-hydroxy-2-phenylacetamide 8-88 2-(4-(3- LRMS (ESI): (calc.) 350.3861632, (found)351 [M + H], fluorobenzylamino)phenyl)- HPLC (215 nM): 93%, RT 3.87 min.N-hydroxy-2- phenylacetamide 8-89 2-(4-(3-(1H-imidazol-1- LRMS (ESI):(calc.) 350.41428, (found) 351 [M + H], HPLC yl)propylamino)phenyl)-N-(215 nM): 98%, RT 2.39 min. 1H NMR (250 MHz, MeOD)hydroxy-2-phenylacetamide d ppm 7.84 (1H, br. s.), 7.15-7.46 (6H, m),6.90-7.15 (3H, m), 6.56 (2H, d, J = 8.53 Hz), 4.65 (1H, s), 4.17 (2H, t,J = 7.01 Hz), 3.05 (2H, t, J = 6.55 Hz), 1.85-2.18 (2H, m) 8-90N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.) 352.45, (found) 353 [M +H], HPLC (thiophen-2- (215 nM): 94%, RT 3.81 min.yl)ethylamino)phenyl)acetamide 8-91 2-(4- LRMS (ESI): (calc.) 354.4858,(found) 355 [M + H], HPLC (diisobutylamino)phenyl)-N- (215 nM): 97%, RT4.72 min. hydroxy-2-phenylacetamide 8-92 N-hydroxy-2-(4-(2- LRMS (ESI):(calc.) 355.4308, (found) 356 [M + H], HPLCmorpholinoethylamino)phenyl)- (215 nM): 94%, RT 2.36 min. 1H NMR (250MHz, MeOD) 2-phenylacetamide d ppm 7.11-7.34 (5H, m), 7.03 (2H, m, J =8.22 Hz), 6.55 (2H, m, J = 8.53 Hz), 4.59 (1H, s), 3.59-3.70 (4H, m),3.16 (2H, t, J = 6.55 Hz), 2.53 (2H, t, J = 6.55 Hz), 2.36-2.49 (4H, m)8-93 2-(4-(3,4-dihydroisoquinolin- LRMS (ESI): (calc.) 358.43298,(found) 359 [M + H], HPLC 2(1H)-yl)phenyl)-N-hydroxy- (215 nM): 98%, RT3.98 min. 1H NMR (250 MHz, MeOD) 2-phenylacetamide d ppm 7.27-7.36 (4H,m), 7.18-7.27 (3H, m), 7.09-7.18 (4H, m), 6.89-7.04 (2H, m), 4.71 (1H,s), 4.34 (2H, s), 3.52 (2H, t, J = 5.94 Hz), 2.95 (2H, t, J = 5.79 Hz)8-94 N-hydroxy-2-(4-(methyl(2- LRMS (ESI): (calc.) 361.43692, (found)362 [M + H], HPLC (pyridin-2- (215 nM): 95%, RT 2.69 min.yl)ethyl)amino)phenyl)-2- phenylacetamide 8-95 N-hydroxy-2-(4-(2- LRMS(ESI): (calc.) 362.42168, (found) 363 [M + H], HPLCphenoxyethylamino)phenyl)- (215 nM): 92%, RT 3.86 min. 2-phenylacetamide8-96 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 362.42168, (found) 363 [M +H], HPLC methoxybenzylamino)phenyl)- (215 nM): 93%, RT 3.61 min.2-phenylacetamide 8-97 2-(4-(4- LRMS (ESI): (calc.) 366.84076, (found)367 [M + H], HPLC chlorobenzylamino)phenyl)- (215 nM): 93%, RT 4.06 min.N-hydroxy-2- phenylacetamide 8-98 2-(4-(4-acetyl-1,4-diazepan- LRMS(ESI): (calc.) 367.4415, (found) 368 [M + H], HPLC1-yl)phenyl)-N-hydroxy-2- (215 nM): 93%, RT 3.16 min. phenylacetamide8-99 N-hydroxy-2-(4-(3-(2- LRMS (ESI): (calc.) 367.4415, (found) 368[M + H], HPLC oxopyrrolidin-1- (215 nM): 98%, RT 2.74 min.yl)propylamino)phenyl)-2- phenylacetamide 8-1002-(4-(4-butylpiperazin-1- LRMS (ESI): (calc.) 367.48456, (found) 368[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 90%, RT 2.72 min.phenylacetamide 8-101 N-hydroxy-2-(4-(4-(2- LRMS (ESI): (calc.)369.45738, (found) 370 [M + H], HPLC methoxyethyl)piperazin-1- (215 nM):96%, RT 2.49 min. yl)phenyl)-2-phenylacetamide 8-102 N-hydroxy-2-(4-(3-LRMS (ESI): (calc.) 369.45738, (found) 370 [M + H], HPLCmorpholinopropylamino)phenyl)- (215 nM): 98%, RT 2.33 min.2-phenylacetamide 8-103 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.)378.3881496, (found) 379 [M + H], (trifluoromethyl)piperidin-1- HPLC(215 nM): 95%, RT 3.8 min. 1H NMR (250 MHz, yl)phenyl)acetamide MeOD) dppm 7.13-7.40 (7H, m), 6.97 (2H, d, J = 8.83 Hz), 4.71 (1H, s),3.62-3.85 (2H, m), 2.60-2.88 (2H, m), 2.16-2.47 (1H, m), 1.88-2.07 (2H,m), 1.57-1.86 (2H, m) 8-104 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI):(calc.) 386.48614, (found) 387 [M + H], HPLC phenylpiperidin-1- (215nM): 100%, RT 3.45 min. yl)phenyl)acetamide 8-105N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.) 389.45032, (found) 390[M + H], HPLC (pyrazin-2-yl)piperazin-1- (215 nM): 96%, RT 3.44 min.yl)phenyl)acetamide 8-106 2-(4-(1,4′-bipiperidin-1′- LRMS (ESI): (calc.)393.52184, (found) 394 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):89%, RT 2.61 min. phenylacetamide 8-107 2-(4-(benzyl(2- LRMS (ESI):(calc.) 403.51666, (found) 404 [M + H], HPLC(dimethylamino)ethyl)amino)phenyl)- (215 nM): 91%, RT 3.01 min.N-hydroxy-2- phenylacetamide 8-108 N-hydroxy-2-(4-(4-(4- LRMS (ESI):(calc.) 417.50018, (found) 418 [M + H], HPLC methoxyphenyl)piperazin-1-(215 nM): 100%, RT 3.43 min. yl)phenyl)-2-phenylacetamide 8-109N-hydroxy-2-(4-(4-(2- LRMS (ESI): (calc.) 424.53588, (found) 425 [M +H], HPLC morpholinoethyl)piperazin-1- (215 nM): 97%, RT 2.26 min.yl)phenyl)-2-phenylacetamide 8-110 N-(4-(2-(hydroxyamino)-2- LRMS (ESI):(calc.) 338.40028, (found) 339 [M + H], HPLC oxo-1- (215 nM): 96%, RT3.54 min. phenylethyl)phenyl)cyclopentaneanecarboxamide 8-111 2-(4-(2-LRMS (ESI): (calc.) 352.42686, (found) 353 [M + H], HPLCcyclopentylacetamido)phenyl)- (215 nM): 89%, RT 3.71 min. N-hydroxy-2-phenylacetamide 8-112 N-(4-(2-(hydroxyamino)-2- LRMS (ESI): (calc.)374.43238, (found) 375 [M + H], HPLC oxo-1-phenylethyl)phenyl)- (215nM): 98%, RT 3.74 min. 2,3-dimethylbenzamide 8-1132-(3-(allylamino)phenyl)-N- LRMS (ESI): (calc.) 282.33702, (found) 283[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 100%, RT 3.11 min.8-114 2-(4-(3,4- LRMS (ESI): (calc.) 392.44766, (found) 393 [M + H],HPLC dimethoxybenzylamino)phenyl)- (215 nM): 100%, RT 3.39 min.N-hydroxy-2- phenylacetamide 8-115 2-(4-(2,4- LRMS (ESI): (calc.)401.28582, (found) 401 [M + H], HPLC dichlorobenzylamino)phenyl)- (215nM): 91%, RT 4.4 min. N-hydroxy-2- phenylacetamide 8-116 2-(3- LRMS(ESI): (calc.) 291.34378, (found) 292 [M + H], HPLC(cyclopropylethynyl)phenyl)- (215 nM): 91%, RT 3.98 min. N-hydroxy-2-phenylacetamide 8-117 N-hydroxy-2-(3-(pent-1- LRMS (ESI): (calc.)293.35966, (found) 294 [M + H], HPLC ynyl)phenyl)-2- (215 nM): 93%, RT4.18 min. phenylacetamide 8-118 N-hydroxy-2-(3-(pent-1- LRMS (ESI):(calc.) 293.35966, (found) 296 [M + H], HPLC ynyl)phenyl)-2- (215 nM):100%, RT 4.33 min. phenylacetamide 8-119 N-hydroxy-2-(3-(3- LRMS (ESI):(calc.) 295.33248, (found) 296 [M + H], HPLC methoxyprop-1-ynyl)phenyl)-(215 nM): 100%, RT 3.6 min. 2-phenylacetamide 8-1202-(3-(hex-1-ynyl)phenyl)-N- LRMS (ESI): (calc.) 307.38624, (found) 308[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 93%, RT 4.41 min.8-121 N-hydroxy-2-(3-(4- LRMS (ESI): (calc.) 307.38624, (found) 308 [M +H], HPLC methylpent-1-ynyl)phenyl)-2- (215 nM): 91%, RT 4.38 min.phenylacetamide 8-122 2-(3-(3,3-dimethylbut-1- LRMS (ESI): (calc.)307.38624, (found) 308 [M + H], HPLC ynyl)phenyl)-N-hydroxy-2- (215 nM):93%, RT 4.34 min. phenylacetamide 8-123 N-hydroxy-2-phenyl-2-(3- LRMS(ESI): (calc.) 328.36394, (found) 329 [M + H], HPLC (pyridin-2- (215nM): 85%, RT 3.55 min. ylethynyl)phenyl)acetamide 8-124 2-(3- LRMS(ESI): (calc.) 333.42352, (found) 334 [M + H], HPLC(cyclohexylethynyl)phenyl)- (215 nM): 94%, RT 4.67 min. N-hydroxy-2-phenylacetamide 8-125 2-(3- LRMS (ESI): (calc.) 333.42352, (found) 334[M + H], HPLC (cyclohexylethynyl)phenyl)- (215 nM): 94%, RT 4.67 min.N-hydroxy-2- phenylacetamide 8-126 N-hydroxy-2-(3-(oct-1- LRMS (ESI):(calc.) 335.4394, (found) 336 [M + H], HPLC ynyl)phenyl)-2- (215 nM):93%, RT 4.89 min. phenylacetamide 8-127 2-(3-(3-tert-butoxyprop-1- LRMS(ESI): (calc.) 337.41222, (found) 675 [2M + H],ynyl)phenyl)-N-hydroxy-2- HPLC (215 nM): 91%, RT 4.09 min.phenylacetamide 8-128 2-(3-(3-cyclohexylprop-1- LRMS (ESI): (calc.)347.4501, (found) 348 [M + H], HPLC ynyl)phenyl)-N-hydroxy-2- (215 nM):92%, RT 4.89 min. phenylacetamide 8-129 N-hydroxy-2-phenyl-2-(3-(4- LRMS(ESI): (calc.) 355.42904, (found) 356 [M + H], HPLC phenylbut-1- (215nM): 89%, RT 4.44 min. ynyl)phenyl)acetamide 8-130 2-(3-((4- LRMS (ESI):(calc.) 355.42904, (found) 356 [M + H], HPLCethylphenyl)ethynyl)phenyl)- (215 nM): 89%, RT 4.75 min. N-hydroxy-2-phenylacetamide 8-131 N-hydroxy-2-(3-((4- LRMS (ESI): (calc.) 357.40186,(found) 358 [M + H], HPLC methoxyphenyl)ethynyl)phenyl)- (215 nM): 100%,RT 4.29 min. 1H NMR (250 MHz, MeOD) 2-phenylacetamide d ppm 7.17-7.50(11H, m), 6.92 (2H, d, J = 9.14 Hz), 4.79 (1H, s), 3.81 (3H, s) 8-132N-hydroxy-2-(3-((3- LRMS (ESI): (calc.) 357.40186, (found) 358 [M + H],HPLC methoxyphenyl)ethynyl)phenyl)- (215 nM): 90%, RT 4.33 min.2-phenylacetamide 8-133 2-(3-((2,4- LRMS (ESI): (calc.) 363.3568064,(found) 364 [M + H], difluorophenyl)ethynyl)phenyl)- HPLC (215 nM): 90%,RT 4.37 min. N-hydroxy-2- phenylacetamide 8-134N-hydroxy-2-phenyl-2-(3-((4- LRMS (ESI): (calc.) 385.45502, (found) 386[M + H], HPLC propoxyphenyl)ethynyl)phenyl)acetamide (215 nM): 94%, RT4.77 min. 8-135 N-hydroxy-2-phenyl-2-(3-((2- LRMS (ESI): (calc.)395.3738496, (found) 396 [M + H],(trifluoromethyl)phenyl)ethynyl)phenyl)acetamide HPLC (215 nM): 93%, RT4.5 min. 8-136 N-hydroxy-2-phenyl-2-(3-((3- LRMS (ESI): (calc.)395.3738496, (found) 396 [M + H],(trifluoromethyl)phenyl)ethynyl)phenyl)acetamide HPLC (215 nM): 100%, RT4.66 min. 8-138 2-(4- LRMS (ESI): (calc.) 291.34378, (found) 292 [M +H], HPLC (cyclopropylethynyl)phenyl)- (215 nM): 90%, RT 3.99 min.N-hydroxy-2- phenylacetamide 8-140 (E)—N-hydroxy-2-(4-(pent-1- LRMS(ESI): (calc.) 295.38, (found) 296 [M + H], HPLC enyl)phenyl)-2- (215nM): 100%, RT 4.37 min. 1H NMR (250 MHz, MeOD) phenylacetamide d ppm7.00-7.42 (9H, m), 5.98-6.46 (2H, m), 4.75 (1H, s), 2.17 (2H, q),1.35-1.62 (2H, m), 0.95 (3H, t, J = 7.46 Hz) 8-141 N-hydroxy-2-(4-(3-LRMS (ESI): (calc.) 295.33248, (found) 296 [M + H], HPLCmethoxyprop-1-ynyl)phenyl)- (215 nM): 89%, RT 3.6 min. 2-phenylacetamide8-142 2-(4-(hex-1-ynyl)phenyl)-N- LRMS (ESI): (calc.) 307.38624, (found)308 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 90%, RT 4.43 min.8-143 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 307.38624, (found) 308 [M +H], HPLC methylpent-1-ynyl)phenyl)-2- (215 nM): 92%, RT 4.41 min.phenylacetamide 8-144 2-(4-(3,3-dimethylbut-1- LRMS (ESI): (calc.)307.38624, (found) 308 [M + H], HPLC ynyl)phenyl)-N-hydroxy-2- (215 nM):90%, RT 4.37 min. phenylacetamide 8-145 2-(4- LRMS (ESI): (calc.)319.39694, (found) 320 [M + H], HPLC (cyclopentylethynyl)phenyl)- (215nM): 100%, RT 4.48 min. N-hydroxy-2- phenylacetamide 8-146N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 328.36394, (found) 329 [M +H], HPLC (pyridin-2- (215 nM): 100%, RT 3.52 min.ylethynyl)phenyl)acetamide 8-147 2-(4- LRMS (ESI): (calc.) 333.42352,(found) 334 [M + H], HPLC (cyclohexylethynyl)phenyl)- (215 nM): 95%, RT4.7 min. 1H NMR (250 MHz, MeOD) d N-hydroxy-2- ppm 7.11-7.36 (9H, m),4.74 (1H, s), 2.39-2.65 (1H, m), phenylacetamide 1.62-1.92 (4H, m),1.22-1.58 (6H, m) 8-148 2-(4- LRMS (ESI): (calc.), (found) [M + H], HPLC(215 nM): %, (cyclohexylethynyl)phenyl)- RT min. N-hydroxy-2-phenylacetamide 8-149 N-hydroxy-2-(4-(oct-1- LRMS (ESI): (calc.)335.4394, (found) 336 [M + H], HPLC ynyl)phenyl)-2- (215 nM): 94%, RT4.9 min. phenylacetamide 8-150 2-(4-(3-(diethylamino)prop-1- LRMS (ESI):(calc.) 336.42746, (found) 337 [M + H], HPLC ynyl)phenyl)-N-hydroxy-2-(215 nM): 90%, RT 2.67 min. 1H NMR (250 MHz, MeOD) phenylacetamide d ppm7.10-7.42 (9H, m), 4.75 (1H, s), 3.64 (2H, s), 2.66 (4H, q, J = 7.11Hz), 1.10 (6H, t, J = 7.16 Hz) 8-151 2-(4-(3-tert-butoxyprop-1- LRMS(ESI): (calc.) 337.41222, (found) 338 [M + H], HPLCynyl)phenyl)-N-hydroxy-2- (215 nM): 100%, RT 4.09 min. phenylacetamide8-152 N-hydroxy-2-phenyl-2-(4-(p- LRMS (ESI): (calc.) 341.40246, (found)342 [M + H], HPLC tolylethynyl)phenyl)acetamide (215 nM): 100%, RT 4.54min. 1H NMR (250 MHz, MeOD) d ppm 7.23-7.48 (11H, m), 7.17 (2H, d, J =7.61 Hz), 4.79 (1H, s), 2.34 (3H, s) 8-153 2-(4-((2- LRMS (ESI): (calc.)345.3663432, (found) 346 [M + H], fluorophenyl)ethynyl)phenyl)- HPLC(215 nM): 88%, RT 4.3 min. N-hydroxy-2- phenylacetamide 8-1542-(4-(3-cyclohexylprop-1- LRMS (ESI): (calc.) 347.4501, (found) 348 [M +H], HPLC ynyl)phenyl)-N-hydroxy-2- (215 nM): 94%, RT 4.92 min.phenylacetamide 8-155 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.)355.42904, (found) 356 [M + H], HPLC phenylbut-1- (215 nM): 94%, RT 4.46min. ynyl)phenyl)acetamide 8-156 2-(4-((4- LRMS (ESI): (calc.)355.42904, (found) 356 [M + H], HPLC ethylphenyl)ethynyl)phenyl)- (215nM): 94%, RT 4.74 min. N-hydroxy-2- phenylacetamide 8-157N-hydroxy-2-(4-((4- LRMS (ESI): (calc.) 357.40186, (found) 358 [M + H],HPLC methoxyphenyl)ethynyl)phenyl)- (215 nM): 89%, RT 4.29 min.2-phenylacetamide 8-158 N-hydroxy-2-(4-((3- LRMS (ESI): (calc.)357.40186, (found) 358 [M + H], HPLC methoxyphenyl)ethynyl)phenyl)- (215nM): 91%, RT 4.33 min. 2-phenylacetamide 8-159 2-(4-((2- LRMS (ESI):(calc.) 361.82094, (found) 362 [M + H], HPLCchlorophenyl)ethynyl)phenyl)- (215 nM): 88%, RT 4.48 min. N-hydroxy-2-phenylacetamide 8-160 2-(4-((4- LRMS (ESI): (calc.) 361.82094, (found)362 [M + H], HPLC chlorophenyl)ethynyl)phenyl)- (215 nM): 86%, RT 4.62min. N-hydroxy-2- phenylacetamide 8-161 2-(4-((2,4- LRMS (ESI): (calc.)363.3568064, (found) 364 [M + H], difluorophenyl)ethynyl)phenyl)- HPLC(215 nM): 94%, RT 4.38 min. N-hydroxy-2- phenylacetamide 8-162N-hydroxy-2-phenyl-2-(4-((4- LRMS (ESI): (calc.) 395.3738496, (found)396 [M + H], (trifluoromethyl)phenyl)ethynyl)phenyl)acetamide HPLC (215nM): 94%, RT 4.67 min. 1H NMR (250 MHz, MeOD) d ppm 7.68 (4H, s),7.46-7.55 (2H, m), 7.25-7.41 (7H, m), 4.81 (1H, s) 8-163N-hydroxy-2-phenyl-2-(4-((2- LRMS (ESI): (calc.) 395.3738496, (found)396 [M + H], (trifluoromethyl)phenyl)ethynyl)phenyl)acetamide HPLC (215nM): 90%, RT 4.52 min. 8-164 N-hydroxy-2-phenyl-2-(4-((3- LRMS (ESI):(calc.) 395.3738496, (found) 396 [M + H],(trifluoromethyl)phenyl)ethynyl)phenyl)acetamide HPLC (215 nM): 94%, RT4.67 min. 8-166 2-(4′-(ethylsulfonyl)biphenyl- LRMS (ESI): (calc.)395.47144, (found) 396 [M + H], HPLC 3-yl)-N-hydroxy-2- (215 nM): 93%,RT 3.66 min. 1H NMR (250 MHz, MeOD) phenylacetamide d ppm 7.91 (2H, m, J= 8.53 Hz), 7.78 (2H, m, J = 8.22 Hz), 7.65 (1H, s), 7.50-7.59 (1H, m),7.17-7.46 (7H, m), 4.87 (1H, s-masked by H2O), 3.19 (2H, q, J = 7.31Hz), 1.19 (3H, t, J = 7.46 Hz) 8-167 N-hydroxy-2-(4′-(N- LRMS (ESI):(calc.) 396.4595, (found) 397 [M + H], HPLC methylsulfamoyl)biphenyl-3-(215 nM): 92%, RT 3.55 min. yl)-2-phenylacetamide 8-168 N-hydroxy-2-(3′-LRMS (ESI): (calc.) 396.4595, (found) 397 [M + H], HPLC(methylsulfonamido)biphenyl- (215 nM): 100%, RT 4.33 min.3-yl)-2-phenylacetamide 8-169 N-hydroxy-2-(4′- LRMS (ESI): (calc.)396.4595, (found) 397 [M + H], HPLC (methylsulfonamido)biphenyl- (215nM): 100%, RT 3.55 min. 3-yl)-2-phenylacetamide 8-170 2-(3′-chloro-4′-LRMS (ESI): (calc.) 405.7975096, (found) 406 [M + H],(trifluoromethyl)biphenyl-3- HPLC (215 nM): 93%, RT 4.57 min.yl)-N-hydroxy-2- phenylacetamide 8-171 N-hydroxy-2-phenyl-2-m- LRMS(ESI): (calc.) 241.2851, (found) 242 [M + H], HPLC tolylacetamide (215nM): 93%, RT 3.54 min. 8-172 2-(3-butylphenyl)-N- LRMS (ESI): (calc.)283.36484, (found) 284 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):94%, RT 4.2 min. 8-173 N-hydroxy-2-(3- LRMS (ESI): (calc.) 283.36484,(found) 284 [M + H], HPLC isobutylphenyl)-2- (215 nM): 88%, RT 4.17 min.phenylacetamide 8-174 2-(3-cyclopentylphenyl)-N- LRMS (ESI): (calc.)295.37554, (found) 296 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):94%, RT 4.22 min. 8-175 N-hydroxy-2-phenyl-2-(3- LRMS (ESI): (calc.)304.34254, (found) 305 [M + H], HPLC (pyridin-3- (215 nM): 97%, RT 2.65min. yl)phenyl)acetamide 8-176 N-hydroxy-2-phenyl-2-(3- LRMS (ESI):(calc.) 305.3306, (found) 306 [M + H], HPLC (pyrimidin-5- (215 nM): 93%,RT 3.13 min. yl)phenyl)acetamide 8-177 N-hydroxy-2-phenyl-2-(3- LRMS(ESI): (calc.) 309.3822, (found) 310 [M + H], HPLC (thiophen-3- (215nM): 91%, RT 3.9 min. yl)phenyl)acetamide 8-178 2-(3-hexylphenyl)-N-LRMS (ESI): (calc.) 311.418, (found) 312 [M + H], HPLChydroxy-2-phenylacetamide (215 nM): 92%, RT 4.67 min. 8-180N-hydroxy-2-(4′- LRMS (ESI): (calc.) 317.38106, (found) 318 [M + H],HPLC methylbiphenyl-3-yl)-2- (215 nM): 93%, RT 4.22 min. 1H NMR (250MHz, MeOD) phenylacetamide d ppm 7.57 (1H, s), 7.41-7.52 (3H, m),7.13-7.41 (9H, m), 4.85 (1H, s), 2.35 (3H, s) 8-181 N-hydroxy-2-(3′-LRMS (ESI): (calc.) 317.38106, (found) 318 [M + H], HPLCmethylbiphenyl-3-yl)-2- (215 nM): 87%, RT 4.21 min. phenylacetamide8-182 N-hydroxy-2-(2′- LRMS (ESI): (calc.) 317.38106, (found) 318 [M +H], HPLC methylbiphenyl-3-yl)-2- (215 nM): 93%, RT 4.17 min.phenylacetamide 8-183 2-(4′-fluorobiphenyl-3-yl)-N- LRMS (ESI): (calc.)321.3449432, (found) 322 [M + H], hydroxy-2-phenylacetamide HPLC (215nM): 92%, RT 4.06 min. 8-184 2-(3′-fluorobiphenyl-3-yl)-N- LRMS (ESI):(calc.) 321.3449432, (found) 322 [M + H], hydroxy-2-phenylacetamide HPLC(215 nM): 93%, RT 4.06 min. 8-185 2-(2′-fluorobiphenyl-3-yl)-N- LRMS(ESI): (calc.) 321.3449432, (found) 322 [M + H],hydroxy-2-phenylacetamide HPLC (215 nM): 92%, RT 4.01 min. 8-1862-(3-(2-fluoropyridin-3- LRMS (ESI): (calc.) 322.3330032, (found) 323[M + H], yl)phenyl)-N-hydroxy-2- HPLC (215 nM): 100%, RT 3.6 min.phenylacetamide 8-187 2-(3-(6-fluoropyridin-3- LRMS (ESI): (calc.)322.3330032, (found) 361 [M + H], yl)phenyl)-N-hydroxy-2- HPLC (215 nM):93%, RT 3.37 min. phenylacetamide 8-188 2-(3-(3,5-dimethylisoxazol-4-LRMS (ESI): (calc.) 322.35782, (found) 323 [M + H], HPLCyl)phenyl)-N-hydroxy-2- (215 nM): 92%, RT 3.58 min. phenylacetamide8-189 N-hydroxy-2-(3-(4- LRMS (ESI): (calc.) 323.40878, (found) 324 [M +H], HPLC methylthiophen-3-yl)phenyl)- (215 nM): 90%, RT 4.08 min.2-phenylacetamide 8-190 2-(2′-cyanobiphenyl-3-yl)-N- LRMS (ESI): (calc.)328.36394, (found) 329 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):100%, RT 3.77 min. 8-191 (E)—N-hydroxy-2-phenyl-2- LRMS (ESI): (calc.)329.39176, (found) 330 [M + H], HPLC (3-styrylphenyl)acetamide (215 nM):92%, RT 4.26 min. 8-193 N-hydroxy-2-(4′- LRMS (ESI): (calc.) 333.38046,(found) 334 [M + H], HPLC methoxybiphenyl-3-yl)-2- (215 nM): 91%, RT3.98 min. phenylacetamide 8-194 N-hydroxy-2-(3′- LRMS (ESI): (calc.)333.38046, (found) 334 [M + H], HPLC methoxybiphenyl-3-yl)-2- (215 nM):92%, RT 4 min. phenylacetamide 8-195 N-hydroxy-2-(2′- LRMS (ESI):(calc.) 333.38046, (found) 334 [M + H], HPLC methoxybiphenyl-3-yl)-2-(215 nM): 93%, RT 3.99 min. phenylacetamide 8-196 N-hydroxy-2-(4′- LRMS(ESI): (calc.) 333.38046, (found) 334 [M + H], HPLC(hydroxymethyl)biphenyl-3- (215 nM): 91%, RT 3.45 min.yl)-2-phenylacetamide 8-197 N-hydroxy-2-(3′- LRMS (ESI): (calc.)333.38046, (found) 334 [M + H], HPLC (hydroxymethyl)biphenyl-3- (215nM): 90%, RT 3.49 min. yl)-2-phenylacetamide 8-198 N-hydroxy-2-(3-(6-LRMS (ESI): (calc.) 334.36852, (found) 335 [M + H], HPLCmethoxypyridin-3-yl)phenyl)- (215 nM): 94%, RT 3.7 min.2-phenylacetamide 8-199 2-(4′-fluoro-2′- LRMS (ESI): (calc.)335.3715232, (found) 336 [M + H], methylbiphenyl-3-yl)-N- HPLC (215 nM):92%, RT 4.22 min. hydroxy-2-phenylacetamide 8-2002-(3′-chlorobiphenyl-3-yl)-N- LRMS (ESI): (calc.) 337.79954, (found) 338[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 93%, RT 4.27 min.8-201 2-(3-(6-chloropyridin-3- LRMS (ESI): (calc.) 338.7876, (found) 339[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 100%, RT 3.76 min.phenylacetamide 8-203 2-(2′,5′-difluorobiphenyl-3- LRMS (ESI): (calc.)339.3354064, (found) 340 [M + H], yl)-N-hydroxy-2- HPLC (215 nM): 91%,RT 4.06 min. phenylacetamide 8-204 2-(2′,4′-difluorobiphenyl-3- LRMS(ESI): (calc.) 339.3354064, (found) 340 [M + H], yl)-N-hydroxy-2- HPLC(215 nM): 93%, RT 4.09 min. phenylacetamide 8-2052-(3′,4′-difluorobiphenyl-3- LRMS (ESI): (calc.) 339.3354064, (found)340 [M + H], yl)-N-hydroxy-2- HPLC (215 nM): 94%, RT 4.14 min.phenylacetamide 8-206 2-(3-(5-chlorothiophen-2- LRMS (ESI): (calc.)343.82726, (found) 344 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):94%, RT 4.31 min. 1H NMR (250 MHz, MeOD) phenylacetamide d ppm 7.52-7.58(1H, m), 7.42-7.50 (1H, m), 7.24-7.40 (7H, m), 7.17 (1H, d, J = 3.65Hz), 6.95 (1H, d, J = 3.96 Hz), 4.82 (1H, s) 8-207 N-hydroxy-2-(4′- LRMS(ESI): (calc.) 345.43422, (found) 346 [M + H], HPLCisopropylbiphenyl-3-yl)-2- (215 nM): 92%, RT 4.6 min. phenylacetamide8-208 N-hydroxy-2-phenyl-2-(4′- LRMS (ESI): (calc.) 345.43422, (found)346 [M + H], HPLC propylbiphenyl-3- (215 nM): 91%, RT 4.65 min.yl)acetamide 8-210 2-(3′- LRMS (ESI): (calc.) 346.42228, (found) 347[M + H], HPLC (dimethylamino)biphenyl-3- (215 nM): 90%, RT 3.35 min.yl)-N-hydroxy-2- phenylacetamide 8-212 2-(3-(benzo[d][1,3]dioxol-5- LRMS(ESI): (calc.) 347.36398, (found) 348 [M + H], HPLCyl)phenyl)-N-hydroxy-2- (215 nM): 91%, RT 3.94 min. phenylacetamide8-213 2-(2′-ethoxybiphenyl-3-yl)-N- LRMS (ESI): (calc.) 347.40704,(found) 348 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 92%, RT4.18 min. 8-214 2-(3′-ethoxybiphenyl-3-yl)-N- LRMS (ESI): (calc.)347.40704, (found) 348 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):100%, RT 4.22 min. 8-215 2-(4′-ethoxybiphenyl-3-yl)-N- LRMS (ESI):(calc.) 347.40704, (found) 348 [M + H], HPLC hydroxy-2-phenylacetamide(215 nM): 100%, RT 4.21 min. 8-216 N-hydroxy-2-(4′- LRMS (ESI): (calc.)347.40704, (found) 348 [M + H], HPLC (methoxymethyl)biphenyl-3- (215nM): 94%, RT 3.55 min. yl)-2-phenylacetamide 8-217 N-hydroxy-2-(4′- LRMS(ESI): (calc.) 349.44606, (found) 350 [M + H], HPLC(methylthio)biphenyl-3-yl)-2- (215 nM): 100%, RT 4.23 min. 1H NMR (250MHz, MeOD) phenylacetamide d ppm 7.56-7.63 (1H, m), 7.44-7.55 (3H, m),7.19-7.42 (9H, m), 4.85 (1H, s), 2.48 (3H, s) 8-218 N-hydroxy-2-(3′-LRMS (ESI): (calc.) 349.44606, (found) 350 [M + H], HPLC(methylthio)biphenyl-3-yl)-2- (215 nM): 100%, RT 4.23 min.phenylacetamide 8-220 2-(5′-fluoro-2′- LRMS (ESI): (calc.) 351.3709232,(found) 352 [M + H], methoxybiphenyl-3-yl)-N- HPLC (215 nM): 93%, RT4.05 min. hydroxy-2-phenylacetamide 8-221 2-(3′-fluoro-4′- LRMS (ESI):(calc.) 351.3709232, (found) 352 [M + H], methoxybiphenyl-3-yl)-N- HPLC(215 nM): 93%, RT 4.01 min. hydroxy-2-phenylacetamide 8-2222-(3′-chloro-4′- LRMS (ESI): (calc.) 351.82612, (found) 352 [M + H],HPLC methylbiphenyl-3-yl)-N- (215 nM): 100%, RT 4.09 min.hydroxy-2-phenylacetamide 8-223 N-hydroxy-2-phenyl-2-(3- LRMS (ESI):(calc.) 354.40122, (found) 355 [M + H], HPLC (quinolin-8- (215 nM): 89%,RT 3.36 min. yl)phenyl)acetamide 8-224 N-hydroxy-2-(3-(isoquinolin- LRMS(ESI): (calc.) 354.40122, (found) 355 [M + H], HPLC 5-yl)phenyl)-2- (215nM): 90%, RT 2.95 min. phenylacetamide 8-226 N-hydroxy-2-phenyl-2-(3-LRMS (ESI): (calc.) 354.40122, (found) 355 [M + H], HPLC (quinolin-3-(215 nM): 100%, RT 3.4 min. yl)phenyl)acetamide 8-228 2-(3′-chloro-4′-LRMS (ESI): (calc.) 355.7900032, (found) 356 [M + H],fluorobiphenyl-3-yl)-N- HPLC (215 nM): 92%, RT 4.31 min.hydroxy-2-phenylacetamide 8-229 2-(4′-chloro-3′- LRMS (ESI): (calc.)355.7900032, (found) 356 [M + H], fluorobiphenyl-3-yl)-N- HPLC (215 nM):93%, RT 4.33 min. hydroxy-2-phenylacetamide 8-231 2-(4′-chloro-2′- LRMS(ESI): (calc.) 355.7900032, (found) 356 [M + H], fluorobiphenyl-3-yl)-N-HPLC (215 nM): 100%, RT 4.33 min. hydroxy-2-phenylacetamide 8-232N-hydroxy-2-(3-(1-methyl- LRMS (ESI): (calc.) 356.4171, (found) 357 [M +H], HPLC 1H-indol-5-yl)phenyl)-2- (215 nM): 91%, RT 3.53 min.phenylacetamide 8-233 2-(3-(benzo[b]thiophen-2- LRMS (ESI): (calc.)359.44088, (found) 360 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):92%, RT 4.4 min. phenylacetamide 8-234 2-(3-(benzo[b]thiophen-3- LRMS(ESI): (calc.) 359.44088, (found) 360 [M + H], HPLCyl)phenyl)-N-hydroxy-2- (215 nM): 100%, RT 4.35 min. phenylacetamide8-235 2-(3′-acetamidobiphenyl-3- LRMS (ESI): (calc.) 360.4058, (found)361 [M + H], HPLC yl)-N-hydroxy-2- (215 nM): 90%, RT 3.5 min.phenylacetamide 8-236 3′-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.)360.4058, (found) 361 [M + H], HPLC 1-phenylethyl)-N- (215 nM): 93%, RT3.37 min. methylbiphenyl-4- carboxamide 8-237 2-(3-(2,3- LRMS (ESI):(calc.) 361.39056, (found) 362 [M + H], HPLC dihydrobenzo[b][1,4]dioxin-(215 nM): 89%, RT 3.93 min. 6-yl)phenyl)-N-hydroxy-2- phenylacetamide8-239 N-hydroxy-2-(4′- LRMS (ESI): (calc.) 361.43362, (found) 362 [M +H], HPLC isopropoxybiphenyl-3-yl)-2 (215 nM): 92%, RT 4.36 min.phenylacetamide 8-241 N-hydroxy-2-(4′-(3- LRMS (ESI): (calc.) 361.43362,(found) 362 [M + H], HPLC hydroxypropyl)biphenyl-3- (215 nM): 91%, RT4.06 min. yl)-2-phenylacetamide 8-242 2-(4′-acetamidobiphenyl-3- LRMS(ESI): (calc.) 360.4058, (found) 361 [M + H], HPLC yl)-N-hydroxy-2- (215nM): 87%, RT 3.46 min. phenylacetamide 8-243 (E)-2-(3-(4- LRMS (ESI):(calc.) 363.83682, (found) 364 [M + H], HPLC chlorostyryl)phenyl)-N-(215 nM): 89%, RT 4.55 min. hydroxy-2-phenylacetamide 8-245N-hydroxy-2-(3-(4- LRMS (ESI): (calc.) 367.43974, (found) 368 [M + H],HPLC methylnaphthalen-1- (215 nM): 88%, RT 4.56 min.yl)phenyl)-2-phenylacetamide 8-247 2-(5′-chloro-2′- LRMS (ESI): (calc.)367.82552, (found) 368 [M + H], HPLC methoxybiphenyl-3-yl)-N- (215 nM):90%, RT 4.25 min. hydroxy-2-phenylacetamide 8-248 2-(3′-chloro-4′- LRMS(ESI): (calc.) 367.82552, (found) 368 [M + H], HPLCmethoxybiphenyl-3-yl)-N- (215 nM): 100%, RT 4.18 min.hydroxy-2-phenylacetamide 8-249 2-(2′,5′-difluoro-4′- LRMS (ESI):(calc.) 369.3613864, (found) 370 [M + H], methoxybiphenyl-3-yl)-N- HPLC(215 nM): 100%, RT 4.08 min. hydroxy-2-phenylacetamide 8-2512-(4′-(2-cyanopropan-2- LRMS (ESI): (calc.) 370.44368, (found) 371 [M +H], HPLC yl)biphenyl-3-yl)-N-hydroxy- (215 nM): 100%, RT 4.12 min.2-phenylacetamide 8-252 N-hydroxy-2-phenyl-2-(3′- LRMS (ESI): (calc.)371.3524496, (found) 372 [M + H], (trifluoromethyl)biphenyl-3- HPLC (215nM): 94%, RT 4.35 min. yl)acetamide 1H NMR (250 MHz, MeOD) d ppm7.73-7.88 (2H, m), 7.57-7.68 (3H, m), 7.54 (1H, d, J = 7.61 Hz),7.17-7.47 (7H, m), 4.89 (1H, s-masked by H2O) 8-253N-hydroxy-2-phenyl-2-(4′- LRMS (ESI): (calc.) 371.3524496, (found) 372[M + H], (trifluoromethyl)biphenyl-3- HPLC (215 nM): 94%, RT 4.37 min.yl)acetamide 8-254 2-(4′- LRMS (ESI): (calc.) 374.43238, (found) 375[M + H], HPLC (acetamidomethyl)biphenyl- (215 nM): 93%, RT 4.79 min.3-yl)-N-hydroxy-2- phenylacetamide 8-255 3′-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 374.43238, (found) 375 [M + H], HPLC1-phenylethyl)-N,N- (215 nM): 91%, RT 3.53 min. dimethylbiphenyl-3-carboxamide 8-256 2-(3′- LRMS (ESI): (calc.) 374.43238, (found) 375 [M +H], HPLC (acetamidomethyl)biphenyl- (215 nM): 93%, RT 3.68 min.3-yl)-N-hydroxy-2- phenylacetamide 8-257 methyl 3′-(2-(hydroxyamino)-LRMS (ESI): (calc.) 376.4052, (found) 377 [M + H], HPLC 2-oxo-1- (215nM): 88%, RT 3.72 min. phenylethyl)biphenyl-4- ylcarbamate 8-258N-hydroxy-2-(4′- LRMS (ESI): (calc.) 377.49922, (found) 378 [M + H],HPLC (isopropylthio)biphenyl-3-yl)- (215 nM): 87%, RT 4.62 min.2-phenylacetamide 8-259 N-cyclopropyl-3′-(2- LRMS (ESI): (calc.)386.44308, (found) 387 [M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM):94%, RT 3.55 min. phenylethyl)biphenyl-4- carboxamide 8-260N-hydroxy-2-phenyl-2-(2′- LRMS (ESI): (calc.) 387.3518496, (found) 388[M + H], (trifluoromethoxy)biphenyl- HPLC (215 nM): 92%, RT 4.29 min.3-yl)acetamide 8-261 N-hydroxy-2-phenyl-2-(4′- LRMS (ESI): (calc.)387.3518496, (found) 388 [M + H], (trifluoromethoxy)biphenyl- HPLC (215nM): 93%, RT 4.44 min. 3-yl)acetamide 8-262 N-hydroxy-2-phenyl-2-(3′-LRMS (ESI): (calc.) 387.3518496, (found) 388 [M + H],(trifluoromethoxy)biphenyl- HPLC (215 nM): 91%, RT 4.42 min.3-yl)acetamide 8-263 N-hydroxy-2-(4′- LRMS (ESI): (calc.) 388.45896,(found) 389 [M + H], HPLC morpholinobiphenyl-3-yl)-2- (215 nM): 90%, RT4.08 min. phenylacetamide 8-264 N-hydroxy-2-phenyl-2-p- LRMS (ESI):(calc.) 241.2851, (found) 242 [M + H], HPLC tolylacetamide (215 nM):95%, RT 3.55 min. 1H NMR (250 MHz, MeOD) d ppm 7.01-7.38 (9H, m), 4.74(1H, s), 2.30 (3H, s) 8-265 2-(4-ethylphenyl)-N-hydroxy- LRMS (ESI):(calc.) 255.31168, (found) 256 [M + H], HPLC 2-phenylacetamide (215 nM):95%, RT 3.78 min. 8-266 2-(4-butylphenyl)-N- LRMS (ESI): (calc.)283.36484, (found) 284 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):93%, RT 4.25 min. 8-267 N-hydroxy-2-(4- LRMS (ESI): (calc.) 283.36484,(found) 284 [M + H], HPLC isobutylphenyl)-2- (215 nM): 92%, RT 4.21 min.phenylacetamide 8-268 2-(4-cyclopentylphenyl)-N- LRMS (ESI): (calc.)295.37554, (found) 296 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):92%, RT 4.27 min. 8-269 2-(4-hexylphenyl)-N- LRMS (ESI): (calc.)311.418, (found) 312 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM):94%, RT 4.78 min, 1H NMR (250 MHz, MeOD) d ppm 7.16-7.36 (7H, m), 7.11(2H, d), 4.75 (1H, s), 2.34-2.71 (2H, m), 1.47-1.70 (2H, m), 1.15-1.43(6H, m), 0.89 (3H, t) 8-270 N-hydroxy-2-(4′- LRMS (ESI): (calc.)317.38106, (found) 318 [M + H], HPLC methylbiphenyl-4-yl)-2- (215 nM):89%, RT 4.24 min. phenylacetamide 8-271 N-hydroxy-2-(2′- LRMS (ESI):(calc.) 317.38106, (found) 318 [M + H], HPLC methylbiphenyl-4-yl)-2-(215 nM): 100%, RT 4.19 min. phenylacetamide 8-2722-(3′-fluorobiphenyl-4-yl)-N- LRMS (ESI): (calc.) 321.3449432, (found)322 [M + H], hydroxy-2-phenylacetamide HPLC (215 nM): 90%, RT 4.08 min.8-273 2-(2′-fluorobiphenyl-4-yl)-N- LRMS (ESI): (calc.) 321.3449432,(found) 322 [M + H], hydroxy-2-phenylacetamide HPLC (215 nM): 87%, RT4.04 min. 8-274 2-(4-(2-fluoropyridin-3- LRMS (ESI): (calc.)322.3330032, (found) 323 [M + H], yl)phenyl)-N-hydroxy-2- HPLC (215 nM):100%, RT 3.55 min. phenylacetamide 8-275 2-(4-(6-fluoropyridin-3- LRMS(ESI): (calc.) 322.3330032, (found) 323 [M + H], yl)phenyl)-N-hydroxy-2-HPLC (215 nM): 100%, RT 3.61 min. phenylacetamide 8-2762-(4-(3,5-dimethylisoxazol-4- LRMS (ESI): (calc.) 322.35782, (found) 323[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 100%, RT 3.55 min.phenylacetamide 8-277 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 323.40878,(found) 324 [M + H], HPLC methylthiophen-3-yl)phenyl)- (215 nM): 90%, RT4.1 min. 2-phenylacetamide 8-278 2-(2′-cyanobiphenyl-4-yl)-N- LRMS(ESI): (calc.) 328.36394, (found) 329 [M + H], HPLChydroxy-2-phenylacetamide (215 nM): 88%, RT 3.81 min. 8-279N-hydroxy-2-(3′- LRMS (ESI): (calc.) 333.38046, (found) 334 [M + H],HPLC methoxybiphenyl-4-yl)-2- (215 nM): 92%, RT 4.02 min.phenylacetamide 8-280 N-hydroxy-2-(2′- LRMS (ESI): (calc.) 333.38046,(found) 334 [M + H], HPLC methoxybiphenyl-4-yl)-2- (215 nM): 95%, RT4.02 min. 1H NMR (250 MHz, MeOD) phenylacetamide d ppm 7.16-7.50 (11H,m), 6.83-7.10 (2H, m), 4.82 (1H, s), 3.75 (3H, s) 8-281 N-hydroxy-2-(3′-LRMS (ESI): (calc.) 333.38046, (found) 334 [M + H], HPLC(hydroxymethyl)biphenyl-4- (215 nM): 88%, RT 3.46 min.yl)-2-phenylacetamide 8-282 N-hydroxy-2-(4-(6- LRMS (ESI): (calc.)334.36852, (found) 335 [M + H], HPLC methoxypyridin-3-yl)phenyl)- (215nM): 86%, RT 3.72 min. 2-phenylacetamide 8-283 2-(4′-fluoro-2′- LRMS(ESI): (calc.) 335.3715232, (found) 336 [M + H], methylbiphenyl-4-yl)-N-HPLC (215 nM): 91%, RT 4.24 min. hydroxy-2-phenylacetamide 8-2842-(3′-chlorobiphenyl-4-yl)-N- LRMS (ESI): (calc.) 337.79954, (found) 338[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 93%, RT 4.29 min.8-285 2-(4-(6-chloropyridin-3- LRMS (ESI): (calc.) 338.7876, (found) 339[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 90%, RT 3.76 min.phenylacetamide 8-286 2-(2′,5′-difluorobiphenyl-4- LRMS (ESI): (calc.)339.3354064, (found) 340 [M + H], yl)-N-hydroxy-2- HPLC (215 nM): 89%,RT 4.1 min, 1H NMR (250 MHz, phenylacetamide MeOD) d ppm 7.05-7.53 (12H,m), 4.85 (1H, s) 8-287 2-(2′,4′-difluorobiphenyl-4- LRMS (ESI): (calc.)339.3354064, (found) 340 [M + H], yl)-N-hydroxy-2- HPLC (215 nM): 89%,RT 4.12 min. phenylacetamide 8-288 2-(4-(5-chlorothiophen-2- LRMS (ESI):(calc.) 343.82726, (found) 344 [M + H], HPLC yl)phenyl)-N-hydroxy-2-(215 nM): 98%, RT 4.37 min. phenylacetamide 8-289 N-hydroxy-2-(4′- LRMS(ESI): (calc.) 345.43422, (found) 346 [M + H], HPLCisopropylbiphenyl-4-yl)-2- (215 nM): 100%, RT 4.64 min. phenylacetamide8-290 N-hydroxy-2-phenyl-2-(4′- LRMS (ESI): (calc.) 345.43422, (found)346 [M + H], HPLC propylbiphenyl-4- (215 nM): 93%, RT 4.69 min.yl)acetamide 8-291 2-(3′- LRMS (ESI): (calc.) 346.42228, (found) 347[M + H], HPLC (dimethylamino)biphenyl-4- (215 nM): 100%, RT 3.36 min.yl)-N-hydroxy-2- phenylacetamide 8-292 2-(4-(benzo[d][1,3]dioxol-5- LRMS(ESI): (calc.) 347.36398, (found) 348 [M + H], HPLCyl)phenyl)-N-hydroxy-2- (215 nM): 88%, RT 3.94 min. phenylacetamide8-293 (E)-2-(4-(4- LRMS (ESI): (calc.) 347.3822232, (found) 348 [M + H],fluorostyryl)phenyl)-N- HPLC (215 nM): 96%, RT 4.33 min.hydroxy-2-phenylacetamide 8-294 2-(2′-ethoxybiphenyl-4-yl)-N- LRMS(ESI): (calc.) 347.40704, (found) 348 [M + H], HPLChydroxy-2-phenylacetamide (215 nM): 91%, RT 4.21 min. 8-2952-(3′-ethoxybiphenyl-4-yl)-N- LRMS (ESI): (calc.) 347.40704, (found) 348[M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 100%, RT 4.24 min.8-296 2-(4′-ethoxybiphenyl-4-yl)-N- LRMS (ESI): (calc.) 347.40704,(found) 348 [M + H], HPLC hydroxy-2-phenylacetamide (215 nM): 94%, RT4.21 min. 8-297 N-hydroxy-2-(4′- LRMS (ESI): (calc.) 347.40704, (found)348 [M + H], HPLC (methoxymethyl)biphenyl-4- (215 nM): 92%, RT 3.94 min.yl)-2-phenylacetamide 8-298 N-hydroxy-2-(3′- LRMS (ESI): (calc.)349.44606, (found) 350 [M + H], HPLC (methylthio)biphenyl-4-yl)-2- (215nM): 100%, RT 4.26 min. phenylacetamide 8-299 2-(5′-fluoro-2′- LRMS(ESI): (calc.) 351.3709232, (found) 352 [M + H],methoxybiphenyl-4-yl)-N- HPLC (215 nM): 94%, RT 4.08 min. 1H NMR (250MHz, hydroxy-2-phenylacetamide MeOD) d ppm 7.16-7.49 (9H, m), 6.87-7.07(3H, m), 4.80 (1H, s), 3.70 (3H, s) 8-300 2-(3′-fluoro-4′- LRMS (ESI):(calc.) 351.3709232, (found) 352 [M + H], methoxybiphenyl-4-yl)-N- HPLC(215 nM): 100%, RT 4.02 min. 1H NMR (250 MHz, hydroxy-2-phenylacetamideMeOD) d ppm 7.46-7.61 (2H, m), 7.20-7.45 (9H, m), 7.00-7.20 (1H, m),4.81 (1H, s), 3.88 (3H, s) 8-301 2-(3′-chloro-4′- LRMS (ESI): (calc.)351.82612, (found) 352 [M + H], HPLC methylbiphenyl-4-yl)-N- (215 nM):92%, RT 4.52 min. hydroxy-2-phenylacetamide 8-302N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 354.40122, (found) 355 [M +H], HPLC (quinolin-8- (215 nM): 100%, RT 3.44 min. yl)phenyl)acetamide8-303 N-hydroxy-2-(4-(isoquinolin- LRMS (ESI): (calc.) 354.40122,(found) 355 [M + H], HPLC 5-yl)phenyl)-2- (215 nM): 86%, RT 2.93 min.phenylacetamide 8-304 2-(3′-chloro-4′- LRMS (ESI): (calc.) 355.7900032,(found) 356 [M + H], fluorobiphenyl-4-yl)-N- HPLC (215 nM): 87%, RT 4.33min. hydroxy-2-phenylacetamide 8-305 2-(4′-chloro-3′- LRMS (ESI):(calc.) 355.7900032, (found) 356 [M + H], fluorobiphenyl-4-yl)-N- HPLC(215 nM): 95%, RT 4.36 min. hydroxy-2-phenylacetamide 8-3062-(4′-chloro-2′- LRMS (ESI): (calc.) 355.7900032, (found) 356 [M + H],fluorobiphenyl-4-yl)-N- HPLC (215 nM): 93%, RT 4.36 min.hydroxy-2-phenylacetamide 8-307 N-hydroxy-2-(4-(1-methyl- LRMS (ESI):(calc.) 356.4171, (found) 357 [M + H], HPLC 1H-indol-5-yl)phenyl)-2-(215 nM): 100%, RT 4.13 min. phenylacetamide 8-3082-(4-(benzo[b]thiophen-2- LRMS (ESI): (calc.) 359.44088, (found) 360[M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM): 98%, RT 4.46 min.phenylacetamide 8-309 2-(4-(benzo[b]thiophen-3- LRMS (ESI): (calc.)359.44088, (found) 360 [M + H], HPLC yl)phenyl)-N-hydroxy-2- (215 nM):93%, RT 4.38 min. phenylacetamide 8-310 2-(3′-acetamidobiphenyl-4- LRMS(ESI): (calc.) 360.4058, (found) 361 [M + H], HPLC yl)-N-hydroxy-2- (215nM): 92%, RT 3.48 min. phenylacetamide 8-311 2-(4-(2,3- LRMS (ESI):(calc.) 361.39056, (found) 362 [M + H], HPLC dihydrobenzo[b][1,4]dioxin-(215 nM): 89%, RT 3.93 min. 6-yl)phenyl)-N-hydroxy-2- phenylacetamide8-312 N-hydroxy-2-(4′- LRMS (ESI): (calc.) 361.43362, (found) 362 [M +H], HPLC isopropoxybiphenyl-4-yl)-2- (215 nM): 96%, RT 4.39 min.phenylacetamide 8-313 N-hydroxy-2-(4′-(3- LRMS (ESI): (calc.) 361.43362,(found) 362 [M + H], HPLC hydroxypropyl)biphenyl-4- (215 nM): 91%, RT3.66 min. 1H NMR (250 MHz, MeOD) yl)-2-phenylacetamide d ppm 7.43-7.64(4H, m), 7.08-7.42 (9H, m), 4.83 (1H, br. s.), 3.58 (2H, t, J = 6.09Hz), 2.70 (2H, t, J = 7.31 Hz), 1.68-1.98 (2H, m) 8-314 2-(4′-ethoxy-3′-LRMS (ESI): (calc.) 365.3975032, (found) 366 [M + H],fluorobiphenyl-4-yl)-N- HPLC (215 nM): 100%, RT 4.23 min.hydroxy-2-phenylacetamide 8-315 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.)367.43974, (found) 368 [M + H], HPLC methylnaphthalen-1- (215 nM): 91%,RT 4.61 min. yl)phenyl)-2-phenylacetamide 8-316 2-(5′-chloro-2′- LRMS(ESI): (calc.) 367.82552, (found) 368 [M + H], HPLCmethoxybiphenyl-4-yl)-N- (215 nM): 91%, RT 4.29 min.hydroxy-2-phenylacetamide 8-317 2-(3′-chloro-4′- LRMS (ESI): (calc.)367.82552, (found) 368 [M + H], HPLC methoxybiphenyl-4-yl)-N- (215 nM):92%, RT 4.17 min. hydroxy-2-phenylacetamide 8-318 2-(2′,5′-difluoro-4′-LRMS (ESI): (calc.) 369.3613864, (found) 370 [M + H],methoxybiphenyl-4-yl)-N- HPLC (215 nM): 87%, RT 4.08 min.hydroxy-2-phenylacetamide 8-319 N-hydroxy-2-(4-(6- LRMS (ESI): (calc.)369.41256, (found) 370 [M + H], HPLC hydroxynaphthalen-2- (215 nM): 92%,RT 3.76 min. yl)phenyl)-2-phenylacetamide 8-320 2-(4′-(2-cyanopropan-2-LRMS (ESI): (calc.) 370.44368, (found) 371 [M + H], HPLCyl)biphenyl-4-yl)-N-hydroxy- (215 nM): 100%, RT 4.1 min.2-phenylacetamide 8-321 N-hydroxy-2-phenyl-2-(3′- LRMS (ESI): (calc.)371.3524496, (found) 372 [M + H], (trifluoromethyl)biphenyl-4- HPLC (215nM): 91%, RT 4.36 min. yl)acetamide 8-322 N-hydroxy-2-phenyl-2-(4′- LRMS(ESI): (calc.) 371.3524496, (found) 372 [M + H],(trifluoromethyl)biphenyl-4- HPLC (215 nM): 92%, RT 4.4 min.yl)acetamide 8-323 2-(4′- LRMS (ESI): (calc.) 374.43238, (found) 375[M + H], HPLC (acetamidomethyl)biphenyl- (215 nM): 95%, RT 3.36 min.4-yl)-N-hydroxy-2- phenylacetamide 8-324 4′-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 374.43238, (found) 375 [M + H], HPLC1-phenylethyl)-N,N- (215 nM): 90%, RT 3.5 min. dimethylbiphenyl-3-carboxamide 8-325 2-(3′- LRMS (ESI): (calc.) 374.43238, (found) 375 [M +H], HPLC (acetamidomethyl)biphenyl- (215 nM): 97%, RT 3.4 min.4-yl)-N-hydroxy-2- phenylacetamide 8-326 methyl 4′-(2-(hydroxyamino)-LRMS (ESI): (calc.) 376.4052, (found) 377 [M + H], HPLC 2-oxo-1- (215nM): 94%, RT 3.69 min. phenylethyl)biphenyl-4- ylcarbamate 8-327N-hydroxy-2-(4′- LRMS (ESI): (calc.) 377.49922, (found) 378 [M + H],HPLC (isopropylthio)biphenyl-4-yl)- (215 nM): 98%, RT 4.66 min.2-phenylacetamide 8-328 N-hydroxy-2-(3′- LRMS (ESI): (calc.) 381.44486,(found) 382 [M + H], HPLC (methylsulfonyl)biphenyl-4- (215 nM): 93%, RT3.53 min. yl)-2-phenylacetamide 8-329 N-cyclopropyl-4′-(2- LRMS (ESI):(calc.) 386.44308, (found) 387 [M + H], HPLC (hydroxyamino)-2-oxo-1-(215 nM): 86%, RT 3.53 min. phenylethyl)biphenyl-4- carboxamide 8-330N-hydroxy-2-phenyl-2-(2′- LRMS (ESI): (calc.) 387.3518496, (found) 388[M + H], (trifluoromethoxy)biphenyl- HPLC (215 nM): 92%, RT 4.32 min.4-yl)acetamide 8-331 N-hydroxy-2-phenyl-2-(4′- LRMS (ESI): (calc.)387.3518496, (found) 388 [M + H], (trifluoromethoxy)biphenyl- HPLC (215nM): 94%, RT 4.46 min. 1H NMR (250 MHz, 4-yl)acetamide MeOD) d ppm 7.69(2H, d, J = 8.83 Hz), 7.58 (2H, d), 7.19-7.47 (9H, m), 4.84 (1H, s)8-332 N-hydroxy-2-phenyl-2-(3′- LRMS (ESI): (calc.) 387.3518496, (found)388 [M + H], (trifluoromethoxy)biphenyl- HPLC (215 nM): 92%, RT 4.46min. 4-yl)acetamide 8-333 N-hydroxy-2-(4′-(N- LRMS (ESI): (calc.)396.4595, (found) 397 [M + H], HPLC methylsulfamoyl)biphenyl-4- (215nM): 94%, RT 3.52 min. 1H NMR (250 MHz, MeOD) yl)-2-phenylacetamide dppm 7.70-8.02 (4H, m), 7.60 (2H, d, J = 7.01 Hz), 7.03-7.50 (7H, m),4.87 (1H, s), 2.52 (3H, s) 8-334 N-hydroxy-2-(3′- LRMS (ESI): (calc.)396.4595, (found) 397 [M + H], HPLC (methylsulfonamido)biphenyl- (215nM): 93%, RT 3.54 min. 4-yl)-2-phenylacetamide 8-335 N-hydroxy-2-(4′-LRMS (ESI): (calc.) 396.4595, (found) 397 [M + H], HPLC(methylsulfonamido)biphenyl- (215 nM): 90%, RT 3.48 min.4-yl)-2-phenylacetamide 8-336 2-(3′-chloro-4′- LRMS (ESI): (calc.)405.7975096, (found) 406 [M + H], (trifluoromethyl)biphenyl-4- HPLC (215nM): 94%, RT 4.6 min. yl)-N-hydroxy-2- phenylacetamide 8-337N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 291.34554, (found) 292.11[M + H], propionylpiperazin-1- HPLC (215 nM): 98%, RT 2.05 min.yl)acetamide 8-338 2-(4-(cyclopropanecarbonyl)- LRMS (ESI): (calc.)317.38282, (found) 318.18 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM):98.14%, RT 2.03 min. hydroxy-2-phenylacetamide 8-339 2-(4- LRMS (ESI):(calc.) 303.35624, (found) 304.13 [M + H],(cyclopropanecarbonyl)piperazin- HPLC (215 nM): 93.9%, RT 2.16 min.1-yl)-N-hydroxy-2- phenylacetamide 8-340 N-hydroxy-2-(4-isobutyryl- LRMS(ESI): (calc.) 319.3987, (found) 320.2 [M + H], HPLC1,4-diazepan-1-yl)-2- (215 nM): 87.81%, RT 2.17 min. phenylacetamide8-341 N-hydroxy-2-(4- LRMS (ESI): (calc.) 305.37212, (found) 306.14 [M +H], isobutyrylpiperazin-1-yl)-2- HPLC (215 nM): 100%, RT 2.32 min.phenylacetamide 8-342 N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 331.4094,(found) 332.17 [M + H], methylbut-2-enoyl)-1,4- HPLC (215 nM): 95.55%,RT 2.32 min. diazepan-1-yl)-2- phenylacetamide 8-343 N-hydroxy-2-(4-(3-LRMS (ESI): (calc.) 317.38282, (found) 318.18 [M + H],methylbut-2-enoyl)piperazin- HPLC (215 nM): 94%, RT 2.46 min. 1H NMR(250 MHz, 1-yl)-2-phenylacetamide DMSO-d6) d ppm 10.85 (1H, s), 8.92(1H, s), 7.23-7.48 (5H, m), 5.86 (1H, s), 3.67 (1H, s), 3.39-3.54 (4H,m), 2.15-2.40 (4H, m), 1.74-1.83 (6H, m) 8-344 2-(4- LRMS (ESI): (calc.)317.38282, (found) 318.12 [M + H], (cyclobutanecarbonyl)piperazin- HPLC(215 nM): 91.6%, RT 2.48 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-345N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 333.42528, (found) 334.18 [M +H], methylbutanoyl)-1,4- HPLC (215 nM): 89.3%, RT 2.43 min.diazepan-1-yl)-2- phenylacetamide 8-346 N-hydroxy-2-(4-(3- LRMS (ESI):(calc.) 319.3987, (found) 320.19 [M + H], methylbutanoyl)piperazin-1-HPLC (215 nM): 98.07%, RT 2.6 min. yl)-2-phenylacetamide 8-347N-hydroxy-2-(4-(2- LRMS (ESI): (calc.) 333.42528, (found) 334.2 [M + H],methylbutanoyl)-1,4- HPLC (215 nM): 89.12%, RT 2.41 min.diazepan-1-yl)-2- phenylacetamide 8-348 N-hydroxy-2-(4-(2- LRMS (ESI):(calc.) 319.3987, (found) 320.13 [M + H], methylbutanoyl)piperazin-1-HPLC (215 nM): 90%, RT 2.58 min. yl)-2-phenylacetamide 8-3492-(4-(furan-3-carbonyl)-1,4- LRMS (ESI): (calc.) 343.37704, (found)344.14 [M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 92.62%, RT2.18 min. phenylacetamide 8-350 2-(4-(furan-3- LRMS (ESI): (calc.)329.35046, (found) 330.14 [M + H], carbonyl)piperazin-1-yl)-N- HPLC (215nM): 100%, RT 2.39 min. hydroxy-2-phenylacetamide 8-3512-(4-(cyclopentanecarbonyl)- LRMS (ESI): (calc.) 345.43598, (found)346.31 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM): 93.61%, RT 2.47min. hydroxy-2-phenylacetamide 8-352 2-(4- LRMS (ESI): (calc.) 331.4094,(found) 332.17 [M + H], (cyclopentanecarbonyl)piperazin- HPLC (215 nM):96%, RT 2.67 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-353N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 346.42404, (found) 347.233[M + H], (pyrrolidine-1-carbonyl)-1,4- HPLC (215 nM): 88.42%, RT 2.3min. diazepan-1-yl)acetamide 8-354 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 332.39746, (found) 333.15 [M + H], (pyrrolidine-1- HPLC (215nM): 97%, RT 2.3 min. carbonyl)piperazin-1- yl)acetamide 8-3552-(4-(3,3-dimethylbutanoyl)- LRMS (ESI): (calc.) 347.45186, (found)348.23 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM): 94.68%, RT 2.63min. hydroxy-2-phenylacetamide 8-356 2-(4-(3,3- LRMS (ESI): (calc.)333.42528, (found) 334.18 [M + H], dimethylbutanoyl)piperazin- HPLC (215nM): 92.28%, RT 2.78 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-3572-(4-(2-ethylbutanoyl)-1,4- LRMS (ESI): (calc.) 347.45186, (found)348.23 [M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 92.9%, RT2.62 min. phenylacetamide 8-358 2-(4-(2- LRMS (ESI): (calc.) 333.42528,(found) 334.18 [M + H], ethylbutanoyl)piperazin-1- HPLC (215 nM): 95%,RT 2.81 min. 1H NMR (250 MHz, yl)-N-hydroxy-2- DMSO-d6) d ppm 10.83 (1H,s), 8.91 (1H, s), 7.18-7.56 (5H, phenylacetamide m), 3.63 (1H, s), 3.50(4H, br. s.), 2.27 (4H, br. s.), 1.19-1.57 (5H, m), 0.74 (6H, t, J =7.23 Hz) 8-359 N-hydroxy-2-(4-((R)-2- LRMS (ESI): (calc.) 347.45186,(found) 348.29 [M + H], methylpentanoyl)-1,4- HPLC (215 nM): 88.26%, RT2.62 min. diazepan-1-yl)-2- phenylacetamide 8-360 N-hydroxy-2-(4-(2-LRMS (ESI): (calc.) 333.42528, (found) 334.18 [M + H],methylpentanoyl)piperazin-1- HPLC (215 nM): 95.97%, RT 2.84 min.yl)-2-phenylacetamide 8-361 2-(4-benzoyl-1,4-diazepan-1- LRMS (ESI):(calc.) 353.41492, (found) 354.16 [M + H], yl)-N-hydroxy-2- HPLC (215nM): 100%, RT 2.45 min. phenylacetamide 8-3622-(4-benzoylpiperazin-1-yl)- LRMS (ESI): (calc.) 339.38834, (found)340.17 [M + H], N-hydroxy-2- HPLC (215 nM): 95.84%, RT 2.68 min.phenylacetamide 8-363 2-(4-(2- LRMS (ESI): (calc.) 339.81718, (found)340.11 [M + H], chlorobutanoyl)piperazin-1- HPLC (215 nM): 94.83%, RT2.79 min. 1H NMR (250 MHz, yl)-N-hydroxy-2- DMSO-d6) d ppm 10.87 (1H,s), 8.94 (1H, s), 7.24-7.49 (5H, phenylacetamide m), 4.82 (1H, t, J =6.70 Hz), 3.64-3.74 (1H, m), 3.43-3.63 (4H, m), 2.24-2.42 (4H, m),1.68-2.00 (2H, m), 0.91 (3H, t, J = 7.23 Hz) 8-364 N-hydroxy-2-(4-(5-LRMS (ESI): (calc.) 358.39168, (found) 359.2 [M + H],methylisoxazole-3-carbonyl)- HPLC (215 nM): 88.3%, RT 2.36 min.1,4-diazepan-1-yl)-2- phenylacetamide 8-365 N-hydroxy-2-(4-(5- LRMS(ESI): (calc.) 344.3651, (found) 345.23 [M + H], methylisoxazole-3- HPLC(215 nM): 100%, RT 2.6 min. carbonyl)piperazin-1-yl)-2- phenylacetamide8-366 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 345.41606, (found)346.09 [M + H], (thiophene-3- HPLC (215 nM): 97.07%, RT 2.58 min.carbonyl)piperazin-1- yl)acetamide 8-367 N-hydroxy-2-phenyl-2-(4- LRMS(ESI): (calc.) 359.44264, (found) 360.14 [M + H],(thiophene-2-carbonyl)-1,4- HPLC (215 nM): 92.58%, RT 2.39 min.diazepan-1-yl)acetamide 8-368 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 345.41606, (found) 346.09 [M + H], (thiophene-2- HPLC (215 nM):100%, RT 2.63 min. carbonyl)piperazin-1- yl)acetamide 8-3692-(4-(2-cyclopentylacetyl)- LRMS (ESI): (calc.) 359.46256, (found)360.22 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM): 89.58%, RT 2.74min. hydroxy-2-phenylacetamide 8-370 2-(4-(2- LRMS (ESI): (calc.)345.43598, (found) 346.16 [M + H], cyclopentylacetyl)piperazin- HPLC(215 nM): 100%, RT 2.92 min. 1H NMR (250 MHz, 1-yl)-N-hydroxy-2-DMSO-d6) d ppm 10.86 (1H, s), 8.93 (1H, s), 7.22-7.50 (5H,phenylacetamide m), 3.65 (1H, s), 3.38-3.54 (4H, m), 2.28 (6H, d, J =7.01 Hz), 2.00-2.16 (1H, m), 1.64-1.79 (2H, m), 1.37-1.62 (4H, m),0.99-1.18 (2H, m) 8-371 2-(4-(cyclohexanecarbonyl)- LRMS (ESI): (calc.)359.46256, (found) 360.2 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM):100%, RT 2.68 min. hydroxy-2-phenylacetamide 8-372N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 361.43538, (found) 362.16[M + H], (tetrahydro-2H-pyran-4- HPLC (215 nM): 100%, RT 2.02 min. 1HNMR (250 MHz, carbonyl)-1,4-diazepan-1- DMSO-d6) d ppm 10.81 (1H, br.s.), 8.93 (1H, br. s.), yl)acetamide 7.17-7.53 (5H, m), 3.90-4.16 (1H,m), 3.75-3.90 (2H, m), 3.37-3.67 (6H, m), 3.22-3.31 (1H, m), 2.53-2.90(4H, m), 1.42-1.84 (6H, m) 8-373 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 347.4088, (found) 348.17 [M + H], (tetrahydro-2H-pyran-4- HPLC(215 nM): 100%, RT 2.16 min. carbonyl)piperazin-1- yl)acetamide 8-374N-hydroxy-2-(4-(morpholine- LRMS (ESI): (calc.) 348.39686, (found)349.26 [M + H], 4-carbonyl)piperazin-1-yl)-2- HPLC (215 nM): 98%, RT2.04 min. phenylacetamide 8-375 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.)353.41492, (found) 354.16 [M + H], methylbenzoyl)piperazin-1- HPLC (215nM): 100%, RT 2.91 min. yl)-2-phenylacetamide 8-376 2-(4-(3-chloro-2,2-LRMS (ESI): (calc.) 353.84376, (found) 354 [M + H], HPLCdimethylpropanoyl)piperazin- (215 nM): 89%, RT 2.72 min.1-yl)-N-hydroxy-2- phenylacetamide 8-377 phenyl 4-(2-(hydroxyamino)-LRMS (ESI): (calc.) 369.41432, (found) 370 [M + H], HPLC2-oxo-1-phenylethyl)-1,4- (215 nM): 92%, RT 2.76 min.diazepane-1-carboxylate 8-378 2-(4-(2-fluorobenzoyl)-1,4- LRMS (ESI):(calc.) 371.4053832, (found) 372.17 [M + H], diazepan-1-yl)-N-hydroxy-2-HPLC (215 nM): 88.83%, RT 2.52 min. phenylacetamide 8-379 2-(4-(2- LRMS(ESI): (calc.) 357.3788032, (found) 358.13 [M + H],fluorobenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.78 min.yl)-N-hydroxy-2- phenylacetamide 8-380 2-(4-(4-fluorobenzoyl)-1,4- LRMS(ESI): (calc.) 371.4053832, (found) 372.17 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 91.3%, RT 2.56 min.phenylacetamide 8-381 2-(4-(4- LRMS (ESI): (calc.) 357.3788032, (found)358.14 [M + H], fluorobenzoyl)piperazin-1- HPLC (215 nM): 91.7%, RT 2.79min. yl)-N-hydroxy-2- phenylacetamide 8-382 2-(4-(3-fluorobenzoyl)-1,4-LRMS (ESI): (calc.) 371.4053832, (found) 372.17 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 89.97%, RT 2.55 min.phenylacetamide 8-383 2-(4-(3- LRMS (ESI): (calc.) 357.3788032, (found)358.13 [M + H], fluorobenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.82min. yl)-N-hydroxy-2- phenylacetamide 8-384 2-(4-(2,5-dimethylfuran-3-LRMS (ESI): (calc.) 371.4302, (found) 372.19 [M + H],carbonyl)-1,4-diazepan-1-yl)- HPLC (215 nM): 93.24%, RT 2.61 min.N-hydroxy-2- phenylacetamide 8-385 2-(4-(2,5-dimethylfuran-3- LRMS(ESI): (calc.) 357.40362, (found) 358.13 [M + H],carbonyl)piperazin-1-yl)-N- HPLC (215 nM): 94.92%, RT 2.83 min.hydroxy-2-phenylacetamide 8-386 2-(4-(1,3-dimethyl-1H- LRMS (ESI):(calc.) 371.4335, (found) 372.23 [M + H], pyrazole-5-carbonyl)-1,4- HPLC(215 nM): 90.69%, RT 2.3 min. diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-387 2-(4-(1,3-dimethyl-1H- LRMS (ESI): (calc.)357.40692, (found) 358.14 [M + H], pyrazole-5- HPLC (215 nM): 88.07%, RT2.54 min. carbonyl)piperazin-1-yl)-N- hydroxy-2-phenylacetamide 8-388N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.) 373.46922, (found)374.14 [M + H], (thiophen-2-yl)acetyl)-1,4- HPLC (215 nM): 93.44%, RT2.5 min. diazepan-1-yl)acetamide 8-389 N-hydroxy-2-phenyl-2-(4-(2- LRMS(ESI): (calc.) 359.44264, (found) 360.08 [M + H], (thiophen-2- HPLC (215nM): 100%, RT 2.71 min. yl)acetyl)piperazin-1- yl)acetamide 8-390N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 373.46922, (found) 374.13 [M +H], methylthiophene-2-carbonyl)- HPLC (215 nM): 86.94%, RT 2.56 min.1,4-diazepan-1-yl)-2- phenylacetamide 8-391 N-hydroxy-2-(4-(3- LRMS(ESI): (calc.) 359.44264, (found) 360.14 [M + H], methylthiophene-2-HPLC (215 nM): 93.51%, RT 2.84 min. carbonyl)piperazin-1-yl)-2-phenylacetamide 8-392 2-(4-(3- LRMS (ESI): (calc.) 373.48914, (found)374.25 [M + H], cyclopentylpropanoyl)-1,4- HPLC (215 nM): 92%, RT 2.97min. diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-393 2-(4-(3- LRMS(ESI): (calc.) 359.46256, (found) 360.2 [M + H],cyclopentylpropanoyl)piperazin- HPLC (215 nM): 96.18%, RT 3.19 min.1-yl)-N-hydroxy-2- phenylacetamide 8-394 2-(4-(3,4-dimethylbenzoyl)-LRMS (ESI): (calc.) 381.46808, (found) 382.23 [M + H],1,4-diazepan-1-yl)-N- HPLC (215 nM): 92.92%, RT 2.85 min.hydroxy-2-phenylacetamide 8-395 2-(4-(3,4- LRMS (ESI): (calc.) 367.4415,(found) 368 [M + H], HPLC dimethylbenzoyl)piperazin-1- (215 nM): 92%, RT3.1 min. yl)-N-hydroxy-2- phenylacetamide 8-396 2-(4-(2,3- LRMS (ESI):(calc.) 367.4415, (found) 368.14 [M + H], dimethylbenzoyl)piperazin-1-HPLC (215 nM): 92.79%, RT 3.06 min. yl)-N-hydroxy-2- phenylacetamide8-397 2-(4-(4-ethylbenzoyl)-1,4- LRMS (ESI): (calc.) 381.46808, (found)382.25 [M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 93.16%, RT2.87 min. phenylacetamide 8-398 2-(4-(4- LRMS (ESI): (calc.) 367.4415,(found) 368 [M + H], HPLC ethylbenzoyl)piperazin-1-yl)- (215 nM): 95%,RT 3.14 min. N-hydroxy-2- phenylacetamide 8-399 N-hydroxy-2-(4-(2- LRMS(ESI): (calc.) 383.4409, (found) 384.2 [M + H], HPLCphenoxyacetyl)-1,4-diazepan- (215 nM): 100%, RT 2.62 min.1-yl)-2-phenylacetamide 8-400 N-hydroxy-2-(4-(2- LRMS (ESI): (calc.)369.41432, (found) 370 [M + H], HPLC phenoxyacetyl)piperazin-1- (215nM): 88%, RT 2.68 min. yl)-2-phenylacetamide 8-401 N-hydroxy-2-(4-(4-LRMS (ESI): (calc.) 383.4409, (found) 384.2 [M + H], HPLCmethoxybenzoyl)-1,4- (215 nM): 91.2%, RT 2.57 min. diazepan-1-yl)-2-phenylacetamide 8-402 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 369.41432,(found) 370.16 [M + H], methoxybenzoyl)piperazin-1- HPLC (215 nM): 100%,RT 2.74 min. yl)-2-phenylacetamide 8-403 N-hydroxy-2-(4-(3- LRMS (ESI):(calc.) 369.41432, (found) 370.16 [M + H], methoxybenzoyl)piperazin-1-HPLC (215 nM): 94.88%, RT 2.81 min. yl)-2-phenylacetamide 8-4042-(4-(2-(4- LRMS (ESI): (calc.) 385.4319632, (found) 386.22 [M + H],fluorophenyl)acetyl)-1,4- HPLC (215 nM): 96.3%, RT 2.68 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-405 2-(4-(2-(4- LRMS(ESI): (calc.) 371.4053832, (found) 372.13 [M + H],fluorophenyl)acetyl)piperazin- HPLC (215 nM): 95%, RT 2.88 min.1-yl)-N-hydroxy-2- phenylacetamide 8-406 2-(4-(5-fluoro-2- LRMS (ESI):(calc.) 385.4319632, (found) 386.22 [M + H],methylbenzoyl)-1,4-diazepan- HPLC (215 nM): 90.26%, RT 2.73 min.1-yl)-N-hydroxy-2- phenylacetamide 8-407 2-(4-(5-fluoro-2- LRMS (ESI):(calc.) 371.4053832, (found) 372.15 [M + H], methylbenzoyl)piperazin-1-HPLC (215 nM): 92.01%, RT 3.01 min. yl)-N-hydroxy-2- phenylacetamide8-408 2-(4-(3-fluoro-4- LRMS (ESI): (calc.) 385.4319632, (found) 386.16[M + H], methylbenzoyl)-1,4-diazepan- HPLC (215 nM): 90.65%, RT 2.78min. 1-yl)-N-hydroxy-2- phenylacetamide 8-409 2-(4-(3-fluoro-4- LRMS(ESI): (calc.) 371.4053832, (found) 372.17 [M + H],methylbenzoyl)piperazin-1- HPLC (215 nM): 88.85%, RT 3.05 min.yl)-N-hydroxy-2- phenylacetamide 8-410 2-(4-(4-fluoro-3- LRMS (ESI):(calc.) 385.4319632, (found) 386.22 [M + H],methylbenzoyl)-1,4-diazepan- HPLC (215 nM): 98%, RT 2.77 min.1-yl)-N-hydroxy-2- phenylacetamide 8-411 2-(4-(4-fluoro-3- LRMS (ESI):(calc.) 371.4053832, (found) 372.17 [M + H], methylbenzoyl)piperazin-1-HPLC (215 nM): 92.1%, RT 3.04 min. 1H NMR (250 MHz, yl)-N-hydroxy-2-DMSO-d6) d ppm 10.87 (1H, s), 8.92 (1H, s), 7.08-7.50 (8H,phenylacetamide m), 3.69 (1H, s), 3.37-3.66 (4H, m), 2.27-2.45 (4H, m),2.24 (3H, s) 8-412 2-(4-(3- LRMS (ESI): (calc.) 387.51572, (found) 388.3[M + H], cyclohexylpropanoyl)-1,4- HPLC (215 nM): 95.55%, RT 3.13 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-413 2-(4-(3- LRMS (ESI):(calc.) 373.48914, (found) 374.2 [M + H], cyclohexylpropanoyl)piperazin-HPLC (215 nM): 100%, RT 3.38 min. 1-yl)-N-hydroxy-2- phenylacetamide8-414 2-(4-(2- LRMS (ESI): (calc.) 373.8334, (found) 374.13 [M + H],chlorobenzoyl)piperazin-1- HPLC (215 nM): 94.15%, RT 2.92 min.yl)-N-hydroxy-2- phenylacetamide 8-415 2-(4-(3-chlorobenzoyl)-1,4- LRMS(ESI): (calc.) 387.85998, (found) 388.11 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 92.78%, RT 2.76 min.phenylacetamide 8-416 2-(4-(3- LRMS (ESI): (calc.) 373.8334, (found)374.13 [M + H], chlorobenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 3.03min. yl)-N-hydroxy-2- phenylacetamide 8-417 2-(4-(4- LRMS (ESI): (calc.)373.8334, (found) 374.2 [M + H], HPLC chlorobenzoyl)piperazin-1- (215nM): 86.95%, RT 3.03 min. yl)-N-hydroxy-2- phenylacetamide 8-4182-(4-(6- LRMS (ESI): (calc.) 374.82146, (found) 375.15 [M + H],chloronicotinoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.64 min.yl)-N-hydroxy-2- phenylacetamide 8-419 2-(4-(2-chloroisonicotinoyl)-LRMS (ESI): (calc.) 388.84804, (found) 389.13 [M + H],1,4-diazepan-1-yl)-N- HPLC (215 nM): 100%, RT 2.4 min.hydroxy-2-phenylacetamide 8-420 2-(4-(2- LRMS (ESI): (calc.) 374.82146,(found) 375.14 [M + H], chloroisonicotinoyl)piperazin- HPLC (215 nM):100%, RT 2.65 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-421 2-(4-(3,4-LRMS (ESI): (calc.) 375.3692664, (found) 376.14 [M + H],difluorobenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.95 min.yl)-N-hydroxy-2- phenylacetamide 8-422 2-(4-(3,5-difluorobenzoyl)- LRMS(ESI): (calc.) 389.3958464, (found) 390.19 [M + H],1,4-diazepan-1-yl)-N- HPLC (215 nM): 91.53%, RT 2.67 min.hydroxy-2-phenylacetamide 8-423 2-(4-(3,5- LRMS (ESI): (calc.)375.3692664, (found) 376.21 [M + H], difluorobenzoyl)piperazin-1- HPLC(215 nM): 92%, RT 2.95 min. yl)-N-hydroxy-2- phenylacetamide 8-4242-(4-(2,2-dimethylbutanoyl)- LRMS (ESI): (calc.) 347.45186, (found)348.23 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM): 90.73%, RT 2.58min. hydroxy-2-phenylacetamide 8-425 2-(4-(2,2- LRMS (ESI): (calc.)333.42528, (found) 334.18 [M + H], dimethylbutanoyl)piperazin- HPLC (215nM): 100%, RT 2.77 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-4262-(4-(2,5- LRMS (ESI): (calc.) 375.3692664, (found) 376.21 [M + H],difluorobenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.89 min.yl)-N-hydroxy-2- phenylacetamide 8-427 2-(4-(5-chloro-1-methyl-1H- LRMS(ESI): (calc.) 391.85198, (found) 392.14 [M + H],pyrazole-4-carbonyl)-1,4- HPLC (215 nM): 98.36%, RT 2.2 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-4282-(4-(5-chloro-1-methyl-1H- LRMS (ESI): (calc.) 377.8254, (found) 378.09[M + H], pyrazole-4- HPLC (215 nM): 91.73%, RT 2.42 min.carbonyl)piperazin-1-yl)-N- hydroxy-2-phenylacetamide 8-429N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.) 381.46808, (found) 382[M + H], HPLC phenylbutanoyl)piperazin-1- (215 nM): 91%, RT 3.18 min.yl)acetamide 8-430 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.)381.46808, (found) 382.19 [M + H], propylbenzoyl)piperazin-1- HPLC (215nM): 92.69%, RT 3.37 min. yl)acetamide 8-431 2-(4-(4- LRMS (ESI):(calc.) 396.48272, (found) 397.24 [M + H], (dimethylamino)benzoyl)- HPLC(215 nM): 100%, RT 2.58 min 1H NMR (250 MHz, 1,4-diazepan-1-yl)-N-DMSO-d6) d ppm 10.83 (1H, br. s.), 8.94 (1H, br. s.),hydroxy-2-phenylacetamide 7.17-7.53 (7H, m), 6.69 (2H, d, J = 8.98 Hz),4.02 (1H, br. s.), 3.42-3.70 (4H, m), 2.93 (6H, s), 2.55-2.84 (4H, m),1.50-1.89 (2H, m) 8-432 2-(4-(4- LRMS (ESI): (calc.) 382.45614, (found)383.26 [M + H], (dimethylamino)benzoyl)piperazin- HPLC (215 nM): 100%,RT 2.75 min. 1H NMR (250 MHz, 1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.86(1H, s), 8.93 (1H, s), 7.15-7.56 (7H, phenylacetamide m), 6.61-6.76 (2H,m), 3.64-3.74 (1H, m), 3.50 (4H, br. s.), 2.93 (6H, s), 2.34 (4H, br.s.) 8-433 2-(4-(benzo[d][1,3]dioxole-5- LRMS (ESI): (calc.) 397.42442,(found) 398.19 [M + H], carbonyl)-1,4-diazepan-1-yl)- HPLC (215 nM):91%, RT 2.49 min. N-hydroxy-2- phenylacetamide 8-4342-(4-(benzo[d][1,3]dioxole-5- LRMS (ESI): (calc.) 383.39784, (found)384.14 [M + H], carbonyl)piperazin-1-yl)-N- HPLC (215 nM): 90.71%, RT2.7 min. hydroxy-2-phenylacetamide 8-435 N-hydroxy-2-(4-(2-(4- LRMS(ESI): (calc.) 383.4409, (found) 384.2 [M + H], HPLCmethoxyphenyl)acetyl)piperazin- (215 nM): 93.41%, RT 2.82 min.1-yl)-2-phenylacetamide 8-436 N-hydroxy-2-(4-(2-(3- LRMS (ESI): (calc.)383.4409, (found) 384.14 [M + H], methoxyphenyl)acetyl)piperazin- HPLC(215 nM): 100%, RT 2.85 min. 1-yl)-2-phenylacetamide 8-437N-hydroxy-2-(4-(2- LRMS (ESI): (calc.) 383.4409, (found) 384 [M + H],HPLC phenoxypropanoyl)piperazin- (215 nM): 87%, RT 3.02 min. 1H NMR (250MHz, DMSO- 1-yl)-2-phenylacetamide d6) d ppm 10.85 (1H, s), 8.92 (1H,br. s.), 7.16-7.51 (7H, m), 6.87-6.97 (1H, m), 6.76-6.86 (2H, m),5.08-5.29 (1H, m), 3.66 (1H, s), 3.38-3.64 (4H, m), 2.19-2.39 (4H, m),1.39 (3H, d, J = 6.09 Hz) 8-438 2-(4-(2-(benzyloxy)acetyl)- LRMS (ESI):(calc.) 397.46748, (found) 398 [M + H], HPLC 1,4-diazepan-1-yl)-N- (215nM): 91%, RT 2.67 min. hydroxy-2-phenylacetamide 8-439 2-(4-(2- LRMS(ESI): (calc.) 383.4409, (found) 384 [M + H], HPLC(benzyloxy)acetyl)piperazin- (215 nM): 86%, RT 2.68 min.1-yl)-N-hydroxy-2- phenylacetamide 8-440 2-(4-(4-ethoxybenzoyl)-1,4-LRMS (ESI): (calc.) 397.46748, (found) 398.24 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 89.56%, RT 2.75 min. 1H NMR(250 MHz, phenylacetamide DMSO-d6) d ppm 10.82 (1H, s), 8.92 (1H, s),7.14-7.54 (7H, m), 6.94 (2H, d, J = 8.53 Hz), 3.91-4.18 (3H, m),3.39-3.87 (4H, m), 2.55-2.84 (4H, m), 1.48-1.90 (2H, m), 1.33 (3H, t, J= 7.01 Hz) 8-441 2-(4-(4- LRMS (ESI): (calc.) 383.4409, (found) 384.14[M + H], ethoxybenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 2.96 min.yl)-N-hydroxy-2- phenylacetamide 8-442 2-(4-(2-ethoxybenzoyl)-1,4- LRMS(ESI): (calc.) 397.46748, (found) 398.19 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 92.85%, RT 2.7 min.phenylacetamide 8-443 2-(4-(2- LRMS (ESI): (calc.) 383.4409, (found)384.2 [M + H], HPLC ethoxybenzoyl)piperazin-1- (215 nM): 90.1%, RT 2.94min. yl)-N-hydroxy-2- phenylacetamide 8-444 N-hydroxy-2-(4-(2- LRMS(ESI): (calc.) 384.3859, (found) 385.22 [M + H],nitrobenzoyl)piperazin-1-yl)- HPLC (215 nM): 93%, RT 2.76 min.2-phenylacetamide 8-445 N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 384.3859,(found) 385.22 [M + H], nitrobenzoyl)piperazin-1-yl)- HPLC (215 nM):100%, RT 2.84 min. 2-phenylacetamide 8-446 N-hydroxy-2-phenyl-2-(4-(2-LRMS (ESI): (calc.) 399.5065, (found) 400.2 [M + H], HPLC(phenylthio)acetyl)-1,4- (215 nM): 91.41%, RT 2.8 min.diazepan-1-yl)acetamide 8-447 N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI):(calc.) 385.47992, (found) 386.1 [M + H], (phenylthio)acetyl)piperazin-HPLC (215 nM): 100%, RT 3.03 min. 1-yl)acetamide 8-448 2-(4-(3-fluoro-4-LRMS (ESI): (calc.) 401.4313632, (found) 402.16 [M + H],methoxybenzoyl)-1,4- HPLC (215 nM): 95.14%, RT 2.62 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-449 2-(4-(3-fluoro-4- LRMS(ESI): (calc.) 387.4047832, (found) 388.17 [M + H],methoxybenzoyl)piperazin-1- HPLC (215 nM): 94.68%, RT 2.84 min. 1H NMR(250 MHz, yl)-N-hydroxy-2- DMSO-d6) d ppm 10.86 (1H, s), 8.91 (1H, s),7.05-7.50 (8H, phenylacetamide m), 3.85 (3H, s), 3.68 (1H, s), 3.47 (4H,br. s.), 2.34 (4H, br. s.) 8-450 2-(4-(2-(4- LRMS (ESI): (calc.)387.85998, (found) 388.11 [M + H], chlorophenyl)acetyl)piperazin- HPLC(215 nM): 98%, RT 3.11 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-4512-(4-(1-naphthoyl)piperazin- LRMS (ESI): (calc.) 389.44702, (found)390.15 [M + H], 1-yl)-N-hydroxy-2- HPLC (215 nM): 93%, RT 3.15 min.phenylacetamide 8-452 2-(4-(2-chloro-4- LRMS (ESI): (calc.) 391.8238632,(found) 392.08 [M + H], fluorobenzoyl)piperazin-1- HPLC (215 nM): 100%,RT 3.05 min. yl)-N-hydroxy-2- phenylacetamide 8-453N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 407.3863096, (found) 408.23[M + H], (2,4,5-trifluorobenzoyl)-1,4- HPLC (215 nM): 90.04%, RT 2.73min. diazepan-1-yl)acetamide 8-454 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 393.3597296, (found) 394.22 [M + H], (2,4,5- HPLC (215 nM):92.34%, RT 3.02 min. trifluorobenzoyl)piperazin-1- yl)acetamide 8-455N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 407.4623, (found) 408.2 [M + H],HPLC methylbenzofuran-2- (215 nM): 92.86%, RT 2.98 min.carbonyl)-1,4-diazepan-1-yl)- 2-phenylacetamide 8-456 N-hydroxy-2-(4-(3-LRMS (ESI): (calc.) 393.43572, (found) 394.16 [M + H],methylbenzofuran-2- HPLC (215 nM): 100%, RT 3.3 min.carbonyl)piperazin-1-yl)-2- phenylacetamide 8-457 2-(4-(chroman-3- LRMS(ESI): (calc.) 395.4516, (found) 396.17 [M + H],carbonyl)piperazin-1-yl)-N- HPLC (215 nM): 94.69%, RT 3.11 min.hydroxy-2-phenylacetamide 8-458 2-(4-(benzo[b]thiophene-2- LRMS (ESI):(calc.) 395.47474, (found) 396.17 [M + H], carbonyl)piperazin-1-yl)-N-HPLC (215 nM): 100%, RT 3.22 min. hydroxy-2-phenylacetamide 8-4592-(4-(benzo[b]thiophene-3- LRMS (ESI): (calc.) 409.50132, (found) 410.15[M + H], carbonyl)-1,4-diazepan-1-yl)- HPLC (215 nM): 88.32%, RT 2.88min. N-hydroxy-2- phenylacetamide 8-460 2-(4-(4-tert-butylbenzoyl)- LRMS(ESI): (calc.) 409.52124, (found) 410.23 [M + H], 1,4-diazepan-1-yl)-N-HPLC (215 nM): 100%, RT 3.17 min. hydroxy-2-phenylacetamide 8-4612-(4-(4-tert- LRMS (ESI): (calc.) 395.49466, (found) 396.24 [M + H],butylbenzoyl)piperazin-1-yl)- HPLC (215 nM): 92.48%, RT 3.46 min. 1H NMR(250 MHz, N-hydroxy-2- DMSO-d6) d ppm 10.86 (1H, br. s.), 8.92 (1H, br.s.), phenylacetamide 7.22-7.48 (9H, m), 3.67-3.73 (1H, m), 3.35-3.66(4H, m), 2.24-2.45 (4H, m), 1.28 (9H, s) 8-462 2-(4-(2,3- LRMS (ESI):(calc.) 411.451, (found) 412.18 [M + H], HPLCdihydrobenzo[b][1,4]dioxine- (215 nM): 93.42%, RT 2.81 min.2-carbonyl)-1,4-diazepan-1- yl)-N-hydroxy-2- phenylacetamide 8-4632-(4-(2,6- LRMS (ESI): (calc.) 399.4403, (found) 400.14 [M + H],dimethoxybenzoyl)piperazin- HPLC (215 nM): 100%, RT 2.75 min. 1H NMR(250 MHz, 1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.87 (1H, br. s.), 8.94(1H, br. s.), phenylacetamide 7.18-7.54 (6H, m), 6.66 (2H, d, J = 8.38Hz), 3.71 (7H, d, J = 3.81 Hz), 3.47-3.66 (2H, m), 3.00-3.17 (2H, m),2.09-2.45 (4H, m) 8-464 2-(4-(3,5-dimethoxybenzoyl)- LRMS (ESI): (calc.)413.46688, (found) 414.23 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM):89.57%, RT 2.7 min. hydroxy-2-phenylacetamide 8-465 2-(4-(3,5- LRMS(ESI): (calc.) 399.4403, (found) 400.14 [M + H],dimethoxybenzoyl)piperazin- HPLC (215 nM): 97.52%, RT 2.93 min. 1H NMR(250 MHz, 1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.86 (1H, br. s.), 8.92(1H, br. s.), phenylacetamide 7.22-7.48 (5H, m), 6.53 (1H, d, J = 2.28Hz), 6.46 (2H, d, J = 2.28 Hz), 3.74 (6H, s), 3.70 (1H, br. s.),3.37-3.67 (4H, m), 2.19-2.45 (4H, m) 8-466 2-(4-(2-(4- LRMS (ESI):(calc.) 403.85938, (found) 404.17 [M + H],chlorophenoxy)acetyl)piperazin- HPLC (215 nM): 100%, RT 3.15 min.1-yl)-N-hydroxy-2- phenylacetamide 8-467 2-(4-(2-chloro-6- LRMS (ESI):(calc.) 418.87402, (found) 419.12 [M + H], methoxyisonicotinoyl)-1,4-HPLC (215 nM): 96.46%, RT 2.83 min. diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-468 2-(4-(6-chloro-2-fluoro-3- LRMS (ESI): (calc.)405.8504432, (found) 406.12 [M + H], methylbenzoyl)piperazin-1- HPLC(215 nM): 91%, RT 3.25 min. yl)-N-hydroxy-2- phenylacetamide 8-469N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.) 407.3863096, (found)408.14 [M + H], (trifluoromethyl)benzoyl)piperazin- HPLC (215 nM): 100%,RT 3.25 min. 1-yl)acetamide 8-470 N-hydroxy-2-phenyl-2-(4-(3- LRMS(ESI): (calc.) 421.4128896, (found) 422.18 [M + H],(trifluoromethyl)benzoyl)- HPLC (215 nM): 100%, RT 2.92 min.1,4-diazepan-1-yl)acetamide 8-471 N-hydroxy-2-phenyl-2-(4-(3- LRMS(ESI): (calc.) 407.3863096, (found) 408.14 [M + H],(trifluoromethyl)benzoyl)piperazin- HPLC (215 nM): 91%, RT 3.22 min.1-yl)acetamide 8-472 2-(4-(3,4-dichlorobenzoyl)- LRMS (ESI): (calc.)422.30504, (found) 422.12 [M + H], 1,4-diazepan-1-yl)-N- HPLC (215 nM):92.3%, RT 3.02 min. hydroxy-2-phenylacetamide 8-473 2-(4-(3,4- LRMS(ESI): (calc.) 408.27846, (found) 408.13 [M + H],dichlorobenzoyl)piperazin-1- HPLC (215 nM): 98%, RT 3.28 min.yl)-N-hydroxy-2- phenylacetamide 8-474 N-hydroxy-2-(4-(4-methyl- LRMS(ESI): (calc.) 424.49282, (found) 425.21 [M + H], 3,4-dihydro-2H- HPLC(215 nM): 91.98%, RT 2.66 min. benzo[b][1,4]oxazine-7-carbonyl)-1,4-diazepan-1-yl)- 2-phenylacetamide 8-475N-hydroxy-2-(4-(4-methyl- LRMS (ESI): (calc.) 410.46624, (found) 411.19[M + H], 3,4-dihydro-2H- HPLC (215 nM): 90.31%, RT 2.83 min.benzo[b][1,4]oxazine-7- carbonyl)piperazin-1-yl)-2- phenylacetamide8-476 2-(4-(4- LRMS (ESI): (calc.) 411.49406, (found) 412.17 [M + H],butoxybenzoyl)piperazin-1- HPLC (215 nM): 100%, RT 3.46 min.yl)-N-hydroxy-2- phenylacetamide 8-477 2-(4-(2-(3,4- LRMS (ESI): (calc.)413.46688, (found) 414.19 [M + H], dimethoxyphenyl)acetyl)piperazin-HPLC (215 nM): 100%, RT 2.69 min. 1-yl)-N-hydroxy-2- phenylacetamide8-478 N-hydroxy-2-(4-(5-methyl-3- LRMS (ESI): (calc.) 434.48764, (found)435.22 [M + H], phenylisoxazole-4-carbonyl)- HPLC (215 nM): 93.4%, RT2.88 min. 1,4-diazepan-1-yl)-2- phenylacetamide 8-479N-hydroxy-2-(4-(5-methyl-3- LRMS (ESI): (calc.) 420.46106, (found)421.18 [M + H], phenylisoxazole-4- HPLC (215 nM): 92.58%, RT 3.16 min.carbonyl)piperazin-1-yl)-2- phenylacetamide 8-480N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.) 435.5386, (found) 436.16[M + H], (thiophen-2-yl)benzoyl)-1,4- HPLC (215 nM): 86.15%, RT 3.1 min.diazepan-1-yl)acetamide 8-481 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI):(calc.) 437.4122896, (found) 438.18 [M + H], (trifluoromethoxy)benzoyl)-HPLC (215 nM): 89.54%, RT 3.02 min. 1,4-diazepan-1-yl)acetamide 8-482N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.) 423.3857096, (found)424.14 [M + H], (trifluoromethoxy)benzoyl)piperazin- HPLC (215 nM):87.48%, RT 3.31 min. 1H NMR (250 MHz, 1-yl)acetamide DMSO-d6) d ppm10.87 (1H, br. s.), 8.92 (1H, br. s.), 7.23-7.58 (9H, m), 3.37-3.76 (5H,m), 2.26-2.44 (4H, m) 8-483 N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI):(calc.) 437.4122896, (found) 438.18 [M + H], (trifluoromethoxy)benzoyl)-HPLC (215 nM): 90.38%, RT 3.01 min. 1,4-diazepan-1-yl)acetamide 8-484N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI): (calc.) 423.3857096, (found)424.14 [M + H], (trifluoromethoxy)benzoyl)piperazin- HPLC (215 nM):100%, RT 3.31 min. 1-yl)acetamide 8-485 2-(4-(2-fluoro-4- LRMS (ESI):(calc.) 425.3767728, (found) 426.15 [M + H],(trifluoromethyl)benzoyl)piperazin- HPLC (215 nM): 100%, RT 3.4 min.1-yl)-N-hydroxy-2- phenylacetamide 8-486 2-(4-(4-fluoro-2- LRMS (ESI):(calc.) 425.3767728, (found) 426.09 [M + H],(trifluoromethyl)benzoyl)piperazin- HPLC (215 nM): 100%, RT 3.22 min.1-yl)-N-hydroxy-2- phenylacetamide 8-487 2-(4-(2-(4-tert- LRMS (ESI):(calc.) 439.54722, (found) 440.26 [M + H], butylphenoxy)acetyl)-1,4-HPLC (215 nM): 91.53%, RT 3.32 min. 1H NMR (250 MHz,diazepan-1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.73-10.91 (1H, m),8.86-9.00 (1H, phenylacetamide m), 7.19-7.50 (7H, m), 6.74-6.88 (2H, m),4.65-4.85 (2H, m), 3.94-4.11 (1H, m), 3.39-3.60 (4H, m), 2.53-2.82 (4H,m), 1.57-1.84 (2H, m), 1.24 (9H, s) 8-488 2-(4-(2-(4-tert- LRMS (ESI):(calc.) 425.52064, (found) 426 [M + H], HPLCbutylphenoxy)acetyl)piperazin- (215 nM): 92%, RT 3.62 min.1-yl)-N-hydroxy-2- phenylacetamide 8-489 N-hydroxy-2-(4-(4-methoxy- LRMS(ESI): (calc.) 437.4122896, (found) 438 [M + H], 3- HPLC (215 nM): 98%,RT 3.23 min. (trifluoromethyl)benzoyl)piperazin- 1-yl)-2-phenylacetamide 8-490 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.)453.4778896, (found) 454.17 [M + H], (trifluoromethylthio)benzoyl)- HPLC(215 nM): 89.54%, RT 3.18 min. 1,4-diazepan-1-yl)acetamide 8-491N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.) 439.4513096, (found)440.13 [M + H], (trifluoromethylthio)benzoyl)piperazin- HPLC (215 nM):96.3%, RT 3.5 min. 1-yl)acetamide 8-492 2-(4-(3-(2-chlorophenyl)-5- LRMS(ESI): (calc.) 468.9327, (found) 469.16 [M + H],methylisoxazole-4-carbonyl)- HPLC (215 nM): 95.62%, RT 2.91 min.1,4-diazepan-1-yl)-N- hydroxy-2-phenylacetamide 8-4932-(4-(3-(2-chlorophenyl)-5- LRMS (ESI): (calc.) 454.90612, (found)455.12 [M + H], methylisoxazole-4- HPLC (215 nM): 93.38%, RT 3.25 min.carbonyl)piperazin-1-yl)-N- hydroxy-2-phenylacetamide 8-494N-ethyl-4-(2- LRMS (ESI): (calc.) 306.36018, (found) 307 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 95%, RT 1.81 min. 1H NMR (500 MHz,DMSO- phenylethyl)piperazine-1- d6) d ppm 10.84 (1H, br. s.), 8.90 (1H,br. s.), 7.39-7.47 (2H, carboxamide m), 7.24-7.38 (3H, m), 6.42 (1H, br.s.), 3.62 (1H, br. s.), 3.18-3.29 (4H, m), 2.97-3.07 (2H, m), 2.17-2.34(4H, m), 0.98 (3H, t, J = 7.09 Hz) 8-495 4-(2-(hydroxyamino)-2-oxo- LRMS(ESI): (calc.) 334.41334, (found) 335 [M + H], HPLC1-phenylethyl)-N-propyl-1,4- (215 nM): 96.01%, RT 2.13 min.diazepane-1-carboxamide 8-496 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 320.38676, (found) 321 [M + H], HPLC 1-phenylethyl)-N- (215 nM):98.02%, RT 2.12 min. propylpiperazine-1- carboxamide 8-497 N-butyl-4-(2-LRMS (ESI): (calc.) 348.43992, (found) 349 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 96.24%, RT 2.42 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-498 N-butyl-4-(2- LRMS(ESI): (calc.) 334.41334, (found) 335 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 95.33%, RT 2.42 min.phenylethyl)piperazine-1- carboxamide 8-499 N-tert-butyl-4-(2- LRMS(ESI): (calc.) 348.43992, (found) 349 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 96.57%, RT 2.4 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-500 N-tert-butyl-4-(2- LRMS(ESI): (calc.) 334.41334, (found) 335 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 95.98%, RT 2.39 min.phenylethyl)piperazine-1- carboxamide 8-501 N-cyclopentyl-4-(2- LRMS(ESI): (calc.) 360.45062, (found) 361 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 93.81%, RT 2.42 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-502 N-cyclopentyl-4-(2- LRMS(ESI): (calc.) 346.42404, (found) 347 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 95.31%, RT 2.45 min.phenylethyl)piperazine-1- carboxamide 8-503 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 354.40298, (found) 355 [M + H], HPLC1-phenylethyl)-N- (215 nM): 95.56%, RT 2.53 min. phenylpiperazine-1-carboxamide 8-504 N-(furan-2-ylmethyl)-4-(2- LRMS (ESI): (calc.)372.41826, (found) 373 [M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM):88.08%, RT 2.21 min. phenylethyl)-1,4-diazepane- 1-carboxamide 8-505N-(furan-2-ylmethyl)-4-(2- LRMS (ESI): (calc.) 358.39168, (found) 359[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 91.94%, RT 2.26 min.phenylethyl)piperazine-1- carboxamide 8-506 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 360.4307, (found) 361 [M + H], HPLC1-phenylethyl)-N-(thiophen- (215 nM): 91.46%, RT 2.5 min.2-yl)piperazine-1- carboxamide 8-507 N-cyclohexyl-4-(2- LRMS (ESI):(calc.) 374.4772, (found) 375 [M + H], HPLC (hydroxyamino)-2-oxo-1- (215nM): 94.74%, RT 2.63 min. phenylethyl)-1,4-diazepane- 1-carboxamide8-508 N-cyclohexyl-4-(2- LRMS (ESI): (calc.) 360.45062, (found) 361 [M +H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 93.38%, RT 2.65 min.phenylethyl)piperazine-1- carboxamide 8-509 N-benzyl-4-(2- LRMS (ESI):(calc.) 382.45614, (found) 383 [M + H], HPLC (hydroxyamino)-2-oxo-1-(215 nM): 92.94%, RT 2.49 min. phenylethyl)-1,4-diazepane- 1-carboxamide8-510 N-benzyl-4-(2- LRMS (ESI): (calc.) 368.42956, (found) 369 [M + H],HPLC (hydroxyamino)-2-oxo-1- (215 nM): 100%, RT 2.56 min.phenylethyl)piperazine-1- carboxamide 8-511 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 382.45614, (found) 383 [M + H], HPLC1-phenylethyl)-N-m-tolyl- (215 nM): 92.76%, RT 2.63 min.1,4-diazepane-1-carboxamide 8-512 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 368.42956, (found) 369 [M + H], HPLC 1-phenylethyl)-N-m- (215nM): 90.38%, RT 2.74 min. tolylpiperazine-1- carboxamide 8-5134-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 382.45614, (found) 383[M + H], HPLC 1-phenylethyl)-N-p-tolyl-1,4- (215 nM): 93.39%, RT 2.62min. diazepane-1-carboxamide 8-514 4-(2-(hydroxyamino)-2-oxo- LRMS(ESI): (calc.) 368.42956, (found) 369 [M + H], HPLC 1-phenylethyl)-N-p-(215 nM): 93.87%, RT 2.69 min. tolylpiperazine-1- carboxamide 8-515N-(4-fluorophenyl)-4-(2- LRMS (ESI): (calc.) 386.4200232, (found) 387[M + H], (hydroxyamino)-2-oxo-1- HPLC (215 nM): 96.14%, RT 2.52 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-516 N-(4-fluorophenyl)-4-(2-LRMS (ESI): (calc.) 372.3934432, (found) 373 [M + H],(hydroxyamino)-2-oxo-1- HPLC (215 nM): 95.93%, RT 2.62 min.phenylethyl)piperazine-1- carboxamide 8-517 N-(2-fluorophenyl)-4-(2-LRMS (ESI): (calc.) 386.4200232, (found) 387 [M + H],(hydroxyamino)-2-oxo-1- HPLC (215 nM): 87.5%, RT 2.4 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-518 N-(2-fluorophenyl)-4-(2-LRMS (ESI): (calc.) 372.3934432, (found) 373 [M + H],(hydroxyamino)-2-oxo-1- HPLC (215 nM): 93.26%, RT 2.54 min.phenylethyl)piperazine-1- carboxamide 8-519 N-(3,5-dimethylisoxazol-4-LRMS (ESI): (calc.) 387.4329, (found) 388 [M + H], HPLCyl)-4-(2-(hydroxyamino)-2- (215 nM): 99%, RT 2.05 min. 1H NMR (500 MHz,DMSO- oxo-1-phenylethyl)-1,4- d6) d ppm 10.82 (1H, br. s.), 8.93 (1H,br. s.), 7.69 (1H, br. diazepane-1-carboxamide s.), 7.14-7.56 (5H, m),4.05 (1H, br. s.), 3.39-3.59 (4H, m), 2.56-2.84 (4H, m), 2.22 (3H, s),2.05 (3H, s), 1.61-1.81 (2H, m) 8-520 N-benzoyl-4-(2- LRMS (ESI):(calc.) 396.43966, (found) 397 [M + H], HPLC (hydroxyamino)-2-oxo-1-(215 nM): 87.37%, RT 2.45 min. phenylethyl)-1,4-diazepane- 1-carboxamide8-521 N-benzoyl-4-(2- LRMS (ESI): (calc.) 382.41308, (found) 383 [M +H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 100%, RT 2.58 min.phenylethyl)piperazine-1- carboxamide 8-522 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 396.48272, (found) 397 [M + H], HPLC1-phenylethyl)-N-(2- (215 nM): 92.8%, RT 2.67 min.methylbenzyl)-1,4-diazepane- 1-carboxamide 8-5234-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 382.45614, (found) 383[M + H], HPLC 1-phenylethyl)-N-(2- (215 nM): 90.93%, RT 2.74 min.methylbenzyl)piperazine-1- carboxamide 8-524N-(2,6-dimethylphenyl)-4-(2- LRMS (ESI): (calc.) 396.48272, (found) 397[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92.19%, RT 2.54 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-525N-(2,5-dimethylphenyl)-4-(2- LRMS (ESI): (calc.) 396.48272, (found) 397[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92%, RT 2.77 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-526N-(2,5-dimethylphenyl)-4-(2- LRMS (ESI): (calc.) 382.45614, (found) 383[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92%, RT 2.83 min.phenylethyl)piperazine-1- carboxamide 8-527 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 396.48272, (found) 397 [M + H], HPLC1-phenylethyl)-N-phenethyl- (215 nM): 90.59%, RT 2.65 min.1,4-diazepane-1-carboxamide 8-528 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 382.45614, (found) 383 [M + H], HPLC 1-phenylethyl)-N- (215 nM):91.65%, RT 2.7 min. phenethylpiperazine-1- carboxamide 8-529N-(2-ethylphenyl)-4-(2- LRMS (ESI): (calc.) 382.45614, (found) 383 [M +H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92.9%, RT 2.76 min.phenylethyl)piperazine-1- carboxamide 8-530 N-(4-ethylphenyl)-4-(2- LRMS(ESI): (calc.) 396.48272, (found) 397 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 87.65%, RT 2.83 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-531 N-(4-ethylphenyl)-4-(2-LRMS (ESI): (calc.) 382.45614, (found) 383 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 92.16%, RT 2.96 min.phenylethyl)piperazine-1- carboxamide 8-532 N-(2,3-dimethylphenyl)-4-(2-LRMS (ESI): (calc.) 396.48272, (found) 397 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 93.58%, RT 2.63 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-533N-(2,3-dimethylphenyl)-4-(2- LRMS (ESI): (calc.) 382.45614, (found) 383[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92.81%, RT 2.74 min.phenylethyl)piperazine-1- carboxamide 8-534 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 398.45554, (found) 399 [M + H], HPLC1-phenylethyl)-N-(4- (215 nM): 88.68%, RT 2.44 min. methoxyphenyl)-1,4-diazepane-1-carboxamide 8-535 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 384.42896, (found) 385 [M + H], HPLC 1-phenylethyl)-N-(4- (215nM): 93.83%, RT 2.53 min. methoxyphenyl)piperazine-1- carboxamide 8-5364-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 398.45554, (found) 399[M + H], HPLC 1-phenylethyl)-N-(2- (215 nM): 100%, RT 2.6 min.methoxyphenyl)-1,4- diazepane-1-carboxamide 8-5374-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 384.42896, (found) 385[M + H], HPLC 1-phenylethyl)-N-(2- (215 nM): 100%, RT 2.68 min.methoxyphenyl)piperazine-1- carboxamide 8-538N-(5-fluoro-2-methylphenyl)- LRMS (ESI): (calc.) 400.4466032, (found)401 [M + H], 4-(2-(hydroxyamino)-2-oxo- HPLC (215 nM): 86.51%, RT 2.58min. 1-phenylethyl)-1,4- diazepane-1-carboxamide 8-539N-(5-fluoro-2-methylphenyl)- LRMS (ESI): (calc.) 386.4200232, (found)387 [M + H], 4-(2-(hydroxyamino)-2-oxo- HPLC (215 nM): 91.74%, RT 2.74min. 1-phenylethyl)piperazine-1- carboxamide 8-5404-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 402.51044, (found) 403[M + H], HPLC 1-phenylethyl)-N-(2- (215 nM): 94.49%, RT 2.59 min.(thiophen-2-yl)ethyl)-1,4- diazepane-1-carboxamide 8-5414-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 388.48386, (found) 389[M + H], HPLC 1-phenylethyl)-N-(2- (215 nM): 90.3%, RT 2.61 min.(thiophen-2- yl)ethyl)piperazine-1- carboxamide 8-542N-(3-chlorophenyl)-4-(2- LRMS (ESI): (calc.) 388.84804, (found) 389 [M +H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 98%, RT 2.95 min.phenylethyl)piperazine-1- carboxamide 8-543 N-(4-chlorophenyl)-4-(2-LRMS (ESI): (calc.) 388.84804, (found) 389 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 93.87%, RT 2.9 min.phenylethyl)piperazine-1- carboxamide 8-544 N-(3,4-difluorophenyl)-4-(2-LRMS (ESI): (calc.) 404.4104864, (found) 405 [M + H],(hydroxyamino)-2-oxo-1- HPLC (215 nM): 94.1%, RT 2.64 min. 1H NMR (500MHz, phenylethyl)-1,4-diazepane- DMSO-d6) d ppm 10.81 (1H, br. s.), 8.92(1H, br. s.), 1-carboxamide 8.42 (1H, br. s.), 7.56-7.76 (1H, m),7.38-7.48 (2H, m), 7.21-7.36 (5H, m), 4.02 (1H, br. s.), 3.38-3.61 (4H,m), 2.54-2.78 (4H, m), 1.61-1.83 (2H, m) 8-5454-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 410.5093, (found) 411[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 87.88%, RT 3.01 min.isopropylphenyl)-1,4- diazepane-1-carboxamide 8-5464-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 396.48272, (found) 397[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 87.12%, RT 3.13 min.isopropylphenyl)piperazine- 1-carboxamide 8-5474-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 410.5093, (found) 411[M + H], HPLC 1-phenylethyl)-N-mesityl- (215 nM): 90.93%, RT 2.74 min.1,4-diazepane-1-carboxamide 8-548 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 396.48272, (found) 397 [M + H], HPLC 1-phenylethyl)-N- (215 nM):100%, RT 2.87 min. mesitylpiperazine-1- carboxamide 8-549 N-(4- LRMS(ESI): (calc.) 411.49736, (found) 206 [M + H], HPLC(dimethylamino)phenyl)-4-(2- (215 nM): 90%, RT 0.75 min. 1H NMR (250MHz, DMSO- (hydroxyamino)-2-oxo-1- d6) d ppm 10.80 (1H, br. s.), 8.91(1H, br. s.), 7.88 (1H, s), phenylethyl)-1,4-diazepane- 7.05-7.58 (7H,m), 6.63 (2H, d, J = 9.14 Hz), 4.01 (1H, br. 1-carboxamide s.),3.39-3.67 (4H, m), 2.81 (6H, s), 2.56-2.73 (4H, m), 1.52-1.88 (2H, m)8-550 N-(4- LRMS (ESI): (calc.) 397.47078, (found) 199 [M + H], HPLC(dimethylamino)phenyl)-4-(2- (215 nM): 95%, RT 1.88 min. 1H NMR (500MHz, DMSO- (hydroxyamino)-2-oxo-1- d6) d ppm 10.86 (1H, br. s.), 8.93(1H, br. s.), 8.17 (1H, br. phenylethyl)piperazine-1- s.), 7.40-7.50(2H, m), 7.26-7.40 (3H, m), 7.20 (2H, m, carboxamide J = 8.83 Hz), 6.64(2H, m, J = 8.67 Hz), 3.67 (1H, br. s.), 3.36-3.46 (4H, m), 2.82 (6H,s), 2.25-2.44 (4H, m) 8-551 N-(benzo[d][1,3]dioxol-5-yl)- LRMS (ESI):(calc.) 412.43906, (found) 413 [M + H], HPLC 4-(2-(hydroxyamino)-2-oxo-(215 nM): 87.59%, RT 2.41 min. 1-phenylethyl)-1,4-diazepane-1-carboxamide 8-552 N-(benzo[d][1,3]dioxol-5-yl)- LRMS (ESI):(calc.) 398.41248, (found) 399 [M + H], HPLC 4-(2-(hydroxyamino)-2-oxo-(215 nM): 100%, RT 2.55 min. 1-phenylethyl)piperazine-1- carboxamide8-553 N-(2-ethoxyphenyl)-4-(2- HPLC (215 nM): %, RT min. 1H NMR (500MHz, DMSO- (hydroxyamino)-2-oxo-1- d6) d ppm 10.80 (1H, s), 8.91 (1H,s), 7.81 (1H, dd, J = 7.88, phenylethyl)-1,4-diazepane- 0.95 Hz), 7.42(2H, d, J = 7.09 Hz), 7.18-7.36 (4H, m), 1-carboxamide 6.91-7.00 (2H,m), 6.81-6.90 (1H, m), 3.94-4.08 (3H, m), 3.51-3.59 (2H, m), 3.47 (2H,t, J = 4.97 Hz), 2.61-2.74 (2H, m), 2.58 (2H, t, J = 5.44 Hz), 1.74 (2H,br. s.), 1.31 (3H, t, J = 6.94 Hz) 8-554 N-(2-ethoxyphenyl)-4-(2- LRMS(ESI): (calc.) 398.45554, (found) 399 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 96%, RT 2.94 min.phenylethyl)piperazine-1- carboxamide 8-555 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 412.48212, (found) 413 [M + H], HPLC1-phenylethyl)-N-(2- (215 nM): 92.82%, RT 2.63 min. methoxybenzyl)-1,4-diazepane-1-carboxamide 8-556 4-(2-(hydroxyamino)-2-oxo- LRMS (ESI):(calc.) 398.45554, (found) 399 [M + H], HPLC 1-phenylethyl)-N-(2- (215nM): 94.18%, RT 2.7 min. methoxybenzyl)piperazine-1- carboxamide 8-5574-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 412.48212, (found) 413[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 93.36%, RT 2.55 min.methoxybenzyl)-1,4- diazepane-1-carboxamide 8-5584-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 398.45554, (found) 399[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 98%, RT 2.63 min.methoxybenzyl)piperazine-1- carboxamide 8-559 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 413.42712, (found) 414 [M + H], HPLC1-phenylethyl)-N-(2- (215 nM): 89.55%, RT 2.74 min. 1H NMR (500 MHz,nitrophenyl)-1,4-diazepane-1- DMSO-d6) d ppm 10.81 (1H, br. s.), 9.26(1H, s), 8.93 (1H, carboxamide br. s.), 7.99 (1H, dd, J = 8.28, 1.18Hz), 7.93 (1H, d, J = 8.04 Hz), 7.62-7.70 (1H, m), 7.38-7.48 (2H, m),7.24-7.37 (3H, m), 7.12-7.22 (1H, m), 4.04 (1H, s), 3.42-3.63 (4H, m),2.55-2.76 (4H, m), 1.75 (2H, br. s.) 8-560 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 399.40054, (found) 400 [M + H], HPLC1-phenylethyl)-N-(2- (215 nM): 96.73%, RT 2.9 min. 1H NMR (500 MHz,nitrophenyl)piperazine-1- DMSO-d6) d ppm 10.88 (1H, br. s.), 9.24 (1H,s), 8.94 (1H, carboxamide br. s.), 7.92 (1H, d, J = 8.20 Hz), 7.62 (2H,d, J = 3.94 Hz), 7.43-7.50 (2H, m), 7.26-7.41 (3H, m), 7.13-7.24 (1H,m), 3.70 (1H, br. s.), 3.39-3.54 (4H, m), 2.25-2.43 (4H, m) 8-5614-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 414.52114, (found) 415[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 100%, RT 2.8 min.(methylthio)phenyl)-1,4- diazepane-1-carboxamide 8-5624-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 400.49456, (found) 401[M + H], HPLC 1-phenylethyl)-N-(4- (215 nM): 97%, RT 2.9 min.(methylthio)phenyl)piperazine- 1-carboxamide 8-563N-(4-tert-butylphenyl)-4-(2- LRMS (ESI): (calc.) 424.53588, (found) 425[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 88.34%, RT 3.12 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-564N-(4-tert-butylphenyl)-4-(2- LRMS (ESI): (calc.) 410.5093, (found) 411[M + H], HPLC (hydroxyamino)-2-oxo-1- (215 nM): 92.82%, RT 3.27 min.phenylethyl)piperazine-1- carboxamide 8-565 N-(2,4-dimethoxyphenyl)-4-LRMS (ESI): (calc.) 428.48152, (found) 429 [M + H], HPLC(2-(hydroxyamino)-2-oxo-1- (215 nM): 100%, RT 2.58 min.phenylethyl)-1,4-diazepane- 1-carboxamide 8-566N-(2,4-dimethoxyphenyl)-4- LRMS (ESI): (calc.) 414.45494, (found) 415[M + H], HPLC (2-(hydroxyamino)-2-oxo-1- (215 nM): 88.52%, RT 2.61 min.phenylethyl)piperazine-1- carboxamide 8-567 N-(3,5-dimethoxyphenyl)-4-LRMS (ESI): (calc.) 414.45494, (found) 415 [M + H], HPLC(2-(hydroxyamino)-2-oxo-1- (215 nM): 94%, RT 2.76 min.phenylethyl)piperazine-1- carboxamide 8-568 N-(2,4-dichlorophenyl)-4-(2-LRMS (ESI): (calc.) 423.2931, (found) 423 [M + H], HPLC(hydroxyamino)-2-oxo-1- (215 nM): 87%, RT 3.11 min.phenylethyl)piperazine-1- carboxamide 8-569 4-(2-(hydroxyamino)-2-oxo-LRMS (ESI): (calc.) 438.4003496, (found) 439 [M + H],1-phenylethyl)-N-(4- HPLC (215 nM): 87.26%, RT 3.16 min.(trifluoromethoxy)phenyl)piperazine- 1-carboxamide 8-570N-benzhydryl-4-(2- HPLC (215 nM): 93%, RT min. 1H NMR (500 MHz,(hydroxyamino)-2-oxo-1- DMSO-d6) d ppm 10.83 (1H, br. s.), 8.91 (1H, s),7.43 (2H, phenylethyl)piperazine-1- d, J = 7.09 Hz), 7.24-7.37 (11H, m),7.19-7.24 (2H, m), carboxamide 7.16 (1H, d, J = 8.67 Hz), 6.04 (1H, d, J= 8.67 Hz), 3.64 (1H, s), 3.35-3.41 (4H, m), 2.18-2.32 (4H, m) 8-5714-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 458.5075, (found) 459[M + H], HPLC 1-phenylethyl)-N-(3,4,5- (215 nM): 95%, RT 2.57 min.trimethoxybenzyl)piperazine- 1-carboxamide 8-572 N-hydroxy-2-(4- LRMS(ESI): (calc.) 313.37266, (found) 314.08 [M + H],(methylsulfonyl)piperazin-1- HPLC (215 nM): 88.73%, RT 2.22 min.yl)-2-phenylacetamide 8-573 N-hydroxy-2-(4- LRMS (ESI): (calc.)327.39924, (found) 328.14 [M + H], (methylsulfonyl)-1,4- HPLC (215 nM):98.28%, RT 1.84 min. 1H NMR (250 MHz, diazepan-1-yl)-2- DMSO-d6) d ppm10.58-11.10 (1H, m), 8.68-9.19 (1H, phenylacetamide m), 7.18-7.54 (5H,m), 3.86-4.24 (1H, m), 3.13-3.32 (4H, m), 2.91 (3H, s), 2.66 (4H, m),1.58-1.83 (2H, m) 8-574 2-(4-(ethylsulfonyl)piperazin- LRMS (ESI):(calc.) 327.39924, (found) 328.14 [M + H], 1-yl)-N-hydroxy-2- HPLC (215nM): 90.73%, RT 2.43 min. phenylacetamide 8-5752-(4-(ethylsulfonyl)-1,4- LRMS (ESI): (calc.) 341.42582, (found) 342.15[M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 98.02%, RT 2.15 min.phenylacetamide 8-576 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.)341.42582, (found) 342.19 [M + H], (propylsulfonyl)piperazin-1- HPLC(215 nM): 93.75%, RT 2.72 min. yl)acetamide 8-577N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 355.4524, (found) 356.17[M + H], (propylsulfonyl)-1,4- HPLC (215 nM): 92.22%, RT 2.44 min.diazepan-1-yl)acetamide 8-578 2-(4-(butylsulfonyl)piperazin- LRMS (ESI):(calc.) 355.4524, (found) 356.17 [M + H], 1-yl)-N-hydroxy-2- HPLC (215nM): 90.25%, RT 3.02 min. phenylacetamide 8-5792-(4-(butylsulfonyl)-1,4- LRMS (ESI): (calc.) 369.47898, (found) 370.21[M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 100%, RT 2.69 min.phenylacetamide 8-580 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.)389.46862, (found) 390.19 [M + H], (phenylsulfonyl)-1,4- HPLC (215 nM):91.46%, RT 2.76 min. diazepan-1-yl)acetamide 8-581N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 381.46976, (found) 382.13[M + H], (thiophen-2- HPLC (215 nM): 95%, RT 3.2 min.ylsulfonyl)piperazin-1- yl)acetamide 8-582 N-hydroxy-2-phenyl-2-(4- LRMS(ESI): (calc.) 395.49634, (found) 396.11 [M + H],(thiophen-2-ylsulfonyl)-1,4- HPLC (215 nM): 93.67%, RT 2.72 min.diazepan-1-yl)acetamide 8-583 2-(4- LRMS (ESI): (calc.) 389.46862,(found) 390.19 [M + H], (benzylsulfonyl)piperazin-1- HPLC (215 nM):97.8%, RT 3.13 min. yl)-N-hydroxy-2- phenylacetamide 8-5842-(4-(benzylsulfonyl)-1,4- LRMS (ESI): (calc.) 403.4952, (found) 404.17[M + H], diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 90.24%, RT 2.8 min.phenylacetamide 8-585 N-hydroxy-2-phenyl-2-(4-(p- LRMS (ESI): (calc.)389.46862, (found) 390.22 [M + H], tolylsulfonyl)piperazin-1- HPLC (215nM): 90.12%, RT 3.36 min. yl)acetamide 8-586 N-hydroxy-2-phenyl-2-(4-(p-LRMS (ESI): (calc.) 403.4952, (found) 404.17 [M + H],tolylsulfonyl)-1,4-diazepan-1- HPLC (215 nM): 92.7%, RT 2.94 min.yl)acetamide 8-587 N-hydroxy-2-phenyl-2-(4-(o- LRMS (ESI): (calc.)389.46862, (found) 390.19 [M + H], tolylsulfonyl)piperazin-1- HPLC (215nM): 92.43%, RT 3.35 min. 1H NMR (250 MHz, yl)acetamide DMSO-d6) d ppm10.83 (1H, s), 8.90 (1H, s), 7.76 (1H, d, J = 7.92 Hz), 7.53-7.65 (1H,m), 7.21-7.50 (7H, m), 3.69 (1H, s), 3.03 (4H, br. s.), 2.55 (3H, s),2.26-2.46 (4H, m) 8-588 N-hydroxy-2-phenyl-2-(4-(o- LRMS (ESI): (calc.)403.4952, (found) 404.22 [M + H], tolylsulfonyl)-1,4-diazepan-1- HPLC(215 nM): 92.91%, RT 2.95 min. yl)acetamide 8-589N-hydroxy-2-phenyl-2-(4-(m- LRMS (ESI): (calc.) 389.46862, (found)390.19 [M + H], tolylsulfonyl)piperazin-1- HPLC (215 nM): 88.69%, RT3.42 min. yl)acetamide 8-590 N-hydroxy-2-phenyl-2-(4-(m- LRMS (ESI):(calc.) 403.4952, (found) 404.17 [M + H], tolylsulfonyl)-1,4-diazepan-1-HPLC (215 nM): 933%, RT 2.98 min. yl)acetamide 8-591 2-(4-(3- LRMS(ESI): (calc.) 393.4325032, (found) 394.16 [M + H],fluorophenylsulfonyl)piperazin- HPLC (215 nM): 100%, RT 3.36 min.1-yl)-N-hydroxy-2- phenylacetamide 8-592 2-(4-(3- LRMS (ESI): (calc.)407.4590832, (found) 408.17 [M + H], fluorophenylsulfonyl)-1,4- HPLC(215 nM): 89.53%, RT 2.9 min. diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-593 2-(4-(2- LRMS (ESI): (calc.) 393.4325032, (found)394.16 [M + H], fluorophenylsulfonyl)piperazin- HPLC (215 nM): 91.61%,RT 3.26 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-594 2-(4-(2- LRMS(ESI): (calc.) 407.4590832, (found) 408.15 [M + H],fluorophenylsulfonyl)-1,4- HPLC (215 nM): 90.79%, RT 2.83 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-595 2-(4-(1,2-dimethyl-1H-LRMS (ESI): (calc.) 393.46062, (found) 394.16 [M + H], imidazol-4- HPLC(215 nM): 92.87%, RT 2.4 min. 1H NMR (250 MHz,ylsulfonyl)piperazin-1-yl)-N- DMSO-d6) d ppm 10.83 (1H, s), 8.89 (1H,s), 7.71 (1H, s), hydroxy-2-phenylacetamide 7.19-7.40 (5H, m), 3.55-3.68(4H, m), 2.96 (4H, br. s.), 2.26-2.44 (7H, m) 8-5962-(4-(1,2-dimethyl-1H- LRMS (ESI): (calc.) 407.4872, (found) 408.2 [M +H], HPLC imidazol-4-ylsulfonyl)-1,4- (215 nM): 92.92%, RT 2.21 min. 1HNMR (250 MHz, diazepan-1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.79 (1H, br.s.), 8.92 (1H, br. s.), phenylacetamide 7.67 (1H, s), 7.20-7.46 (5H, m),4.02 (1H, s), 3.59 (3H, s), 3.06-3.31 (4H, m), 2.54-2.75 (4H, m), 2.30(3H, s), 1.54-1.79 (2H, m) 8-597 2-(4-(3,5-dimethylisoxazol-4- LRMS(ESI): (calc.) 394.44538, (found) 395.16 [M + H],ylsulfonyl)piperazin-1-yl)-N- HPLC (215 nM): 95.88%, RT 3.23 min.hydroxy-2-phenylacetamide 8-598 2-(4-(3,4- LRMS (ESI): (calc.) 403.4952,(found) 404.26 [M + H], dimethylphenylsulfonyl)piperazin- HPLC (215 nM):87.99%, RT 3.52 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-599 2-(4-(3,4-LRMS (ESI): (calc.) 417.52178, (found) 418.22 [M + H],dimethylphenylsulfonyl)-1,4- HPLC (215 nM): 90.88%, RT 3.09 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-600 2-(4-(2,5- LRMS (ESI):(calc.) 403.4952, (found) 404.17 [M + H],dimethylphenylsulfonyl)piperazin- HPLC (215 nM): 89.93%, RT 3.54 min.1-yl)-N-hydroxy-2- phenylacetamide 8-601 2-(4-(2,5- LRMS (ESI): (calc.)417.52178, (found) 418.22 [M + H], dimethylphenylsulfonyl)-1,4- HPLC(215 nM): 92.34%, RT 3.14 min. diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-602 2-(4-(3,5- LRMS (ESI): (calc.) 403.4952, (found)404.26 [M + H], dimethylphenylsulfonyl)piperazin- HPLC (215 nM): 92.44%,RT 3.57 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-603 2-(4-(3,5- LRMS(ESI): (calc.) 417.52178, (found) 418.22 [M + H],dimethylphenylsulfonyl)-1,4- HPLC (215 nM): 95.15%, RT 3.13 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-604 N-hydroxy-2-(4-(4-LRMS (ESI): (calc.) 405.46802, (found) 406.19 [M + H],methoxyphenylsulfonyl)piperazin- HPLC (215 nM): 91.23%, RT 3.25 min.1-yl)-2-phenylacetamide 8-605 N-hydroxy-2-(4-(4- LRMS (ESI): (calc.)419.4946, (found) 420.19 [M + H], methoxyphenylsulfonyl)-1,4- HPLC (215nM): 90.91%, RT 2.84 min. diazepan-1-yl)-2- phenylacetamide 8-606N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 419.4946, (found) 420.17 [M + H],methoxyphenylsulfonyl)-1,4- HPLC (215 nM): 90.53%, RT 2.91 min.diazepan-1-yl)-2- phenylacetamide 8-607 2-(4-(4-fluoro-2- LRMS (ESI):(calc.) 407.4590832, (found) 408.16 [M + H],methylphenylsulfonyl)piperazin- HPLC (215 nM): 95.24%, RT 3.46 min.1-yl)-N-hydroxy-2- phenylacetamide 8-608 2-(4-(4-fluoro-2- LRMS (ESI):(calc.) 421.4856632, (found) 422.18 [M + H], methylphenylsulfonyl)-1,4-HPLC (215 nM): 88.01%, RT 3.05 min. diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-609 2-(4-(4- LRMS (ESI): (calc.) 409.8871, (found)410.09 [M + H], chlorophenylsulfonyl)piperazin- HPLC (215 nM): 92.86%,RT 3.55 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-610 2-(4-(4- LRMS(ESI): (calc.) 423.91368, (found) 424.14 [M + H],chlorophenylsulfonyl)-1,4- HPLC (215 nM): 88.4%, RT 3.07 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-611 2-(4-(2- LRMS (ESI):(calc.) 409.8871, (found) 410.09 [M + H],chlorophenylsulfonyl)piperazin- HPLC (215 nM): 94.27%, RT 3.34 min.1-yl)-N-hydroxy-2- phenylacetamide 8-612 2-(4-(3- LRMS (ESI): (calc.)409.8871, (found) 410.09 [M + H], chlorophenylsulfonyl)piperazin- HPLC(215 nM): 89.4%, RT 3.57 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-6132-(4-(5-chlorothiophen-2- LRMS (ESI): (calc.) 415.91482, (found) 416.07[M + H], ylsulfonyl)piperazin-1-yl)-N- HPLC (215 nM): 96.25%, RT 3.64min. hydroxy-2-phenylacetamide 8-614 2-(4-(5-chlorothiophen-2- LRMS(ESI): (calc.) 429.9414, (found) 430.12 [M + H],ylsulfonyl)-1,4-diazepan-1- HPLC (215 nM): 94.73%, RT 3.14 min.yl)-N-hydroxy-2- phenylacetamide 8-615 N-hydroxy-2-(4-(2-methoxy- LRMS(ESI): (calc.) 419.4946, (found) 420.17 [M + H], 4- HPLC (215 nM):87.87%, RT 3.2 min. methylphenylsulfonyl)piperazin-1-yl)-2-phenylacetamide 8-616 N-hydroxy-2-(4-(2-methoxy- LRMS (ESI):(calc.) 433.52118, (found) 434.21 [M + H], 4-methylphenylsulfonyl)-1,4-HPLC (215 nM): 93.72%, RT 2.91 min. diazepan-1-yl)-2- phenylacetamide8-617 2-(4-(3-chloro-4- LRMS (ESI): (calc.) 423.91368, (found) 424.17[M + H], methylphenylsulfonyl)piperazin- HPLC (215 nM): 93.92%, RT 3.73min. 1H NMR (250 MHz, 1-yl)-N-hydroxy-2- DMSO-d6) d ppm 10.69-10.93 (1H,m), 8.79-8.98 (1H, phenylacetamide m), 7.55-7.74 (3H, m), 7.17-7.41 (5H,m), 3.59-3.77 (1H, m), 2.74-3.03 (4H, m), 2.27-2.46 (7H, m) 8-6182-(4-(3-chloro-4- LRMS (ESI): (calc.) 437.94026, (found) 438.12 [M + H],methylphenylsulfonyl)-1,4- HPLC (215 nM): 88.01%, RT 3.25 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-619 2-(4-(4- LRMS (ESI):(calc.) 423.91368, (found) 424.17 [M + H],chlorobenzylsulfonyl)piperazin- HPLC (215 nM): 90.85%, RT 3.41 min.1-yl)-N-hydroxy-2- phenylacetamide 8-620 2-(4-(4- LRMS (ESI): (calc.)437.94026, (found) 438.14 [M + H], chlorobenzylsulfonyl)-1,4- HPLC (215nM): 90.9%, RT 3.08 min. diazepan-1-yl)-N-hydroxy-2- phenylacetamide8-621 2-(4-(3- LRMS (ESI): (calc.) 423.91368, (found) 424.17 [M + H],chlorobenzylsulfonyl)piperazin- HPLC (215 nM): 88.33%, RT 3.41 min.1-yl)-N-hydroxy-2- phenylacetamide 8-622 N-hydroxy-2-(4-(naphthalen-LRMS (ESI): (calc.) 425.50072, (found) 426.19 [M + H],2-ylsulfonyl)piperazin-1-yl)- HPLC (215 nM): 90.45%, RT 3.64 min.2-phenylacetamide 8-623 N-hydroxy-2-(4-(naphthalen- LRMS (ESI): (calc.)439.5273, (found) 440.17 [M + H], 2-ylsulfonyl)-1,4-diazepan-1- HPLC(215 nM): 90.78%, RT 3.2 min. 1H NMR (250 MHz, yl)-2-phenylacetamideDMSO-d6) d ppm 10.76 (1H, br. s.), 8.90 (1H, br. s.), 8.38-8.52 (1H, m),8.02-8.25 (3H, m), 7.61-7.86 (3H, m), 7.20-7.38 (5H, m), 3.89-4.10 (1H,m), 3.23-3.31 (4H, m), 2.54-2.69 (4H, m), 1.49-1.83 (2H, m) 8-6242-(4-(4-tert- LRMS (ESI): (calc.) 445.57494, (found) 446.24 [M + H],butylphenylsulfonyl)-1,4- HPLC (215 nM): 91.16%, RT 3.45 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-625 2-(4-(4- LRMS (ESI):(calc.) 432.49336, (found) 433.24 [M + H],acetamidophenylsulfonyl)piperazin- HPLC (215 nM): 94.38%, RT 2.87 min.1-yl)-N-hydroxy-2- phenylacetamide 8-626 2-(4-(4- LRMS (ESI): (calc.)446.51994, (found) 447.18 [M + H], acetamidophenylsulfonyl)- HPLC (215nM): 87.99%, RT 2.58 min. 1,4-diazepan-1-yl)-N-hydroxy-2-phenylacetamide 8-627 2-(4-(3,4- LRMS (ESI): (calc.) 435.494,(found) 436.16 [M + H], HPLC dimethoxyphenylsulfonyl)piperazin- (215nM): 90.85%, RT 3.13 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-6282-(4-(3,4- LRMS (ESI): (calc.) 449.52058, (found) 450.21 [M + H],dimethoxyphenylsulfonyl)- HPLC (215 nM): 95.23%, RT 2.8 min.1,4-diazepan-1-yl)-N- hydroxy-2-phenylacetamide 8-629N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI): (calc.) 443.4400096, (found)444.16 [M + H], (trifluoromethyl)phenylsulfonyl)piperazin- HPLC (215nM): 93.18%, RT 3.73 min. 1-yl)acetamide 8-630N-hydroxy-2-phenyl-2-(4-(3- LRMS (ESI): (calc.) 457.4665896, (found)458.17 [M + H], (trifluoromethyl)phenylsulfonyl)- HPLC (215 nM): 93.52%,RT 3.24 min. 1,4-diazepan-1- yl)acetamide 8-6312-(4-(2,5-dichlorothiophen-3- LRMS (ESI): (calc.) 450.35988, (found)450.05 [M + H], ylsulfonyl)piperazin-1-yl)-N- HPLC (215 nM): 92.97% RT3.78 min. hydroxy-2-phenylacetamide 8-632 2-(4- LRMS (ESI): (calc.)289.37272, (found) 290 [M + H], HPLC (cyclopropylmethyl)piperazin- (215nM): 91.32%, RT 2.01 min. 1-yl)-N-hydroxy-2- phenylacetamide 8-633N-hydroxy-2-(4- LRMS (ESI): (calc.) 291.3886, (found) 292 [M + H], HPLCisobutylpiperazin-1-yl)-2- (215 nM): 96.04%, RT 2.18 min.phenylacetamide 8-634 N-hydroxy-2-(4- LRMS (ESI): (calc.) 305.41518,(found) 306 [M + H], HPLC isopentylpiperazin-1-yl)-2- (215 nM): 90.43%,RT 2.39 min. 1H NMR (250 MHz, phenylacetamide DMSO-d6) d ppm 10.92 (1H,s), 8.95 (1H, br. s.), 7.16-7.53 (5H, m), 3.73 (1H, s), 3.16-3.56 (4H,m), 2.61-3.06 (6H, m), 1.30-1.65 (3H, m), 0.88 (6H, d, J = 6.40 Hz)8-635 2-(4-(2-ethylbutyl)-1,4- LRMS (ESI): (calc.) 333.46834, (found)334 [M + H], HPLC diazepan-1-yl)-N-hydroxy-2- (215 nM): 88.76%, RT 2.68min. phenylacetamide 8-636 N-hydroxy-2-(4-(2- LRMS (ESI): (calc.)333.46834, (found) 334 [M + H], HPLC methylpentyl)-1,4-diazepan- (215nM): 90%, RT 2.68 min. 1-yl)-2-phenylacetamide 8-6372-(4-(3,3-dimethylbutyl)-1,4- LRMS (ESI): (calc.) 333.46834, (found) 334[M + H], HPLC diazepan-1-yl)-N-hydroxy-2- (215 nM): 92.59%, RT 2.72 min.phenylacetamide 8-638 2-(4-(3,3- LRMS (ESI): (calc.) 319.44176, (found)320 [M + H], HPLC dimethylbutyl)piperazin-1- (215 nM): 98.91%, RT 2.57min. 1H NMR (250 MHz, yl)-N-hydroxy-2- DMSO-d6) d ppm 10.92 (1H, br.s.), 8.95 (1H, br. s.), phenylacetamide 7.15-7.54 (5H, m), 3.71 (1H, br.s.), 3.21-3.55 (4H, m), 2.57-3.04 (6H, m), 1.46 (2H, br. s.), 0.89 (9H,s) 8-639 N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 340.41946, (found)341 [M + H], HPLC (pyridin-4-ylmethyl)-1,4- (215 nM): 91%, RT 1.3 min.diazepan-1-yl)acetamide 8-640 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 326.39288, (found) 327 [M + H], HPLC (pyridin-4- (215 nM): 96%,RT 1.22 min. ylmethyl)piperazin-1- yl)acetamide 8-641N-hydroxy-2-(4-((1-methyl- LRMS (ESI): (calc.) 342.43534, (found) 343[M + H], HPLC 1H-pyrrol-2-yl)methyl)-1,4- (215 nM): 87.99%, RT 2.44 min.diazepan-1-yl)-2- phenylacetamide 8-642 N-hydroxy-2-(4-((1-methyl- LRMS(ESI): (calc.) 328.40876, (found) 329 [M + H], HPLC 1H-pyrrol-2- (215nM): 100%, RT 2.34 min. yl)methyl)piperazin-1-yl)-2- phenylacetamide8-643 N-hydroxy-2-(4-((1-methyl- LRMS (ESI): (calc.) 343.4234, (found)344 [M + H], HPLC 1H-imidazol-2-yl)methyl)- (215 nM): 96%, RT 1.26 min.1,4-diazepan-1-yl)-2- phenylacetamide 8-644 N-hydroxy-2-(4-((1-methyl-LRMS (ESI): (calc.) 329.39682, (found) 330 [M + H], HPLC 1H-imidazol-2-(215 nM): 97%, RT 1.19 min. yl)methyl)piperazin-1-yl)-2- phenylacetamide8-645 2-(4-(cyclohex-3- LRMS (ESI): (calc.) 343.46316, (found) 344 [M +H], HPLC enylmethyl)-1,4-diazepan-1- (215 nM): 90.58%, RT 2.62 min.yl)-N-hydroxy-2- phenylacetamide 8-646 2-(4- LRMS (ESI): (calc.)331.45246, (found) 332 [M + H], HPLC (cyclohexylmethyl)piperazin- (215nM): 95.17%, RT 2.61 min. 1H NMR (250 MHz, 1-yl)-N-hydroxy-2- DMSO-d6) dppm 10.84 (1H, br. s.), 8.90 (1H, br. s.), phenylacetamide 7.13-7.51(5H, m), 3.64 (1H, br. s.), 3.11-3.51 (4H, m), 1.96-2.43 (6H, m),1.33-1.81 (6H, m), 1.08-1.33 (3H, m), 0.54-0.93 (2H, m) 8-647N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 346.44718, (found) 347 [M +H], HPLC (thiazol-2-ylmethyl)-1,4- (215 nM): 95.64%, RT 2.2 min.diazepan-1-yl)acetamide 8-648 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 332.4206, (found) 333 [M + H], HPLC (thiazol-2- (215 nM):96.27%, RT 2.07 min. ylmethyl)piperazin-1- yl)acetamide 8-649N-hydroxy-2-(4-(2- LRMS (ESI): (calc.) 339.4314, (found) 340 [M + H],HPLC methylbenzyl)piperazin-1-yl)- (215 nM): 86.39%, RT 2.55 min.2-phenylacetamide 8-650 N-hydroxy-2-(4-((6- LRMS (ESI): (calc.)354.44604, (found) 355 [M + H], HPLC methylpyridin-2-yl)methyl)- (215nM): 91%, RT 2.21 min. 1,4-diazepan-1-yl)-2- phenylacetamide 8-651N-hydroxy-2-(4-(3- LRMS (ESI): (calc.) 341.40422, (found) 342 [M + H],HPLC hydroxybenzyl)piperazin-1- (215 nM): 94.05%, RT 2.25 min.yl)-2-phenylacetamide 8-652 2-(4-(2-fluorobenzyl)-1,4- LRMS (ESI):(calc.) 357.4218632, (found) 358 [M + H], diazepan-1-yl)-N-hydroxy-2-HPLC (215 nM): 87.96%, RT 2.53 min. phenylacetamide 8-653 2-(4-(2- LRMS(ESI): (calc.) 343.3952832, (found) 344 [M + H],fluorobenzyl)piperazin-1-yl)- HPLC (215 nM): 89.36%, RT 2.41 min.N-hydroxy-2- phenylacetamide 8-654 2-(4-(3- LRMS (ESI): (calc.)343.3952832, (found) 344 [M + H], fluorobenzyl)piperazin-1-yl)- HPLC(215 nM): 86.07%, RT 2.46 min. N-hydroxy-2- phenylacetamide 8-6552-(4-(2-ethylhexyl)-1,4- LRMS (ESI): (calc.) 361.5215, (found) 362 [M +H], HPLC diazepan-1-yl)-N-hydroxy-2- (215 nM): 91.16%, RT 3.12 min.phenylacetamide 8-656 2-(4-(2-ethylhexyl)piperazin- LRMS (ESI): (calc.)347.49492, (found) 348 [M + H], HPLC 1-yl)-N-hydroxy-2- (215 nM):86.75%, RT 2.94 min. phenylacetamide 8-657 (E)-2-(4-cinnamyl-1,4- LRMS(ESI): (calc.) 365.46868, (found) 366 [M + H], HPLCdiazepan-1-yl)-N-hydroxy-2- (215 nM): 91.15%, RT 2.87 min.phenylacetamide 8-658 N-hydroxy-2-phenyl-2-(4-(2- LRMS (ESI): (calc.)353.45798, (found) 354 [M + H], HPLC phenylpropyl)piperazin-1- (215 nM):99.03% RT 2.68 min. yl)acetamide 8-659 2-(4-(3,5-dimethylbenzyl)- LRMS(ESI): (calc.) 367.48456, (found) 368 [M + H], HPLC1,4-diazepan-1-yl)-N- (215 nM): 89.26%, RT 2.9 min.hydroxy-2-phenylacetamide 8-660 2-(4-(3,5- LRMS (ESI): (calc.)353.45798, (found) 354 [M + H], HPLC dimethylbenzyl)piperazin-1- (215nM): 97.92%, RT 2.87 min. yl)-N-hydroxy-2- phenylacetamide 8-661N-hydroxy-2-(4-(2- LRMS (ESI): (calc.) 369.45738, (found) 370 [M + H],HPLC methoxybenzyl)-1,4- (215 nM): 88.35%, RT 2.65 min.diazepan-1-yl)-2- phenylacetamide 8-662 N-hydroxy-2-(4-(2- LRMS (ESI):(calc.) 355.4308, (found) 356 [M + H], HPLC methoxybenzyl)piperazin-1-(215 nM): 97.75%, RT 2.56 min. yl)-2-phenylacetamide 8-6632-(4-(2-chlorobenzyl)-1,4- LRMS (ESI): (calc.) 373.87646, (found) 374[M + H], HPLC diazepan-1-yl)-N-hydroxy-2- (215 nM): 89.17%, RT 2.69 min.phenylacetamide 8-664 2-(4-(2- LRMS (ESI): (calc.) 359.84988, (found)360 [M + H], HPLC chlorobenzyl)piperazin-1-yl)- (215 nM): 87.3%, RT 2.55min. N-hydroxy-2- phenylacetamide 8-665 2-(4-((1H-indol-5-yl)methyl)-LRMS (ESI): (calc.) 378.46744, (found) 379 [M + H], HPLC1,4-diazepan-1-yl)-N- (215 nM): 88.07%, RT 2.6 min.hydroxy-2-phenylacetamide 8-666 2-(4-((1H-indol-5- LRMS (ESI): (calc.)364.44086, (found) 365 [M + H], HPLC yl)methyl)piperazin-1-yl)-N- (215nM): 100%, RT 2.53 min. hydroxy-2-phenylacetamide 8-667 2-(4-((2,3- LRMS(ESI): (calc.) 367.4415, (found) 368 [M + H], HPLC dihydrobenzofuran-5-(215 nM): 91.82%, RT 2.51 min. yl)methyl)piperazin-1-yl)-N-hydroxy-2-phenylacetamide 8-668 N-hydroxy-2-(4-(4-methoxy- LRMS (ESI):(calc.) 383.48396, (found) 384 [M + H], HPLC 3-methylbenzyl)-1,4- (215nM): 88.45%, RT 2.83 min. diazepan-1-yl)-2- phenylacetamide 8-669N-hydroxy-2-(4-(4- LRMS (ESI): (calc.) 371.4964, (found) 372 [M + H],HPLC (methylthio)benzyl)piperazin- (215 nM): 88.08%, RT 2.73 min.1-yl)-2-phenylacetamide 8-670 N-hydroxy-2-phenyl-2-(4- LRMS (ESI):(calc.) 390.47814, (found) 196 [M + H], HPLC (quinolin-4-ylmethyl)-1,4-(215 nM): 93.74%, RT 2.29 min. diazepan-1-yl)acetamide 8-671N-hydroxy-2-phenyl-2-(4- LRMS (ESI): (calc.) 376.45156, (found) 189 [M +H], HPLC (quinolin-4- (215 nM): 89.27%, RT 2.18 min.ylmethyl)piperazin-1- yl)acetamide 8-672 (E)-N-hydroxy-2-(4-(3-(4- LRMS(ESI): (calc.) 395.49466, (found) 396 [M + H], HPLCmethoxyphenyl)allyl)-1,4- (215 nM): 90.72%, RT 2.89 min.diazepan-1-yl)-2- phenylacetamide 8-673 (E)-N-hydroxy-2-(4-(3-(2- LRMS(ESI): (calc.) 381.46808, (found) 382 [M + H], HPLCmethoxyphenyl)allyl)piperazin- (215 nM): 90.83%, RT 2.89 min.1-yl)-2-phenylacetamide 8-674 2-(4-(4-tert-butylbenzyl)-1,4- LRMS (ESI):(calc.) 395.53772, (found) 396 [M + H], HPLC diazepan-1-yl)-N-hydroxy-2-(215 nM): 88.93%, RT 3.2 min. phenylacetamide 8-675 2-(4-((2,3- LRMS(ESI): (calc.) 397.46748, (found) 398 [M + H], HPLCdihydrobenzo[b][1,4]dioxin- (215 nM): 90.8%, RT 2.64 min.6-yl)methyl)-1,4-diazepan-1- yl)-N-hydroxy-2- phenylacetamide 8-6762-(4-((2,3- LRMS (ESI): (calc.) 383.4409, (found) 384 [M + H], HPLCdihydrobenzo[b][1,4]dioxin- (215 nM): 97.98%, RT 2.59 min.6-yl)methyl)piperazin-1-yl)- N-hydroxy-2- phenylacetamide 8-6772-(4-(3,4- LRMS (ESI): (calc.) 385.45678, (found) 386 [M + H], HPLCdimethoxybenzyl)piperazin- (215 nM): 91.98%, RT 2.42 min.1-yl)-N-hydroxy-2- phenylacetamide 8-678 N-hydroxy-2-phenyl-2-(4-(3-LRMS (ESI): (calc.) 393.4027896, (found) 394 [M + H],(trifluoromethyl)benzyl)piperazin- HPLC (215 nM): 87.06%, RT 2.8 min.1-yl)acetamide 8-679 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI): (calc.)393.4027896, (found) 394 [M + H], (trifluoromethyl)benzyl)piperazin-HPLC (215 nM): 97.92%, RT 2.82 min. 1-yl)acetamide 8-6802-(4-(2,4-dichlorobenzyl)- LRMS (ESI): (calc.) 408.32152, (found) 408[M + H], HPLC 1,4-diazepan-1-yl)-N- (215 nM): 94.16%, RT 2.94 min.hydroxy-2-phenylacetamide 8-681 2-(4-(2,4- LRMS (ESI): (calc.)394.29494, (found) 394 [M + H], HPLC dichlorobenzyl)piperazin-1- (215nM): 88.52%, RT 2.81 min. yl)-N-hydroxy-2- phenylacetamide 8-6822-(4-(biphenyl-4-ylmethyl)- LRMS (ESI): (calc.) 415.52736, (found) 416[M + H], HPLC 1,4-diazepan-1-yl)-N- (215 nM): 90.33%, RT 3.15 min.hydroxy-2-phenylacetamide 8-683 N-hydroxy-2-phenyl-2-(4-(4- LRMS (ESI):(calc.) 416.51542, (found) 209 [M + 2H]/2, (pyridin-2-yl)benzyl)-1,4-HPLC (215 nM): 90.84%, RT 2.52 min. 1H NMR (250 MHz,diazepan-1-yl)acetamide DMSO-d6) d ppm 10.82-11.01 (1H, m), 8.85-9.09(1H, m), 8.57-8.74 (1H, m), 8.07-8.24 (2H, m), 7.98-8.06 (1H, m),7.82-7.97 (1H, m), 7.56-7.77 (2H, m), 7.13-7.53 (6H, m), 4.17-4.58 (2H,m), 4.04-4.17 (1H, m), 2.59-3.25 (8H, m), 1.76-2.10 (2H, m) 8-6842-(4-(3-(benzo[d][1,3]dioxol- LRMS (ESI): (calc.) 425.52064, (found) 426[M + H], HPLC 5-yl)-2-methylpropyl)-1,4- (215 nM): 85.93%, RT 2.92 min.diazepan-1-yl)-N-hydroxy-2- phenylacetamide 8-6852-(4-(3-(benzo[d][1,3]dioxol- LRMS (ESI): (calc.) 411.49406, (found) 412[M + H], HPLC 5-yl)-2- (215 nM): 87.82%, RT 2.82 min.methylpropyl)piperazin-1-yl)- N-hydroxy-2- phenylacetamide 8-6862-(4-bromophenyl)-N- LRMS (ESI): (calc.) 306.15458, (found) 306 [M + H],HPLC hydroxy-2-phenylacetamide (215 nM): 95%, RT 3.71 min. 8-6872-(3-bromophenyl)-N- LRMS (ESI): (calc.) 306.15458, (found) 306 [M + H],HPLC hydroxy-2-phenylacetamide (215 nM): 93%, RT 3.68 min. 8-6884-(2-(hydroxyamino)-2-oxo- LRMS (ESI): (calc.) 382.45614, (found) 383[M + H], HPLC 1-phenylethyl)-N-((S)-1- (215 nM): 94.57%, RT 2.7 min.phenylethyl)piperazine-1- carboxamide 8-689 2-(4-(4-fluorobenzyl)-1,4-LRMS (ESI): (calc.) 357.4218632, (found) 358 [M + H],diazepan-1-yl)-N-hydroxy-2- HPLC (215 nM): 91.35%, RT 2.59 min.phenylacetamide 8-690 2-(4-(4-chlorobenzyl)-1,4- LRMS (ESI): (calc.)373.87646, (found) 374 [M + H], HPLC diazepan-1-yl)-N-hydroxy-2- (215nM): 88.13%, RT 2.78 min. phenylacetamide

Compositions

In a second aspect, the invention provides compositions comprising apharmaceutically acceptable carrier, excipient, or diluent, and acompound having the Formula (VI):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

M is selected from the group consisting of alkyl, —N(R^(e))OR^(s), —CF₃,—C(O)NR^(e)R^(f), -heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—SR^(e),—CH₂—S(acetyl) and -heterocycloalkyl;

X is selected from the group consisting of CH, C(OH), C(C₁-C₄alkyl),C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y;

L and Y are independently selected from the group consisting ofC₁-C₄alkyl, heteroalkyl, alkenyl, alkynyl, —NR^(a)R^(b), —NR^(c)R^(d),—OR^(e), —C₀-C₃alkyl-aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heterocyclyl, —C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl,—C₂-C₄alkenyl-heteroaryl, —C₂-C₄alkenyl-heterocyclyl,—C₂-C₄alkenyl-cycloalkyl, —C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl-cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH—C₀-C₃alkyl-aryl,—C(O)NH—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))—S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—,—N(R^(e))—C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e)), —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl,

provided that if an L or a Y is bound directly to a nitrogen of X, thenthe L or Y is not —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—S(O)₀₋₁—C₀-C₃alkyl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroaryl or—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl,

in which

each R^(a) and R^(b) together with the nitrogen to which they are boundform a 4 to 7 membered heterocyclyl having 1 or 2 annular heteroatoms,or a 5 to 8 membered bridged heterocyclyl having 1 or 2 annularheteroatoms, the heterocyclyl being optionally substituted with 1-3substituents independently selected from the group consisting of H, OH,oxo (i.e., ═O), —N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl,—C₁-C₆alkyl-aryl, —C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl,—C₂-C₃alkyl-OH, —C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,-C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀₋₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl;

each R^(c) and R^(d) is independently selected from the group consistingof H, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or

R^(c) and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms,

each R^(e) and R^(f) is independently selected from the group consistingof —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl, heteroaryl-aryl,heteroaryl-heteroaryl, C(O)-alkyl and —C(O)CF₃; and

each R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup,

wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moietyis optionally substituted, and

wherein a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl moiety inL is optionally connected to a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl in Y by a bond or by a bridging substituent,

provided that

the compound does not have the formula (C)

in which

each R¹⁰ is selected from the group consisting of H, OH, —CH₂OH, NH₂,COOH and C₁-C₄alkyl; and

each R¹¹ is selected from the group consisting of H, halo, C₁-C₆alkyl,C₁-C₄alkoxy, —OC(O)C₁-C₄alkyl, —NH₂, —NH(C₁-C₄alkyl), —N(C₁-C₄alkyl)₂,—SH, —S—C₁-C₄alkyl, —COOH and —C(O)O—C₁-C₄alkyl; and

the compound is not10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-hydroxamic acid.

In a preferred embodiment of the second aspect of the invention, M is

In a preferred embodiment of the second aspect of the invention, M isNHOH.

In another preferred embodiment of the second aspect of the invention, Mis —H.

In another preferred embodiment of the second aspect of the invention, Xis CH.

In another preferred embodiment of the second aspect of the invention, Xis C(OH) or C(halo).

In another preferred embodiment of the second aspect of the invention, Xis

In another preferred embodiment of the second aspect of the invention, Xis

In another preferred embodiment of the second aspect of the invention, Land Y are independently selected from the group consisting of aryl,heteroaryl, alkyl, —O-aryl, —O-cycloalkyl, heterocyclyl, cycloalkyl,—S-aryl, —S-heteroaryl, —C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, —NHS(O)₂-aryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heterocyclyl-C₀-C₃alkyl-heteroaryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl, -aryl-heteroaryl, -heterocyclyl-O-aryl,-heterocyclyl-O—C₀-C₃alkyl-aryl, -heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.

In another aspect of the second embodiment of the invention, eachcycloalkyl and heterocyclyl moiety is optionally gem or spirosubstituted with —OH, —CN or -alkyl

In another preferred embodiment of the second aspect of the invention, Land Y are independently selected from the group consisting of aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic and mixed aryl and non-aryl polyheterocycle.

In another preferred embodiment of the second aspect of the invention, Land Y are independently selected from aryl, heteroaryl, O-aryl,heterocyclyl, cycloalkyl, —S-aryl, —S-heteroaryl and —C(O)NH-aryl,—S-heteroaryl-aryl, -aryl-heterocyclyl, -heteroaryl-heterocyclyl,—C₁-C₃alkyl-aryl, —S(O)₂-aryl, —S(O)₂-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,heteroaryl-C₀-C₃alkyl-aryl, -aryl-aryl and -heterocyclyl-O-aryl, each ofwhich is optionally substituted.

In another preferred embodiment of the second aspect of the invention,the compound has the Formula (VII):

wherein

R^(c) is as described above with respect to Formula (VI);

each n is independently 0-3; and

R^(g) is selected from the group consisting of —C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl -cycloalkyl,—C₀-C₃alkyl-heterocylyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e)

In another preferred embodiment of the second aspect of the invention,the compound has the Formula (VIII):

wherein

each R¹ is independently alkyl, NO₂, halo or alkoxy,

R² is H or C₁-C₅alkyl, and

A is H, phenyl or OH.

As described above, a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L is optionally connected to a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl in Y by a bond or by a bridgingsubstituent. Such a bridging substituent preferably has 1-6 atoms alongthe shortest path between the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L and the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in Y. For example, another preferred embodiment of thesecond aspect of the invention, the compound has the Formula (IX):

wherein

R⁴ and R⁵ are independently selected from the group consisting of H,halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃;

A is H, phenyl or OH; and

B is a bond, —O—, —N(R⁶)—, —S(O)₀₋₂—, —CH(R⁴)—, —C(R⁵)(R⁴)—,—C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)—, —C(R⁴)—O—, —O—C(R⁴)—,—S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—, —CH(R⁴)—CH(R⁵)—,—C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—, —C(R⁵)(R⁴)—C(R⁵)(R⁴)—,—C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)-, or

in which R⁶ is alkyl, cycloalkyl or heterocyclyl.

In another preferred embodiment of the second aspect of the invention,the compound has the Formula (X):

wherein

n is 0-3;

R^(z) is selected from the group consisting of

R^(c) and L are as described above with respect to Formula (VI),

wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.

In another preferred embodiment of the second aspect of the invention,the compound has the Formula (XI)

wherein

M is H or alkyl; and

L and Y are as defined in Formula (VI).

In another preferred embodiment of the second aspect of the invention,the invention provides compositions comprising a pharmaceuticallyacceptable carrier, excipient, or diluent, and a compound having theFormula (VI-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

M, X, Y and L are as defined for Formula (VI), and wherein

-   Y is further selected from the group consisting of -Z¹-Z-Z²-D, -D,    -Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D, -Z-Z³-Z²-Z-D,    -Z¹-Z-Z², -Z-Z³-D and -Z²-Z¹-Z²-D,    wherein-   Z¹ is selected from the group consisting of chemical bond, alkyl,    aryl, heterocyclyl, bridged heterocyclyl, spiro heterocyclyl,    cycloalkyl, heteroaryl, wherein each aryl, heteroaryl, cycloalkyl    and heterocyclyl moiety is optionally substituted and each of which    is optionally fused to one or more aryl or heteroaryl rings, or one    or more saturated or partially unsaturated cycloalkyl or    heterocyclyl rings, each of which ring is optionally substituted;-   Z is selected from the group consisting of chemical bond, —O—,    —S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—, —C(O)N(R^(c))—,    —N(R^(c))S(O)₂—, —N(R^(c))—, —N(R^(c))(C₂-C₄alkyl-OR^(d))—, —C(O)—,    —C(NOR²¹)—, —CH[C(O)N(R²¹)(R²²)]—C(O)N(R²²)—,    —CH(N(R²¹)(R²²))—C(O)N(R²²)—, —CH[C(O)N(R^(e))(R^(f))]—C(O)N(R²²)—,    —S(O)₂N(R²¹)—, —N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—,    —N(R²¹)C(NR²²)—, —C(NR²²)N(R²¹)—, —N(R²¹)C(O)N(R²²)—, —N(R²¹)C(O)O—,    —OC(O)N(R²¹)—, —N(R²¹)C(S)—, —C(S)N(R²¹)—, —N(R²¹)C(S)N(R²²)—,    —N(R²¹)C(S)O—, —OC(S)N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—,    —N(R²¹)—C₂-C₄alkyl-O—, —N(R¹)—C₂-C₄alkyl-S(O)₀₋₂—,    —N[C₂-C₄alkyl-N(R¹)(R²)]—, —N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—,    —O—C₂-C₄alkyl-N(R^(c))—C₂-C₄alkyl-O—,    —N(R^(c))—C₂-C₄alkyl-N(R^(d))—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,    —O—C₁-C₄alkyl-O—, —O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—,    —S(O)₂N(R¹²)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,    —N(R²)S(O)₂—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-N(R²¹)—,    —N(C(O)—C₁-C₄alkyl)-, —N(R²¹)—C₁-C₄alkyl-C(O)—,    —O—C₁-C₄alkyl-C(O)N(R²¹)—, —C(O)N(R²¹)—C₂-C₄alkyl-O—,    —C(O)—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-S(O)₀₋₂—,    —O—C₂-C₄alkyl-N(R²¹)C(O)—, —N(R²)C(O)—C₁-C₄alkyl-O—,    —N(R²)C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₁-C₄alkyl-C(O)—,    —C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O),    —C(O)—C₁-C₄alkyl-N(R²¹)—, —O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—,    —N(R²¹)—C₁-C₄alkyl-C(S), —C(S)—C₁-C₄alkyl-N(R²¹)—,    —N(R²¹)—C₁-C₄alkyl-C(S)—, —O—C₁-C₄alkyl-C(S)N(R²¹)—,    —C(S)N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)C(S)—,    —N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(S)—C₁-C₄alkyl-O—,    —N(R²¹)—C₁-C₄alkyl-S(O)₂—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,    —S(O)₂N(R²)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,    —N(R²¹)S(O)₂—C₁-C₄alkyl-O—, —O—C₂-C₄alkyl-OC(O)N(R²¹)—,    —O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein each alkyl moiety is optionally    substituted;-   Z² is selected from the group consisting of a chemical bond, alkyl,    alkenyl, alkynyl, alkyl-alkenyl, alkynyl-alkyl and alkyl-alkynyl,    wherein each alkyl, alkenyl and alkynyl moiety is optionally    substituted;-   Z³ is selected from the group consisting of a chemical bond,    —C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-, —C₀-C₅alkyl-heterocyclyl-,    —C₀-C₅alkyl-bridged heterocyclyl-, -spiro heterocyclyl-,    —C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-, wherein each    aryl, heteroaryl, cycloalkyl and heterocyclyl moiety is optionally    substituted and each of which is optionally fused to one or more    aryl or heteroaryl rings, or one or more saturated or partially    unsaturated cycloalkyl or heterocyclyl rings, each of which ring is    optionally substituted;-   D is selected from the group consisting of H, aryl, heteroaryl,    alkyl, alkenyl, alkynyl, heteroalkyl, cycloalyl, heterocyclyl,    bridged heterocyclyl, spiro heterocyclyl, aromatic polycycles,    non-aromatic polycycles, polyheteroaryl groups, non-aromatic    polyheterocyclic, mixed aryl and non-aryl polyheterocycle, each of    which is optionally substituted and each of which is optionally    fused to one or more aryl or heteroaryl rings, or one or more    saturated or partially unsaturated cycloalkyl or heterocyclyl rings,    each of which ring is optionally substituted, wherein-   each R²¹ and R²² is independently selected from the group consisting    of —H, -alkyl, -aryl and heteroaryl, wherein each said aryl and    heteroaryl moiety is optionally substituted; and

L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.

In a preferred embodiment of the second aspect of the invention, eachcycloalkyl, heterocyclyl, aryl, alkyl, alkenyl and heteroaryl moiety inZ, Z₁, Z₂, Z₃ and D is optionally substituted with a substituentselected from the group consisting of —N(R^(e))C(O)—C₁-C₆alkyl,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, —O—CF₃, —S—CF₃, aryl,heteroaryl, cycloalkyl, heterocyclyl, —C₁-C₃alkyl-aryl,—C₁-C₃alkyl-heteroaryl, —C₁-C₃alkyl-cycloalkyl,—C₁-C₃alkyl-heterocyclyl, halo, alkyl, —O-alkyl, —S(O)₀₋₂-alkyl,—C₀-C₃alkyl-CN, NO₂, —C(O)-alkyl and —OH.

In another preferred embodiment of the second aspect of the invention,the invention provides compositions comprising a pharmaceuticallyacceptable carrier, excipient, or diluent, and a compound having theFormula (XX):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃, and —CF₃; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D.

In another preferred embodiment of the second aspect of the invention,the invention provides compositions comprising a pharmaceuticallyacceptable carrier, excipient, or diluent, and a compound having theFormula (XX-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O—CH₃, —CH₃ and —OH; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D;

wherein

Z is selected from the group consisting of —O—, —S(O)₀₋₂—,—N(R^(c))C(O)—, —C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—,—S(O)₂N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d))—, and —O—C₁-C₄alkyl-O—;

Z¹ is selected from the group consisting of aryl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, cycloalkyl and heteroaryl, whereineach aryl, heteroaryl, cycloalkyl and heterocyclyl moiety is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalkyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

In another preferred embodiment of the second aspect of the invention,the invention provides compositions comprising a pharmaceuticallyacceptable carrier, excipient, or diluent, and a compound having theFormula (XX):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃ and —CF₃; and

Y² is -Z²-Z¹-Z²-D, —CH₂-D or D;

wherein

Z¹ is selected from the group consisting of aryl, heterocyclyl,cycloalkyl and heteroaryl, wherein each aryl, heteroaryl, cycloalkyl andheterocyclyl moiety is optionally substituted and each of which isoptionally fused to one or more aryl or heteroaryl rings, or one or moresaturated or partially unsaturated cycloalkyl or heterocyclyl rings,each of which ring is optionally substituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

In another preferred embodiment of the second aspect of the invention,in Formulae (VI)-(XI) each aryl, heterocyclyl, cycloalkyl and heteroarylis independently optionally substituted with one, two or threesubstituents independently selected from the group consisting of H,halo, oxo, OH, C₁-C₃-hydrocarbyl, OCH₃, —CN, —S(O)₀₋₂—C₁-C₄alkyl, —CF₃,—OCF₃, alkyl, —NH₂, —N(alkyl)₂, —NH(alkyl), —N(aryl)(alkyl),—N(-alkyl-aryl)(alkyl), —N(heteroaryl)(alkyl),—N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl), —NH(-alkyl-aryl),—NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-Oalkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—C₂-C₄alkyl-NR^(a)R^(b), C₂-C₄alkyl-NR^(c)R^(d), —S(O)₀₋₁R^(e),—(CR³²R³³)_(s)—NR³⁰R³¹ and (X³⁰—Y³¹—),

in which

R³⁰ and R³¹ are each independently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl, C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-,C₁-C₃alkyl-carboxamido-, carboxamido-C₁-C₃alkyl-, amidino-,C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-, aryl-C₁-C₃ alkyl-,C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or

R³⁰ and R³¹ taken together with the N to which they are attached form aheterocyclyl or heteroaryl, each of which is optionally substituted withfrom 1 to 3 substituents selected from the group consisting of halo,cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, aprotecting group, and (X³⁰—Y³¹—), in which

X³⁰ is selected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, C₀-C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,N(R³⁰)(R³)—C₀-C₃alkenyl-, N(R³⁰)(R³¹)—C₀-C₃alkynyl-,(N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-,C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and

Y³¹ is selected from the group consisting of a direct bond, —O—,—N(R³⁰)—, —C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—,—N(R³⁰)—C(S)—, —C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—,—N(R³⁰)—C(NR³⁰)—N(R³¹)—, —N(R³⁰)—C(NR³¹)—, —C(NR³¹)—N(R³⁰),—N(R³⁰)—C(S)—N(R³¹)—, —N(R³⁰)—C(O)—O—, —O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—,—O—C(S)—N(R³¹)—, —S(O)₀₋₂—, —SO₂N(R³¹)—, —N(R³¹)—SO₂— and—N(R³⁰)—SO₂N(R³¹)—; and

R³² and R³³ are independently selected from hydrogen, halo and hydroxyl.

In another embodiment of the second aspect of the invention, thecompound is selected from the group consisting of

-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide.

In another embodiment of the second aspect of the invention, thecompound is selected from the group consisting of

-   N-hydroxy-2-phenylbutanamide;-   N-hydroxy-2-phenoxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;-   2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-cyclohexyl-N-hydroxy-2-phenylacetamide;-   2-benzyl-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(phenylthio)acetamide;-   N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;-   2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;-   N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;-   2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;-   2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;-   N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;-   2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;-   2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;-   2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and    2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.

In another embodiment of the second aspect of the invention, thecompound is selected from the group consisting of

-   2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;-   N-hydroxy-3,3-diphenylpropanamide;-   2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;-   N-hydroxy-2,2-diphenylpropanamide;-   (E)-N-hydroxy-2,3-diphenylacrylamide;-   N-hydroxy-2,2-di(thiophen-2-yl)acetamide and-   N-hydroxy-9H-xanthene-9-carboxamide.

In another embodiment of the second aspect of the invention, thecompound is selected from the group consisting of

-   N-hydroxy-2,2-diphenylacetamide;-   N-hydroxy-2-phenoxy-2-phenylacetamide;-   N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;-   N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide;-   2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;-   N-hydroxy-3,3-diphenylpropanamide;-   N-hydroxy-9H-xanthene-9-carboxamide;-   2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;-   2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-cyclohexyl-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2,3-diphenylpropanamide;-   N-hydroxy-2-phenyl-2-(phenylthio)acetamide;-   N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;-   N-hydroxy-2,2-diphenylpropanamide;-   2,2-bis(4-chlorophenyl)-N-hydroxyacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;-   2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;-   2,2-bis(4-fluorophenyl)-N-hydroxyacetamide;-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;-   (E)-N-hydroxy-2,3-diphenylacrylamide;-   N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;-   N-hydroxy-2,2-di(thiophen-2-yl)acetamide;-   2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;-   N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;-   N,2-dihydroxy-2,2-diphenylacetamide;-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide;-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;-   N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;-   2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;-   2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamide;-   2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide;-   2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide;-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide and-   2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.

Compositions of the invention may be formulated by any method known inthe art and may be prepared for administration by any route, including,without limitation, parenteral, oral, sublingual, transdermal, topical,intranasal, intratracheal, or intrarectal. In certain preferredembodiments, compositions of the invention are administeredintravenously in a hospital setting. In certain other preferredembodiments, administration may preferably be by the oral route. Thecompositions may be in any form, including but not limited to, liquidsolutions or suspensions; for oral administration, formulations may bein the form of tablets or capsules; and for intranasal formulations, inthe form of powders, nasal drops or aerosols. The compositions of theinvention may be administered systemically or locally.

The characteristics of the carrier will depend on the route ofadministration. As used herein, the term “pharmaceutically acceptable”means a non-toxic material that is compatible with a biological systemsuch as a cell, cell culture, tissue, or organism, and that does notinterfere with the effectiveness of the biological activity of theactive ingredient(s). Thus, compositions according to the invention maycontain, in addition to the inhibitor, diluents, fillers, salts,buffers, stabilizers, solubilizers, or other materials well known in theart. The preparation of pharmaceutically acceptable formulations isdescribed in, e.g., Remington's Pharmaceutical Sciences, 18th Edition,ed. A. Gennaro, Mack Publishing Co., Easton, Pa., 1990.

In a preferred embodiment of the second aspect, the compositioncomprises a compound, N-oxide, hydrate, solvate, pharmaceuticallyacceptable salt, complex or prodrug of a compound according to thepresent invention as described herein present in at least about 30%enantiomeric or diastereomeric excess. In certain desirable embodimentsof the invention, the compound, N-oxide, hydrates, solvate,pharmaceutically acceptable salt, complex or prodrug is present in atleast about 50%, at least about 80%, or even at least about 90%enantiomeric or diastereomeric excess. In certain other desirableembodiments of the invention, the compound, N-oxide, hydrate, solvate,pharmaceutically acceptable salt, complex or prodrug is present in atleast about 95%, more preferably at least about 98% and even morepreferably at least about 99% enantiomeric or diastereomeric excess. Inother embodiments of the invention, a compound, N-oxide, hydrate,solvate, pharmaceutically acceptable salt, complex or prodrug is presentas a substantially racemic mixture. In a preferred embodiment, thecomposition further comprises an additional therapeutic or inhibitoryagent.

As used herein, the term “pharmaceutically acceptable salts” is intendedto mean salts that retain the desired biological activity of theabove-identified compounds and exhibit minimal or no undesiredtoxicological effects. Examples of such salts include, but are notlimited to acid addition salts formed with inorganic acids (for example,hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid,nitric acid, and the like), and salts formed with organic acids such asacetic acid, oxalic acid, tartaric acid, succinic acid, malic acid,ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid,polyglutamic acid, naphthalenesulfonic acid, naphthalenedisulfonic acid,and polygalacturonic acid. The compounds can also be administered aspharmaceutically acceptable quaternary salts known by those skilled inthe art, which specifically include the quaternary ammonium salt of theformula —NR+Z-, wherein R is hydrogen, alkyl, or benzyl, and Z is acounterion, including chloride, bromide, iodide, —O-alkyl,toluenesulfonate, methylsulfonate, sulfonate, phosphate, or carboxylate(such as benzoate, succinate, acetate, glycolate, maleate, malate,citrate, tartrate, ascorbate, benzoate, cinnamoate, mandeloate,benzyloate, and diphenylacetate). As used herein, the term “salt” isalso meant to encompass complexes, such as with an alkaline metal or analkaline earth metal.

The active compound is included in the pharmaceutically acceptablecarrier or diluent in an amount sufficient to deliver an inhibitioneffective amount without causing serious toxic effects. The effectivedosage range of the pharmaceutically acceptable derivatives can becalculated based on the weight of the parent compound to be delivered.If the derivative exhibits activity in itself, the effective dosage canbe estimated as above using the weight of the derivative, or by othermeans known to those skilled in the art.

Depending on the particular condition or disease to be treated, anadditional HDAC inhibitory agent or an additional therapeutic agent,that could be normally administered to treat that condition or diseasemay also be present in the compositions of this invention. In otherwords, compounds of this invention can be administered as the solepharmaceutical agent or in combination with one or more other additionaltherapeutic (pharmaceutical) agents where the combination causes nounacceptable adverse effects. As used herein, additional therapeuticagents that are normally administered to treat a particular disease orcondition are known as “appropriate for the disease or condition beingtreated”. Administration of such agents may be done sequentially orconcurrently. In certain preferred embodiments of the present inventionthe composition comprises at least one compound according to the presentinvention and at least one other HDAC inhibitor known in the art orwhich will be discovered. The active ingredients of such compositionspreferably act synergistically to produce a therapeutic effect.

In certain preferred embodiments of the second and third aspects of theinvention, the additional agent is an antisense oligonucleotide thatinhibits the expression of a histone deacetylase gene. The combined useof a nucleic acid level inhibitor (e.g., antisense oligonucleotide) anda protein level inhibitor (i.e., inhibitor of histone deacetylase enzymeactivity) results in an improved inhibitory effect, thereby reducing theamounts of the inhibitors required to obtain a given inhibitory effectas compared to the amounts necessary when either is used individually.The antisense oligonucleotide according to this aspect of the inventionis complementary to regions of RNA or double-stranded DNA that encodeone or more of, for example, HDAC-1, HDAC-2, HDAC-3, HDAC-4, HDAC-5,HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11 (see e.g., GenBankAccession Number U50079 for HDAC-1, GenBank Accession Number U31814 forHDAC-2, and GenBank Accession Number U75697 for HDAC-3).

Inhibition of Histone Deacetylase

In a third aspect, the present invention provides a method of inhibitinga histone deacetylase selected from the group consisting of HDAC-4,HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11. Oneembodiment according to the third aspect comprises contacting thehistone deacetylase with an inhibition effective amount of an inhibitorof histone deacetylase having the structure (XII):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

M is selected from the group consisting of alkyl, —N(R^(e))OR^(s), —CF₃,—C(O)NR^(e)R^(f), -heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—S(acetyl),—CH₂—SR^(e) and -heterocycloalkyl;

X is selected from the group consisting of CH, C(OH), C(C₁-C₄alkyl),C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y;

L and Y are independently selected from the group consisting ofC₁-C₄alkyl, heteroalkyl, alkenyl, alkynyl, —NR^(a)R^(b), —NR^(c)R^(d),—OR^(e), —C₀-C₃alkyl-aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heterocyclyl, —C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl,—C₂-C₄alkenyl-heteroaryl, —C₂-C₄alkenyl-heterocyclyl,—C₂-C₄alkenyl-cycloalkyl, —C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl-cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH—C₀-C₃alkyl-aryl,—C(O)NH—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))—S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—, —N(R^(e))C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e))—, —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl,

provided that if an L or a Y is bound directly to a nitrogen of X, thenthe L or Y is not —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—S(O)₀₋₁—C₀-C₃alkyl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroaryl or—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl,

in which

each R^(a) and R^(b) together with the nitrogen to which they are boundform a 4 to 7 membered heterocyclyl having 1 or 2 annular heteroatoms,or a 5 to 8 membered bridged heterocyclyl having 1 or 2 annularheteroatoms, the heterocyclyl being optionally substituted with 1-3substituents independently selected from the group consisting of H, OH,oxo (i.e., ═O), —N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl,—C₁-C₆alkyl-aryl, —C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl,—C₂-C₃alkyl-OH, —C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,—C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀₋₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl;

each R^(c) and R^(d) is independently selected from the group consistingof H, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or

R^(c) and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms;

each R^(e) and R^(f) is independently selected from the group consistingof —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl, heteroaryl-aryl,heteroaryl-heteroaryl, C(O)-alkyl and —C(O)CF₃; and

each R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup

wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moietyis optionally substituted, and

wherein a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl moiety inL is optionally connected to a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl in Y by a bond or by a bridging substituent.

In a preferred embodiment of the second aspect of the invention, M is

In a preferred embodiment of the third aspect of the invention, M isNHOH.

In another preferred embodiment of the third aspect of the invention, Mis —H.

In another preferred embodiment of the third aspect of the invention, Xis CH.

In another preferred embodiment of the third aspect of the invention, Xis C(OH) or C(halo).

In another preferred embodiment of the third aspect of the invention, Xis

In another preferred embodiment of the third aspect of the invention, Xis

In a preferred embodiment of the third aspect of the invention, L and Yare independently selected from the group consisting of aryl,heteroaryl, alkyl, —O-aryl, —O-cycloalkyl, heterocyclyl, cycloalkyl,—S-aryl, —S-heteroaryl, —C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, —NHS(O)₂-aryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heterocyclyl-C₀-C₃alkyl-heteroaryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl, -aryl-heteroaryl, -heterocyclyl-O-aryl,-heterocyclyl-O—C₀-C₃alkyl-aryl, -heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.

In another preferred embodiment of the third aspect of the invention,each cycloalkyl and heterocyclyl moiety is optionally gem or spirosubstituted with —OH, —CN or -alkyl.

In another preferred embodiment of the third aspect of the invention, Land Y are independently selected from the group consisting of aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic, and mixed aryl and non-aryl polyheterocycle.

In another preferred embodiment of the third aspect of the invention, Land Y are independently selected from aryl, heteroaryl, O-aryl,heterocyclyl, cycloalkyl, —S-aryl, —S-heteroaryl and —C(O)NH-aryl,—S-heteroaryl-aryl, -aryl-heterocyclyl, -heteroaryl-heterocyclyl,—C₁-C₃alkyl-aryl, —S(O)₂-aryl, —S(O)₂-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl, heteroaryl-C₀-C₃alkyl-heteroaryl,heteroaryl-C₀-C₃alkyl-aryl, -aryl-aryl and -heterocyclyl-O-aryl, each ofwhich is optionally substituted.

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XIII):

wherein

R^(c) is as described above with respect to Formula (XII);

each n is independently 0-3; and

R^(g) is selected from the group consisting of —C₀-C₃alkyl -aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl -cycloalkyl,—C₀-C₃alkyl-heterocylyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e)

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XIV):

wherein

R¹ is alkyl, NO₂, halo or alkoxy,

R² is H or C₁-C₅alkyl, and

A is H, phenyl or OH.

As described above, a cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L is optionally connected to a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl in Y by a bond or by a bridgingsubstituent. Such a bridging substituent desirably has 1-6 atoms alongthe shortest path between the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in L and the cycloalkyl, heterocyclyl, aryl, alkyl orheteroaryl moiety in Y. For example, in another preferred embodiment ofthe third aspect of the invention, the compound has the Formula (XV):

wherein

R⁴ and R⁵ are independently selected from the group consisting of H,halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃;

A is H, phenyl or OH; and

B is a bond, —O—, —N(R⁶)—, —S(O)₀₋₂—, —CH(R⁴)—, —C(R⁵)(R⁴)—,—C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)—, —C(R⁴)—O—, —O—C(R⁴)—,—S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—, —CH(R⁴)—CH(R⁵)—,—C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—, —C(R⁵)(R⁴)—C(R⁵)(R⁴)—,—C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)-, or

in which R⁶ is alkyl, cycloalkyl or heterocyclyl.

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XVI):

wherein

n is 0-3;

R^(z) is selected from the group consisting of

R^(c) and L are as described above with respect to Formula (XII),wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.

In another preferred embodiment of the third aspect of the invention thecompound has the Formula (XVII)

wherein

M is H or alkyl; and

L and Y are as defined in Formula (XII).

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XII-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

M, X, Y and L are as defined for Formula (XII), and wherein

Y is further selected from the group consisting of -Z¹-Z-Z²-D, -D,-Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D, -Z-Z³-Z²-Z-D,-Z¹-Z-Z³-D and -Z²-Z¹-Z²-D,

wherein

Z¹ is selected from the group consisting of chemical bond, alkyl, aryl,heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, cycloalkyl,heteroaryl, wherein each aryl, heteroaryl, cycloalkyl and heterocyclylmoiety is optionally substituted and each of which is optionally fusedto one or more aryl or heteroaryl rings, or one or more saturated orpartially unsaturated cycloalkyl or heterocyclyl rings, each of whichring is optionally substituted;

Z is selected from the group consisting of chemical bond, —O—,—S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—, —C(O)N(R^(c))—,—N(R^(c))S(O)₂—, —N(R^(c))—, —N(R^(c))(C₂-C₄alkyl-OR^(d))—, —C(O)—,—C(NOR²¹)—, —CH[C(O)N(R²)(R²²)]—C(O)N(R²²)—,—CH(N(R²¹)(R²²))—C(O)N(R²²)—, —CH[C(O)N(R^(e))(R^(f))]—C(O)N(R²²)—,—S(O)₂N(R²¹)—, —N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—, —N(R²¹)C(NR²²)—,—C(NR²²)N(R²¹)—, —N(R²¹)C(O)N(R²²), —N(R²¹)C(O), —OC(O)N(R²¹)—,—N(R²¹)C(S)—, —C(S)N(R²¹)—, —N(R²¹)C(S)N(R²²)—, —N(R²¹)C(S)O—,—OC(S)N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R¹)—C₂-C₄alkyl-S(O)₀₋₂—, —N[C₂-C₄alkyl-N(R¹)(R²)]—,—N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(c))—,—N(R^(c))—C₂-C₄alkyl-O—, —N(R^(c))—C₂-C₄alkyl-N(R²¹)—,—O—C₁-C₄alkyl-S(O)₂N(R²¹)—, —O—C₁-C₄alkyl-O—,—O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—, —S(O)₂N(R²¹)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)S(O)₂—, —N(R²¹)S(O)₂—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-N(R²¹)—, —N(C(O)—C₁-C₄alkyl)-,—N(R²¹)—C₁-C₄alkyl-C(O)—, —O—C₁-C₄alkyl-C(O)N(R²¹)—,—C(O)N(R²¹)—C₂-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₂-C₄alkyl-N(R²¹)C(O)—,—N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(O)—C₁-C₄alkyl-S(O)₀₋₂—,—O—C₁-C₄alkyl-C(O)—, —C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O),—C(O)—C₁-C₄alkyl-N(R²¹)—, —O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-C(S), —C(S)—C₁-C₄alkyl-N(R²¹)—,—N(R²¹)—C₁-C₄alkyl-C(S)—, —O—C₁-C₄alkyl-C(S)N(R²¹)—,—C(S)N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)C(S)—,—N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-S(O)₂—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,—S(O)₂N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,—N(R²¹)S(O)₂—C₁-C₄alkyl-O—, —O—C₂-C₄alkyl-OC(O)N(R²¹)—,—O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein each alkyl moiety is optionallysubstituted;

Z² is selected from the group consisting of a chemical bond, alkyl,alkenyl, alkynyl, alkyl-alkenyl, alkynyl-alkyl and alkyl-alkynyl,wherein each alkyl, alkenyl and alkynyl moiety is optionallysubstituted;

Z³ is selected from the group consisting of a chemical bond,—C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-, —C₀-C₅alkyl-heterocyclyl-,—C₀-C₅alkyl-bridged heterocyclyl-, -spiro heterocyclyl-,—C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-, wherein each aryl,heteroaryl, cycloalkyl and heterocyclyl moiety is optionally substitutedand each of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted;

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,alkenyl, alkynyl, heteroalkyl, cycloalyl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, aromatic polycycles, non-aromaticpolycycles, polyheteroaryl groups, non-aromatic polyheterocyclic, mixedaryl and non-aryl polyheterocycle, each of which is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted, wherein

each R²¹ and R²² is independently selected from the group consisting of—H, -alkyl, -aryl and heteroaryl, wherein each said aryl and heteroarylmoiety is optionally substituted; and

L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.

In a preferred embodiment of the second aspect of the invention, eachcycloalkyl, heterocyclyl, aryl, alkyl, alkenyl and heteroaryl moiety inZ, Z₁, Z₂, Z₃ and D is optionally substituted with a substituentselected from the group consisting of —N(R^(e))C(O)—C₁-C₆alkyl,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, —O—CF₃, —S—CF₃, aryl,heteroaryl, cycloalkyl, heterocyclyl, —C₁-C₃alkyl-aryl,—C₁-C₃alkyl-heteroaryl, —C₁-C₃alkyl-cycloalkyl,—C₁-C₃alkyl-heterocyclyl, halo, alkyl, —O-alkyl, —S(O)₀₋₂-alkyl,—C₀-C₃alkyl-CN, NO₂, —C(O)-alkyl and —OH.

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XX):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃, and —CF₃; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D.

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XX-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O—CH₃, —CH₃ and —OH; and

Y¹ is selected from the group consisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-Dand D;

wherein

Z is selected from the group consisting of —O—, —S(O)₀₋₂—,—N(R^(c))C(O)—, —C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—,—S(O)₂N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d))—, and —O—C₁-C₄alkyl-O—;

Z¹ is selected from the group consisting of aryl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, cycloalkyl and heteroaryl, whereineach aryl, heteroaryl, cycloalkyl and heterocyclyl moiety is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalkyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

In another preferred embodiment of the third aspect of the invention,the compound has the Formula (XX):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein

each L¹ is independently selected from the group consisting of H, halo,—O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃ and —CF₃; and

Y² is -Z²-Z¹-Z²-D, —CH₂-D or D;

wherein

Z¹ is selected from the group consisting of aryl, heterocyclyl,cycloalkyl and heteroaryl, wherein each aryl, heteroaryl, cycloalkyl andheterocyclyl moiety is optionally substituted and each of which isoptionally fused to one or more aryl or heteroaryl rings, or one or moresaturated or partially unsaturated cycloalkyl or heterocyclyl rings,each of which ring is optionally substituted;

Z² is a chemical bond or an optionally substituted alkyl; and

D is selected from the group consisting of H, aryl, heteroaryl, alkyl,cycloalyl and heterocyclyl, each of which is optionally substituted andeach of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted.

Another preferred embodiment of the third aspect of the invention, inFormulae (XII)-(XVII) each aryl, heterocyclyl, cycloalkyl and heteroarylis independently optionally substituted with one, two or threesubstituents independently selected from the group consisting of H,halo, ═O, OH, C₁-C₃-hydrocarbyl, OCH₃, —CN, —S(O)₀₋₂—C₁-C₄alkyl, —CF₃,—OCF₃, alkyl, —NH₂, —N(alkyl)₂, —NH(alkyl), —N(aryl)(alkyl),—N(-alkyl-aryl)(alkyl), —N(heteroaryl)(alkyl),—N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl), —NH(-alkyl-aryl),—NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-Oalkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—C₂-C₄alkyl-NR^(a)R^(b), C₂-C₄alkyl-NR^(c)R^(d), —S(O)₀₋₁R^(e),—(CR³²R³³)_(s)—NR³⁰R³¹, and (X³⁰—Y³¹—),

in which

R³⁰ and R³¹ are each independently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl, C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-,C₁-C₃alkyl-carboxamido-, carboxamido-C₁-C₃alkyl-, amidino-,C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-, aryl-C₁-C₃ alkyl-,C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or

R³⁰ and R³¹ taken together with the N to which they are attached form aheterocyclyl or heteroaryl, each of which is optionally substituted withfrom 1 to 3 substituents selected from the group consisting of halo,cyano, oxo, carboxy, formyl, nitro, amino, amidino, guanidino, aprotecting group, and (X³⁰—Y³¹—), in which

X³⁰ is selected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, CO—C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,N(R³⁰)(R³)—C₀-C₃alkenyl-, N(R³⁰)(R³)—C₀-C₃alkynyl-, (N(R³⁰)(R³¹))₂—C═N—,C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-, C₁-C₈heteroalkyl, aryl,cycloalkyl, heterocyclyl, heteroaryl, aryl-C₁-C₃alkyl-,cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and

Y³¹ is selected from the group consisting of a direct bond, —O—,—N(R³⁰)—, —C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—,—N(R³⁰)—C(S)—, —C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—,—N(R³⁰)—C(NR³⁰)—N(R³¹)—, —N(R³⁰)—C(NR³¹)—, —C(N³¹)—N(R³⁰),—N(R³⁰)—C(S)—N(R³¹)—, —N(R³⁰)—C(O)—O—, —O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—,—O—C(S)—N(R³¹)—, —S(O)₀₋₂—, —SO₂N(R³¹)—, —N(R³¹)—SO₂— and—N(R³⁰)—SO₂N(R³¹)—; and

R³² and R³³ are independently selected from hydrogen, halo and hydroxyl.

In another embodiment of the third aspect of the invention, the compoundis selected from the group consisting of

-   N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide.

In another embodiment of the third aspect of the invention, the compoundis selected from the group consisting of

-   N-hydroxy-2-phenylbutanamide;-   N-hydroxy-2-phenoxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;-   2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-cyclohexyl-N-hydroxy-2-phenylacetamide;-   2-benzyl-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(phenylthio)acetamide;-   N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;-   2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;-   N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;-   2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;-   2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;-   N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;-   2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;-   2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;-   2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and-   2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.

In another embodiment of the third aspect of the invention, the compoundis selected from the group consisting of

-   2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;-   N-hydroxy-3,3-diphenylpropanamide;-   2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;-   N-hydroxy-2,2-diphenylpropanamide;-   (E)-N-hydroxy-2,3-diphenylacrylamide;-   N-hydroxy-2,2-di(thiophen-2-yl)acetamide and-   N-hydroxy-9H-xanthene-9-carboxamide.

In another embodiment of the third aspect of the invention, the compoundis selected from the group consisting of

-   N-hydroxy-2,2-diphenylacetamide;-   N-hydroxy-2-phenoxy-2-phenylacetamide;-   N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;-   N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide;-   2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;-   N-hydroxy-3,3-diphenylpropanamide;-   N-hydroxy-9H-xanthene-9-carboxamide;-   2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;-   2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-cyclohexyl-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2,3-diphenylpropanamide;-   N-hydroxy-2-phenyl-2-(phenylthio)acetamide;-   N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;-   N-hydroxy-2,2-diphenylpropanamide;-   2,2-bis(4-chlorophenyl)-N-hydroxyacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;-   2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;-   2,2-bis(4-fluorophenyl)-N-hydroxyacetamide;-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;-   (E)-N-hydroxy-2,3-diphenylacrylamide;-   N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;-   N-hydroxy-2,2-di(thiophen-2-yl)acetamide;-   2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;-   N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;-   N,2-dihydroxy-2,2-diphenylacetamide;-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;-   2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide;-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;-   N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;-   2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;-   2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;-   2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamide;-   2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamide;-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide;-   2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;-   N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;-   N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide;-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide and-   2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.

In one embodiment of the third aspect, the contacting is performed in acell.

In another embodiment of the third aspect, the invention provides amethod of inhibiting a histone deacetylase selected from the groupconsisting of HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10and HDAC-11 preferably in a cell, comprising contacting the histonedeacetylase (or the cell) with a histone deacetylase inhibiting amountof a composition comprising a compound according to any of Formulae(VI)-(XI), (VI-A), (XX), (XX-A) and (XXI), or a preferred embodimentthereof, or an N-oxide, hydrate, solvate, pharmaceutically-acceptablesalt, prodrug or complex thereof, or a racemic or scalemic mixture,diasteromer or enantiomer thereof, and a pharmaceutically-acceptablecarrier as described herein.

In another embodiment of the third aspect, the invention provides amethod of inhibiting a histone deacetylase selected from the groupconsisting of HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC10 andHDAC-11, preferably in a cell, comprising contacting the histonedeacetylase (or the cell in which inhibition of histone deacetylase isdesired) with a histone deacetylase inhibiting amount of a compoundaccording to any of Formulae (XII)-(XVII), (XII-A), (XX), (XX-A) and(XXI) or a preferred embodiment thereof, or an N-oxide, hydrate,solvate, pharmaceutically-acceptable salt, prodrug or complex thereof,or a racemic or scalemic mixture, diasteromer or enantiomer thereof,optionally in a composition with a pharmaceutically-acceptable carrier,as described herein.

Because compounds of the invention inhibit histone deacetylase, they areuseful research tools for in vitro study histone deacetylases and theirrole in biological processes.

Measurement of the enzymatic activity of a histone deacetylase can beachieved using known methodologies. For Example, Yoshida et al., J.Biol. Chem., 265: 17174-17179 (1990), describes the assessment ofhistone deacetylase enzymatic activity by the detection of acetylatedhistones in trichostatin A treated cells. Taunton et al., Science, 272:408-411 (1996), similarly describes methods to measure histonedeacetylase enzymatic activity using endogenous and recombinant HDAC-1.

In another embodiment of the third aspect of the invention, a cell inwhich inhibition of histone deacetylase is desired is contacted with thecompound, N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug, complex, racemic or scalemic mixture, diasteromer or enantiomeras described above. Desirably, the cell is in a mammal, preferably ahuman.

The compounds of the present invention are preferably selective forinhibiting class II histone deacetylase. In another preferred embodimentthe compounds of the present invention are selective HDAC-4, HDAC-5and/or HDAC-7 inhibitors, and may additionally be active againstHDAC-11. A subset of the compounds of the present invention preferablyhas selective inhibitory activity against HDAC-8. Another subset of thecompounds of the present invention preferably has selective inhibitoryactivity against HDAC-11. Another subset of the compounds of the presentinvention preferably has selective inhibitory activity against HDAC-4,HDAC-5, HDAC-6 HDAC-7, HDAC-8 and/or HDAC-11.

In certain preferred embodiments of the third aspect of the invention,the method further comprises contacting a histone deacetylase enzyme ora cell expressing histone deacetylase activity with an additionalinhibitory agent. The combined use of separate agents results in animproved inhibitory effect, thereby reducing the amounts of individualinhibitors required to obtain a given inhibitory effect as compared tothe amounts necessary when either is used alone. Administration of suchseparate agents may be done sequentially or concurrently. Whenco-administered, the separate agents preferably act synergistically toproduce a therapeutic effect.

In certain preferred embodiments of the third aspect of the invention,the method further comprises contacting a histone deacetylase enzyme ora cell expressing histone deacetylase activity with an antisenseoligonucleotide that inhibits the expression of a histone deacetylasegene. The combined use of a nucleic acid level inhibitor (e.g.,antisense oligonucleotide) and a protein level inhibitor (i.e.,inhibitor of histone deacetylase enzyme activity) results in an improvedinhibitory effect, thereby reducing the amounts of the inhibitorsrequired to obtain a given inhibitory effect as compared to the amountsnecessary when either is used individually.

The exact nucleotide sequence and chemical structure of an antisenseoligonucleotide utilized in the invention can be varied, so long as theoligonucleotide retains its ability to inhibit expression of the gene ofinterest. This is readily determined by testing whether the particularantisense oligonucleotide is active. Useful assays for this purposeinclude quantitating the mRNA encoding a product of the gene, a Westernblotting analysis assay for the product of the gene, an activity assayfor an enzymatically active gene product, or a soft agar growth assay,or a reporter gene construct assay, or an in vivo tumor growth assay,all of which are known in the art, or are as described in detail in thisspecification or in, for example, Ramchandani et al. (1997) Proc. Natl.Acad. Sci. USA 94: 684-689.

Particularly preferred oligonucleotides have nucleotide sequences offrom about 13 to about 35 nucleotides. Yet additional particularlypreferred oligonucleotides have nucleotide sequences of from about 15 toabout 26 nucleotides.

In a preferred embodiment of the third aspect of the invention, theinvention provides a method of treating a patient having a disease orcondition ameliorated by modulating HDAC activity comprisingadministering to the patient a treatment effective amount of a compoundaccording to any of Formulae (I)-(V), (XII)-(XVII), (XII-A), (XX),(XX-A) and (XXI) or a preferred embodiment thereof, or an N-oxide,hydrate, solvate, pharmaceutically-acceptable salt, prodrug or complexthereof, or a racemic or scalemic mixture, diasteromer or enantiomerthereof, or a composition comprising a compound according to any ofFormulae (VI)-(XI), (VI-A), (XX), (XX-A) and (XXI), or a preferredembodiment thereof, or an N-oxide, hydrate, solvate,pharmaceutically-acceptable salt, prodrug or complex thereof, or aracemic or scalemic mixture, diasteromer or enantiomer thereof, with apharmaceutically-acceptable carrier.

In a preferred embodiment of the third aspect of the invention, thedisease or condition ameliorated by modulating HDAC activity is selectedfrom the group consisting of a cell proliferative disease (such ascancer), diabetes, inflammation, cardiac disease, stroke, epilepsy,depression, immunological disease and viral or fungal infection.

In a preferred embodiment of any of the first, second and third aspectsof the invention, the compound is selected from the group consisting of

-   2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4′-methoxybiphenyl-4-yl)-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(pyridin-4-yl)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(pyridin-3-yl)phenyl)acetamide,-   2-(4′-(dimethylamino)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(pyrimidin-5-yl)phenyl)acetamide and    N-hydroxy-2-(4′-morpholinobiphenyl-4-yl)-2-phenylacetamide.

In a preferred embodiment of any of the first, second and third aspectsof the invention, the compound is selected from the group consisting of

-   2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide,-   N-hydroxy-2-(4-morpholinophenyl)-2-phenylacetamide,-   2-(4-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide,-   2-(3-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide,-   2-(3-fluorophenyl)-N-hydroxy-2-(4-(pyrrolidin-1-yl)phenyl)acetamide    and-   2-(4-(diethylamino)phenyl)-2-(3-fluorophenyl)-N-hydroxyacetamide.

In another preferred embodiment of any of the first, second and thirdaspects of the invention, the compound is selected from the groupconsisting of

-   2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)acetamide,-   N-hydroxy-2-(4-(1-methylpiperidin-4-yloxy)phenyl)-2-phenylacetamide,-   2-(4-(1-benzylpiperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-morpholinophenyl)-2-m-tolylacetamide,-   2-(4-(1-(cyclopropylmethyl)piperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-morpholinophenyl)-2-o-tolylacetamide and-   N-hydroxy-2-(4-(2-morpholino-2-oxoethoxy)phenyl)-2-phenylacetamide.

In another preferred embodiment of any of the first, second and thirdaspects of the invention, the compound is selected from the groupconsisting of

-   2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide,-   2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide and-   N-hydroxy-2-(naphthalen-2-ylthio)-2-phenylacetamide.

In another preferred embodiment of any of the first, second and thirdaspects of the invention, the compound is selected from the groupconsisting of

-   2-(4′-(dimethylamino)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(4-benzylpiperidin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-propylphenyl)acetamide,-   2-(3-(4-fluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-morpholino-2-oxoethoxy)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-phenethoxyphenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methoxybenzyloxy)phenyl)-2-phenylacetamide,-   2-(4-(4-fluorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbutanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cyclohexanecarboxamide,-   4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,5-dimethylfuran-3-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylthiophene-2-carboxamide,-   N-hydroxy-2-(4-(2-phenoxyacetamido)phenyl)-2-phenylacetamide,-   N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxybenzamide,-   3-cyclohexyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propanamide,-   3-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   2-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isonicotinamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide,-   N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide,-   N-hydroxy-2-(4-(isopentylamino)phenyl)-2-phenylacetamide,-   2-(4-(benzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(pyridin-4-ylmethylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(3-(pyridin-4-ylmethylamino)phenyl)acetamide,-   2-(4-(cyclohexylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methoxybenzylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(3-(3-methoxybenzylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(propylsulfonamido)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(phenylsulfonamido)phenyl)acetamide,-   2-(4-(4-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(3-(pyridin-3-ylethynyl)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(phenylethynyl)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(3-propylphenyl)acetamide,-   2-(4′-(dimethylamino)biphenyl-3-yl)-N-hydroxy-2-phenylacetamide,-   2-(3′,4′-dimethoxybiphenyl-3-yl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(2′-(trifluoromethyl)biphenyl-3-yl)acetamide,-   3′-(2-(hydroxyamino)-2-oxo-1-phenylethyl)-N,N-dimethylbiphenyl-4-carboxamide,-   N-hydroxy-2-(4′-(methylsulfonyl)biphenyl-3-yl)-2-phenylacetamide,-   2-(4′-ethylbiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   2-(4′-chlorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3′,4′-dimethoxybiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   2-(4′-(ethylthio)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,-   4′-(2-(hydroxyamino)-2-oxo-1-phenylethyl)-N,N-dimethylbiphenyl-4-carboxamide,-   2-(3-(benzo[d][1,3]dioxol-5-ylmethylbenzo[d][1,3]dioxol-5-ylmethoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   (E)-2-(3-(cinnamyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-(3-chlorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(benzo[d][1,3]dioxol-5-ylmethylbenzo[d][1,3]dioxol-5-ylmethoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-(3-(dimethylamino)propoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-(3-(dimethylamino)-2-methylpropoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(3-(2-(1-methylpyrrolidin-2-yl)ethoxy)phenyl)-2-phenylacetamide,-   2-(4-ethoxyphenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(prop-2-ynyloxy)phenyl)acetamide,-   2-(4-(allyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-isopropoxyphenyl)-2-phenylacetamide,-   2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-methoxyethoxy)phenyl)-2-phenylacetamide,-   2-(4-((3,5-dimethylisoxazol-4-yl)methoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methylbut-2-enyloxy)phenyl)-2-phenylacetamide,-   2-(4-(2-ethylbutoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(1-phenylethoxy)phenyl)acetamide,-   2-(4-(2-fluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-cyanobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-phenoxyethoxy)phenyl)-2-phenylacetamide,-   2-(4-(2-chlorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2,4-difluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-(benzyloxy)ethoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-(4-fluorophenoxy)ethoxy)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(phenylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(pyridin-2-ylmethylamino)phenyl)acetamide,-   2-(4-(4-acetylpiperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(4-(4-fluorophenyl)piperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-(2-methoxyethoxy)ethoxy)phenyl)-2-phenylacetamide,-   2-(4-(4-chlorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propionamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cyclopropanecarboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)butyramide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isobutyramide,-   N-hydroxy-2-(4-(2-methoxyacetamido)phenyl)-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbutanamide,-   N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbutanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pivalamide,-   N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pivalamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)furan-2-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)furan-3-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,3-dimethylbutanamide,-   2-ethyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)butanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,2-dimethylbutanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylpentanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isonicotinamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-methylisoxazole-3-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)thiophene-2-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)tetrahydro-2H-pyran-4-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methylbenzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbenzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,-   5-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pentanamide,-   2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide,-   3-cyclopentyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cinnamamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-phenylpropanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,4-dimethylbenzamide,-   4-ethyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   2-(4-(2-(4-fluorophenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   5-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbenzamide,-   3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methylbenzamide,-   4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,-   4-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   3,4-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   3,5-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   2,5-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   5-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1-methyl-1H-pyrazole-4-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-phenylbutanamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-propylbenzamide,-   4-(dimethylamino)-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-hydroxy-2-(4-(2-(4-methoxyphenyl)acetamido)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(2-(3-methoxyphenyl)acetamido)phenyl)-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-phenoxypropanamide,-   2-(4-(2-(benzyloxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   4-ethoxy-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-nitrobenzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-nitrobenzamide,-   N-hydroxy-2-phenyl-2-(4-(2-(phenylthio)acetamido)phenyl)acetamide,-   3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxybenzamide,-   2-(4-(2-(4-chlorophenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   1-acetyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)piperidine-4-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1-naphthamide,-   2,4,5-trifluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzofuran-2-carboxamide,-   4-tert-butyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,6-dimethoxybenzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,5-dimethoxybenzamide,-   2-(4-(2-(4-chlorophenoxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   6-chloro-2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-(trifluoromethyl)benzamide,-   3,4-dichloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   3,5-dichloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxamide,-   4-butoxy-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,-   2-(4-(2-(3,4-dimethoxyphenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-methyl-3-phenylisoxazole-4-carboxamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethoxy)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-(trifluoromethoxy)benzamide,-   2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethyl)benzamide,-   4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-(trifluoromethyl)benzamide,-   2-(4-(2-(4-tert-butylphenoxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxy-3-(trifluoromethyl)benzamide,-   N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-nitrobenzo[b]thiophene-2-carboxamide,-   2-(4-(cyclopropylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(isobutylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methylbut-2-enylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(neopentylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(2-methylbutylamino)phenyl)-2-phenylacetamide,-   2-(4-(cyclopentylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-ethylbutylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-methylpentylamino)phenyl)-2-phenylacetamide,-   2-(4-(3,3-dimethylbutylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(pyridin-3-ylmethylamino)phenyl)acetamide,-   N-hydroxy-2-(4-((1-methyl-1H-imidazol-2-yl)methylamino)phenyl)-2-phenylacetamide,-   2-(4-(cyclohex-3-enylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(thiazol-2-ylmethylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(3-(thiazol-2-ylmethylamino)phenyl)acetamide,-   N-hydroxy-2-(4-(2-methylbenzylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methylbenzylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-((6-methylpyridin-2-yl)methylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(3-hydroxybenzylamino)phenyl)-2-phenylacetamide,-   2-(4-(2-fluorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   (E)-N-hydroxy-2-phenyl-2-(4-(3-(pyridin-3-yl)allylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(2-phenylpropylamino)phenyl)acetamide,-   2-(4-(3,5-dimethylbenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-((1H-indol-5-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-((1H-indol-5-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(benzo[d][1,3]dioxol-5-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-(benzo[d][1,3]dioxol-5-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(4-methoxy-3-methylbenzylamino)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(4-(methylthio)benzylamino)phenyl)-2-phenylacetamide,-   (E)-N-hydroxy-2-(4-(3-(4-methoxyphenyl)allylamino)phenyl)-2-phenylacetamide,-   (E)-N-hydroxy-2-(4-(3-(2-methoxyphenyl)allylamino)phenyl)-2-phenylacetamide,-   2-(4-(4-tert-butylbenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(3-(trifluoromethyl)benzylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(3-(3-(trifluoromethyl)benzylamino)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(4-(trifluoromethyl)benzylamino)phenyl)acetamide,-   2-(4-(biphenyl-4-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(methylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(ethylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(1-methylethylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(butylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3-chloropropylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(2,2,2-trifluoroethylsulfonamido)phenyl)acetamide,-   N-hydroxy-2-phenyl-2-(4-(phenylmethylsulfonamido)phenyl)acetamide,-   N-hydroxy-2-(4-(4-methylphenylsulfonamido)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(2-methylphenylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(4-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(1,2-dimethyl-1H-imidazole-4-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3,5-dimethylisoxazole-4-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3,4-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2,5-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(4-ethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3,5-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(3-methoxyphenylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(4-fluoro-2-methylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(3-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2,6-difluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(2,4-difluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(5-chlorothiophene-2-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(2-methoxy-4-methylphenylsulfonamido)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(2-nitrophenylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(3-chloro-4-methylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-(naphthalene-1-sulfonamido)phenyl)-2-phenylacetamide,-   N-hydroxy-2-(4-(naphthalene-2-sulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(4-tert-butylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-(4-((2-nitrophenyl)methylsulfonamido)phenyl)-2-phenylacetamide,-   2-(4-(3,4-dimethoxyphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(3-(3,4-dimethoxyphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   N-hydroxy-2-phenyl-2-(4-(3-(trifluoromethyl)phenylsulfonamido)phenyl)acetamide,-   2-(4-(2,5-dichlorothiophene-3-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   2-(4-(4,5-dichlorothiophene-2-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,-   (E)-2-(4-(cinnamylamino)phenyl)-N-hydroxy-2-phenylacetamide and    2-(4-(benzo[c][1,2,5]thiadiazole-5-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide.

The following examples are intended to further illustrate certainpreferred embodiments of the invention, and are not intended to limitthe scope of the invention.

ASSAY EXAMPLES Assay Example 1 Inhibition of Histone DeacetylaseEnzymatic Activity Inhibition of HDAC-1, 2, 3, 6 and 8

The following protocol is used to assay the compounds of the invention.In the assay, the buffer used is 25 mM HEPES, pH 8.0, 137 mM NaCl, 2.7mM KCl, 1 mM MgCl₂ and the substrate is Boc-Lys(Ac)-AMC in a 50 mM stocksolution in DMSO. The enzyme stock solution is 4.08 μg/mL in buffer.

The compounds are pre-incubated (2 μL in DMSO diluted to 13 μL in bufferfor transfer to assay plate) with enzyme (20 μL of 4.08 μg/mL) for 10minutes at room temperature (35 μL pre-incubation volume). The mixtureis pre-incubated for 5 minutes at room temperature. The reaction isstarted by bringing the temperature to 37° C. and adding 15 μLsubstrate. Total reaction volume is 50 μL. The reaction is stopped after20 minutes by addition of 50 μL developer, prepared as directed byBiomol (FLUOR DE LYS™ developer, Cat. # KI-105). A plate is incubated inthe dark for 10 minutes at room temperature before reading (λ_(Ex)=360nm, λ_(Em)=470 nm, Cutoff filter at 435 nm).

Inhibition of Class II HDAC and HDAC-11

A 30 mM stock of Boc-Lys(trifluoroacetyl)-AMC substrate is prepared inDMSO. 2 μL test compound in DMSO is diluted to 50 μL in buffer (25 mMHEPES, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl₂, 0.1% BSA) andpre-incubated with HDAC enzyme (30 μL of a final enzyme concentration of0.1-0.2 nM) for 10 minutes at room temperature. Reaction is started byadding 18 μL Boc-Lys(trifluoroacetyl)-AMC substrate and incubating at37° C. for 20-30 minutes. The reaction is stopped by adding 50 μLtrypsin (1 mg/mL) and a known HDAC inhibitor. The plate is thenincubated in the dark for 20 minutes at room temperature and read withEx=360 nm, Em=470 nm, cutoff filter at 435 nm.

All compounds exemplified have an IC₅₀ value less than or equal to 15 μMagainst one or more of HDAC-4, HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9,HDAC-10 and HDAC-11.

Table 3 shows selected examples. In Table 3, A≦1 uM and 1 uM<C<15 uM.

TABLE 3 Cpd HDAC Cpd HDAC Cpd HDAC number IC50(uM) number IC50(uM)number IC50(uM) 1-1 A 1-3 A 1-5 C 1-2 A 1-4 A 1-6 A 1-7 A 5-15 A 5-69 A1-8 A 5-16 C 5-70 A 1-9 A 5-17 A 5-71 C 1-10 A 5-18 A 5-72 A 1-11 C 5-19C 5-73 A 1-12 A 5-20 A 5-74 A 1-13 C 6-45 A 5-75 A 1-14 A 5-21 A 5-76 A1-15 A 5-22 A 5-77 A 1-16 A 5-23 A 5-78 A 1-17 C 5-24 A 5-79 A 1-18 A5-25 A 5-80 A 1-19 A 5-26 A 5-81 A 1-20 A ′5-27 A 5-82 A 1-21 A 5-28 A5-83 A 1-22 C 5-29 A 5-84 A 1-23 C 5-30 A 5-85 A 1-24 A 5-31 C 5-86 A1-25 C 5-32 C 5-87 C 1-26 A 5-33 A 5-88 A 1-27 C 5-34 A 5-89 A 1-28 A5-35 A 5-90 A 1-29 A 5-36 A 5-91 A 1-30 A 5-37 A 5-92 A 1-31 A 5-38 A5-93 A 1-32 A 5-39 C 5-94 A 1-33 A 5-40 A 5-95 A 1-34 A 5-41 A 5-96 A1-35 A 5-42 C 5-97 A 1-36 A 5-43 A 5-98 C 1-37 A 5-44 A 5-99 A 1-38 A5-45 A 5-100 A 1-39 A 5-46 A 5-101 A 1-40 A 5-47 A 5-102 A 1-41 A 5-48 A5-103 C 1-42 C 5-49 A 5-104 A 1-43 A 5-50 A 5-105 A 1-44 A 5-51 A 5-106A 1-45 A 5-52 A 5-107 A 1-46 A 5-53 A 5-108 A 1-47 A 5-54 C 5-109 A 5-1A 5-55 A 5-110 A 5-2 A 5-56 A 5-111 A 5-3 A 5-57 C 5-112 A 5-4 A 5-58 A5-113 A 5-5 A 5-59 A 5-113b C 5-6 C 5-60 C 5-114 C 5-7 A 5-61 C 5-115 C5-8 A 5-62 A 5-116 A 5-9 A 5-63 A 5-117 C 5-10 A 5-64 A 5-118 A 5-11 A5-65 A 5-119 C 5-12 A 5-66 A 5-120 C 5-13 A 5-67 A 5-121 C 5-14 C 5-68 A5-122 A 5-123 A 2-54 C 2-109 A 5-125 A 2-55 A 2-110 A 5-126 C 2-56 C2-111 A 5-127 C 2-57 A 2-112 A 5-128 C 2-58 C 2-113 A 5-129 C 2-59 A2-114 A 6-16 A 2-60 A 2-115 A 5-130 A 2-61 A 2-116 A 6-17 A 2-62 A 2-117A 6-18 C 2-63 A 6-23 A 5-131 A 2-64 C 6-24 C 5-132 A 2-65 A 6-25 A 6-19A 2-66 C 3-5 A 6-20 C 2-67 A 3-6 A 2-5 C 2-68 A 3-7 A 2-6 A 2-69 A 3-8 C2-7 C 2-70 A 3-9 A 2-8 A 2-71 A 3-10 A 2-9 2-72 A 3-11 A 2-10 C 2-73 C3-12 A 2-11 A 2-74 A 3-13 A 2-12 A 2-75 A 3-14 C 2-13 A 2-76 A 3-15 A2-14 A 2-77 A 3-16 A 2-15 C 2-78 A 3-17 A 2-16 C 2-79 C 3-18 C 2-21 C2-80 A 3-19 A 2-22 C 2-81 A 3-20 A 2-23 C 2-82 A 3-21 C 2-24 C 2-83 C3-22 A 2-27 C 2-84 A 3-24 C 2-28 C 2-85 A 3-25 C 2-29 C 2-86 A 3-26 C2-31 C 2-87 C 3-27 C 2-34 C 2-88 A 3-29 C 2-36 C 2-89 C 3-30 C 2-37 C2-90 A 3-31 C 2-38 A 2-91 C 3-32 C 2-39 C 2-92 A 3-33 C 2-40 C 2-93 C3-34 A 2-41 C 2-94 C 3-35 A 2-42 C 2-95 A 3-36 A 2-43 A 2-96 A 3-42 A2-44 A 2-97 A 3-43 A 2-45 C 2-98 A 3-44 A 2-46 C 2-99 A 3-45 A 2-47 C2-100 C 3-46 A 2-48 C 2-101 A 3-47 A 2-49 A 2-102 A 3-49 A 6-21 C 2-103A 3-50 A 6-22 A 2-104 A 3-51 A 2-50 A 2-105 A 3-52 A 2-51 A 2-106 A 3-53A 2-52 C 2-107 A 3-54 C 2-53 A 2-108 A 3-55 A 3-56 A 3-78 C 6-40 A 3-57A 3-79 A 6-42 C 3-58 A 3-80 A 6-43 A 3-59 A 3-81 A 7-1 C 3-60 A 3-82 A7-2 C 3-61 A 3-83 A 7-5 C 3-62 A 3-84 A 7-11 C 3-64 A 3-85 A 7-17 C 3-65A 3-86 A 7-18 C 3-66 A 3-87 C 7-20 C 3-67 A 3-88 C 7-31 A 3-68 A 3-89 A7-33 C 3-69 A 3-90 A 7-34 c 3-70 A 6-26 C 7-35 C 3-71 A 6-27 A 7-36 C3-72 C 6-29 C 7-37 C 3-73 C 6-37 A 7-41 C 3-74 A 6-38 C 7-42 C 3-75 A6-39 A 7-44 C 3-76 A 6-46 A

While the invention has been described in connection with specificembodiments thereof, it will be understood that it is capable of furthermodifications and this application is intended to cover any variations,uses, or adaptations of the invention following, in general, theprinciples of the invention and including such departures from thepresent disclosure as come within known or customary practice within theart to which the invention pertains and as may be applied to theessential features hereinbefore set forth, and as follows in the scopeof the appended claims.

1. A compound of the Formula (I):

and N-oxides, hydrates, solvates, pharmaceutically acceptable salts,prodrugs and complexes thereof, and racemic and scalemic mixtures,diastereomers and enantiomers thereof, wherein M is selected from thegroup consisting of alkyl, —N(R^(e))OR^(s), —CF₃, —C(O)N(R^(e))(R^(f)),-heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—S(acetyl), —CH₂—SR^(e) and-heterocycloalkyl; X is selected from the group consisting of CH, C(OH),C(C₁-C₄alkyl), C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y; L and Y are independentlyselected from the group consisting of C₁-C₄alkyl, heteroalkyl, alkenyl,alkynyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl, —C₂-C₄alkenyl-heteroaryl,—C₂-C₄alkenyl-heterocyclyl, —C₂-C₄alkenyl-cycloalkyl,—C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl -cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH—C₀-C₃alkyl-aryl,—C(O)NH—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))_S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—,—N(R^(e))—C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e))—, —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl, provided that ifan L or a Y is bound directly to a nitrogen of X, then the L or Y is not—NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl, in which each R^(a) andR^(b) together with the nitrogen to which they are bound form a 4 to 7membered heterocyclyl having 1 or 2 annular heteroatoms, or a 5 to 8membered bridged heterocyclyl having 1 or 2 annular heteroatoms, theheterocyclyl being optionally substituted with 1-3 substituentsindependently selected from the group consisting of H, OH, oxo,N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl, —C₁-C₆alkyl-aryl,—C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl, —C₂-C₃alkyl-OH,—C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,—C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀₋₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl; eachR^(c) and R^(d) is independently selected from the group consisting ofH, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or R^(c)and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms, each R^(e) and R^(f) is independently selected from thegroup consisting of —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl,heteroaryl-aryl, heteroaryl-heteroaryl, —C(O)-alkyl and —C(O)CF₃; andeach R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup, wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroarylmoiety is optionally substituted, and wherein a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl moiety in L is optionallyconnected to a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl in Yby a bond or by a bridging substituent, provided that the compound doesnot have the formula (A)

in which each R¹⁰ is selected from the group consisting of H, OH,—CH₂OH, NH₂, COOH and C₁-C₄alkyl; and each R¹¹ is selected from thegroup consisting of H, halo, C₁-C₆alkyl, C₁-C₄alkoxy, —OC(O)C₁-C₄alkyl,—NH₂, —NH(C₁-C₄alkyl), —N(C₁-C₄alkyl)₂, —SH, —S—C₁-C₄alkyl, —COOH and—C(O)O—C₁-C₄alkyl; the compound does not have the formula (B)

in which R¹² is H, alkyl, halo or alkoxy; R¹³ is hydrogen or C₁-C₅alkyl;and R¹⁴ is H or OH; the compound does not have the formula (B) whereinR¹⁴ is H, R¹² is NO₂ and R¹³ is H; and the compound is not10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-hydroxamic acid.
 2. Thecompound according to claim 1, wherein M is NHOH.
 3. The compoundaccording to claim 1, wherein M is


4. The compound according to claim 1, wherein M is —H.
 5. The compoundaccording to claim 1, wherein X is CH.
 6. The compound according toclaim 1, wherein X is C(OH) or C(halo).
 7. The compound according toclaim 1, wherein X is


8. The compound according to claim 1, wherein X is


9. The compound according to claim 1, wherein L and Y are independentlyselected from aryl, heteroaryl, O-aryl, heterocyclyl, cycloalkyl,—S-aryl, —S-heteroaryl and —C(O)NH-aryl, —S-heteroaryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, -heterocyclyl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl and -heterocyclyl-O-aryl, each of which is optionallysubstituted.
 10. The compound according to claim 1, wherein L and Y areindependently selected from the group consisting of aryl, heteroaryl,alkyl, —O-aryl, —O-cycloalkyl, heterocyclyl, cycloalkyl, —S-aryl,—S-heteroaryl, —C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, —NHS(O)₂-aryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heterocyclyl-C₀-C₃alkyl-heteroaryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl, -aryl-heteroaryl, -heterocyclyl-O-aryl,-heterocyclyl-O—C₀-C₃alkyl-aryl, -heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.
 11. Thecompound according to claim 10, wherein each cycloalkyl and heterocyclylmoiety is optionally gem or spiro substituted with —OH, —CN or -alkyl.12. The compound according to claim 1, wherein L and Y are independentlyselected from the group consisting of aromatic polycycle, non-aromaticpolycycle, polyheteroaryl, non-aromatic polyheterocyclic and mixed aryland non-aryl polyheterocycle.
 13. The compound according to claim 1,wherein the compound has the Formula (II):

wherein each n is independently 0-3; and R^(g) is selected from thegroup consisting of —C₀-C₃alkyl -aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-cycloalkyl, —C₀-C₃alkyl-heterocylyl, —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e).
 14. The compound according to claim 1, whereinthe compound has the Formula (III):

wherein R⁴ and R⁵ are independently selected from the group consistingof H, halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃; A is H, phenyl or OH; B is a bond, —O—, —N(R⁶)—, S(O)₀₋₂, —CH(R⁴)—,—C(R⁵)(R⁴)—, —C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)—, —C(R⁴)—O—, —O—C(R⁴)—,—S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—, —CH(R⁴)—CH(R⁵)—,—C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—, —C(R⁵)(R⁴)—C(R⁵)(R⁴)—,—C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)—, or

 in which R⁶ is alkyl, cycloalkyl or heterocyclyl.
 15. The compoundaccording to claim 1, wherein each aryl, heterocyclyl, cycloalkyl andheteroaryl is independently optionally substituted with one, two orthree substituents independently selected from the group consisting ofH, halo, oxo, OH, C₁-C₃hydrocarbyl, OCH₃, —CN, —S(O)₀₋₂—C₁-C₄alkyl,—CF₃, —OCF₃, alkyl, —NH₂, —N(alkyl)₂, —NH(alkyl), —N(aryl)(alkyl),—N(-alkyl-aryl)(alkyl), —N(heteroaryl)(alkyl),—N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl), —NH(-alkyl-aryl),—NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-Oalkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —N_(a)R_(b), —NR_(c)R_(d), —OR^(e),—C₂-C₄alkyl-NR^(a)R^(b), C₂-C₄alkyl-NR^(c)R^(d), —S(O)₀₋₁R^(e),—(CR³²R³³)_(s)—NR³⁰R³¹, and (X³⁰—Y³¹—), in which R³⁰ and R³¹ are eachindependently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl,C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-, C₁-C₃alkyl-carboxamido-,carboxamido-C₁-C₃alkyl-, amidino-, C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-,aryl-C₁-C₃alkyl-, C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or R³⁰ and R³¹ taken together with the N to which theyare attached form a heterocyclyl or heteroaryl, each of which isoptionally substituted with from 1 to 3 substituents selected from thegroup consisting of halo, cyano, oxo, carboxy, formyl, nitro, amino,amidino, guanidino, a protecting group, and (X³⁰—Y³¹-), in which X³⁰ isselected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, C₀-C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³)—C₀-C₃alkyl-,N(R³⁰)(R³¹)—C₀-C₃alkenyl-, N(R³⁰)(R³)—C₀-C₃alkynyl-,(N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-,C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and Y³¹ isselected from the group consisting of a direct bond, —O—, —N(R³⁰)—,—C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—, —N(R³⁰)—C(S)—,—C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—, —N(R³⁰)—C(NR³⁰)—N(R³¹),—N(R³⁰)—C(NR³¹)—, —C(NR³)—N(R³⁰), —N(R³⁰)—C(S)—N(R³¹)—, —N(R³⁰)—C(O)—O—,—O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—, —O—C(S)—N(R³¹)—, —S(O)₀₋₂—,—SO₂N(R³¹)—, —N(R³¹)—SO₂— and —N(R³⁰)—SO₂N(R³¹)—; and R₃₂ and R₃₃ areindependently selected from hydrogen, halo and hydroxyl.
 16. Thecompound according to claim 1, wherein the compound has the Formula(IV):

wherein n is 0-3; and R^(z) is selected from the group consisting of

wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—-C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.
 17. The compound accordingto claim 1, wherein the compound has the Formula (V):

where M is H or alkyl.
 18. The compound according to claim 1, wherein Yis further selected from the group consisting of -Z¹-Z-Z²-D, -D,-Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D, -Z-Z³-Z²-Z-D,-Z¹-Z-Z², -Z-Z³-D and Z²-Z¹-Z²-D wherein Z¹ is selected from the groupconsisting of chemical bond, alkyl, aryl, heterocyclyl, bridgedheterocyclyl, spiro heterocyclyl, cycloalkyl, heteroaryl, wherein eacharyl, heteroaryl, cycloalkyl and heterocyclyl moiety is optionallysubstituted and each of which is optionally fused to one or more aryl orheteroaryl rings, or one or more saturated or partially unsaturatedcycloalkyl or heterocyclyl rings, each of which ring is optionallysubstituted; Z is selected from the group consisting of chemical bond,—O—, —S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—, —C(O)N(R^(c))—,—N(R^(c))S(O)₂—, —N(R^(c))—, —N(R^(c))(C₂-C₄alkyl-OR^(d))—C(O)—,—C(NOR²¹)—, —CH[C(O)N(R²¹)(R²²)]—C(O)N(R²²)—,—CH(N(R²¹)(R²²))—C(O)N(R²²)—, —CH[C(O)N(R^(e))(R^(f))]—C(O)N(R²²)—,—S(O)₂N(R²¹)—, —N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—, —N(R²¹)C(NR²²)—,—C(NR²²)N(R²¹)—, —N(R²¹)C(O)N(R²²)—, —N(R²)C(O)O—, —OC(O)N(R²¹)—,—N(R²¹)C(S)—, —C(S)N(R²¹)—, —N(R²)C(S)N(R²²)—, —N(R²¹)C(S)O—,—OC(S)N(R²¹)—, —O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R¹)—C₂-C₄alkyl-S(O)₀₋₂—, —N[C₂-C₄alkyl-N(R¹)(R²)]—,—N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R^(c))—N(R^(c))—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d)), —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,—O—C₁-C₄alkyl-O—, —O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—,—S(O)₂N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,—N(R²)S(O)₂—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-N(R²¹)—,—N(C(O)—C₁-C₄alkyl)-, —N(R²¹)—C₁-C₄alkyl-C(O)—,—O—C₁-C₄alkyl-C(O)N(R²¹)—, —C(O)N(R²¹)—C₂-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-S(O)₀₋₂—,—O—C₂-C₄alkyl-N(R²¹)C(O)—, —N(R²)C(O)—C₁-C₄alkyl-O—,—N(R²)C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₁-C₄alkyl-C(O)—,—C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O), —C(O)—C₁-C₄alkyl-N(R²¹)—,—O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(S),—C(S)—C₁-C₄alkyl-N(R²¹)—, —N(R²¹)—C₁-C₄alkyl-C(S)—,—O—C₁-C₄alkyl-C(S)N(R²¹)—, —C(S)N(R²¹)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)C(S)—, —N(R²¹)C(O)—C₁-C₄alkyl-O—,—N(R²¹)C(S)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-S(O)₂—,—O—C₁-C₄alkyl-S(O)₂N(R²¹)—, —S(O)₂N(R²)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)S(O)₂—, —N(R²¹)S(O)₂—C₁-C₄alkyl-O—,—O—C₂-C₄alkyl-OC(O)N(R²¹)—, —O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein eachalkyl moiety is optionally substituted; Z² is selected from the groupconsisting of a chemical bond, alkyl, alkenyl, alkynyl, alkyl-alkenyl,alkynyl-alkyl and alkyl-alkynyl, wherein each alkyl, alkenyl and alkynylmoiety is optionally substituted; Z³ is selected from the groupconsisting of a chemical bond, —C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-,—C₀-C₅alkyl-heterocyclyl-, —C₀-C₅alkyl-bridged heterocyclyl-, -spiroheterocyclyl-, —C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-,wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl moiety isoptionally substituted and each of which is optionally fused to one ormore aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted; D is selected from the group consisting of H,aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalyl,heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, aromaticpolycycles, non-aromatic polycycles, polyheteroaryl groups, non-aromaticpolyheterocyclic, mixed aryl and non-aryl polyheterocycle, each of whichis optionally substituted and each of which is optionally fused to oneor more aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted, wherein each R²¹ and R²² is independentlyselected from the group consisting of —H, -alkyl, -aryl and heteroaryl,wherein each said aryl and heteroaryl moiety is optionally substituted;and L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.
 19. The compound according to claim 18, wherein eachcycloalkyl, heterocyclyl, aryl, alkyl, alkenyl and heteroaryl moiety inZ, Z₁, Z₂, Z₃ and D is optionally substituted with a substituentselected from the group consisting of —N(R^(e))C(O)—C₁-C₆alkyl,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, —O—CF₃, —S—CF₃, aryl,heteroaryl, cycloalkyl, heterocyclyl, —C₁-C₃alkyl-aryl,—C₁-C₃alkyl-heteroaryl, —C₁-C₃alkyl-cycloalkyl,—C₁-C₃alkyl-heterocyclyl, halo, alkyl, —O-alkyl, —S(O)₀₋₂-alkyl,—C₀-C₃alkyl-CN, NO₂, —C(O)-alkyl and —OH.
 20. The compound according toclaim 18, wherein the compound has Formula XX:

wherein each L¹ is independently selected from the group consisting ofH, halo, —O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃, and —CF₃; and Y¹ is selected from the groupconsisting of -Z-Z² D, -Z¹-Z²-D, —CH₂-D and D.
 21. The compoundaccording to claim 20, wherein the compound has Formula XX-A:

wherein each L¹ is independently selected from the group consisting ofH, halo, —O—CH₃, —CH₃ and —OH; and Y¹ is selected from the groupconsisting of -Z-Z²-D, -Z¹-Z²-D, —CH₂-D and D; wherein Z is selectedfrom the group consisting of —O—, —S(O)₀₋₂—, —N(R^(c))C(O)—,—C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—, —S(O)₂N(R²¹)—,—O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d))—, and —O—C₁-C₄alkyl-O—; Z¹ is selectedfrom the group consisting of aryl, heterocyclyl, bridged heterocyclyl,spiro heterocyclyl, cycloalkyl and heteroaryl, wherein each aryl,heteroaryl, cycloalkyl and heterocyclyl moiety is optionally substitutedand each of which is optionally fused to one or more aryl or heteroarylrings, or one or more saturated or partially unsaturated cycloalkyl orheterocyclyl rings, each of which ring is optionally substituted; Z² isa chemical bond or an optionally substituted alkyl; and D is selectedfrom the group consisting of H, aryl, heteroaryl, alkyl, cycloalkyl andheterocyclyl, each of which is optionally substituted and each of whichis optionally fused to one or more aryl or heteroaryl rings, or one ormore saturated or partially unsaturated cycloalkyl or heterocyclylrings, each of which ring is optionally substituted.
 22. The compoundaccording to claim 18, wherein the compound has the Formula XXI:

wherein each L¹ is independently selected from the group consisting ofH, halo, —O-alkyl, —S-alkyl, —NO₂, —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl, —N(R^(a))(R^(b)), —N(R^(c))(R^(d)),—OH, -alkyl, —OCF₃ and —CF₃; and Y² is -Z²Z¹-Z²-D, —CH₂-D or D; whereinZ¹ is selected from the group consisting of aryl, heterocyclyl,cycloalkyl and heteroaryl, wherein each aryl, heteroaryl, cycloalkyl andheterocyclyl moiety is optionally substituted and each of which isoptionally fused to one or more aryl or heteroaryl rings, or one or moresaturated or partially unsaturated cycloalkyl or heterocyclyl rings,each of which ring is optionally substituted; Z² is a chemical bond oran optionally substituted alkyl; and D is selected from the groupconsisting of H, aryl, heteroaryl, alkyl, cycloalyl and heterocyclyl,each of which is optionally substituted and each of which is optionallyfused to one or more aryl or heteroaryl rings, or one or more saturatedor partially unsaturated cycloalkyl or heterocyclyl rings, each of whichring is optionally substituted.
 23. The compound according to claim 1,selected from the group consisting of2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide, or an N-oxide,hydrate, solvate, pharmaceutically acceptable salt, prodrug or complexthereof, or a racemic or scalemic mixture, diastereomer or enantiomerthereof.
 24. The compound according to claim 1, selected from the groupconsisting of N-hydroxy-2-phenylbutanamide;N-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;2-benzyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide, or an N-oxide,hydrate, solvate, pharmaceutically acceptable salt, prodrug or complexthereof, or a racemic or scalemic mixture, diastereomer or enantiomerthereof.
 25. The compound according to claim 1, selected from the groupconsisting of 2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;N-hydroxy-2,2-diphenylpropanamide; (E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide andN-hydroxy-9H-xanthene-9-carboxamide, or an N-oxide, hydrate, solvate,pharmaceutically acceptable salt, prodrug or complex thereof, or aracemic or scalemic mixture, diastereomer or enantiomer thereof.
 26. Thecompound according to claim 1, selected from the group consisting ofN-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide;2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide; N-hydroxy-9H-xanthene-9-carboxamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2,3-diphenylpropanamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2,2-diphenylpropanamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;(E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide;2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide;2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide, or an N-oxide,hydrate, solvate, pharmaceutically acceptable salt, prodrug or complexthereof, or a racemic or scalemic mixture, diastereomer or enantiomerthereof.
 27. A composition comprising a pharmaceutically acceptablecarrier, excipient or diluent, and a compound of Formula (VI):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein M is selected from the groupconsisting of alkyl, —N(R^(e))OR^(s), —CF₃, —C(O)N(R^(e))(R^(f)),-heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—S(acetyl), —CH₂—SR^(e) and-heterocycloalkyl; X is selected from the group consisting of CH, C(OH),C(C₁-C₄alkyl), C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y; L and Y are independentlyselected from the group consisting of C₁-C₄alkyl, heteroalkyl, alkenyl,alkynyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl, —C₂-C₄alkenyl-heteroaryl,—C₂-C₄alkenyl-heterocyclyl, —C₂-C₄alkenyl-cycloalkyl,—C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl-cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH-C₀-C₃alkyl-aryl,—C(O)NH-C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))—S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—,—N(R^(e))—C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e))—, —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl, provided that ifan L or a Y is bound directly to a nitrogen of X, then the L or Y is not—NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl, in which each R^(a) andR^(b) together with the nitrogen to which they are bound form a 4 to 7membered heterocyclyl having 1 or 2 annular heteroatoms, or a 5 to 8membered bridged heterocyclyl having 1 or 2 annular hetero atoms, theheterocyclyl being optionally substituted with 1-3 substituentsindependently selected from the group consisting of H. OH, oxo,N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl, —C₁-C₆alkyl-aryl,—C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl, —C₂-C₃alkyl-OH,—C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,—C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀-C₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₀-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl; eachR^(c) and R^(d) is independently selected from the group consisting ofH, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or R^(c)and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms, each R^(e) and R^(f) is independently selected from thegroup consisting of —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl,heteroaryl-aryl, heteroaryl-heteroaryl, —C(O)-alkyl and —C(O)CF₃; andeach R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup, wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroarylmoiety is optionally substituted, and wherein a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl moiety in L is optionallyconnected to a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl in Yby a bond or by a bridging substituent, provided that the compound doesnot have the formula (C)

in which each R¹⁰ is selected from the group consisting of H, OH,—CH₂OH, NH₂, COOH and C₁-C₄alkyl; and each R¹¹ is selected from thegroup consisting of H, halo, C₁-C₆alkyl, C₁-C₄alkoxy, —OC(O)C₁-C₄alkyl,—NH₂, —NH(C₁-C₄alkyl), —N(C₁-C₄alkyl)₂, —SH, —S—C₁-C₄alkyl, —COOH and—C(O)O—C₁-C₄alkyl; and the compound is not10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-hydroxamic acid.
 28. Thecomposition according to claim 27, wherein M is NHOH.
 29. Thecomposition according to claim 27, wherein M is


30. The composition according to claim 27, wherein M is —H.
 31. Thecomposition according to claim 27, wherein X is CH.
 32. The compositionaccording to claim 27, wherein X is C(OH) or C(halo).
 33. Thecomposition according to claim 27, wherein X is


34. The composition according to claim 27, wherein X is


35. The composition according to claim 27, wherein L and Y areindependently selected from the group consisting of aryl, heteroaryl,alkyl, —O-aryl, —O-cycloalkyl, heterocyclyl, cycloalkyl, —S-aryl,—S-heteroaryl, —C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, —NHS(O)₂-aryl,-heterocyclyl-C₀-C₃alkyl-aryl, -heterocyclyl-C₀-C₃alkyl-heteroaryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl, -aryl-heteroaryl, -heterocyclyl-O-aryl,-heterocyclyl-O—C₀-C₃alkyl-aryl, -heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.
 36. Thecomposition according to claim 35, wherein each cycloalkyl andheterocyclyl moiety is optionally gem or spiro substituted with —OH, —CNor -alkyl.
 37. The composition according to claim 27, wherein L and Yare independently selected from the group consisting of aromaticpolycycle, non-aromatic polycycle, polyheteroaryl, non-aromaticpolyheterocyclic and mixed aryl and non-aryl polyheterocycle.
 38. Thecomposition according to claim 27, wherein L and Y are independentlyselected from aryl, heteroaryl, O-aryl, heterocyclyl, cycloalkyl,—S-aryl, —S-heteroaryl and —C(O)NH-aryl, —S-heteroaryl-aryl,-aryl-heterocyclyl, -heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl,—S(O)₂-aryl, —S(O)₂-heteroaryl, -heterocyclyl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl and -heterocyclyl-O-aryl, each of which is optionallysubstituted.
 39. The composition according to claim 27, wherein thecompound has the Formula (VII):

wherein each n is independently 0-3; and R^(g) is selected from thegroup consisting of —C₀-C₃alkyl-aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-cycloalkyl, —C₀-C₃alkyl-heterocylyl, —NR^(a)R^(b),—NR^(c)R^(d), —OR_(e).
 40. The composition according to claim 27,wherein the compound has the Formula (VIII):

wherein each R¹ is independently alkyl, NO₂, halo or alkoxy, R² is H orC₁-C₅alkyl, and A is H, phenyl or OH.
 41. The composition according toclaim 27, wherein the compound has the Formula (IX):

wherein R₄ and R₅ are independently selected from the group consistingof H, halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃; A is H, phenyl or OH; B is a bond, —O—, —N(R⁶)—, —S(O)₀₋₂—,—CH(R⁴)—, —C(R⁵)(R⁴)—, —C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)_, —C(R⁴)—O—,—O—C(R⁴)—, —S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—,—CH(R⁴)—CH(R⁵)—, —C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—,—C(R⁵)(R⁴)—C(R⁵)(R⁴)—, —C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)-, or

 in which R⁶ is alkyl, cycloalkyl or heterocyclyl.
 42. The compositionaccording to claim 27, wherein M is H and X is


43. The composition according to claim 27, wherein each aryl,heterocyclyl, cycloalkyl and heteroaryl is independently optionallysubstituted with one, two or three substituents independently selectedfrom the group consisting of H, halo, oxo, OH, C₁-C₃hydrocarbyl, OCH₃,—CN, —S(O)₀₋₂—C₁-C₄alkyl, —CF₃, —OCF₃, alkyl, —NH₂, —N(alkyl)₂,—NH(alkyl), —N(aryl)(alkyl), —N(-alkyl-aryl)(alkyl),—N(heteroaryl)(alkyl), —N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl),—NH(-alkyl-aryl), —NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-Oalkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e),—C₂-C₄alkyl-NR^(a)R^(b), C₂-C₄alkyl-NR^(c)R^(d), —S(O)₀₋₁R^(e),—(CR³²R³³)_(s)—NR³⁰R³¹, and (X³⁰—Y³¹—), in which R³⁰ and R³¹ are eachindependently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl,C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-, C₁-C₃alkyl-carboxamido-,carboxamido-C₁-C₃alkyl-, amidino-, C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-,aryl-C₁-C₃ alkyl-, C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or R³⁰ and R³¹ taken together with the N to which theyare attached form a heterocyclyl or heteroaryl, each of which isoptionally substituted with from 1 to 3 substituents selected from thegroup consisting of halo, cyano, oxo, carboxy, formyl, nitro, amino,amidino, guanidino, a protecting group, and (X³⁰—Y³¹—), in which X³⁰ isselected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, CO—C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,N(R³⁰)(R³¹)—C₀-C₃alkenyl-, N(R³⁰)(R³)—C₀-C₃alkynyl-,(N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-,C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and Y³¹ isselected from the group consisting of a direct bond, —O—, —N(R³⁰)—,—C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—, —N(R³⁰)—C(S)—,—C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—, —N(R³⁰)—C(NR³⁰)—N(R³¹),—N(R³⁰)—C(NR³¹)—, —C(NR³¹)—N(R³⁰), —N(R³⁰)—C(S)—N(R³¹)—,—N(R³⁰)—C(O)—O—, —O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—, —O—C(S)—N(R³¹)—,—S(O)₀₋₂—, —SO₂N(R³¹)—, —N(R³¹)—SO₂— and —N(R³⁰)—SO₂N(R³¹)—; and R₃₂ andR₃₃ are independently selected from hydrogen, halo and hydroxyl.
 44. Thecomposition according to claim 27, wherein the compound has the Formula(X):

wherein n is 0-3; and R^(z) is selected from the group consisting of

wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.
 45. The compositionaccording to claim 27, wherein the compound has the formula (XI)

wherein M is H or alkyl.
 46. A composition comprising a pharmaceuticallyacceptable carrier, excipient, or diluent, and a compound having theFormula (VI-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein M, X, Y and L are as definedin claim 24, and wherein Y is further selected from the group consistingof -Z¹-Z-Z²-D, -D, -Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D,-Z-Z³-Z²-Z-D, -Z¹-Z-Z², -Z-Z³-D and -Z²-Z¹-Z²-D, wherein Z¹ is selectedfrom the group consisting of chemical bond, alkyl, aryl, heterocyclyl,bridged heterocyclyl, spiro heterocyclyl, cycloalkyl, heteroaryl,wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl moiety isoptionally substituted and each of which is optionally fused to one ormore aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted; Z is selected from the group consisting ofchemical bond, —O—, —S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—,—C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—,—N(R^(c))(C₂-C₄alkyl-OR^(d))—, —C(O)—, —C(NOR²¹)—,—CH[C(O)N(R²¹)(R²²)]—C(O)N(R²²)—, —CH(N(R²¹)(R²²))—C(O)N(R²²)—,—CH[C(O)N(R^(e))(R^(f))]-C(O)N(R²²)—, —S(O)₂N(R²¹)—,—N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—, —N(R²¹)C(NR²²)—, —C(NR²²)N(R²¹)—,—N(R²¹)C(O)N(R²²)—, —N(R²¹)C(O)O—, —OC(O)N(R²¹)—, —N(R²¹)C(S)—,—C(S)N(R²¹)—, —N(R²¹)C(S)N(R²²)—, —N(R²¹)C(S)O—, —OC(S)N(R²¹)—,—O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—, —N(R¹)—C₂-C₄alkyl-S(O)₀₋₂,—N[C₂-C₄alkyl-N(R¹)(R²)]—, —N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R^(c))—, —N(R^(c))—C₂-C₄alkyl-O—,—N(R^(c))—C₂-C₄alkyl-N(R^(d))—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,—O—C₁-C₄alkyl-O—, —O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—,—S(O)₂N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,—N(R²)S(O)₂—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-N(R²¹)—,—N(C(O)—C₁-C₄alkyl)-, —N(R²¹)—C₁-C₄alkyl-C(O)—,—O—C₁-C₄alkyl-C(O)N(R²¹)—, —C(O)N(R²¹)—C₂-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-S(O)₀₋₂—,—O—C₂-C₄alkyl-N(R²¹)C(O)—, —N(R²)C(O)—C₁-C₄alkyl-O—,—N(R²)C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₁-C₄alkyl-C(O)—,—C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O), —C(O)—C₁-C₄alkyl-N(R²¹)—,—O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(S),—C(S)—C₁-C₄alkyl-N(R²¹)—, —N(R²¹)—C₁-C₄alkyl-C(S)—,—O—C₁-C₄alkyl-C(S)N(R²¹)—, —C(S)N(R²¹)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)C(S)—, —N(R²¹)C(O)—C₁-C₄alkyl-O—,—N(R²¹)C(S)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-S(O)₂—,—O—C₁-C₄alkyl-S(O)₂N(R²¹)—, —S(O)₂N(R²)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)S(O)₂—, —N(R²¹)S(O)₂—C₁-C₄alkyl-O—,—O—C₂-C₄alkyl-OC(O)N(R²¹)—, —O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein eachalkyl moiety is optionally substituted; Z² is selected from the groupconsisting of a chemical bond, alkyl, alkenyl, alkynyl, alkyl-alkenyl,alkynyl-alkyl and alkyl-alkynyl, wherein each alkyl, alkenyl and alkynylmoiety is optionally substituted; Z³ is selected from the groupconsisting of a chemical bond, —C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-,—C₀-C₅alkyl-heterocyclyl-, —C₀-C₅alkyl-bridged heterocyclyl-, -spiroheterocyclyl-, —C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-,wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl moiety isoptionally substituted and each of which is optionally fused to one ormore aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted; D is selected from the group consisting of H,aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalyl,heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, aromaticpolycycles, non-aromatic polycycles, polyheteroaryl groups, non-aromaticpolyheterocyclic, mixed aryl and non-aryl polyheterocycle, each of whichis optionally substituted and each of which is optionally fused to oneor more aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted, wherein each R²¹ and R²² is independentlyselected from the group consisting of —H, -alkyl, -aryl and heteroaryl,wherein each said aryl and heteroaryl moiety is optionally substituted;and L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.
 47. The composition according to claim 27, in which thecompound is selected from the group consisting of2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide.
 48. Thecomposition according to claim 27, wherein the compound is selected fromthe group consisting of N-hydroxy-2-phenylbutanamide;N-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;2-benzyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.
 49. The compositionaccording to claim 27, wherein the compound is selected from the groupconsisting of 2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;N-hydroxy-2,2-diphenylpropanamide; (E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide andN-hydroxy-9H-xanthene-9-carboxamide.
 50. A composition according toclaim 27, wherein the compound is selected from the group consisting ofN-hydroxy-2,2-diphenylacetamide; N-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide;2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide; N-hydroxy-9H-xanthene-9-carboxamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2,3-diphenylpropanamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2,2-diphenylpropanamide;2,2-bis(4-chlorophenyl)-N-hydroxyacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;2,2-bis(4-fluorophenyl)-N-hydroxyacetamide;2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;(E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide;2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;N,2-dihydroxy-2,2-diphenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide;2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.
 51. The compositionaccording to claim 27 further comprising an additional inhibitory agentthat inhibits a histone deacetylase.
 52. A method of inhibiting ahistone deacetylase selected from the group consisting of HDAC-4,HDAC-5, HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11 comprisingcontacting the histone deacetylase with a histone deacetylase inhibitingamount of a compound having the Formula (XII)

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein M is selected from the groupconsisting of alkyl, —N(R^(e))OR^(s), —CF₃, —C(O)N(R^(e))(R^(f)),-heteroaryl, —H, —OH, —C(O)OR^(e), —CH₂—S(acetyl), —CH₂—SR^(e) and-heterocycloalkyl; X is selected from the group consisting of CH, C(OH),C(C₁-C₄alkyl), C(halo), C(aryl), C(heteroaryl), C(R^(c)),

wherein * represents the point of attachment to group L and **represents the point of attachment to group Y; L and Y are independentlyselected from the group consisting of C₁-C₄alkyl, heteroalkyl, alkenyl,alkynyl, —NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl, —C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-cycloalkyl, —C₂-C₄alkenyl-aryl, —C₂-C₄alkenyl-heteroaryl,—C₂-C₄alkenyl-heterocyclyl, —C₂-C₄alkenyl-cycloalkyl,—C₂-C₄alkynyl-aryl, —C₂-C₄alkynyl-heteroaryl,—C₂-C₄alkynyl-heterocyclyl, —C₂-C₄alkynyl-cycloalkyl,—O—C₀-C₃alkyl-aryl, —O—C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-cycloalkyl,—O—C₀-C₃alkyl-heterocycloalkyl, —C(O)NH—C₀-C₃alkyl-aryl,—C(O)NH-C₀-C₃alkyl-heteroaryl, —O—C₀-C₃alkyl-aryl-aryl,—O—C₀-C₃alkyl-heteroaryl-aryl, —O—C₀-C₃alkyl-aryl-heteroaryl,—O—C₀-C₃alkyl-heteroaryl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl, —S(O)₀₋₂—C₀-C₃alkyl-aryl-heteroaryl,—S(O)₀₋₂—C₀-C₃alkyl-heteroaryl-heteroaryl, -aryl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₂alkyl-N(R^(e))—S(O)₂—C₀-C₂alkyl-heteroaryl,—N(R^(e))—S(O)₂—N(R^(f))—, —N(R^(e))—C(O)—, —C(O)—N(R^(e))—,—N(R^(e))—C(O)—N(R^(f))—, —N(R^(e))—C(O)—O—, —O—C(O)—N(R^(e))—, —O—,—N(R^(e))—C(O)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(e))—,-heterocyclyl-C₀-C₃alkyl-aryl, -cycloalkyl-C₀-C₃alkyl-aryl,-aryl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -cycloalkyl-C₀-C₃alkyl-heteroaryl,-aryl-C₀-C₃alkyl-heterocyclyl, -heteroaryl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-heterocyclyl,-cycloalkyl-C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-O—C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-aryl-C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)NH—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-aryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-C(O)O—C₀-C₃alkyl-alkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-C(O)O—C₀-C₃alkyl-heterocyclyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-aryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-alkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-cycloalkyl,-heterocyclyl-S(O)₂—NH—C₀-C₃alkyl-heterocyclyl,—C₀-C₃alkyl-heterocyclyl-C₂-C₄alkenyl-aryl,—C₀-C₃alkyl-heterocyclyl-CH(aryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(heteroaryl)₂,—C₀-C₃alkyl-heterocyclyl-CH(aryl)(heteroaryl),—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-aryl,—C₀-C₃alkyl-aryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C₀-C₃alkyl-heterocyclyl-C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-S(O)₂-heteroaryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-S(O)₂-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)-heteroaryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)NR^(e)-heteroaryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-heteroaryl-NR^(e)C(O)-heterocyclyl-heteroaryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-aryl,—C₀-C₃alkyl-aryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-heteroaryl-heterocyclyl-C(O)O-heteroaryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-aryl,—C₀-C₃alkyl-aryl-OC(O)-heterocyclyl-heteroaryl, and—C₀-C₃alkyl-heteroaryl-OC(O)-heterocyclyl-heteroaryl, provided that ifan L or a Y is bound directly to a nitrogen of X, then the L or Y is not—NR^(a)R^(b), —NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl, in which each R^(a) andR^(b) together with the nitrogen to which they are bound form a 4 to 7membered heterocyclyl having 1 or 2 annular heteroatoms, or a 5 to 8membered bridged heterocyclyl having 1 or 2 annular heteroatoms, theheterocyclyl being optionally substituted with 1-3 substituentsindependently selected from the group consisting of H, OH, oxo,N(R^(c))(R^(d)), C₁-C₆alkyl, aryl, heteroaryl, —C₁-C₆alkyl-aryl,—C₁-C₆alkyl-heteroaryl, —C₁-C₃alkoxy-C₁-C₃alkyl, —C₂-C₃alkyl-OH,—C₂-C₃alkyl-O—C₁-C₄alkyl, —C₅-C₆cycloalkyl,—C₀-C₃alkyl-N(H)—C(O)—C₁-C₃alkyl, —C₀₋₃alkyl-N(H)—C(O)-haloalkyl,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-aryl, —C₀-C₃alkyl-CF₃,—C₀-C₃alkyl-NHC(O)O—C₁-C₃alkyl-heteroaryl and —C₀-C₃alkyl-NH₂, whereinsaid heterocyclyl is optionally fused to an aryl or heteroaryl; eachR^(c) and R^(d) is independently selected from the group consisting ofH, —C₁-C₆alkyl, —C₂-C₃alkyl-OR^(e), aryl, heteroaryl,-heteroaryl-heteroaryl, -heteroaryl-aryl, -aryl-heteroaryl, —C(O)-aryl,—C₁-C₃-alkoxy-C₁-C₃-alkyl, —C₂-C₃alkyl-O—C₁-C₃alkyl,—C₂-C₃alkyl-NR^(e)R^(f), —CH₂—C(CH₃)₂—NR^(e)R^(f), in which each aryland heteroaryl is optionally substituted with one, two or threesubstituents independently selected from amino, OCH₃ and OH; or R^(c)and Y together with the carbon to which they are bound form anoptionally substituted 4 to 7 membered ring system having 0-2 annularheteroatoms, each R^(e) and R^(f) is independently selected from thegroup consisting of —H, -alkyl, -aryl, -aryl-aryl, -hetetoaryl,heteroaryl-aryl, heteroaryl-heteroaryl, —C(O)-alkyl and —C(O)CF₃; andeach R^(s) is independently selected from the group consisting of —H,C₁-C₆alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl and a protectinggroup, wherein each cycloalkyl, heterocyclyl, aryl, alkyl and heteroarylmoiety is optionally substituted, and wherein a cycloalkyl,heterocyclyl, aryl, alkyl or heteroaryl moiety in L is optionallyconnected to a cycloalkyl, heterocyclyl, aryl, alkyl or heteroaryl in Yby a bond or by a bridging substituent.
 53. The method according toclaim 52, wherein M is NHOH.
 54. The method according to claim 52,wherein M is


55. The method according to claim 52, wherein M is —H.
 56. The methodaccording to claim 52, wherein X is CH.
 57. The method according toclaim 52, wherein X is C(OH) or C(halo).
 58. The method according toclaim 52, wherein X is


59. The method according to claim 52, wherein X is


60. The method according to claim 52, wherein L and Y are independentlyselected from the group consisting of aryl, heteroaryl, alkyl, —O-aryl,—O-cycloalkyl, heterocyclyl, cycloalkyl, —S-aryl, —S-heteroaryl,—C(O)NH-aryl, —S-heteroaryl-aryl, —S-aryl-aryl, -aryl-heterocyclyl,-heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl, —S(O)₂-aryl,—S(O)₂-heteroaryl, —NHS(O)₂-aryl, -heterocyclyl-C₀-C₃alkyl-aryl,-heterocyclyl-C₀-C₃alkyl-heteroaryl, -heteroaryl-C₀-C₃alkyl-heteroaryl,heteroaryl-C₀-C₃alkyl-aryl, -aryl-aryl, -aryl-heteroaryl,-heterocyclyl-O-aryl, -heterocyclyl-O—C₀-C₃alkyl-aryl,-heterocyclyl-O—C₀-C₃alkyl-heteroaryl,-heterocyclyl-S(O)₂—C₀-C₃alkyl-aryl and-heterocyclyl-S(O)₂—C₀-C₃alkyl-heteroaryl, wherein each said cycloalkyl,heterocyclyl, aryl, alkyl and heteroaryl moiety of the forgoing L and Yis optionally substituted with a substituent selected from the groupconsisting of —N(R^(e))C(O)—C₀-C₃alkyl-aryl,—N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(e))C(O)—C₀-C₃alkyl-heterocyclyl,—N(R^(e))C(O)—C₀-C₃alkyl-cycloalkyl, —N(R^(e))C(O)—C₀-C₈alkyl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —CF₃, aryl, heteroaryl, cycloalkyl,heterocyclyl, —C₁-C₃alkyl-aryl, —C₁-C₃alkyl-heteroaryl,—C₁-C₃alkyl-cycloalkyl, —C₁-C₃alkyl-heterocyclyl, and wherein eachcycloalkyl, heterocyclyl, aryl, alkyl and heteroaryl moiety in L isfurther optionally substituted with halo or —O—C₁-C₃alkyl.
 61. Themethod according to claim 52, wherein each cycloalkyl and heterocyclylmoiety is optionally gem or spiro substituted with —OH, —CN or -alkyl.62. The method according to claim 52, wherein L and Y are areindependently selected from the group consisting of aromatic polycycle,non-aromatic polycycle, polyheteroaryl, non-aromatic polyheterocyclic,and mixed aryl and non-aryl polyheterocycle.
 63. The method according toclaim 52, wherein L and Y are independently selected from aryl,heteroaryl, O-aryl, heterocyclyl, cycloalkyl, —S-aryl, —S-heteroaryl and—C(O)NH-aryl, —S-heteroaryl-aryl, -aryl-heterocyclyl,-heteroaryl-heterocyclyl, —C₁-C₃alkyl-aryl, —S(O)₂-aryl,—S(O)₂-heteroaryl, -heterocyclyl-C₀-C₃alkyl-aryl,-heteroaryl-C₀-C₃alkyl-heteroaryl, heteroaryl-C₀-C₃alkyl-aryl,-aryl-aryl and -heterocyclyl-O-aryl, each of which is optionallysubstituted.
 64. The method according to claim 52, wherein the compoundhas the Formula (XIII):

wherein each n is independently 0-3; and R^(g) is selected from thegroup consisting of —C₀-C₃alkyl-aryl, —C₀-C₃alkyl-heteroaryl,—C₀-C₃alkyl-cycloalkyl, —C₀-C₃alkyl-heterocylyl, —NR_(a)R_(b),—NR_(c)R_(d), —OR^(e).
 65. The method according to claim 52, wherein thecompound has the Formula (XIV):

wherein R¹ is alkyl, NO₂, halo or alkoxy, R² is H or C₁-C₅alkyl, and Ais H, phenyl or OH.
 66. The method according to claim 52, wherein thecompound has the Formula (XV):

wherein R⁴ and R⁵ are independently selected from the group consistingof H, halo, —NH₂, —NO₂, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —OMe, alkyl, CN andCF₃; A is H, phenyl or OH; B is a bond, —O—, —N(R⁶)—, —S(O)₀₋₂—,—CH(R⁴)—, —C(R⁵)(R⁴)—, —C(R⁴)—N(R^(c))—, —N(R^(c))—C(R⁴)—, —C(R⁴)—O—,—O—C(R⁴)—, —S(O)₀₋₂—C(R⁴)—, —C(R⁴)—S(O)₀₋₂—, —C(R⁴)═C(R⁵)—,—CH(R⁴)—CH(R⁵)—, —C(R⁴)═N(R⁶)—, —C(O)N(R⁶)—, —S(O)₂N(R⁶)—,—C(R⁵)(R⁴)—C(R⁵)(R⁴)—, —C(R⁵)(H)—C(H)(R⁴)—, —N(CH₂Ph)-, or

 in which R⁶ is alkyl, cycloalkyl or heterocyclyl.
 67. The methodaccording to claim 52, wherein each aryl, heterocyclyl, cycloalkyl andheteroaryl is independently optionally substituted with one, two orthree substituents independently selected from the group consisting ofH, halo, oxo, OH, C₁-C₃-hydrocarbyl, OCH₃, —CN, —S(O)₀₋₂—C₁-C₄alkyl,—CF₃, —OCF₃, alkyl, —NH₂, —N(alkyl)₂, —NH(alkyl), —N(aryl)(alkyl),—N(-alkyl-aryl)(alkyl), —N(heteroaryl)(alkyl),—N(-alkyl-heteroalkylaryl)(alkyl), —NH(aryl), —NH(-alkyl-aryl),—NH(heteroaryl), —NH(-alkyl-heteroalkylaryl),—N(—C₂-C₄alkyl-O-alkyl)(alkyl), —NH(—C₂-C₄alkyl-Oalkyl), —NO₂,—O—C₁-C₄alkyl, —C₀-C₄alkyl-aryl, —C₀-C₄alkyl-heteroaryl,—C₀-C₄alkyl-heterocyclyl, —C₀-C₄alkyl-cycloalkyl, —NHS(O)₂-alkyl,—S(O)₂NH-alkyl, —N_(a)R_(b), —NR_(c)R_(d), —OR_(e),—C₂-C₄alkyl-N_(a)R_(b), C₂-C₄alkyl-NR_(c)R_(d), —S(O)₀₋₁R_(e),—(CR³²R³³)_(s)—NR³⁰R³¹, and (X³⁰—Y³¹—), in which R³⁰ and R³¹ are eachindependently hydrogen, cyano, oxo, hydroxyl, C₁-C₈alkyl,C₁-C₈heteroalkyl, C₁-C₈alkenyl, carboxamido-, C₁-C₃alkyl-carboxamido-,carboxamido-C₁-C₃alkyl-, amidino-, C₂-C₈hydroxyalkyl-, C₁-C₃alkyl-aryl-,aryl-C₁-C₃ alkyl-, C₁-C₃alkyl-heteroaryl-, heteroaryl-C₁-C₃alkyl-,C₁-C₃alkyl-heterocyclyl-, heterocyclyl-C₁-C₃alkyl-,C₁-C₃alkyl-cycloalkyl-, cycloalkyl-C₁-C₃alkyl-, C₂-C₈alkoxy-,C₂-C₈alkoxy-C₁-C₄alkyl-, C₁-C₈alkoxy-carbonyl-, aryloxy-carbonyl-,aryl-C₁-C₃alkoxy-carbonyl-, heteroaryloxy-carbonyl-,heteroaryl-C₁-C₃alkoxy-carbonyl-, C₁-C₈acyl, C₀-C₈alkyl-carbonyl-,aryl-C₀-C₈alkyl-carbonyl-, heteroaryl-C₀-C₈alkyl-carbonyl-,cycloalkyl-C₀-C₈alkyl-carbonyl-, C₀-C₈alkyl-NH-carbonyl-,aryl-C₀-C₈alkyl-NH-carbonyl-, heteroaryl-C₀-C₈alkyl-NH-carbonyl-,cycloalkyl-C₀-C₈alkyl-NH-carbonyl-, C₀-C₈alkyl-O-carbonyl-,aryl-C₀-C₈alkyl-O-carbonyl-, heteroaryl-C₀-C₈alkyl-O-carbonyl-,cycloalkyl-C₀-C₈alkyl-O-carbonyl-, C₁-C₈alkylsulfonyl-,aryl-alkyl-sulfonyl-, aryl-sulfonyl-, heteroaryl-alkyl-sulfonyl-,heteroaryl-sulfonyl-, C₁-C₈alkyl-NH-sulfonyl-, aryl-alkyl-NH-sulfonyl-,aryl-NH-sulfonyl-, heteroaryl-alkyl-NH-sulfonyl-,heteroaryl-NH-sulfonyl, aroyl-, aryl-, cycloalkyl-, heterocyclyl-,heteroaryl-, aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-,heterocyclyl-C₁-C₃alkyl-, heteroaryl-C₁-C₃alkyl-, or protecting group,each of which is optionally substituted with one or more substituentsselected from halo, cyano, oxo, carboxy, formyl, nitro, amino, amidinoand guanidino, or R³⁰ and R³¹ taken together with the N to which theyare attached form a heterocyclyl or heteroaryl, each of which isoptionally substituted with from 1 to 3 substituents selected from thegroup consisting of halo, cyano, oxo, carboxy, formyl, nitro, amino,amidino, guanidino, a protecting group, and (X³⁰—Y³¹—), in which X³⁰ isselected from the group consisting of C₁-C₈alkyl-, C₂-C₈alkenyl-,C₂-C₈alkynyl-, C₀-C₃alkyl-C₂-C₈alkenyl-C₀-C₃alkyl-,C₀-C₃alkyl-C₂-C₈alkynyl-C₀-C₃alkyl-, C₀-C₃alkyl-O—C₀-C₃alkyl-,HO—C₀-C₃alkyl-, C₀-C₄alkyl-N(R³⁰)—C₀-C₃alkyl-, N(R³⁰)(R³¹)—C₀-C₃alkyl-,N(R³⁰)(R³¹)—C₀-C₃alkenyl-, N(R³⁰)(R³¹)—C₀-C₃alkynyl-,(N(R³⁰)(R³¹))₂—C═N—, C₀-C₃alkyl-S(O)₀₋₂—C₀-C₃alkyl-, CF₃—C₀-C₃alkyl-,C₁-C₈heteroalkyl, aryl, cycloalkyl, heterocyclyl, heteroaryl,aryl-C₁-C₃alkyl-, cycloalkyl-C₁-C₃alkyl-, heterocyclyl-C₁-C₃alkyl-,heteroaryl-C₁-C₃alkyl-, N(R³⁰)(R³¹)-heterocyclyl-C₁-C₃alkyl-, whereinthe aryl, cycloalkyl, heteroaryl and heterocycyl are optionallysubstituted with from 1 to 3 substituents selected from halo, cyano,oxo, carboxy, formyl, nitro, amino, amidino and guanidino; and Y³¹ isselected from the group consisting of a direct bond, —O—, —N(R³⁰)—,—C(O)—, —O—C(O)—, —C(O)—O—, —N(R³⁰)—C(O)—, —C(O)—N(R³⁰)—, —N(R³⁰)—C(S)—,—C(S)—N(R³⁰)—, —N(R³⁰)—C(O)—N(R³¹)—, —N(R³⁰)—C(NR³⁰)—N(R³¹),—N(R³⁰)—C(NR³¹)—, —C(NR³)—N(R³⁰), —N(R³⁰)—C(S)—N(R³¹)—, —N(R³⁰)—C(O)—O—,—O—C(O)—N(R³¹)—, —N(R³⁰)—C(S)—O—, —O—C(S)—N(R³¹)—, —S(O)₀₋₂—,—SO₂N(R³¹)—, —N(R³¹)—SO₂— and —N(R³⁰)—SO₂N(R³¹)—; and R₃₂ and R₃₃ areindependently selected from hydrogen, halo and hydroxyl.
 68. The methodaccording to claim 52, wherein the compound has the Formula (XVI):

wherein n is 0-3; and R_(z) is selected from the group consisting of

wherein when L is bound directly to N or O, it is not —NR^(a)R^(b),—NR^(c)R^(d), —OR^(e), —S(O)₀₋₁—C₀-C₃alkyl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroarylaryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-aryl,—S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-aryl, —S(O)₀₋₁—C₀-C₃alkyl-aryl-heteroarylor —S(O)₀₋₁—C₀-C₃alkyl-heteroaryl-heteroaryl.
 69. The method accordingto claim 52, wherein the compound has the Formula (XVII)

wherein M is H or alkyl.
 70. A method of inhibiting a histonedeacetylase selected from the group consisting of HDAC-4, HDAC-5,HDAC-6, HDAC-7, HDAC-8, HDAC-9, HDAC-10 and HDAC-11 comprisingcontacting the histone deacetylase with a histone deacetylase inhibitingamount of a compound having the Formula (XII-A):

or an N-oxide, hydrate, solvate, pharmaceutically acceptable salt,prodrug or complex thereof, or a racemic or scalemic mixture,diastereomer or enantiomer thereof, wherein M, X, Y and L are as definedin claim 49, and wherein Y is further selected from the group consistingof -Z¹-Z-Z²-D, -D, -Z¹-Z³-Z-D, -Z¹-Z³-Z²-Z-D, -Z¹-Z²-D, -Z¹-Z-Z³-Z²-D,-Z-Z³-Z²-Z-D, -Z¹-Z-Z², -Z-Z³-D and -Z²-Z¹-Z²-D wherein Z¹ is selectedfrom the group consisting of chemical bond, alkyl, aryl, heterocyclyl,bridged heterocyclyl, spiro heterocyclyl, cycloalkyl, heteroaryl,wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl moiety isoptionally substituted and each of which is optionally fused to one ormore aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted; Z is selected from the group consisting ofchemical bond, —O—, —S(O)₀₋₂—, —N(R^(c))C(O)—, —C(O)N(R^(c))—C(O)—,—C(O)N(R^(c))—, —N(R^(c))S(O)₂—, —N(R^(c))—,—N(R^(c))(C₂-C₄alkyl-OR^(d))—, —C(O)—, —C(NOR²¹)—,—CH[C(O)N(R²¹)(R²²)]-C(O)N(R²²)—, —CH(N(R²¹)(R²²))—C(O)N(R²²)—,—CH[C(O)N(R^(e))(R^(f))]—C(O)N(R²²)—, —S(O)₂N(R²¹)—,—N(R²¹)S(O)₂N(R²²)—, —OC(O)—, —C(O)O—, —N(R²¹)C(NR²²)—, —C(NR²²)N(R²¹)—,—N(R²¹)C(O)N(R²²)—, —N(R²¹)C(O)O—, —OC(O)N(R²¹)—, —N(R²¹)C(S)—,—C(S)N(R²¹)—, —N(R²¹)C(S)N(R²²)—, —N(R²¹)C(S)O—, —OC(S)N(R²¹)—,—O—C₂-C₄alkyl-N(R²¹)—, —N(R²¹)—C₂-C₄alkyl-O—,—N(R¹)—C₂-C₄alkyl-S(O)₀₋₂—, —N[C₂-C₄alkyl-N(R¹)(R²)]—,—N(C₂-C₄alkyl-O-alkyl)-C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R^(c))—,—N(R^(c))—C₂-C₄alkyl-O—, —N(R^(c))—C₂-C₄alkyl-N(R^(d)),—O—C₁-C₄alkyl-S(O)₂N(R²¹)—, —O—C₁-C₄alkyl-O—,—O—C₁-C₄alkyl-O—C₁-C₄alkyl-O—, —S(O)₂N(R²¹)—C₂-C₄alkyl-O—,—O—C₂-C₄alkyl-N(R²¹)S(O)₂—, —N(R²¹)S(O)₂—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-N(R²¹)—, —N(C(O)—C₁-C₄alkyl)-,—N(R²¹)—C₁-C₄alkyl-C(O)—, —O—C₁-C₄alkyl-C(O)N(R²¹)—,—C(O)N(R²¹)—C₂-C₄alkyl-O—, —C(O)—C₁-C₄alkyl-O—,—C(O)—C₁-C₄alkyl-S(O)₀₋₂—, —O—C₂-C₄alkyl-N(R²¹)C(O)—,—N(R²)C(O)—C₁-C₄alkyl-O—, —N(R²)C(O)—C₁-C₄alkyl-S(O)₀₋₂—,—O—C₁-C₄alkyl-C(O)—, —C(O)—C₁-C₄alkyl-O—, —N(R²¹)—C₁-C₄alkyl-C(O),—C(O)—C₁-C₄alkyl-N(R²¹)—, —O—C₁-C₄alkyl-C(S)—, —C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-C(S), —C(S)—C₁-C₄alkyl-N(R²¹)—,—N(R²¹)—C₁-C₄alkyl-C(S)—, —O—C₁-C₄alkyl-C(S)N(R²¹)—,—C(S)N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)C(S)—,—N(R²¹)C(O)—C₁-C₄alkyl-O—, —N(R²¹)C(S)—C₁-C₄alkyl-O—,—N(R²¹)—C₁-C₄alkyl-S(O)₂—, —O—C₁-C₄alkyl-S(O)₂N(R²¹)—,—S(O)₂N(R²¹)—C₂-C₄alkyl-O—, —O—C₂-C₄alkyl-N(R²¹)S(O)₂—,—N(R²¹)S(O)₂—C₁-C₄alkyl-O—, —O—C₂-C₄alkyl-OC(O)N(R²¹)—,—O—C₂-C₄alkyl-OC(S)N(R²¹)—, wherein each alkyl moiety is optionallysubstituted; Z² is selected from the group consisting of a chemicalbond, alkyl, alkenyl, alkynyl, alkyl-alkenyl, alkynyl-alkyl andalkyl-alkynyl, wherein each alkyl, alkenyl and alkynyl moiety isoptionally substituted; Z³ is selected from the group consisting of achemical bond, —C₁-C₅alkyl-, —C₀-C₅alkyl-aryl-,—C₀-C₅alkyl-heterocyclyl-, —C₀-C₅alkyl-bridged heterocyclyl-, -spiroheterocyclyl-, —C₀-C₅alkyl-cycloalkyl- and —C₀-C₅alkyl-heteroaryl-,wherein each aryl, heteroaryl, cycloalkyl and heterocyclyl moiety isoptionally substituted and each of which is optionally fused to one ormore aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted; D is selected from the group consisting of H,aryl, heteroaryl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalyl,heterocyclyl, bridged heterocyclyl, spiro heterocyclyl, aromaticpolycycles, non-aromatic polycycles, polyheteroaryl groups, non-aromaticpolyheterocyclic, mixed aryl and non-aryl polyheterocycle, each of whichis optionally substituted and each of which is optionally fused to oneor more aryl or heteroaryl rings, or one or more saturated or partiallyunsaturated cycloalkyl or heterocyclyl rings, each of which ring isoptionally substituted, wherein each R²¹ and R²² is independentlyselected from the group consisting of —H, -alkyl, -aryl and heteroaryl,wherein each said aryl and heteroaryl moiety is optionally substituted;and L is selected from the group consisting of cycloalkyl, heterocyclyl,aryl and heteroaryl (preferably aryl and heteroaryl), wherein each aryl,heteroaryl, heterocyclyl, cycloalkyl and aryl group is optionally fusedto a heterocyclyl, or is optionally substituted with a substituentselected from the group consisting of halo, —O-alkyl, —S-alkyl, —NO₂,—N(R^(e))C(O)—C₀-C₃alkyl-aryl, —N(R^(e))C(O)—C₀-C₃alkyl-heteroaryl,—N(R^(a))(R^(b)), —N(R^(c))(R^(d)), —OH, -alkyl, aryl, heteroaryl, —OCF₃and —CF₃.
 71. The method according to claim 52, in which the compound isselected from the group consisting ofN-hydroxy-2,2-bis(4-nitrophenyl)acetamide;2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide.
 72. The methodaccording to claim 52, wherein the compound is selected from the groupconsisting of N-hydroxy-2-phenylbutanamide;N-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(piperidin-1-yl)phenyl)acetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;2-benzyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(5-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;2-(benzo[d]thiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.
 73. The methodaccording to claim 52, wherein the compound is selected from the groupconsisting of 2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;N-hydroxy-2,2-diphenylpropanamide; (E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide andN-hydroxy-9H-xanthene-9-carboxamide.
 74. A method according to claim 52,wherein the compound is selected from the group consisting ofN-hydroxy-2,2-diphenylacetamide; N-hydroxy-2-phenoxy-2-phenylacetamide;N-hydroxy-2,2-bis(4-nitrophenyl)acetamide;N-hydroxy-2-phenyl-2-(piperidin-1-yl)acetamide;2-(N-benzylphenylsulfonamido)-N-hydroxyacetamide;N-hydroxy-3,3-diphenylpropanamide; N-hydroxy-9H-xanthene-9-carboxamide;2,2-bis(2,3-dihydrobenzofuran-5-yl)-N-hydroxyacetamide;2-(4-benzylpiperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-cyclohexyl-N-hydroxy-2-phenylacetamide;N-hydroxy-2,3-diphenylpropanamide;N-hydroxy-2-phenyl-2-(phenylthio)acetamide;N-hydroxy-2-phenyl-2-(1H-pyrrol-1-yl)acetamide;N-hydroxy-2,2-diphenylpropanamide;2,2-bis(4-chlorophenyl)-N-hydroxyacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperazin-1-yl)acetamide;2-(4-benzylpiperazin-1-yl)-N-hydroxy-2-phenylacetamide;2,2-bis(4-fluorophenyl)-N-hydroxyacetamide;2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(6-(thiophen-2-yl)-1H-benzo[d]imidazol-2-yl)acetamide;(E)-N-hydroxy-2,3-diphenylacrylamide;N-hydroxy-2-(isoindolin-2-yl)-2-phenylacetamide;N-hydroxy-2,2-di(thiophen-2-yl)acetamide;2-(benzo[d]thiazol-2-ylthio)-N-hydroxy-2-phenylacetamide;2-(5-chloro-6-fluoro-1H-benzo[d]imidazol-2-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl)acetamide;N-hydroxy-2-(4-phenethyl-1H-1,2,3-triazol-1-yl)-2-phenylacetamide;N,2-dihydroxy-2,2-diphenylacetamide;2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide;2-(4-(4-fluorobenzyl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenethylpiperidin-1-yl)-2-phenylacetamide;2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide;N¹-hydroxy-2-phenyl-N³-(3-(trifluoromethyl)phenyl)malonamide;2-(4-(1H-indol-3-yl)piperidin-1-yl)-N-hydroxy-2-phenylacetamide;2-(4-benzyl-1H-1,2,3-triazol-1-yl)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-(pyrimidin-2-yl)piperazin-1-yl)acetamide;2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide;2-(5-(4-bromophenyl)-1,3,4-thiadiazol-2-yl)-N-hydroxy-2-phenylacetamide;2-(biphenyl-4-yl)-2-(4-(dimethylamino)phenyl)-N-hydroxyacetamide;N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide;2-(4,5-diphenyl-1H-imidazol-2-ylthio)-N-hydroxy-2-phenylacetamide;N-hydroxy-2-(4-phenoxypiperidin-1-yl)-2-phenylacetamide;N-hydroxy-2-phenyl-2-(4-phenylpiperidin-1-yl)acetamide;2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide and2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide.
 75. The methodaccording to claim 52, wherein the contacting is performed in vitro. 76.The method according to claim 70, wherein the contacting is performed invitro.
 77. A method of treating a patient having a disease or conditionameliorated by modulating HDAC activity comprising administering to thepatient a treatment effective amount of a compound of claim 1, or acomposition thereof.
 78. A method of treating a patient having a diseaseor condition ameliorated by modulating HDAC activity comprisingadministering to the patient a treatment effective amount of a compoundof claim 18, or a composition thereof.
 79. The method of claim 77,wherein the disease or condition ameliorated by modulating HDAC activityis selected from the group consisting of a cell proliferative disease,diabetes, inflammation, cardiac disease, stroke, epilepsy, depression,immunological disease and viral or fungal infection.
 80. The method ofclaim 78, wherein the disease or condition ameliorated by modulatingHDAC activity is selected from the group consisting of a cellproliferative disease, diabetes, inflammation, cardiac disease, stroke,epilepsy, depression, immunological disease and viral or fungalinfection.
 81. A compound selected from the group consisting of2-(biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,2-(4′-fluorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4′-methoxybiphenyl-4-yl)-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(pyridin-4-yl)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(pyridin-3-yl)phenyl)acetamide,2-(4′-(dimethylamino)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(pyrimidin-5-yl)phenyl)acetamide andN-hydroxy-2-(4′-morpholinobiphenyl-4-yl)-2-phenylacetamide.
 82. Acompound selected from the group consisting of2-(4-(diethylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(dimethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(pyrrolidin-1-yl)phenyl)acetamide,N-hydroxy-2-(4-morpholinophenyl)-2-phenylacetamide,2-(4-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide,2-(3-fluorophenyl)-N-hydroxy-2-(4-morpholinophenyl)acetamide,2-(3-fluorophenyl)-N-hydroxy-2-(4-(pyrrolidin-1-yl)phenyl)acetamide and2-(4-(diethylamino)phenyl)-2-(3-fluorophenyl)-N-hydroxyacetamide.
 83. Acompound selected from the group consisting of2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(2-morpholinoethoxy)phenyl)-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)acetamide,N-hydroxy-2-(4-(1-methylpiperidin-4-yloxy)phenyl)-2-phenylacetamide,2-(4-(1-benzylpiperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-morpholinophenyl)-2-m-tolylacetamide,2-(4-(1-(cyclopropylmethyl)piperidin-4-yloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-morpholinophenyl)-2-o-tolylacetamide andN-hydroxy-2-(4-(2-morpholino-2-oxoethoxy)phenyl)-2-phenylacetamide. 84.A compound selected from the group consisting of2-(4-(4-chlorophenyl)pyrimidin-2-ylthio)-N-hydroxy-2-phenylacetamide,2-(biphenyl-4-ylthio)-N-hydroxy-2-phenylacetamide andN-hydroxy-2-(naphthalen-2-ylthio)-2-phenylacetamide.
 85. A compoundselected from the group consisting of2-(4′-(dimethylamino)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,2-(4-(benzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(4-benzylpiperidin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-propylphenyl)acetamide,2-(3-(4-fluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-morpholino-2-oxoethoxy)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-phenethoxyphenyl)-2-phenylacetamide,N-hydroxy-2-(4-(3-methoxybenzyloxy)phenyl)-2-phenylacetamide,2-(4-(4-fluorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbutanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cyclohexanecarboxamide,4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,5-dimethylfuran-3-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylthiophene-2-carboxamide,N-hydroxy-2-(4-(2-phenoxyacetamido)phenyl)-2-phenylacetamide,N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxybenzamide,3-cyclohexyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propanamide,3-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,2-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isonicotinamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide,N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide,N-hydroxy-2-(4-(isopentylamino)phenyl)-2-phenylacetamide,2-(4-(benzylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(pyridin-4-ylmethylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(3-(pyridin-4-ylmethylamino)phenyl)acetamide,2-(4-(cyclohexylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(3-methoxybenzylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(3-(3-methoxybenzylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(propylsulfonamido)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(phenylsulfonamido)phenyl)acetamide,2-(4-(4-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(3-(pyridin-3-ylethynyl)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(phenylethynyl)phenyl)acetamide,N-hydroxy-2-phenyl-2-(3-propylphenyl)acetamide,2-(4′-(dimethylamino)biphenyl-3-yl)-N-hydroxy-2-phenylacetamide,2-(3′,4′-dimethoxybiphenyl-3-yl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(2′-(trifluoromethyl)biphenyl-3-yl)acetamide,3′-(2-(hydroxyamino)-2-oxo-1-phenylethyl)-N,N-dimethylbiphenyl-4-carboxamide,N-hydroxy-2-(4′-(methylsulfonyl)biphenyl-3-yl)-2-phenylacetamide,2-(4′-ethylbiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,2-(4′-chlorobiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,2-(4-(2,3-dihydrobenzofuran-5-yl)phenyl)-N-hydroxy-2-phenylacetamide,2-(3′,4′-dimethoxybiphenyl-4-yl)-N-hydroxy-2-phenylacetamide,2-(4′-(ethylthio)biphenyl-4-yl)-N-hydroxy-2-phenylacetamide,4′-(2-(hydroxyamino)-2-oxo-1-phenylethyl)-N,N-dimethylbiphenyl-4-carboxamide,2-(3-(benzo[d][1,3]dioxol-5-ylmethylbenzo[d][1,3]dioxol-5-ylmethoxy)phenyl)-N-hydroxy-2-phenylacetamide,(E)-2-(3-(cinnamyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-(3-chlorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(benzo[d][1,3]dioxol-5-ylmethylbenzo[d][1,3]dioxol-5-ylmethoxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-(3-(dimethylamino)propoxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-(3-(dimethylamino)-2-methylpropoxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(3-(2-(1-methylpyrrolidin-2-yl)ethoxy)phenyl)-2-phenylacetamide,2-(4-ethoxyphenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(prop-2-ynyloxy)phenyl)acetamide,2-(4-(allyloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-isopropoxyphenyl)-2-phenylacetamide,2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-methoxyethoxy)phenyl)-2-phenylacetamide,2-(4-((3,5-dimethylisoxazol-4-yl)methoxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(3-methylbut-2-enyloxy)phenyl)-2-phenylacetamide,2-(4-(2-ethylbutoxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(1-phenylethoxy)phenyl)acetamide,2-(4-(2-fluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-cyanobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-phenoxyethoxy)phenyl)-2-phenylacetamide,2-(4-(2-chlorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2,4-difluorobenzyloxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-(benzyloxy)ethoxy)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-(4-fluorophenoxy)ethoxy)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(phenylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(pyridin-2-ylmethylamino)phenyl)acetamide,2-(4-(4-acetylpiperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(4-(4-fluorophenyl)piperazin-1-yl)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-(2-methoxyethoxy)ethoxy)phenyl)-2-phenylacetamide,2-(4-(4-chlorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propionamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cyclopropanecarboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)butyramide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isobutyramide,N-hydroxy-2-(4-(2-methoxyacetamido)phenyl)-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbutanamide,N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbutanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pivalamide,N-(3-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pivalamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)furan-2-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)furan-3-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,3-dimethylbutanamide,2-ethyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)butanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,2-dimethylbutanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylpentanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)isonicotinamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-methylisoxazole-3-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)thiophene-2-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)tetrahydro-2H-pyran-4-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methylbenzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbenzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,5-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)pentanamide,2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide,3-cyclopentyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)propanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)cinnamamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-phenylpropanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,4-dimethylbenzamide,4-ethyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,2-(4-(2-(4-fluorophenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,5-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-methylbenzamide,3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methylbenzamide,4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,4-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,3,4-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,3,5-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,2,5-difluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,5-chloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1-methyl-1H-pyrazole-4-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-phenylbutanamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-propylbenzamide,4-(dimethylamino)-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-hydroxy-2-(4-(2-(4-methoxyphenyl)acetamido)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(2-(3-methoxyphenyl)acetamido)phenyl)-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-phenoxypropanamide,2-(4-(2-(benzyloxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,4-ethoxy-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-nitrobenzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-nitrobenzamide,N-hydroxy-2-phenyl-2-(4-(2-(phenylthio)acetamido)phenyl)acetamide,3-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxybenzamide,2-(4-(2-(4-chlorophenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,1-acetyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)piperidine-4-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-1-naphthamide,2,4,5-trifluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzofuran-2-carboxamide,4-tert-butyl-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2,6-dimethoxybenzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3,5-dimethoxybenzamide,2-(4-(2-(4-chlorophenoxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,6-chloro-2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-methylbenzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-(trifluoromethyl)benzamide,3,4-dichloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,3,5-dichloro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carboxamide,4-butoxy-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)benzamide,2-(4-(2-(3,4-dimethoxyphenyl)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-methyl-3-phenylisoxazole-4-carboxamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethoxy)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-3-(trifluoromethoxy)benzamide,2-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-(trifluoromethyl)benzamide,4-fluoro-N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-2-(trifluoromethyl)benzamide,2-(4-(2-(4-tert-butylphenoxy)acetamido)phenyl)-N-hydroxy-2-phenylacetamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-4-methoxy-3-(trifluoromethyl)benzamide,N-(4-(2-(hydroxyamino)-2-oxo-1-phenylethyl)phenyl)-5-nitrobenzo[b]thiophene-2-carboxamide,2-(4-(cyclopropylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(isobutylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(3-methylbut-2-enylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(neopentylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(2-methylbutylamino)phenyl)-2-phenylacetamide,2-(4-(cyclopentylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-ethylbutylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-methylpentylamino)phenyl)-2-phenylacetamide,2-(4-(3,3-dimethylbutylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(pyridin-3-ylmethylamino)phenyl)acetamide,N-hydroxy-2-(4-((1-methyl-1H-imidazol-2-yl)methylamino)phenyl)-2-phenylacetamide,2-(4-(cyclohex-3-enylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(thiazol-2-ylmethylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(3-(thiazol-2-ylmethylamino)phenyl)acetamide,N-hydroxy-2-(4-(2-methylbenzylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(3-methylbenzylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-((6-methylpyridin-2-yl)methylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(3-hydroxybenzylamino)phenyl)-2-phenylacetamide,2-(4-(2-fluorobenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,(E)-N-hydroxy-2-phenyl-2-(4-(3-(pyridin-3-yl)allylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(2-phenylpropylamino)phenyl)acetamide,2-(4-(3,5-dimethylbenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-((1H-indol-5-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-((1H-indol-5-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(benzo[d][1,3]dioxol-5-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-(benzo[d][1,3]dioxol-5-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(4-methoxy-3-methylbenzylamino)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(4-(methylthio)benzylamino)phenyl)-2-phenylacetamide,(E)-N-hydroxy-2-(4-(3-(4-methoxyphenyl)allylamino)phenyl)-2-phenylacetamide,(E)-N-hydroxy-2-(4-(3-(2-methoxyphenyl)allylamino)phenyl)-2-phenylacetamide,2-(4-(4-tert-butylbenzylamino)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(3-(trifluoromethyl)benzylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(3-(3-(trifluoromethyl)benzylamino)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(4-(trifluoromethyl)benzylamino)phenyl)acetamide,2-(4-(biphenyl-4-ylmethylamino)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(methylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(ethylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(1-methylethylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(butylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3-chloropropylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(2,2,2-trifluoroethylsulfonamido)phenyl)acetamide,N-hydroxy-2-phenyl-2-(4-(phenylmethylsulfonamido)phenyl)acetamide,N-hydroxy-2-(4-(4-methylphenylsulfonamido)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(2-methylphenylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(4-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-fluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(1,2-dimethyl-1H-imidazole-4-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3,5-dimethylisoxazole-4-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3,4-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2,5-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(4-ethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3,5-dimethylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(3-methoxyphenylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(4-fluoro-2-methylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(3-chlorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2,6-difluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(2,4-difluorophenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(5-chlorothiophene-2-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(2-methoxy-4-methylphenylsulfonamido)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(2-nitrophenylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(3-chloro-4-methylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-(naphthalene-1-sulfonamido)phenyl)-2-phenylacetamide,N-hydroxy-2-(4-(naphthalene-2-sulfonamido)phenyl)-2-phenylacetamide,2-(4-(4-tert-butylphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-(4-((2-nitrophenyl)methylsulfonamido)phenyl)-2-phenylacetamide,2-(4-(3,4-dimethoxyphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(3-(3,4-dimethoxyphenylsulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,N-hydroxy-2-phenyl-2-(4-(3-(trifluoromethyl)phenylsulfonamido)phenyl)acetamide,2-(4-(2,5-dichlorothiophene-3-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,2-(4-(4,5-dichlorothiophene-2-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide,(E)-2-(4-(cinnamylamino)phenyl)-N-hydroxy-2-phenylacetamide and2-(4-(benzo[c][1,2,5]thiadiazole-5-sulfonamido)phenyl)-N-hydroxy-2-phenylacetamide.